"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"IRCCS_IFO",2000,38,6.60526315789474,1.89473684210526,0.473684210526316,0.342105263157895,0.473684210526316,1.36538461538462,1.125,1.18181818181818,1.125,0.210526315789474,1,9,4,9,16,0.24,0.11,0.24,0.42,26.05,0.574720267383628,NA,0.157894736842105,0.763157894736842,0.348,0.322,0.291,0.322,"A. DI CARLO;M BELARDI;ALBERTO GIANNETTI;AMALIA GIGLIO;F. AMEGLIO;G. BIOLCATI;E CRESCIMBENI;PAOLA CORDIALI‐FEI;MASSIMO GIULIANI;ETTORE CAPOLUONGO;LUCA MUSCARDIN;GRAZIA PRIGNANO;ANTONIO CRISTAUDO;GIOVANNI REZZA;G MIGLIORE;ANGELA FERRARI;H. PETER SOYER;D. GRISO;ENZO BERARDESCA;F. M. SOLIVETTI","5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","A. DI CARLO;LUCA MUSCARDIN;F. AMEGLIO;SOLIVETTI FM;M. BELLOCCI;G. BIOLCATI;M BELARDI;ALBERTO GIANNETTI;AMALIA GIGLIO;ENZO BERARDESCA;ALESSANDRO PULSONI;PAOLA CORDIALI‐FEI;ANTONIO CRISTAUDO;F. M. SOLIVETTI;MAURO PICARDO;ETTORE CAPOLUONGO;D. GRISO;L. D’AURIA;MASSIMO GIULIANI;E CRESCIMBENI","1.67;0.73;0.68;0.58;0.58;0.54;0.54;0.54;0.54;0.5;0.48;0.46;0.45;0.45;0.39;0.39;0.38;0.38;0.37;0.34","A. DI CARLO;M BELARDI;ALBERTO GIANNETTI;AMALIA GIGLIO;F. AMEGLIO;G. BIOLCATI;E CRESCIMBENI;PAOLA CORDIALI‐FEI;MASSIMO GIULIANI;ETTORE CAPOLUONGO;LUCA MUSCARDIN;GRAZIA PRIGNANO;ANTONIO CRISTAUDO;GIOVANNI REZZA;ANGELA FERRARI;ENZO BERARDESCA;F. M. SOLIVETTI;L. D’AURIA;SOLIVETTI FM;MAURO PICARDO","5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","A. DI CARLO;LUCA MUSCARDIN;F. AMEGLIO;SOLIVETTI FM;M. BELLOCCI;G. BIOLCATI;M BELARDI;ALBERTO GIANNETTI;AMALIA GIGLIO;ENZO BERARDESCA;PAOLA CORDIALI‐FEI;ANTONIO CRISTAUDO;F. M. SOLIVETTI;MAURO PICARDO;ETTORE CAPOLUONGO;L. D’AURIA;MASSIMO GIULIANI;E CRESCIMBENI;GRAZIA PRIGNANO;FRANCESCA MENNITI‐IPPOLITO","1.67;0.73;0.68;0.58;0.58;0.54;0.54;0.54;0.54;0.5;0.46;0.45;0.45;0.39;0.39;0.38;0.37;0.34;0.34;0.33","MAURO PICARDO;ANDREA LENZI;F. DONDERO;L. GANDINI;PAOLO SGRÒ;ROCCO RAGO;VITTORIA MARESCA;ANDREA DIOCIAIUTI;ANDREA PESERICO;ANNA BELLONI FORTINA;ANNALISA BARBA;CINZIA MASINI;DONATELLA SCHENA;ELIANA GOTTI;G NANNI;GIANPAOLO TESSARI;GIUSEPPE REMUZZI;ILARIA LESNONI LA PAROLA;LUIGI NALDI;SILVIA LOVATI","255;200;200;200;200;200;200;115;115;115;115;115;115;115;115;115;115;115;115;115","MAURO PICARDO;VITTORIA MARESCA;ILARIA LESNONI LA PAROLA;ANTONIO CRISTAUDO;B. SANTUCCI;G. BADARACCO;C VALENZANO;MARIAGRAZIA DE ROCCO;BALDASSARRÉ SANTUCCI;F. AMEGLIO;ALESSANDRA NAPOLITANO;EMANUELA CAMERA;MARCO D’ISCHIA;GIORGIA CARDINALI;GRAZIA PRIGNANO;LUCA MUSCARDIN;NORMA CAMELI;L. D’AURIA;M. PIETRAVALLE;PAOLA CORDIALI‐FEI","255;200;115;90;90;89;82;82;79;62;55;55;55;47;35;34;33;32;32;32","AMALIA GIGLIO;G. BIOLCATI;ETTORE CAPOLUONGO;GRAZIA PRIGNANO;LUCA MUSCARDIN;ANGELA FERRARI;ANTONIO CRISTAUDO;B. SANTUCCI;ENZO BERARDESCA;F. AMEGLIO;F. CAPRILLI;F. M. SOLIVETTI;MAURO PICARDO;A. AMANTEA;ALBERTO CHERSI;ALBERTO GIANNETTI;ALESSANDRA NAPOLITANO;ANGELO PAN;ANNELISA MACR�;BALDASSARRÉ SANTUCCI","4;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE","33;16;9;3;2;1;1;1","PATHOLOGY;IMMUNOLOGY;DERMATOLOGY;INTERNAL MEDICINE;GENETICS;SURGERY;BIOCHEMISTRY;MOLECULAR BIOLOGY;RADIOLOGY;ANATOMY;VIROLOGY;GYNECOLOGY;MICROBIOLOGY;OPTICS;PSYCHIATRY;CANCER RESEARCH;CELL BIOLOGY;DEMOGRAPHY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;MEDICAL PHYSICS;ORGANIC CHEMISTRY","18;15;13;13;8;7;6;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2","GENE;ANTIBODY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);CANCER;VIRUS;ALLERGY;BACTERIA;COHORT;DISEASE;IMPETIGO;NEUROLOGY;PHARYNX;PORPHYRIA;CARCINOMA;CATALYSIS;EPIDEMIOLOGY;EPIDERMIS (ZOOLOGY);IN VITRO;INCIDENCE (GEOMETRY);INFLAMMATION;INTERVENTIONAL RADIOLOGY;LESION;MELANOMA;RADIATION THERAPY;RISK FACTOR","11;6;6;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","GENOTYPE;CERVICAL CANCER;CONTACT DERMATITIS;NEURORADIOLOGY;STAPHYLOCOCCUS AUREUS;ACUTE INTERMITTENT PORPHYRIA;ALLERGIC CONTACT DERMATITIS;DERMATOSCOPY;MONOCLONAL ANTIBODY;MUTATION;NEVUS;PATCH TEST;PEPTIDE SEQUENCE;SYPHILIS;VIRAL LOAD;VIRAL REPLICATION;ACTINIC KERATOSES;ALLYLIC REARRANGEMENT;AUTOANTIBODY;BASAL (MEDICINE);BULLOUS PEMPHIGOID;CANCER REGISTRY;CELL TYPE;CODING REGION;CORPUS ALBICANS;CUMULATIVE INCIDENCE;CYTOPATHOLOGY;ENANTIOSELECTIVE SYNTHESIS;EPITOPE;EPSTEIN–BARR VIRUS;EXON;GENE ISOFORM;GERM CELL;HAZARD RATIO;HEAD AND NECK CANCER;HEPATITIS B VIRUS;HERPES SIMPLEX VIRUS;HETEROSEXUALITY;IMMUNOFLUORESCENCE;IMMUNOGOLD LABELLING;INTERNALIZATION;INTRON;KERATINOCYTE;KIDNEY TRANSPLANTATION;LASER DOPPLER VELOCIMETRY;LYTIC CYCLE;MELPHALAN;METALLOTHIONEIN;MYELOPEROXIDASE;NAIL DISEASE;NAIL PLATE;NITRITE;NITRO;ORGAN TRANSPLANTATION;PERCOLL;PLASMACYTOMA;PLATINUM;POLYUNSATURATED FATTY ACID;PROINFLAMMATORY CYTOKINE;RARE DISEASE;RHODIUM;RNA;SEBACEOUS CARCINOMA;SEROLOGY;SKIN CANCER;STOP CODON;THERAPEUTIC DRUG MONITORING;TRYPTASE;VIRAL DISEASE;VIRAL ENVELOPE;VIRAL PROTEIN","5;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PULSED-FIELD GEL ELECTROPHORESIS;CERVICAL INTRAEPITHELIAL NEOPLASIA;SEXUALLY TRANSMITTED DISEASE;ANTIRETROVIRAL THERAPY;DOCOSAHEXAENOIC ACID;GENITAL HERPES;GENITAL WARTS;HERPESVIRIDAE;HPV INFECTION;IMMUNOPEROXIDASE;IRRITANT CONTACT DERMATITIS;MEN WHO HAVE SEX WITH MEN;MICROCOCCACEAE;MISSENSE MUTATION;NAIL MATRIX;NITROALKENE;NITRONATE;OPEN READING FRAME;PATCH TESTING;PEMPHIGOID;RNA SPLICING;SEROSTATUS;SKIN INFECTION;STAPHYLOCOCCAL INFECTIONS;V3 LOOP;VIRAL ENTRY","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;CARCINOMA, SQUAMOUS CELL;HIV INFECTIONS;STAPHYLOCOCCUS AUREUS;AGED;SKIN NEOPLASMS;PAPILLOMAVIRUS INFECTIONS;TUMOR VIRUS INFECTIONS;ADOLESCENT;DERMATITIS, ALLERGIC CONTACT;DERMATITIS, OCCUPATIONAL;UTERINE CERVICAL NEOPLASMS;HIV SEROPOSITIVITY;ITALY;SKIN;DNA, VIRAL","33;22;20;19;17;15;15;14;11;11;10;10;8;8;8;8;7;7;7;6","MOLECULAR MECHANISMS OF HEME BIOSYNTHESIS AND RELATED DISORDERS;SKIN SENSITIZATION AND CONTACT ALLERGY RESEARCH;ACUTE MYELOID LEUKEMIA;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL SKIN INFECTIONS;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MELANOMA;PATHOGENESIS AND TREATMENT OF PEMPHIGOID DISEASES;ACUPUNCTURE MECHANISMS AND CLINICAL APPLICATIONS;CHRONIC RHINOSINUSITIS AND NASAL POLYPS;COPPER AND ZINC IN HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GLOBAL EPIDEMIOLOGY OF HIV AND DRUG USE;GLYCOSYLATION IN HEALTH AND DISEASE;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 INFECTION;INNOVATIONS IN TRANSDERMAL DRUG DELIVERY SYSTEMS","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV;IMPETIGO;MELANOMA;NEURORADIOLOGY;SKIN SENSITIZATION;ACUTE MYELOID LEUKEMIA;CONTACT ALLERGY;DERMATOSCOPY;DERMOSCOPY;EPIDERMIS (ZOOLOGY);HIV TRANSMISSION;INTERVENTIONAL RADIOLOGY;KOILOCYTE;PATCH TEST;PORPHYRIAS;SKIN CANCERS;ACIDITY SCALES;ACTINIC KERATOSES;ALLERGIC CONTACT DERMATITIS;ANGIOKERATOMA","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","SEXUALLY TRANSMITTED;TRANSMITTED DISEASES;ACUTE INTERMITTENT;HMBS GENE;INTERMITTENT PORPHYRIA;PFGE PATTERNS;SKIN LESIONS;ACID COMPOSITION;ACID-PROMOTED REACTIONS;ACUTE LEUKEMIA;ADHESION MOLECULES;ADULT MALE;AI PULSED-FIELD;ALLERGIC CONTACT;ANTI-INTERCELLULAR SUBSTANCE;ANTIBASEMENT MEMBRANE;ANTIBODY LOG;AUREUS PFGE;AUREUS STRAINS;BLISTER FLUIDS;BLOOD NEUTROPHIL;BULLOUS PEMPHIGOID;CANDIDA ALBICANS;CANDIDAL CARRIAGE;CARCINOMAS PREVALENCE;CARRIAGE KARYOTYPE;CD RECEPTORS;CELL PROLIFERATION;CLINICAL MARKER;CLINICAL PHARMACOKINETICS","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SKIN CANCER;FATTY ACIDS;PLASMA CONCENTRATIONS;AUREUS STRAINS;INCREASED RISK;INJECTING DRUG;NONINJECTING-DRUG-USING HETEROSEXUALS;NONMELANOMA SKIN;TRANSPLANT RECIPIENTS;VIRUS TYPE;CD COUNTS;CELL LINE;CELL LINES;CUMULATIVE INCIDENCE;ELECTROPHORESIS PFGE;ESSENTIAL FATTY;FATTY ACID;GEL ELECTROPHORESIS;HEPATITIS VIRUS;HIV-POSITIVE PATIENTS;HTLV-II ANTIBODIES;HTLV-II INFECTION;INCIDENCE RATE;LONG-CHAIN PUFA;NASAL COLONIZATION;NELFINAVIR PLASMA;ORGAN TRANSPLANT;PERCOLL GRADIENT;PHARMACOKINETIC PARAMETERS;PLASMA CONCENTRATION","5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,32,1,1.41,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ZUPI GABRIELLA","1","ISTITUTO REGINA ELENA","1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1;1;1","CANCER","1",NA,NA,"A61K31/70;A61K38/00;C07H21/00;C12N15/113","1;1;1;1","A61K31/7125;A61K38/00;C12N15/1135;C12N2310/314;C12N2310/3145;C12N2310/315","1;1;1;1;1;1",4,9,439.75,8.51,0,0,44.5,0,1,1,0,2,0,0,0,0,4,0,0,0,0,0,0,0,3,1,0,4,0,0,0,0,0,0,0,0,0,"Belgium","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY","4;4;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;ORPHAN DRUG;RARE DISEASES;LUNG;LUNG CANCER;BREAST CANCER;PATIENT SAFETY","4;4;4;3;3;2;2;1;1","CANCER","4","6.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","4;1;1","LUNG CANCER;BREAST CANCER;MELANOMA","2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1;1",3,662227.67,222416.28,4.33333333333333,2.66666666666667,2,0.333333333333333,18,157812.208333333,0.240792524237009,"ISTITUTI FISIOTERAPICI OSPITALIERI;HEINRICH-PETTE-INSTITUTE;INSTITUTE CURIE;INTERNATIONAL AGENCY FOR RESEARCH ON CANCER;MERCK (GERMANY);WEIZMANN INSTITUTE OF SCIENCE","3;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION","2;1","COALITION S;EC & ERC - EUROPEAN UNION","2;2","BUR - BURSARIES, GRANTS, FELLOWSHIPS (FUNDING SCHEME);CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);FP5-HUMAN POTENTIAL - PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""IMPROVING THE HUMAN RESEARCH POTENTIAL AND THE SOCIO-ECONOMIC KNOWLEDGE BASE"" (1998-2002) (PROGRAMME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);TELETHON RESEARCH SERVICES AND FACILITIES - 2000 (PROGRAM)","1;1;1;1;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","BIOTECHNOLOGY;CANCER;GENETICS;LUNG;LUNG CANCER","1;1;1;1;1","CANCER","1","5.1 PHARMACEUTICALS","1","LUNG CANCER;NOT SITE-SPECIFIC CANCER","1;1","1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES","1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IFO",2001,27,7.14814814814815,2.2962962962963,0.333333333333333,0.296296296296296,0.37037037037037,1.32608695652174,0.9,1,0.909090909090909,0.222222222222222,0,3,10,5,8,0.11,0.37,0.19,0.3,34.3,0.750590350093267,NA,0.185185185185185,0.814814814814815,0.407,0.254,0.381,0.25,"MAURO PICARDO;STEFANIA BRIGANTI;EMANUELA CAMERA;G. BORRONI;ENZO BERARDESCA;ANTONIO CRISTAUDO;MARIA ROSARIA TORRISI;FEDERICA POGGIALI;MARCO ARDIGÒ;ETTORE CAPOLUONGO;VITTORIO MAZZARELLO;ANNA PALUMBO;LAURA EIBENSCHUTZ;MARIA MICHELA LAVIERI;PAOLO IACOVELLI;GIUSEPPE LUCANIA;LAURA TURBINO;M BELARDI;G. BIOLCATI;C. P. ESCOUBET","6;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","MAURO PICARDO;G. BORRONI;ENZO BERARDESCA;EMANUELA CAMERA;ANTONIO GIORDANO;MARCO G. PAGGI;STEFANIA BRIGANTI;FEDERICA POGGIALI;MARCO ARDIGÒ;MARIA ROSARIA TORRISI;ANNA PALUMBO;C. BEWICK-SONNTAG;PATRICIA SCHAFER;MARCO D’ISCHIA;COMILLA VASSALLO;MIRIAM CAPRI;LUCA MUSCARDIN;GIUSEPPE ASTARITA;ALDO VENUTI;VALERIO BRAZZELLI","1.03;0.62;0.62;0.53;0.5;0.5;0.49;0.45;0.42;0.27;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25","MAURO PICARDO;STEFANIA BRIGANTI;EMANUELA CAMERA;ENZO BERARDESCA;ANTONIO CRISTAUDO;MARIA ROSARIA TORRISI;MARCO ARDIGÒ;ETTORE CAPOLUONGO;LAURA EIBENSCHUTZ;M BELARDI;G. BIOLCATI;CRISTINA ANDREI;CATELLO DI MARTINO;VITTORIA MARESCA;C. FERRARO;M. B. BAVASSANO‐CATTANEO;MARCO G. PAGGI;LUIGI LAINO;ALESSANDRO POGGI;PAOLA DE SIMONE","6;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","MAURO PICARDO;ENZO BERARDESCA;EMANUELA CAMERA;MARCO G. PAGGI;STEFANIA BRIGANTI;MARCO ARDIGÒ;MARIA ROSARIA TORRISI;LUCA MUSCARDIN;ANTONIO CRISTAUDO;CATELLO DI MARTINO;M. BELLOCCI;FEDERICO DE MARCO;MARIAROSARIA RINALDI;M CATERINO;ETTORE CAPOLUONGO;VITTORIA MARESCA;GIOVANNI LEONE;MASSIMO CAMETTI;ANNA ADELE FABBRI;MARIA LUCIA DELL’ANNA","1.03;0.62;0.53;0.5;0.49;0.42;0.27;0.25;0.21;0.2;0.2;0.2;0.2;0.2;0.18;0.17;0.17;0.17;0.17;0.17","MAURO PICARDO;STEFANIA BRIGANTI;EMANUELA CAMERA;MARIA ROSARIA TORRISI;MARIA LUCIA DELL’ANNA;MARIO FALCHI;VITTORIA MARESCA;ANDREA CURIONI;ANGELO D. B. PERUFFO;B. SANTUCCI;BARBARA SIMONATO;CARLA GEMIGNANI;F. DE LAZZARI;F. POLATO;GIACOMO PASINI;MARIO PLEBANI;MATTEO GIANNATTASIO;ALESSANDRA FELICI;CINZIA MARCHESE;GIUSEPPE LUCANIA","348;238;219;151;125;125;125;85;85;85;85;85;85;85;85;85;85;80;80;80","MAURO PICARDO;STEFANIA BRIGANTI;EMANUELA CAMERA;MARIA ROSARIA TORRISI;MARIA LUCIA DELL’ANNA;VITTORIA MARESCA;B. SANTUCCI;MARIAROSARIA RINALDI;ALESSANDRO POGGI;ANNA RUBARTELLI;CRISTINA ANDREI;LAVINIA VITTORIA LOTTI;MARIA RAFFAELLA ZOCCHI;STEFANIA GARDELLA;MARCO G. PAGGI;ENZO BERARDESCA;ANTONIO CRISTAUDO;LUIGI LAINO;A. M. DILELLIS;E. AMATA","348;238;219;151;125;125;85;77;71;71;71;71;71;71;67;65;62;60;44;44","MAURO PICARDO;ENZO BERARDESCA;STEFANIA BRIGANTI;EMANUELA CAMERA;ANTONIO CRISTAUDO;ETTORE CAPOLUONGO;MARCO ARDIGÒ;MARIA ROSARIA TORRISI;A GIGLIO A;A. M. DILELLIS;ALESSANDRO POGGI;ANNA ADELE FABBRI;ANNA RUBARTELLI;ANTONIO MASTROIANNI;B. SANTUCCI;C. FERRARO;CATELLO DI MARTINO;CATERINA CATRICALÀ;CRISTINA ANDREI;E. AMATA","6;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","BIOLOGY;MEDICINE;CHEMISTRY;PHYSICS;MATERIALS SCIENCE;HISTORY;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE","19;17;12;5;4;1;1;1;1","BIOCHEMISTRY;INTERNAL MEDICINE;GENETICS;PATHOLOGY;CANCER RESEARCH;DERMATOLOGY;IMMUNOLOGY;ANATOMY;ENDOCRINOLOGY;CELL BIOLOGY;FOOD SCIENCE;ORGANIC CHEMISTRY;CHROMATOGRAPHY;GASTROENTEROLOGY;METALLURGY;MICROBIOLOGY;MOLECULAR BIOLOGY;OPTICS;VIROLOGY;ANIMAL SCIENCE;ASTRONOMY;ASTROPHYSICS;ATMOSPHERIC SCIENCES;BIOPHYSICS;BOTANY;COMPOSITE MATERIAL;COMPUTATIONAL PHYSICS;ENVIRONMENTAL HEALTH;EPISTEMOLOGY;GENEALOGY;GEOMETRY;GEOPHYSICS;HORTICULTURE;LAW;MECHANICS;METEOROLOGY;NUCLEAR PHYSICS;NURSING;OPTOELECTRONICS;QUANTUM MECHANICS;RADIOLOGY;STATISTICS;STEREOCHEMISTRY;SURGERY;UROLOGY","12;10;9;8;6;6;5;4;4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENE;CANCER;ENZYME;OXIDATIVE STRESS;VIRUS;ANTIMICROBIAL;ANTIOXIDANT;ATOPIC DERMATITIS;FATTY ACID;HUMAN PAPILLOMAVIRUS;LESION;MELANOMA;REACTIVE OXYGEN SPECIES;RECEPTOR;ACETIC ACID;ACNE;ALLERGY;ALTERNATIVE MEDICINE;AMINO ACID;ANTIBODY;APOPTOSIS;ASCORBIC ACID;ASTHMA;BACTERIA;BOSS;BOUNDARY LAYER;BROTHER;CANDIDA ALBICANS;CARTILAGE;CELL CULTURE;CHEMOTHERAPY;COLD STORAGE;COLONIZATION;COMPUTED TOMOGRAPHY;CUSP (SINGULARITY);DEGREE OF UNSATURATION;DETECTION LIMIT;DIODE;DORSUM;DRY SKIN;EPIDERMIS (ZOOLOGY);ERYTHEMA;ESSENTIAL OIL;FAMILY MEMBER;FOREHEAD;GLUTEN;GUINEA PIG;HERNIA;HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);HUMIDITY;HYPERKERATOSIS;IMMUNOPATHOLOGY;IN VITRO;INDIA INK;INGESTION;INTRACELLULAR;IRRADIATION;IRRITABLE BOWEL SYNDROME;KERATIN;KINASE;LASER;LOCAL TIME;MALIGNANCY;MASS SPECTROMETRY;MECHANISM (BIOLOGY);MELANIN;MYCELIUM;MYRTACEAE;NAIL (FASTENER);NEOPLASM;NITRIC OXIDE;PARONYCHIA;PATHOGENESIS;PHOSPHORYLATION;PHOTOAGING;PLASMA;POPULATION;PORPHYRIA;PRIMARY (ASTRONOMY);QUANTITATIVE ANALYSIS (CHEMISTRY);RELATIVE HUMIDITY;REPEATABILITY;SCANNING ELECTRON MICROSCOPE;SCROTUM;SECRETION;SEQUENCE (BIOLOGY);SEX ORGAN;SILICONE;SKIN CARE;SKIN LESION;SPACE PHYSICS;STRATUM CORNEUM;SUNLIGHT;TOXIN;VITAMIN C;VITILIGO;WATER VAPOR;WHEAT FLOUR;XANTHOMA;YEAST","9;4;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CATALASE;SUPEROXIDE DISMUTASE;CARCINOGENESIS;CELL CYCLE;MUTATION;POLYUNSATURATED FATTY ACID;RETINOBLASTOMA;VITAMIN E;ACANTHOSIS;ACUTE INTERMITTENT PORPHYRIA;ARGININE;ATP SYNTHASE;AUTOCRINE SIGNALLING;BLADDER CANCER;CALMODULIN;CATHEPSIN;CDKN2A;CERVICAL CANCER;CERVIX;COFACTOR;COLORECTAL CANCER;COMPUTED TOMOGRAPHIC;DERIVATIZATION;ELECTROSPRAY;ENDOTHELIN 1;ENDOTHELIN RECEPTOR;EOSINOPHIL;EPIDERMODYSPLASIA VERRUCIFORMIS;EXOCYTOSIS;FIBROBLAST;FIBROBLAST GROWTH FACTOR;FOOD ALLERGY;GENOTYPE;GLABELLA;GLUTATHIONE;GRANULOCYTE COLONY-STIMULATING FACTOR;IMMUNOGLOBULIN E;INGUINAL HERNIA;KERATINOCYTE;LIPID PEROXIDATION;LOCUS (GENETICS);MAGNETIC RECONNECTION;MAGNETOSPHERE;MELANOCYTE;MELANOSOME;MINIMUM INHIBITORY CONCENTRATION;NAIL DISEASE;NAIL PLATE;NITRIC OXIDE SYNTHASE;PARACRINE SIGNALLING;PEPTIDE SEQUENCE;PERIPHERAL BLOOD MONONUCLEAR CELL;PLACEBO;POLYMERASE CHAIN REACTION;PROTEIN PRECIPITATION;SOLAR WIND;SPIRAL COMPUTED TOMOGRAPHY;STAPHYLOCOCCUS AUREUS;STORAGE PROTEIN;TANDEM MASS SPECTROMETRY;TEA TREE OIL;TRANSEPIDERMAL WATER LOSS;VIRAL LOAD","3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RETINOBLASTOMA PROTEIN;BLADDER NEOPLASM;BROTH MICRODILUTION;FIBROBLAST GROWTH FACTOR RECEPTOR 2;FIBROBLAST GROWTH FACTOR RECEPTOR 3;GENITAL WARTS;GLUTATHIONE PEROXIDASE;HPV INFECTION;INGUINAL CANAL;INTERPLANETARY MAGNETIC FIELD;MAGNETOPAUSE;MELALEUCA ALTERNIFOLIA;MISSENSE MUTATION;NAIL MATRIX;NEURONAL NITRIC OXIDE SYNTHASE;OPEN READING FRAME;ORAL ALLERGY SYNDROME;PLASMA SHEET;PROLAMIN;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;SELECTED REACTION MONITORING;STAPHYLOCOCCUS;TETRAHYDROBIOPTERIN;TOCOPHEROL;TUMOR SUPPRESSOR GENE;WHEAT ALLERGY","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;SKIN;MIDDLE AGED;PAPILLOMAVIRIDAE;MITOCHONDRIA;;ANIMALS;ANTIOXIDANTS;CALCIUM;CELL DIVISION;CYCLIN-DEPENDENT KINASE INHIBITOR P16;DENDRITIC CELLS;ENDOTHELIN-1;EPIDERMODYSPLASIA VERRUCIFORMIS;GRAFT VS HOST DISEASE;HEMATOLOGIC NEOPLASMS;HYPERSENSITIVITY, IMMEDIATE","19;12;11;10;9;7;7;5;4;4;4;4;4;4;4;4;4;4;4;4","HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL SKIN INFECTIONS;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;ATOPIC DERMATITIS AND SKIN MICROBIOME;CLINICAL AND PATHOLOGICAL ASPECTS OF URACHAL CARCINOMA;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;DIAGNOSIS AND MANAGEMENT OF URTICARIA;FIBROBLAST GROWTH FACTOR SIGNALING PATHWAY;FORMATION AND HEALTH EFFECTS OF ACRYLAMIDE IN FOOD;GENOMIC REARRANGEMENT DISORDERS IN SKIN DISEASES;IMMUNOBIOLOGY OF DENDRITIC CELLS;INNOVATIONS IN TRANSDERMAL DRUG DELIVERY SYSTEMS;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;MELANIN PIGMENTATION IN MAMMALIAN SKIN;MOLECULAR MECHANISMS OF HEME BIOSYNTHESIS AND RELATED DISORDERS;REDOX ENVIRONMENT AND CELLULAR METABOLISM;ROLE OF NITRIC OXIDE IN HEALTH AND DISEASE;SKIN SCARRING AND REMODELING MECHANISMS","3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HPV VACCINATION;RETINOBLASTOMA;RETINOBLASTOMA PROTEIN;TREATMENT;ACANTHOSIS;ACNE VULGARIS;ANTIFUNGAL THERAPY;APOPTOSIS;BLADDER CANCER;BLADDER NEOPLASM;BOSS;BROTH MICRODILUTION;DEGREE OF UNSATURATION;DENDRITIC CELLS;DRY SKIN;ENDOTHELIAL DYSFUNCTION;ENVIRONMENTAL MAGNETISM;EPIDERMIS (ZOOLOGY);EPIDERMODYSPLASIA VERRUCIFORMIS;ERYTHEMA","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BLOOD MONONUCLEAR;GROWTH FACTOR;MONONUCLEAR CELLS;OXIDATIVE STRESS;PERIPHERAL BLOOD;ACNE VULGARIS;ACTINIC RADIATION;ACTIVE PHASE;ACUTE INTERMITTENT;AGAINSTICANDIDA ALBICANSIMYCELIAL;ALBICANSIMYCELIAL CONVERSION;ANDOR HUMAN;ANTIMICROBIAL COMEDOLYTIC;ANTINFLAMMATORY ANTIMICROBIAL;APOPTOSIS INDUCED;ARGININE BINDING;ATOPIC DERMATITIS;AUREUS STRAINS;BARRIER FUNCTION;BLADDER CANCER;BLOCKADE INHIBITS;CACALMODULIN-DEPENDENT ENZYME;CARTILAGE POLYSACCHARIDES;CHROMATOGRAPHYELECTROSPRAY MASS;CIS ION;CLIMATIC CONDITIONS;CLINICAL OUTCOME;CLINICAL TRIAL;CLUSTER OBSERVATIONS;CODON- POLYMORPHISM","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GROWTH FACTOR;PUBMED SCOPUS;CROSSREF PUBMED;KERATINOCYTE GROWTH;KS IMM;FIBROBLAST GROWTH;IMM CELLS;HUMAN KERATINOCYTES;PUBMED GOOGLE;FACTOR RECEPTOR;AL MARCHESE;AUTOCRINE GROWTH;CELL LINE;AARONSON SA;BIOL CHEM;CHEM -CROSSREF;ENDOTHELIAL CELLS;GROWTH FACTORS;RUBIN JS;RECEPTOR EXPRESSION;DI CASTRO;FINCH PW;HUMAN FIBROBLAST;KAPOSIS SARCOMA;TUMOR CELLS;ACAD SCI;CELL PROLIFERATION;DIFFERENTIATION MARKERS;ET- RECEPTOR;HUMAN CULTURED","106;57;52;45;40;34;28;19;17;15;14;12;12;11;11;11;10;10;10;9;8;8;8;8;8;7;7;7;7;7",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,10,221.75,8.7,0,0,53.5,0,0,3,0,1,0,0,0,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Belgium;Italy","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES","4;4;2","CANCER;CLINICAL RESEARCH;ORPHAN DRUG;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;BRAIN CANCER;BRAIN DISORDERS;CHILDHOOD LEUKEMIA;DENTAL/ORAL AND CRANIOFACIAL DISEASE;HEMATOLOGY;NEUROSCIENCES;PEDIATRIC;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;STEM CELL RESEARCH;UROLOGIC DISEASES","4;4;4;4;3;2;1;1;1;1;1;1;1;1;1;1;1","CANCER","4","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","4;1;1","BLADDER CANCER;BLOOD CANCER;BRAIN TUMOR;HEAD AND NECK CANCER;LEUKEMIA / LEUKAEMIA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","4;1;1",3,342415.67,244963.52,3,3.66666666666667,2,0.333333333333333,13,484305.976851852,0.0557498798084403,"ISTITUTI FISIOTERAPICI OSPITALIERI;ASSOCIATION OF EUROPEAN RENEWABLE ENERGY RESEARCH CENTRES;CENTRE LÉON BÉRARD;CHARITÉ - UNIVERSITY MEDICINE BERLIN;D'APPOLONIA (ITALY);GERMAN CANCER RESEARCH CENTER;OSPEDALE POLICLINICO SAN MARTINO;T4TECH (ITALY);UNIVERSITAIR ZIEKENHUIS BRUSSEL","3;1;1;1;1;1;1;1;1","CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS;EUROPEAN COMMISSION;TELETHON FOUNDATION","1;1;1","COALITION S;DOD - UNITED STATES DEPARTMENT OF DEFENSE;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;US FEDERAL FUNDERS","1;1;1;1;1","ACM - PREPARATORY, ACCOMPANYING AND SUPPORT MEASURES (FUNDING SCHEME);FP5-IST - PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON A ""USER-FRIENDLY INFORMATION SOCIETY, 1998-2002"" (PROGRAMME);IDEA DEVELOPMENT AWARD (FUNDING MECHANISM);PCRP (PROGRAM);TELETHON GRANT PROJECTS - 2001 (PROGRAM)","1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES","2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;PREVENTION;AGING;CANCER;CARDIOVASCULAR;CONGENITAL STRUCTURAL ANOMALIES;ESTROGEN;GENETICS;HEALTH SERVICES;HEART DISEASE;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD);NUTRITION;PEDIATRIC;PROSTATE CANCER;RURAL HEALTH;STEM CELL RESEARCH;UROLOGIC DISEASES","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1;1","NOT SITE-SPECIFIC CANCER;PROSTATE CANCER","1;1","1.1 NORMAL FUNCTIONING;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;1.5 RESOURCES AND INFRASTRUCTURE;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS","1;1;1;1;1","A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;B11 COMPUTER SCIENCE AND INFORMATICS","1;1;1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IFO",2002,31,7.61290322580645,1.96774193548387,0.32258064516129,0.258064516129032,0.32258064516129,1.27083333333333,0.909090909090909,0.888888888888889,0.909090909090909,0.225806451612903,2,9,6,5,9,0.29,0.19,0.16,0.29,56.81,1.02968604995536,NA,0.225806451612903,0.838709677419355,0.386,0.133,0.342,0.133,"MAURO PICARDO;MARIA ROSARIA TORRISI;EMANUELA CAMERA;MASSIMO GIULIANI;GIOVANNI REZZA;STEFANIA BRIGANTI;FRANCESCA BERNASSOLA;MARCO CORAZZARI;GERRY MELINO;MARCO D’ISCHIA;FRANCESCA BELLEUDI;GENNARO CITRO;MASSIMO ANDREONI;CATERINA CATRICALÀ;MARIA DORRUCCI;ALESSANDRA NAPOLITANO;A. DI CARLO;LUIGI FRATI;GERMANA PETRILLI;ANTONIO CRISTAUDO","5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","EDOARDO ARCURI;HENRY H. CHAN;MAURO PICARDO;EMANUELA CAMERA;MARCO D’ISCHIA;ALESSANDRA NAPOLITANO;A. DI CARLO;MARIA ROSARIA TORRISI;STEFANIA BRIGANTI;MASSIMO GIULIANI;C. CANDIANI;FRANCESCA MENNITI‐IPPOLITO;S. PASSI;FRANCESCA BELLEUDI;LUIGI FRATI;FRANCESCA BERNASSOLA;MARCO CORAZZARI;GERRY MELINO;GENNARO CITRO;LUIGI TOMA","1;1;0.85;0.58;0.42;0.42;0.39;0.35;0.34;0.31;0.25;0.25;0.25;0.24;0.24;0.2;0.2;0.2;0.2;0.2","MAURO PICARDO;MARIA ROSARIA TORRISI;EMANUELA CAMERA;MASSIMO GIULIANI;STEFANIA BRIGANTI;MARCO D’ISCHIA;GENNARO CITRO;CATERINA CATRICALÀ;ALESSANDRA NAPOLITANO;A. DI CARLO;ANTONIO CRISTAUDO;LUIGI TOMA;LAURA EIBENSCHUTZ;G. BIOLCATI;L. SERRONE;C. CANDIANI;ALDO MORRONE;MARCELLO BENASSI;LUCA PIERELLI;GIUSEPPE BERTINI","5;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","EDOARDO ARCURI;HENRY H. CHAN;MAURO PICARDO;EMANUELA CAMERA;MARCO D’ISCHIA;ALESSANDRA NAPOLITANO;A. DI CARLO;MARIA ROSARIA TORRISI;STEFANIA BRIGANTI;MASSIMO GIULIANI;C. CANDIANI;GENNARO CITRO;LUIGI TOMA;ALDO MORRONE;MARCELLO BENASSI;OB TCHANGMENA;GENNARO FRANCO;CATERINA CATRICALÀ;LAURA EIBENSCHUTZ;L. SERRONE","1;1;0.85;0.58;0.42;0.42;0.39;0.35;0.34;0.31;0.25;0.2;0.2;0.2;0.2;0.2;0.2;0.19;0.17;0.17","CATERINA CATRICALÀ;HENSIN TSAO;JAMES G. RHEINWALD;JENNY WU;KATHLEEN O’TOOLE;MATTHEW R. RAMSEY;MICHELE DE LUCA;WILLIAM C. HAHN;ZONGYOU GUO;MARIA ROSARIA TORRISI;A. AMANTEA;ADRIANA ALBINI;ALFONSO BALDI;ANTONIO DE LUCA;ARMANDO FELSANI;DANIELA LOMBARDI;DOUGLAS M. NOONAN;FELICIANO BALDI;MARCO G. PAGGI;MONICA MORINI","531;332;332;332;332;332;332;332;332;256;199;199;199;199;199;199;199;199;199;199","CATERINA CATRICALÀ;MARIA ROSARIA TORRISI;A. AMANTEA;GIORGIA CARDINALI;ANDREA MARIOTTI;ETTORE CAPOLUONGO;FRANCO AMEGLIO;GIOVANNI SCAMBIA;GIUSEPPE D’ONOFRIO;GIUSEPPE LEONE;GIUSEPPINA BONANNO;LUCA PIERELLI;SERGIO RUTELLA;SIMONA SICA;ROSA SCIUTO;MAURO PICARDO;GENNARO CITRO;MARIA GABRIELLA DONÀ;ENZO BERARDESCA;JOACHIM W. FLUHR","531;230;199;165;159;159;159;159;159;159;159;159;159;159;142;136;125;95;92;92","MAURO PICARDO;EMANUELA CAMERA;MASSIMO GIULIANI;A. DI CARLO;CATERINA CATRICALÀ;GENNARO CITRO;MARIA ROSARIA TORRISI;STEFANIA BRIGANTI;A. AMANTEA;ALDO MORRONE;ALESSANDRA NAPOLITANO;ANDREA MARIOTTI;ANTONIO CRISTAUDO;B. SANTUCCI;C. CANDIANI;C. CATRICALÀ;EDOARDO ARCURI;EMILIA MIGLIANO;ENZO BERARDESCA;ETTORE CAPOLUONGO","5;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHILOSOPHY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;POLITICAL SCIENCE;MATHEMATICS;PSYCHOLOGY","18;14;8;3;2;2;2;2;1;1","BIOCHEMISTRY;INTERNAL MEDICINE;IMMUNOLOGY;GENETICS;CELL BIOLOGY;DERMATOLOGY;ORGANIC CHEMISTRY;VIROLOGY;CANCER RESEARCH;PATHOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;BIOPHYSICS;BOTANY;ENDOCRINOLOGY;EPISTEMOLOGY;FAMILY MEDICINE;LAW;MEDICINAL CHEMISTRY;ONCOLOGY;SURGERY","13;12;10;8;7;6;6;6;5;5;4;3;3;2;2;2;2;2;2;2;2;2","GENE;CANCER;ENZYME;ANTIBODY;ANTIOXIDANT;CELL CULTURE;INTRACELLULAR;MELANOMA;POPULATION;ALTERNATIVE MEDICINE;AMINO ACID;ASYMPTOMATIC;CELL;CHEMOTHERAPY;DNA;HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;IN VITRO;LYMPH NODE;LYMPHOMA;NITRATE;RECEPTOR;VIRUS","8;5;5;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CD8;CYTOTOXIC T CELL;GLUTAMINE;METASTASIS;MUTATION;NITRITE;SEROCONVERSION;TISSUE TRANSGLUTAMINASE;ABIOTIC STRESS;ACUTE INTERMITTENT PORPHYRIA;ALLERGEN;ALPHA INTERFERON;AMMONIUM ACETATE;ARACHIDONIC ACID;BRAN;BUREAUCRACY;BUTYLATED HYDROXYTOLUENE;CAPILLARY ELECTROCHROMATOGRAPHY;CATALASE;CELL CYCLE;CELL DIVISION;CELLULAR IMMUNITY;CENTRIOLE;CERVICAL CANCER;COMPLEMENTARY DNA;CYCLOBUTANE;CYCLOPHOSPHAMIDE;CYTOSKELETON;DIENE;DNA DAMAGE;ENDOCYTOSIS;ENDOSOME;EPITOPE;ERYTHROCYTE MEMBRANE;FIBROBLAST GROWTH FACTOR;FILARIASIS;FLAVONOID;FOOD ALLERGY;FREE RADICAL SCAVENGER;GENE EXPRESSION;GOLGI APPARATUS;GROWTH FACTOR RECEPTOR;HAEMATOXYLIN;HEALTH SERVICES;HEME;HEPATITIS C VIRUS;HUMAN LEUKOCYTE ANTIGEN;HYDROXYL RADICAL;HYPOGLYCEMIA;IMMUNOELECTRON MICROSCOPY;IMMUNOGLOBULIN E;INSULIN RESISTANCE;INSULINOMA;INTERNALIZATION;INTRAOPERATIVE RADIATION THERAPY;KERATINOCYTE;KNOCKOUT MOUSE;LIPID PEROXIDATION;LYMPHADENECTOMY;MYELODYSPLASTIC SYNDROMES;NEURORADIOLOGY;NICOTIANA BENTHAMIANA;NITRO;PERFORMANCE STATUS;PHENOTYPE;PHOTOPROTECTION;PLACEBO;PLANT BIOCHEMISTRY;PLANT LIPID TRANSFER PROTEINS;PLASMID;POLYUNSATURATED FATTY ACID;PROSTATE;PROSTATE CANCER;PROTEASE;PROTOPORPHYRIN;PROTOPORPHYRINOGEN OXIDASE;REACTIVITY (PSYCHOLOGY);RECEPTOR TYROSINE KINASE;RECOMBINANT DNA;RNA;SCAVENGER;SEROLOGY;SUPEROXIDE DISMUTASE;T CELL;TELOMERE;TUBULIN;TUMOR PROGRESSION;TYROSINE KINASE;VIRAL DISEASE;VIRAL LOAD;VIRAL REPLICATION","2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CTL*;ANTIGEN-PRESENTING CELL;ANTIRETROVIRAL THERAPY;BAND 3;CD28;CELLULAR SENESCENCE;CENTROSOME;CORN FLOUR;CYTOKINESIS;ENDOCYTIC CYCLE;ERYTHROPOIETIC PROTOPORPHYRIA;FERROCHELATASE;FIBROBLAST GROWTH FACTOR RECEPTOR;FLUDARABINE;FUSION PROTEIN;GLUCAGONOMA;GLUCOSE HOMEOSTASIS;HEALTH FACILITY;IL-2 RECEPTOR;INTERFERON ALFA;INTERLEUKIN 21;INTRAOPERATIVE RADIOTHERAPY;KERATINOCYTE GROWTH FACTOR;LOA LOA;MISSENSE MUTATION;MITOTIC CATASTROPHE;NATURAL KILLER T CELL;NS3;ORAL ALLERGY SYNDROME;PROBAND;PYRIMIDINE DIMER;RECEPTOR-MEDIATED ENDOCYTOSIS;REPLICON;SENTINEL LYMPH NODE;SENTINEL NODE;SERINE PROTEASE;SIDA;SINDBIS VIRUS;SPINDLE APPARATUS;SUBGENOMIC MRNA;UROPORPHYRINOGEN III DECARBOXYLASE;WINDOW PERIOD","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;GTP-BINDING PROTEINS;TRANSGLUTAMINASES;ADULT;EPIDERMIS;MELANOMA;;ANIMALS;FEMALE;SKIN NEOPLASMS;AGED;BONE NEOPLASMS;BREAST NEOPLASMS;KERATINOCYTES;MICE;NEOPLASMS, EXPERIMENTAL;ANTIOXIDANTS;CALCIUM;CANCER VACCINES","20;10;8;8;7;7;7;6;6;6;6;5;5;5;5;5;5;4;4;4","BLOOD RHEOLOGY AND COAGULATION MECHANISMS;MELANOMA;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BREATH ANALYSIS TECHNOLOGY;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;DISEASES RELATED TO BLOOD GROUP VARIANTS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;FIBROBLAST GROWTH FACTOR SIGNALING PATHWAY;FORMATION AND HEALTH EFFECTS OF ACRYLAMIDE IN FOOD;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;HEPATITIS C INFECTION AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;IMPACT OF HEALTHCARE LEGISLATION ON PRACTICE AND ETHICS;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;METABOLISM AND FUNCTION OF ARACHIDONIC ACID DERIVATIVES;MOLECULAR MECHANISMS OF HEME BIOSYNTHESIS AND RELATED DISORDERS;NUCLEOPHILIC REACTIVITY IN ORGANIC CHEMISTRY","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CTL*;HIV;MELANOMA;SEROCONVERSION;TISSUE TRANSGLUTAMINASE;TRANSGLUTAMINASES;ACIDITY SCALES;ANTIRETROVIRAL THERAPY;AUTOXIDATION;BAND 3;BIOIMAGE ANALYSIS;BLOOD DONATION;BONE METASTASIS;BONE PAIN;BRCA1;BREAST CANCER;BUREAUCRACY;BUTYLATED HYDROXYTOLUENE;CANCER PAIN;CANCER SUSCEPTIBILITY","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABIOTIC STRESS;ACCELERATORS DEVELOPMENT;ACID-PROMOTED REACTION;ACIDIC CONDITIONS;ACUTE BARRIER;ACUTE MYELOID;ALLE MALATTIE;ANATOMICAL LOCATION;APPROCCIO SINDROMICO;BARRIER DISRUPTION;BARRIER RECOVERY;BIOPSIA DEL;BONE METASTASES;CELLS EXPRESSING;CLINICAL TRIAL;COLONYSTIMULATING FACTOR;CONCOMITANT CUTANEOUS;CONDITIONS UNUSUAL;CORNEUM HYDRATION;CT FINDINGS;CUTANEOUS PLEOMORPHIC;CUTANEOUS T-CELL;DEFICIENT MICE;DEL LINFONODO;DETTAGLI TECNICI;DIAGNOSTIC FLOW-CHART;DISEASE PROGRESSION;ENDOCYTIC PATHWAY;ENDOPLASMIC RETICULUM;EPIDERMAL RECONSTRUCTS","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LIFE SPAN;POST-G CD;ANTIRETROVIRAL THERAPY;PROTECTIVE EFFECT;AMINO ACIDS;AUTOLOGOUS LYMPH;CTL RESPONSES;ENDOPLASMIC RETICULUM;EXTENDED LIFE;HIV-POSITIVE INDIVIDUALS;HLAABINDING PEPTIDES;HTRA EXPRESSION;KERATINOCYTES ENGINEERED;LYMPH NODE;NS PROTEINS;PRE-G CD;PROTEASE HTRA;TR CELLS;ACYCLOVIR DECREASED;ADDITION MEMORY;ADDITIONAL SUBCELLULAR;ADMINISTRATION PRE-G;ADVANCE STATUS;ADVANCED TREATMENT;AFFECT T-CELL;ALLELE CELLS;ALLOANTIGEN-ACTIVATED POST-G;ALLOGENEIC MIXED;ALTERATIONS OBSERVED;ANTI-HERPETIC DRUGS","4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1",1,0.03,3,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,55,55,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,6,369.33,8.33,0,0,45,0,0,2,0,2,0,0,0,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Belgium;Italy","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","4;4","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;AGING;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEMATOLOGY;ORPHAN DRUG;PEDIATRIC;RARE DISEASES;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","3;3;3;2;1;1;1;1;1;1;1;1;1","CANCER","3","6.1 PHARMACEUTICALS","3","BLOOD CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;MELANOMA;PANCREATIC CANCER","1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;1;1",1,439588,439588,2,1,1,0,2,704099.976851852,0.044027838402447,"ISTITUTI FISIOTERAPICI OSPITALIERI","1","CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS","1","DOD - UNITED STATES DEPARTMENT OF DEFENSE;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;US FEDERAL FUNDERS","1;1;1","BCRP (PROGRAM);IDEA-EPIDEMIOLOGY AWARD (FUNDING MECHANISM)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","BREAST CANCER;CANCER;CLINICAL RESEARCH","1;1;1","CANCER","1",NA,NA,"BREAST CANCER","1","2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","1;1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IFO",2003,43,8.06976744186047,2.27906976744186,0.534883720930233,0.255813953488372,0.534883720930233,1.53125,1.04545454545455,1.83333333333333,1.04545454545455,0.209302325581395,0,12,6,5,19,0.28,0.14,0.12,0.44,51.6,0.974998998488216,NA,0.395348837209302,0.906976744186046,0.368,0.246,0.484,0.356,"MAURO PICARDO;MARIA ROSARIA TORRISI;EMANUELA CAMERA;DIANA GIANNARELLI;VITTORIA MARESCA;GIORGIA CARDINALI;F. M. SOLIVETTI;ROBERTO PAGANELLI;ANDREA PACE;LUIGI FRATI;B. SANTUCCI;MARIA LUCIA DELL’ANNA;COSIMA SCHIAVONE;D BACARO;PAOLO IACOVELLI;J. A. SAUVAUD;CARLO VITTORIO CANNISTRACI;LOREDANA BOVE;CARLO RICCARDO ROSSI;A. KORTH","11;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MAURO PICARDO;A. DI CARLO;F. M. SOLIVETTI;ANNA DI NARDO;LUCIA CECERE;FABRIZIO ENSOLI;ALESSANDRA LATINI;GAETANA COGNETTI;FELICE IPPOLITO;MARIA CATERINA SIRIANNI;MASSIMO CARDUCCI;EMANUELA CAMERA;MARIA ROSARIA TORRISI;LUCA MUSCARDIN;DIANA GIANNARELLI;MARIA LUCIA DELL’ANNA;D BACARO;ADRIANO DE MAJO;PAOLO IACOVELLI;GIOVANNI LEONE","1.34;0.67;0.57;0.53;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.47;0.46;0.45;0.44;0.38;0.37;0.37;0.36;0.36","MAURO PICARDO;MARIA ROSARIA TORRISI;EMANUELA CAMERA;VITTORIA MARESCA;GIORGIA CARDINALI;F. M. SOLIVETTI;ANDREA PACE;B. SANTUCCI;MARIA LUCIA DELL’ANNA;PAOLO IACOVELLI;CARLO VITTORIO CANNISTRACI;LOREDANA BOVE;MARCELLA MOTTOLESE;ANNAMARIA BIROCCIO;CARLO LEONETTI;BRIGITTA BUTTARI;GIOVANNI LEONE;FRANCESCO COGNETTI;ANNA DI NARDO;B. JANDOLO","11;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MAURO PICARDO;A. DI CARLO;F. M. SOLIVETTI;ANNA DI NARDO;FABRIZIO ENSOLI;ALESSANDRA LATINI;GAETANA COGNETTI;EMANUELA CAMERA;MARIA ROSARIA TORRISI;LUCA MUSCARDIN;MARIA LUCIA DELL’ANNA;PAOLO IACOVELLI;GIOVANNI LEONE;B. SANTUCCI;MICHÈLE MILELLA;GIORGIA CARDINALI;VITTORIA MARESCA;ANDREA PACE;CARLO VITTORIO CANNISTRACI;B. CAPITANIO","1.34;0.67;0.57;0.53;0.5;0.5;0.5;0.47;0.46;0.45;0.38;0.36;0.36;0.35;0.33;0.31;0.29;0.27;0.25;0.25","MAURO PICARDO;ANDREA PACE;B. JANDOLO;ANNA DI NARDO;VITTORIA MARESCA;ANTONELLA VITIELLO;RICHARD L. GALLO;ANNAMARIA BIROCCIO;CARLO LEONETTI;FRANCESCO COGNETTI;LOREDANA BOVE;ANTONELLA SAVARESE;GIROLAMO DEL MONTE;UMBERTO PACETTI;DIANA GIANNARELLI;ANNA MARIA CIANCIULLI;ANTONELLO VIDIRI;C. M. CARAPELLA;EDVINA GALIÈ;MARIANTONIA CAROSI","823;635;567;496;443;407;407;381;381;381;381;313;313;313;278;254;254;254;254;254","MAURO PICARDO;ANDREA PACE;ANNA DI NARDO;VITTORIA MARESCA;ANNAMARIA BIROCCIO;ANTONELLA SAVARESE;B. JANDOLO;CARLO LEONETTI;FRANCESCO COGNETTI;GIROLAMO DEL MONTE;LOREDANA BOVE;UMBERTO PACETTI;GIOVANNI LEONE;PAOLO IACOVELLI;EMANUELA CAMERA;MARIA LUCIA DELL’ANNA;LUCA MUSCARDIN;ANDREA PARO VIDOLIN;MARIA ROSARIA TORRISI;B. SANTUCCI","823;567;496;443;313;313;313;313;313;313;313;313;204;204;176;172;120;112;105;102","MAURO PICARDO;MARIA ROSARIA TORRISI;EMANUELA CAMERA;VITTORIA MARESCA;B. SANTUCCI;GIORGIA CARDINALI;MARIA LUCIA DELL’ANNA;A. DI CARLO;ANDREA PACE;ANNA DI NARDO;ARIANNA MASTROFRANCESCO;CARLO VITTORIO CANNISTRACI;E. AMATA;F. M. SOLIVETTI;GIOVANNI LEONE;LUCA MUSCARDIN;M. BELLOCCI;PAOLO IACOVELLI;ALBERTO ROMANO;ALESSANDRA LATINI","11;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;BUSINESS;COMPUTER SCIENCE;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY;SOCIOLOGY","29;19;9;4;1;1;1;1;1;1","INTERNAL MEDICINE;BIOCHEMISTRY;IMMUNOLOGY;SURGERY;DERMATOLOGY;CELL BIOLOGY;PATHOLOGY;CANCER RESEARCH;GENETICS;MOLECULAR BIOLOGY;ONCOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;ORGANIC CHEMISTRY;PSYCHIATRY;RADIOLOGY;VIROLOGY;ANESTHESIA;ASTROPHYSICS;CARDIOLOGY;COMPUTATIONAL PHYSICS;ENVIRONMENTAL HEALTH;GEOPHYSICS;OPTICS;PHARMACOLOGY;QUANTUM MECHANICS","22;13;11;11;9;7;7;6;6;6;6;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;IN VITRO;GENE;ANTIOXIDANT;CHEMOTHERAPY;IMMUNE SYSTEM;OXIDATIVE STRESS;ALLERGY;ANTIBODY;DISEASE;INTRACELLULAR;MELANOMA;PSORIASIS;RECEPTOR;SIGNAL TRANSDUCTION;VITILIGO;ANTIGEN;BIOPSY;CLINICAL TRIAL;ENZYME;FAMILY HISTORY;LEUKEMIA;LYMPHOMA;PLASMA;POPULATION;REACTIVE OXYGEN SPECIES;REGIMEN;SARCOMA;SODIUM;STEM CELL;TOXICITY;ULTRASOUND;VIRUS","6;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CONTACT DERMATITIS;GENE EXPRESSION;ALLERGIC CONTACT DERMATITIS;CISPLATIN;COLORECTAL CANCER;EPIDERMAL GROWTH FACTOR;GROWTH FACTOR;INTERNALIZATION;KERATINOCYTE;LIPID PEROXIDATION;MAGNETOSPHERE;NEUROTOXICITY;PERIPHERAL BLOOD MONONUCLEAR CELL;PROSTATE CANCER;SOLAR WIND;TYROSINE KINASE;VITAMIN E;ADENOCARCINOMA;ADJUVANT THERAPY;ALDEHYDE;AMBULATORY BLOOD PRESSURE;ANTIMICROBIAL PEPTIDES;ARACHIDONIC ACID;ASTROCYTOMA;ATOPY;BLADDER CANCER;CALRETICULIN;CANCER REGISTRY;CATALASE;CERAMIDE;CHRONIC IDIOPATHIC URTICARIA;CHRONIC MYELOGENOUS LEUKEMIA;COMPLEMENTARY DNA;CONVENTIONAL PCI;CYSTIC ECHINOCOCCOSIS;CYTOTOXIC T CELL;DACARBAZINE;DEFENSIN;DOXORUBICIN;ENDOCYTOSIS;ENDOSOME;EPSTEIN–BARR VIRUS;EXCIMER;EXCIMER LASER;FOLLICULAR LYMPHOMA;GENE REARRANGEMENT;GLUCOSE TRANSPORTER;GRAVES' DISEASE;HACAT;HAEMATOPOIESIS;HEPATITIS C VIRUS;HUMAN HERPESVIRUS;HUMAN LEUKOCYTE ANTIGEN;IMMUNOGLOBULIN E;IMMUNOGOLD LABELLING;INNATE IMMUNE SYSTEM;LIMB PERFUSION;LYTIC CYCLE;MAGNETIC RECONNECTION;MAJOR HISTOCOMPATIBILITY COMPLEX;MAPK/ERK PATHWAY;METASTASIS;MUTATION;MYCOSIS FUNGOIDES;NAIL PLATE;NEURORADIOLOGY;NONSENSE;NUCLEAR LOCALIZATION SEQUENCE;NUCLEAR MEMBRANE;OLANZAPINE;PATCH TEST;PERFORMANCE STATUS;POLYMERASE CHAIN REACTION;PROGRESSIVE DISEASE;PROINFLAMMATORY CYTOKINE;PROSTATE;PROTEIN KINASE A;PROTOPORPHYRINOGEN OXIDASE;RAJI CELL;REACTIVITY (PSYCHOLOGY);RECEPTOR TYROSINE KINASE;RECURRENT LARYNGEAL NERVE;RESISTIVE INDEX;RETINOIC ACID;RNA;SEROLOGY;SKIN BIOPSY;SOFT TISSUE SARCOMA;SPHINGOMYELIN;STAPHYLOCOCCUS AUREUS;SUPEROXIDE DISMUTASE;T CELL;TARGETED THERAPY;TEMOZOLOMIDE;TRANSFECTION;TYROSINE PHOSPHORYLATION;UNIVARIATE ANALYSIS;VELLUS HAIR;VIRAL PROTEIN;VIRAL REPLICATION","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","KERATINOCYTE GROWTH FACTOR;MAGNETOPAUSE;TBARS;ACUTE PROMYELOCYTIC LEUKEMIA;ALPHA-TOCOPHEROL;BETA DEFENSIN;CATHELICIDIN;CLATHRIN;COLORECTAL ADENOCARCINOMA;CUTANEOUS T-CELL LYMPHOMA;GLUT1;INFERIOR THYROID ARTERY;INTERPLANETARY MAGNETIC FIELD;IRRITANT CONTACT DERMATITIS;KAPOSI'S SARCOMA;LASER CAPTURE MICRODISSECTION;LIPOTEICHOIC ACID;MHC CLASS I;MISSENSE MUTATION;NICKEL ALLERGY;NORTHERN BLOT;OLIGODENDROGLIOMA;PERIPHERAL T-CELL LYMPHOMA;PERITONEAL CARCINOMATOSIS;PROSTATE CARCINOMA;PROSTATE-SPECIFIC ANTIGEN;RECEPTOR-MEDIATED ENDOCYTOSIS;RECTAL EXAMINATION;RNA SPLICING;SEROPREVALENCE;TGF ALPHA;THIOBARBITURIC ACID;TOCOPHEROL;TRANSCRIPTOME;TRANSRECTAL ULTRASONOGRAPHY","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;MIDDLE AGED;ADULT;FEMALE;ANTINEOPLASTIC AGENTS;MELANOMA;AGED;DERMATITIS, ALLERGIC CONTACT;CISPLATIN;KERATINOCYTES;NICKEL;COLORECTAL NEOPLASMS;PSORIASIS;RECEPTORS, FIBROBLAST GROWTH FACTOR;SKIN NEOPLASMS;VITILIGO;ANIMALS;ANTIOXIDANTS;ITALY","36;21;20;17;17;12;12;11;10;8;8;8;7;7;7;7;7;6;6;6","MELANIN PIGMENTATION IN MAMMALIAN SKIN;SKIN SENSITIZATION AND CONTACT ALLERGY RESEARCH;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;SPACE WEATHER AND MAGNETOSPHERIC PHYSICS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;ATOPIC DERMATITIS AND SKIN MICROBIOME;BIOLOGICAL AND THERAPEUTIC PROPERTIES OF BEE PRODUCTS;BIOLOGICAL, EPIDEMIOLOGICAL, AND CLINICAL ASPECTS OF ECHINOCOCCOSIS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLINICAL AND MOLECULAR CHARACTERISTICS OF GLOMUS TUMORS;COPPER AND ZINC IN HEALTH AND DISEASE;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DIAGNOSIS AND MANAGEMENT OF URTICARIA;FOCUSED ULTRASOUND TECHNOLOGY AND APPLICATIONS;GLIOMAS;HEPATITIS C INFECTION AND TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;IMPACT OF HEALTH LITERACY ON HEALTH OUTCOMES;LIPID METABOLISM IN CANCER PATHOGENESIS","3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SKIN SENSITIZATION;CONTACT ALLERGY;ALLERGIC CONTACT DERMATITIS;VITILIGO;CANCER THERAPY;INTERNALIZATION;KAPOSI'S SARCOMA;KERATINOCYTE GROWTH FACTOR;MELANOMA;NEUROPROTECTIVE STRATEGIES;NEUROTOXICITY;REGIMEN;TBARS;TREATMENT;ACUTE PROMYELOCYTIC LEUKEMIA;ADJUVANT THERAPY;ALPHA PARTICLE THERAPY;ALPHA-TOCOPHEROL;ANTIGEN PRESENTATION;ANTIGEN PROCESSING","5;4;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","FACTOR RECEPTOR;GROWTH FACTOR;KERATINOCYTE GROWTH;MONONUCLEAR CELLS;PATIENTS TREATED;ACNEIFORM FOLLICULAR;ACUTE GENERALIZED;ACUTE PROMYELOCYTIC;ADVANCED ACUTE;ADVANCED LIMB;ALLOGENEIC STEM;AMBULATORY BLOOD;ANTIGEN PROCESSING;ANTIGENS LINKED;ANTIMICROBIAL ACTIVITY;ANTIMICROBIAL PEPTIDE;ANTIOXIDANTS ACTIVITIES;ANTITUMOR EFFICACY;ARACHIDONIC ACID;ARRAY STUDY;AUTOLOGOUS SERUM;BFRF GENE;BIO-PATHOLOGICAL FACTORS;BLADDER CARCINOMA;BLOOD MONONUCLEAR;BLOOD PRESSURE;BONE METASTASES;BONE SEEKING;CANCER CLINICAL;CATHELICIDIN ANTIMICROBIAL","3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PUBMED SCOPUS;CROSSREF PUBMED;PUBMED GOOGLE;LIPID RES;PROTEIN KINASE;DE NOVO;RES -ABSTRACT;SERINE PALMITOYLTRANSFERASE;BIOL CHEM;CHEM -CROSSREF;HUMAN KERATINOCYTES;ULTRAVIOLET B-INDUCED;CERAMIDE SYNTHASE;CULTURED HUMAN;ELIAS PM;B-INDUCED APOPTOSIS;CERAMIDE SYNTHESIS;INVEST DERMATOL;NORMAL HUMAN;UVB IRRADIATION;CULTURED NORMAL;HOLLERAN WM;CUSP STRUCTURES;DERMATOL -CROSSREF;HUMAN KERATINOCYTE;HUMAN KERATINOCYTESJ;NOVO CERAMIDE;APOPTOTIC CELLS;CELL CYCLE;CYCLE ARREST","44;39;17;12;12;11;11;11;10;10;10;10;9;9;9;8;8;8;8;8;7;7;6;6;6;6;6;5;5;5",1,0.02,0.25,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,12,12,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,8,8.16,3,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ACCARDI, LUISA;BITTI, ORSOLA;DI BONITO, PAOLA;DIBELLO, FRANCESCO;FRANCONI, ROSELLA;GIORGI, COLOMBA;MARCANTE, MARIA-LUISA;VENUTI, ALDO","1;1;1;1;1;1;1;1","AGENZIA NAZIONALE PER LE NUOVE TECNOLOGIE LENERGIA E LO SVILUPPO ECONOMICO SOSTENIBILE ENEA;ISTITUTI FISIOTERAPICI OSPITALIERI IFO;ISTITUTO SUPERIORE DI SANITA ISS","1;1;1",NA,NA,NA,NA,NA,NA,"A61K36/81;A61K39/39;A61P31/00;C07K14/025;C12N15/82","1;1;1;1;1",NA,NA,5,6.8,556,8.47,1,0.2,26,0,0,0,1,3,0,0,1,0,5,0,0,0,0,0,0,0,3,2,0,4,0,0,1,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES","5;4;3","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BREAST CANCER;ORPHAN DRUG;RARE DISEASES;LUNG;PREVENTION;AGING;COLO-RECTAL CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;CONTRACEPTION/REPRODUCTION;DIGESTIVE DISEASES;ESTROGEN;LUNG CANCER;OVARIAN CANCER","4;4;4;3;3;3;2;2;1;1;1;1;1;1;1;1","CANCER","4","6.1 PHARMACEUTICALS","4","LUNG CANCER;OVARIAN CANCER;BREAST CANCER;COLON AND RECTAL CANCER;STOMACH CANCER","2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;2",1,105000,105000,4,1,1,0,6,450898.476851852,0.0953651480488992,"ISTITUTI FISIOTERAPICI OSPITALIERI","1","TELETHON FOUNDATION","1",NA,NA,"TELETHON GRANT PROJECTS - 2003 (PROGRAM)","1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY","1;1","GENETICS;RARE DISEASES","1;1",NA,NA,"2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IFO",2004,46,9.04347826086956,2,0.347826086956522,0.239130434782609,0.391304347826087,1.34848484848485,1.06666666666667,1.1,1.05882352941176,0.195652173913043,1,19,15,4,6,0.41,0.33,0.09,0.13,39.07,0.830227794554124,NA,0.217391304347826,0.847826086956522,0.37,0.334,0.37,0.321,"ANTONIO CRISTAUDO;MAURO PICARDO;FRANCESCO PETRUCCI;CATERINA CATRICALÀ;MASSIMILIANO SCALVENZI;VINCENZO DE GIORGI;GIOVANNI LO SCOCCO;E. TERZOLI;ROBERTO BETTI;GIORGIA CARDINALI;EMANUELA CAMERA;ANDREA MAURICHI;UGO BOTTONI;SERGIO CAROLI;FRANCESCO SERA;PIERFRANCO SOMA;IGNAZIO STANGANELLI;D. DIOGUARDI;DOMENICO PALLI;PAOLO CARLI","6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","A. DI CARLO;ANTONIO CRISTAUDO;MAURO PICARDO;FRANCESCO PETRUCCI;EMANUELA CAMERA;SERGIO CAROLI;E. TERZOLI;SALVATORE FANALI;MARIA ROSARIA TORRISI;FRANCESCA BELLEUDI;GIORGIA CARDINALI;GABRIELLA ZUPI;VINCENZO SEVERINO;MARIAGRAZIA DE ROCCO;ALESSANDRA LATINI;ENZO BERARDESCA;F. VAILATI;CLAUDIA RONA;M. CARDUCCI;FRANCESCO SERA","1;0.93;0.71;0.6;0.52;0.46;0.41;0.4;0.36;0.36;0.35;0.35;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33","ANTONIO CRISTAUDO;MAURO PICARDO;CATERINA CATRICALÀ;E. TERZOLI;GIORGIA CARDINALI;EMANUELA CAMERA;MARIA ROSARIA TORRISI;VINCENZO SEVERINO;ANNA MARIA CIANCIULLI;MARIA CONCETTA PETTI;MICHÈLE MILELLA;MARIAGRAZIA DE ROCCO;ALESSANDRA LATINI;B. CAPITANIO;R MARZANO;ROBERTA MEROLA;FRANCESCO PISANI;MASSIMO GIULIANI;A. AMANTEA;FIORELLA GUADAGNI","6;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","A. DI CARLO;ANTONIO CRISTAUDO;MAURO PICARDO;EMANUELA CAMERA;E. TERZOLI;MARIA ROSARIA TORRISI;GIORGIA CARDINALI;VINCENZO SEVERINO;MARIAGRAZIA DE ROCCO;ALESSANDRA LATINI;ENZO BERARDESCA;M. CARDUCCI;B. CAPITANIO;A. BAGARONE;G. BIOLCATI;G BERLUTTI;GIOVANNI CASELLI;CATERINA CATRICALÀ;A. AMANTEA;R MARZANO","1;0.93;0.71;0.52;0.41;0.36;0.35;0.33;0.33;0.33;0.33;0.33;0.31;0.25;0.25;0.25;0.25;0.25;0.24;0.23","MAURO PICARDO;FRANCESCO SERA;ANTONIO CRISTAUDO;MASSIMILIANO SCALVENZI;PIER GIORGIO NATALI;CATERINA CATRICALÀ;ALESSANDRO CHIOMINTO;ANGELA FERRARI;ANTONINO CARBONE;GAETANO DE ROSA;GERARDO FERRARA;GIUSEPPE ARGENZIANO;H. PETER SOYER;IRIS ZALAUDEK;JOSEP MALVEHY;KETTY PERIS;LORENZA CICALE;LORENZO CERRONI;MARIA ANTONIETTA PIZZICHETTA;R HOFMANN‐WELLENHOF","363;354;277;251;190;166;148;148;148;148;148;148;148;148;148;148;148;148;148;148","MAURO PICARDO;ANTONIO CRISTAUDO;CATERINA CATRICALÀ;ANGELA FERRARI;MARIAGRAZIA DE ROCCO;EUGENIO LELLA;VINCENZO SEVERINO;ANNA BAGNATO;B. CAPITANIO;GIOVANNI LEONE;PAOLO IACOVELLI;GIORGIA CARDINALI;MARIA CONCETTA PETTI;FRANCESCO PISANI;DANIELA KOVACS;EMANUELA CAMERA;ENZO BERARDESCA;PAOLA CORDIALI‐FEI;MARIA ROSARIA TORRISI;A. AMANTEA","363;277;166;148;142;131;131;127;125;125;125;121;109;107;95;81;81;75;66;63","ANTONIO CRISTAUDO;MAURO PICARDO;CATERINA CATRICALÀ;EMANUELA CAMERA;GIORGIA CARDINALI;DANIELA KOVACS;E. TERZOLI;MARIA CONCETTA PETTI;MARIA ROSARIA TORRISI;MARIAGRAZIA DE ROCCO;MASSIMO GIULIANI;VINCENZO SEVERINO;A. AMANTEA;A. BAGARONE;A. DI CARLO;ALBERTO ROMANO;ALBINARITA ZAPPAL�;ALESSANDRA LATINI;AM CIANCIULLI;ANDREA MENGARELLI","6;5;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;MATERIALS SCIENCE;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;ENGINEERING;ENVIRONMENTAL SCIENCE;GEOLOGY;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY","32;20;16;2;2;2;1;1;1;1;1;1;1","BIOCHEMISTRY;INTERNAL MEDICINE;IMMUNOLOGY;DERMATOLOGY;PATHOLOGY;CANCER RESEARCH;GENETICS;CHROMATOGRAPHY;GASTROENTEROLOGY;ORGANIC CHEMISTRY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;SURGERY;VIROLOGY;RADIOLOGY;ENVIRONMENTAL CHEMISTRY;PHARMACOLOGY;ANIMAL SCIENCE;BIOPHYSICS;FOOD SCIENCE;ONCOLOGY;OPTICS","16;15;14;11;11;10;9;6;6;6;5;5;5;5;5;4;3;3;2;2;2;2;2","GENE;CANCER;ANTIBODY;MELANOMA;APOPTOSIS;POPULATION;RECEPTOR;CATALYSIS;MASS SPECTROMETRY;URINE;ALLERGY;BIOMONITORING;CELL;DETECTION LIMIT;HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY;SIGNAL TRANSDUCTION;TOXICITY;VIRUS;ANALYTICAL CHEMISTRY (JOURNAL);ANTIGEN;BONE MARROW;CELL CULTURE;CHEMOTHERAPY;CONFIDENCE INTERVAL;DISEASE;HEPATITIS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNOHISTOCHEMISTRY;IMMUNOPATHOLOGY;IN VITRO;LESION;PARTICULATES;REPEATABILITY;TRANSPLANTATION","12;8;6;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PLATINUM;ALLERGIC CONTACT DERMATITIS;AUTOANTIBODY;CHROMOSOME;COLORECTAL CANCER;CONTACT DERMATITIS;AUTOIMMUNE DISEASE;BULLOUS PEMPHIGOID;CELL CYCLE;ELECTROSPRAY;ELECTROSPRAY IONIZATION;FLUOROURACIL;GROWTH FACTOR;INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY;LIQUID CHROMATOGRAPHY–MASS SPECTROMETRY;MYELODYSPLASTIC SYNDROMES;NODULAR MELANOMA;PATCH TEST;RECOMBINANT DNA;TYROSINE KINASE;VIRAL DISEASE","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PLATINUM GROUP;FLUORESCENCE IN SITU HYBRIDIZATION;PEMPHIGOID;ABL;ANDROGEN DEFICIENCY;ANEUPLOIDY;ANTI-NUCLEAR ANTIBODY;ANTIRETROVIRAL THERAPY;AUTOIMMUNE THYROIDITIS;AUTOPHOSPHORYLATION;CHROMOSOME 17 (HUMAN);CHROMOSOME INSTABILITY;COMET ASSAY;CONTACT URTICARIA;DESMOGLEIN;DESMOGLEIN 1;DESMOGLEIN 3;ENDOCYTIC CYCLE;EPITOPE MAPPING;FOLINIC ACID;GIANT CELL ARTERITIS;GROWTH FACTOR RECEPTOR INHIBITOR;HEPACIVIRUS;HERPESVIRIDAE;KARYOTYPE;KERATINOCYTE GROWTH FACTOR;LENTIVIRUS;MELANOCYTIC NEVUS;ORTHOTOPIC LIVER TRANSPLANTATION;PARANEOPLASTIC PEMPHIGUS;PEMPHIGUS FOLIACEUS;PHILADELPHIA CHROMOSOME;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;SH2 DOMAIN;SHIGELLA;SIDA;SINGLE-CHAIN VARIABLE FRAGMENT;SISTER CHROMATIDS;TERBINAFINE;TRANSLATION (BIOLOGY);TRASTUZUMAB;UBIQUITIN LIGASE","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MALE;MELANOMA;MIDDLE AGED;SKIN NEOPLASMS;AGED;COLORECTAL NEOPLASMS;RNA, MESSENGER;APOPTOSIS;;KERATINOCYTES;RECEPTORS, FIBROBLAST GROWTH FACTOR;THYROIDITIS;TIME FACTORS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;CELL LINE, TUMOR;FLUOROURACIL","36;24;21;20;20;14;12;9;9;9;8;7;7;7;7;7;6;6;6;6","MELANOMA;OCCUPATIONAL ASTHMA AND HEALTH IMPACTS IN WORK ENVIRONMENTS;FIBROBLAST GROWTH FACTOR SIGNALING PATHWAY;INTEGRIN SIGNALING IN INFLAMMATION AND CANCER;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;PATHOGENESIS AND TREATMENT OF PEMPHIGOID DISEASES;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CHIRAL SEPARATION IN CHROMATOGRAPHY;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;DIAGNOSIS AND MANAGEMENT OF APPENDICITIS;DIAGNOSIS AND MANAGEMENT OF URTICARIA;EFFICACY AND RESISTANCE IN CML TREATMENT;ENDOPLASMIC RETICULUM STRESS AND UNFOLDED PROTEIN RESPONSE;HEALTH EFFECTS OF AIR POLLUTION;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;HYPERSENSITIVITY REACTIONS TO DRUGS AND MEDICATIONS","4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MELANOMA;PLATINUM GROUP;WORK-RELATED EXPOSURE;BULLOUS PEMPHIGOID;FIBROBLAST GROWTH FACTOR;HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC);HIV INFECTION;NODULAR MELANOMA;PATCH TEST;REPEATABILITY;SKIN SENSITIZATION;T CELL ACTIVATION;TUMOR STAGING;ABL;ADAPTIVE IMMUNITY REGULATION;ADVERSE DRUG REACTION;AGING;ALLERGEN EXPOSURE;ALLERGIC CONTACT DERMATITIS;ANDROGEN DEFICIENCY","5;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","COLORECTAL CANCER;FACTOR RECEPTOR;GROWTH FACTOR;ACTIVE ANTIRETROVIRAL;ANTIRETROVIRAL THERAPY;AUTOIMMUNE DISEASES;HIGHLY ACTIVE;KERATINOCYTE GROWTH;MASS SPECTROMETRY;MYELODYSPLASTIC SYNDROME;NODULAR-TYPE MELANOMA;OCCUPATIONAL HYPERSENSITIVITY;PLATINUM-GROUP ELEMENTS;SUPERFICIAL SPREADING;ACID FA;ADVANCED COLORECTAL;ADVANCED PANCREATIC;ALKYLATING AGENTS;ANALYTICAL METHOD;ANTI-BP IGG;ANTIGEN-BASED ASSAYS;ANTISENSE OLIGONUCLEOTIDES;APOPTOSIS INDUCTION;APOPTOSIS SUSCEPTIBILITY;APPENDICEAL LITHIASIS;AUTHOR REPLY;AUTOANTIBODY PROFILE;BCL- EXPRESSION;BCL-BCL-XL BISPECIFIC;BGENEAMPLIFIED BREAST","3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BULLOUS PEMPHIGOID;DISEASE PROGRESSION;GSH CONTENT;HAART ERA;AIRBORNE PARTICULATE;ALKYLATING AGENTS;ANTISENSE TRANSFECTANTS;APOPTOSIS INDUCED;C-MYC ANTISENSE;C-MYC LOW-EXPRESSING;CONFIDENCE INTERVAL;CUTANEOUS MELANOMA;ET- LEADS;ETBR PATHWAY;HCV INFECTION;HIV DISEASE;IV INFUSION;MELANOMA CELLS;MEMBRANE PEMPHIGOID;MICE INFECTED;MUCOUS MEMBRANE;ORAL CELECOXIB;PARTICULATE MATTER;PERSON-TIME SPENT;PRE-HAART ERA;PRO-INFLAMMATORY CYTOKINES;RESULTS DEMONSTRATE;SIGNALING PATHWAYS;SIGNIFICANT DIFFERENCE;THERAPEUTIC TARGET","4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",2,0.04,5.25,2.5,0,0,0,0,1,0,0,2.5,0,0,0,0,2,0,0,0,0,0,0,19,19,1,1,1,0,0,0,0,0,0,0,0,0,2,0,0,1,8,17.98,3,0,2,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ACCARDI LUISA;BITTI ORSOLA;DI BONITO PAOLA;DIBELLO FRANCESCO;FRANCONI ROSELLA;GIORGI COLOMBA;VENUTI ALDO;MARCANTE MARIA LUISA;MARCANTE MARIA-LUISA","2;2;2;2;2;2;2;1;1","AGENZIA NAZIONALE PER LE NUOVE TECNOLOGIE LENERGIA E LO SVILUPPO ECONOMICO SOSTENIBILE ENEA;ISTITUTI FISIOTERAPICI OSPITALIERI IFO;ISTITUTO SUPERIORE DI SANITA ISS","2;2;2","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3108 PLANT BIOLOGY","4;1;1","IMMUNIZATION;VACCINE RELATED;COMPLEMENTARY AND INTEGRATIVE HEALTH","2;2;1",NA,NA,"A61K36/81;A61K39/12;A61K39/39;A61P31/00;C07K14/025;C12N15/82;A01H5/00;A61K35/78","2;2;2;2;2;2;1;1","A61K39/39;A61P31/00;C07K14/005;C12N15/8258;C12N2710/20022","2;2;2;2;2",6,6,253,9.84,1,0.17,20.33,1,0,4,1,0,0,0,0,0,3,0,0,0,0,0,0,0,5,1,0,3,3,0,0,0,0,0,0,0,0,"Italy;Belgium","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","6;5;1;1;1;1;1;1","CANCER;CHILDHOOD LEUKEMIA;HEMATOLOGY;PEDIATRIC;PEDIATRIC CANCER;RARE DISEASES;BIOTECHNOLOGY;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;IMMUNIZATION;ORPHAN DRUG;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;TRANSPLANTATION;VACCINE RELATED","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;NEUROLOGICAL","5;1","6.1 PHARMACEUTICALS;3.4 VACCINES;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","2;1;1;1","LEUKEMIA / LEUKAEMIA;BRAIN TUMOR;BREAST CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","2;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","4;2;2;1",3,5070947,685665.61,6,12.3333333333333,7,0.666666666666667,20,439943.557359307,0.104558867224032,"ISTITUTI FISIOTERAPICI OSPITALIERI;DANISH CANCER SOCIETY;HEINRICH-PETTE-INSTITUTE;KAROLINSKA INSTITUTET;WEIZMANN INSTITUTE OF SCIENCE;ANTONI VAN LEEUWENHOEK HOSPITAL;ASPER BIOTECH (ESTONIA);ASTELLAS PHARMA (GERMANY);CONSORZIO INTERUNIVERSITARIO PER LE BIOTECNOLOGIE;DÉLÉGATION PARIS 11;FONDAZIONE ANDREA CESALPINO;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;HEBREW UNIVERSITY OF JERUSALEM;INNOVA (ITALY);INSTITUT BERGONIÉ;INSTITUTE OF BIOPHYSICS;INTERNATIONAL AGENCY FOR RESEARCH ON CANCER;JOHANNES GUTENBERG UNIVERSITY OF MAINZ;LEIDEN UNIVERSITY MEDICAL CENTER;MEDICAL RESEARCH COUNCIL","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;NATIONAL CANCER INSTITUTE","2;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;NIH - NATIONAL INSTITUTES OF HEALTH;US FEDERAL FUNDERS","2;2;1;1;1","FP6-2002-LIFESCIHEALTH (CALL FOR PROPOSAL);FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);IP - INTEGRATED PROJECT (FUNDING SCHEME);NON-SBIR/STTR (FUNDING MECHANISM)","2;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","3;3;2;1;1;1","CANCER;BREAST CANCER;CLINICAL RESEARCH;GENETICS;AGING;BIOTECHNOLOGY;CONTRACEPTION/REPRODUCTION;ESTROGEN;PREVENTION","3;2;2;2;1;1;1;1;1","CANCER","3","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","2;2;1","BREAST CANCER;NOT SITE-SPECIFIC CANCER","2;2","1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER","2;1","A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IFO",2005,52,8.03846153846154,2.59615384615385,0.365384615384615,0.346153846153846,0.346153846153846,1.97058823529412,1.11764705882353,1.63636363636364,1.2,0.403846153846154,1,22,16,3,6,0.42,0.31,0.06,0.12,46.77,0.883376218010798,NA,0.384615384615385,0.846153846153846,0.421,0.343,0.476,0.44,"MAURO PICARDO;MARIA ROSARIA TORRISI;GIORGIA CARDINALI;ELISABETTA TRENTO;VALENTINA BORDIGNON;STEFANIA BRIGANTI;VITTORIA MARESCA;ENRICA FLORI;ANTONIO CRISTAUDO;GIOVANNA D’AGOSTO;ALESSANDRA LATINI;ENZO BERARDESCA;PAOLA CORDIALI FEI;SALVATORE RAFFA;A. AMANTEA;A. MUSSI;DANIELA KOVACS;LUIGI FRATI;M. CARDUCCI;MARCO CIOTTI","12;7;6;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2","MAURO PICARDO;ENZO BERARDESCA;MARIALUISA APPETECCHIA;GRAZIA PRIMAVERA;MARIA ROSARIA TORRISI;GIOVANNI LEONE;GIORGIA CARDINALI;ELISABETTA TRENTO;ALESSIA PACIFICO;STEFANIA BRIGANTI;VALENTINA BORDIGNON;ALDO MORRONE;MARTA MASCHIO;B. JANDOLO;ALESSANDRA LATINI;M. CARDUCCI;VITTORIA MARESCA;ENRICA FLORI;RICHARD L. GALLO;ANNA DI NARDO","1.68;1.12;1;1;0.77;0.75;0.72;0.71;0.67;0.58;0.54;0.53;0.5;0.5;0.49;0.48;0.43;0.43;0.42;0.42","MAURO PICARDO;MARIA ROSARIA TORRISI;GIORGIA CARDINALI;ELISABETTA TRENTO;VALENTINA BORDIGNON;STEFANIA BRIGANTI;VITTORIA MARESCA;ENRICA FLORI;ANTONIO CRISTAUDO;GIOVANNA D’AGOSTO;ALESSANDRA LATINI;ENZO BERARDESCA;PAOLA CORDIALI FEI;A. AMANTEA;A. MUSSI;DANIELA KOVACS;M. CARDUCCI;ALDO MORRONE;FRANCESCA STIVALI;E. TERZOLI","12;7;6;6;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2","MAURO PICARDO;ENZO BERARDESCA;MARIALUISA APPETECCHIA;GRAZIA PRIMAVERA;MARIA ROSARIA TORRISI;GIOVANNI LEONE;GIORGIA CARDINALI;ELISABETTA TRENTO;ALESSIA PACIFICO;STEFANIA BRIGANTI;VALENTINA BORDIGNON;ALDO MORRONE;MARTA MASCHIO;ALESSANDRA LATINI;M. CARDUCCI;VITTORIA MARESCA;ENRICA FLORI;ANNA DI NARDO;ANTONIO CRISTAUDO;A. AMANTEA","1.68;1.12;1;1;0.77;0.75;0.72;0.71;0.67;0.58;0.54;0.53;0.5;0.49;0.48;0.43;0.43;0.42;0.4;0.35","MARIA ROSARIA TORRISI;ANNA DI NARDO;MARISSA H. BRAFF;RICHARD L. GALLO;MAURO PICARDO;GIORGIA CARDINALI;ELISABETTA TRENTO;VALENTINA BORDIGNON;BELÉN LÓPEZ‐GARCÍA;CATHY WONG;DONALD Y.M. LEUNG;JOANNE E. STREIB;KENNETH H. LIN;MICHAEL HOWELL;MI‘I A. HAWKINS;ROBERT A. DORSCHNER;GIOVANNA D’AGOSTO;SALVATORE RAFFA;LUIGI FRATI;ALBERTO FAGGIONI","554;473;473;473;444;365;341;297;272;272;272;272;272;272;272;272;254;253;245;212","ANNA DI NARDO;MAURO PICARDO;MARIA ROSARIA TORRISI;GIORGIA CARDINALI;ELISABETTA TRENTO;VALENTINA BORDIGNON;GIOVANNA D’AGOSTO;ENRICA FLORI;VITTORIA MARESCA;DANIELA KOVACS;ENZO BERARDESCA;PAOLA CORDIALI FEI;A. MUSSI;STEFANIA BRIGANTI;PAOLA CORDIALI‐FEI;M. CARDUCCI;NICAELA ASPITE;A. AMANTEA;FABRIZIO ENSOLI;E. TERZOLI","473;444;422;365;317;273;254;195;195;177;168;155;142;136;123;121;120;118;108;98","MAURO PICARDO;GIORGIA CARDINALI;MARIA ROSARIA TORRISI;ELISABETTA TRENTO;ENRICA FLORI;STEFANIA BRIGANTI;VALENTINA BORDIGNON;VITTORIA MARESCA;A. AMANTEA;A. MUSSI;ANTONIO CRISTAUDO;DANIELA KOVACS;ENZO BERARDESCA;GIOVANNA D’AGOSTO;M. CARDUCCI;ALDO MORRONE;ALESSANDRA LATINI;ALESSIA PACIFICO;ANNA DI NARDO;CHIARA PANETTA","12;6;6;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;MATERIALS SCIENCE;PHILOSOPHY;PHYSICS;SOCIOLOGY;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY;PSYCHOLOGY","40;24;17;3;3;2;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;BIOCHEMISTRY;DERMATOLOGY;IMMUNOLOGY;CELL BIOLOGY;GENETICS;CANCER RESEARCH;PATHOLOGY;SURGERY;ENDOCRINOLOGY;GASTROENTEROLOGY;VIROLOGY;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;ONCOLOGY;ANATOMY;FOOD SCIENCE;METALLURGY;NURSING;PALEONTOLOGY;RADIOLOGY","20;18;17;15;10;10;9;9;6;5;5;5;4;4;4;3;3;3;3;3;3","CANCER;GENE;CELL CULTURE;PSORIASIS;RECEPTOR;CYTOKINE;MELANIN;VIRUS;DISEASE;ENZYME;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;IN VITRO;MELANOMA;TUMOR NECROSIS FACTOR ALPHA;ACETIC ACID;ADVERSE EFFECT;ALLERGY;ANTIBODY;ANTIMICROBIAL;COHORT;DNA;EPIDERMIS (ZOOLOGY);FATTY ACID;FERRITIN;INCIDENCE (GEOMETRY);MULTIVARIATE ANALYSIS;OXIDATIVE STRESS;PHOTOTYPE;POPULATION;QUALITY OF LIFE (HEALTHCARE);REACTIVE OXYGEN SPECIES;SIGNAL TRANSDUCTION;STAGE (STRATIGRAPHY);THROMBOSIS","9;9;6;6;6;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","KERATINOCYTE;GROWTH FACTOR;ALLERGIC CONTACT DERMATITIS;ANTIMICROBIAL PEPTIDES;BREAST CANCER;CERVICAL CANCER;CONTACT DERMATITIS;EPSTEIN–BARR VIRUS;FIBROBLAST GROWTH FACTOR;GENE EXPRESSION;HERPES SIMPLEX VIRUS;INFLIXIMAB;LYTIC CYCLE;MUTANT;PATCH TEST;PROSTATE CANCER;SUPEROXIDE DISMUTASE;SURVIVIN;SYPHILIS;TOLERABILITY;TRANSFECTION;VENOUS THROMBOSIS;VIRAL REPLICATION","4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","KERATINOCYTE GROWTH FACTOR;CATHELICIDIN;CERVICAL INTRAEPITHELIAL NEOPLASIA;ACUTE PROMYELOCYTIC LEUKEMIA;BASIC FIBROBLAST GROWTH FACTOR;BETA DEFENSIN;CREB;ENDOCYTIC CYCLE;EPIRUBICIN;FGF10;FIBROBLAST GROWTH FACTOR RECEPTOR 3;FLUORESCENCE IN SITU HYBRIDIZATION;HPV INFECTION;INDOLE-3-ACETIC ACID;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INTRAEPITHELIAL NEOPLASIA;IRRITANT CONTACT DERMATITIS;LENTIVIRUS;LYMPHOPROLIFERATIVE RESPONSE;MEN WHO HAVE SEX WITH MEN;METHYLENETETRAHYDROFOLATE REDUCTASE;MUTATION TESTING;NICKEL ALLERGY;NUCLEOPLASM;OSTEOCALCIN;PAPILLOMAVIRIDAE;PROMOTER;PROSTAGLANDIN E2 RECEPTOR;RNA INTERFERENCE;SECONDARY SYPHILIS;SEXUALLY TRANSMITTED DISEASE;SIDA;SUPERANTIGEN;TELOMERASE REVERSE TRANSCRIPTASE;UROCANIC ACID;VINORELBINE;XERODERMA PIGMENTOSUM","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;SKIN;PSORIASIS;KERATINOCYTES;MELANOCYTES;AGED;CYTOKINES;;APOPTOSIS;SUPEROXIDE DISMUTASE;VIRAL PROTEINS;CATALASE;DNA, VIRAL;FERRITINS;MEMBRANE PROTEINS;PAPILLOMAVIRIDAE","41;23;19;18;17;15;14;13;12;10;10;9;9;9;8;7;7;7;7;7","VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;FIBROBLAST GROWTH FACTOR SIGNALING PATHWAY;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;ATOPIC DERMATITIS AND SKIN MICROBIOME;INNOVATIONS IN TRANSDERMAL DRUG DELIVERY SYSTEMS;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;MELANIN PIGMENTATION IN MAMMALIAN SKIN;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;SKIN SENSITIZATION AND CONTACT ALLERGY RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BIOLOGICAL ACTIVITIES OF TRITERPENOIDS AND SAPONINS;BIOLOGICAL BASIS AND CLINICAL MANAGEMENT OF SYPHILIS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CANCER OF UNKNOWN PRIMARY SITE;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;EMERGING ZOONOTIC DISEASES AND ONE HEALTH APPROACH","4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","KERATINOCYTE GROWTH FACTOR;PSORIASIS;SKIN SENSITIZATION;ANTIMICROBIAL PEPTIDES;CATHELICIDIN;CONTACT ALLERGY;EPIDERMIS (ZOOLOGY);FIBROBLAST GROWTH FACTOR;HIV;HPV VACCINATION;HUMAN HERPESVIRUS 8;LYTIC CYCLE;MELANIN;PATCH TEST;PHOTOTYPE;SKIN MICROBIOME;SKIN PERMEATION ENHANCEMENT;SURVIVIN;TOLERABILITY;UV RADIATION","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GROWTH FACTOR;HUMAN PAPILLOMAVIRUS;KERATINOCYTE GROWTH;BREAST CANCER;CERVICAL CANCER;CERVICAL INTRAEPITHELIAL;EPSTEIN-BARR VIRUS;HIGH-RISK HUMAN;INTRAEPITHELIAL NEOPLASIA;VIRUS CLEARANCE;ACID -S-HYDROXY-ZE-OCTADECADIENOIC;ACID FORMATION;ACIDS PARTIALLY;ACQUIRED RISK;ACUTE PROMYELOCYTIC;ADDITIONAL MARKERS;ADVANCED BREAST;ALCOHOL CONSUMPTION;AMP RESPONSE;ANEMIC PATIENTS;ANGIOGENIC FACTORS;ANTIGEN SPECIFIC;ANTIMICROBIAL PEPTIDE;ANTIMICROBIAL PROPERTIES;ANTITAT ANTIBODIES;APL RECEIVING;APOPTOSIS INDUCED;ASBESTOS CROCIDOLITE;ATOPIC DERMATITIS;ATPC GENE","4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PUBMED SCOPUS;CROSSREF PUBMED;MELANOSOME TRANSFER;GROWTH FACTOR;DERMATOL -CROSSREF;INVEST DERMATOL;KERATINOCYTE GROWTH;ATPC GENE;HAILEYHAILEY DISEASE;RES -CROSSREF;CELL RES;LATEX BEADS;KGF TREATMENT;HUMAN KERATINOCYTES;LOW PHOTOTYPE;NUCLEAR MEMBRANE;PUBMED GOOGLE;RECONSTRUCTED EPIDERMIS;GENET -CROSSREF;HUMAN SKIN;PHAGOCYTIC PROCESS;POLYUNSATURATED FATTY;SINGLET OXYGEN;SURVIVIN EXPRESSION;ULTRAVIOLET RADIATION;UVA IRRADIATION;ALHAILEYHAILEY DISEASE;ANALYSIS REVEALED;ATPC ENCODING;CELL SCI","67;65;28;25;24;18;15;14;14;10;9;9;8;7;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5",6,0.12,3,2,1,0,0,0,3,0,0,4.25,0,0,1,0,0,1,0,1,0,0,0,23.75,23.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,7,426.33,8.06,2,0.4,35.6,0,0,2,0,2,0,1,0,0,3,0,0,0,0,0,0,0,5,0,0,3,2,0,0,0,0,0,0,0,0,"Belgium;Canada;Italy;United Kingdom","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","5;3;3;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;AUTOIMMUNE DISEASE;BRAIN CANCER;BRAIN DISORDERS;CANCER;HEMATOLOGY;ORPHAN DRUG;PATIENT SAFETY;PSORIASIS;RARE DISEASES","3;2;1;1;1;1;1;1;1;1;1","CANCER;SKIN","3;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","4;1;1","BRAIN TUMOR;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER","1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IFO",2006,50,7.84,2.72,0.5,0.44,0.5,1.55172413793103,1,1.57142857142857,1,0.22,0,13,13,7,14,0.26,0.26,0.14,0.28,36.84,0.721246927674435,NA,0.42,0.74,0.462,0.348,0.432,0.34,"MAURO PICARDO;ENZO BERARDESCA;CARLO COTA;MANUELA CARRERA;F. M. SOLIVETTI;LUCA MUSCARDIN;LUCIANO MARIANI;MARCO CIOTTI;MARIALUISA APPETECCHIA;LUISA ACCARDI;MARCELLA MOTTOLESE;GRAZIA PRIMAVERA;PAOLA DI BONITO;PAOLA CORDIALI‐FEI;KARÍ SYRJÄNEN;PATRIZIO GIACOMINI;A. AMANTEA;MARIA BENEVOLO;DANIELA KOVACS;COLOMBA GIORGI","9;8;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","ENZO BERARDESCA;MAURO PICARDO;MANUELA CARRERA;F. M. SOLIVETTI;CARLO COTA;MARIALUISA APPETECCHIA;LUCA MUSCARDIN;G. BIOLCATI;GRAZIA PRIMAVERA;A. AMANTEA;EMANUELA CAMERA;NORMA CAMELI;CARLA DOLAZZA;MARCO ARDIGÒ;DANIELA KOVACS;ALDO MORRONE;GENNARO FRANCO;ALESSIA PACIFICO;ANTONIO MAINI;PIER ANTONIO BACCI","1.96;1.75;1.33;1.12;1;0.81;0.77;0.67;0.67;0.52;0.5;0.5;0.5;0.42;0.42;0.4;0.4;0.37;0.37;0.33","MAURO PICARDO;ENZO BERARDESCA;CARLO COTA;MANUELA CARRERA;F. M. SOLIVETTI;LUCA MUSCARDIN;LUCIANO MARIANI;MARCO CIOTTI;MARIALUISA APPETECCHIA;LUISA ACCARDI;MARCELLA MOTTOLESE;GRAZIA PRIMAVERA;PAOLA DI BONITO;PAOLA CORDIALI‐FEI;KARÍ SYRJÄNEN;A. AMANTEA;MARIA BENEVOLO;DANIELA KOVACS;COLOMBA GIORGI;PAOLO IACOVELLI","9;8;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2","ENZO BERARDESCA;MAURO PICARDO;MANUELA CARRERA;F. M. SOLIVETTI;CARLO COTA;MARIALUISA APPETECCHIA;LUCA MUSCARDIN;G. BIOLCATI;GRAZIA PRIMAVERA;A. AMANTEA;EMANUELA CAMERA;NORMA CAMELI;CARLA DOLAZZA;MARCO ARDIGÒ;DANIELA KOVACS;ALDO MORRONE;GENNARO FRANCO;ALESSIA PACIFICO;ANTONIO MAINI;LUCIANO MARIANI","1.96;1.75;1.33;1.12;1;0.81;0.77;0.67;0.67;0.52;0.5;0.5;0.5;0.42;0.42;0.4;0.4;0.37;0.37;0.3","MAURO PICARDO;ENZO BERARDESCA;AMINA VOCATURO;MARCELLA MOTTOLESE;MARIA BENEVOLO;LUCIANO MARIANI;MANUELA CARRERA;F. M. SOLIVETTI;FRANCESCO COGNETTI;GIULIA MARIA PIPERNO;ISABELLA SPERDUTI;R. PERRONE DONNORSO;PAOLA CORDIALI‐FEI;FERDINANDO MARANDINO;ARIANNA MASTROFRANCESCO;CHRISTOS C. ZOUBOULIS;ENRICA FLORI;MONICA OTTAVIANI;THEODOSIS ALESTAS;PAOLA CANALINI","439;348;282;205;205;201;189;183;176;166;166;166;165;159;153;153;153;153;153;141","MAURO PICARDO;ENZO BERARDESCA;MANUELA CARRERA;PAOLA CORDIALI‐FEI;ARIANNA MASTROFRANCESCO;ENRICA FLORI;MONICA OTTAVIANI;F. M. SOLIVETTI;GRAZIA PRIMAVERA;FRANCESCO COGNETTI;PAOLA PAPALDO;CARLO COTA;ALESSIA PACIFICO;VALENTINA BORDIGNON;NORMA CAMELI;GIOVANNI LEONE;ANDREA PARO VIDOLIN;PAOLO IACOVELLI;A. DI CARLO;DANIELA KOVACS","439;348;189;165;153;153;153;147;139;135;135;125;112;91;81;76;72;72;70;66","MAURO PICARDO;ENZO BERARDESCA;CARLO COTA;MANUELA CARRERA;LUCA MUSCARDIN;F. M. SOLIVETTI;LUCIANO MARIANI;A. AMANTEA;DANIELA KOVACS;GRAZIA PRIMAVERA;PAOLA CORDIALI‐FEI;A. DI CARLO;ALESSIA PACIFICO;CATERINA CATRICALÀ;G. BIOLCATI;GIOVANNI LEONE;GIUSTINO MARIANI;MARCO ARDIGÒ;NORMA CAMELI;VALENTINA BORDIGNON","9;8;5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;GEOLOGY;PSYCHOLOGY;ECONOMICS;MATERIALS SCIENCE","46;22;7;4;2;2;1;1","INTERNAL MEDICINE;PATHOLOGY;DERMATOLOGY;GENETICS;BIOCHEMISTRY;CANCER RESEARCH;IMMUNOLOGY;RADIOLOGY;SURGERY;ONCOLOGY;CELL BIOLOGY;MOLECULAR BIOLOGY;PHARMACOLOGY;VIROLOGY;GASTROENTEROLOGY;PALEONTOLOGY;DEVELOPMENTAL PSYCHOLOGY;OPTICS;PSYCHIATRY;ACOUSTICS;ANATOMY;BIOTECHNOLOGY;CLINICAL PSYCHOLOGY;COMPUTATIONAL BIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;FOOD SCIENCE;GYNECOLOGY;INTENSIVE CARE MEDICINE;MACROECONOMICS;MEDICINAL CHEMISTRY;METALLURGY;NURSING;OBSTETRICS;OCEANOGRAPHY;ORGANIC CHEMISTRY;PHYSICAL THERAPY;STEREOCHEMISTRY;THERMODYNAMICS","29;21;15;14;11;11;10;8;8;6;5;4;4;4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENE;IMMUNOHISTOCHEMISTRY;ANTIBODY;ADVERSE EFFECT;HUMAN IMMUNODEFICIENCY VIRUS (HIV);LYMPHOMA;MELANOMA;PSORIASIS;ALTERNATIVE MEDICINE;CELLULITIS;CHEMOTHERAPY;IN VITRO;SIGNAL TRANSDUCTION;ACNE;ADIPOSE TISSUE;ANTIGEN;CARCINOMA;CELL CULTURE;CLINICAL TRIAL;DIFFERENTIAL DIAGNOSIS;ERYTHEMA;HUMAN PAPILLOMAVIRUS;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);LEUKEMIA;MELASMA;NODULE (GEOLOGY);ODDS RATIO;PYRUVIC ACID;RADIATION THERAPY;THYROID;ULTRASONOGRAPHY;ULTRASOUND","17;14;8;5;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CERVICAL CANCER;BREAST CANCER;DOWNREGULATION AND UPREGULATION;CARCINOGENESIS;CELLULITE;GENE EXPRESSION;METASTASIS;MYCOSIS FUNGOIDES;TOLERABILITY;COLORECTAL CANCER;GENOTYPE;MELANOCYTE;MUTATION;POLYMERASE CHAIN REACTION;PROSTATE;THYROID NODULES;VIRAL LOAD;ALCOHOL OXIDATION;ALLELE;AVIDITY;BLADDER CANCER;CALCITRIOL RECEPTOR;CARBAMAZEPINE;CARCINOMA IN SITU;CD30;CD8;CDKN2A;CELL CYCLE;CERVIX;CHROMOGRANIN A;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;COLOR DOPPLER;COMMON ILIAC ARTERY;COMPLEMENTARY DNA;CONTRAST-ENHANCED ULTRASOUND;CYTOTOXICITY;ECHOGENICITY;EPIGENETICS;ERBB;EXON;FIBROBLAST GROWTH FACTOR;FINE-NEEDLE ASPIRATION;GAP JUNCTION;GERMLINE;GLUCAGON;GOITER;HACAT;HALO SIGN;HEME;HEPATECTOMY;HUMAN LEUKOCYTE ANTIGEN;INSULIN RESISTANCE;KERATINOCYTE;LEVETIRACETAM;LIPID PEROXIDATION;LIPOLYSIS;LYMPHOPROLIFERATIVE DISORDERS;LYTIC CYCLE;METALLOPROTEINASE;MONOCLONAL ANTIBODY;NECK DISSECTION;OCCULT;OCTREOTIDE;OVARIAN CANCER;PACLITAXEL;PARACRINE SIGNALLING;PERIPHERAL BLOOD MONONUCLEAR CELL;PHOSPHATASE;PIROXICAM;PLAQUE PSORIASIS;POWER DOPPLER;PROINFLAMMATORY CYTOKINE;PROTEIN TYROSINE PHOSPHATASE;PROTOPORPHYRIN;PSORIATIC ARTHRITIS;RECEPTOR TYROSINE KINASE;RECOMBINANT DNA;RETINOBLASTOMA;RHABDOMYOSARCOMA;SALVAGE THERAPY;SEROLOGY;SOMATOSTATIN RECEPTOR;STAIN;STAT3;SYPHILIS;T CELL;TAZAROTENE;THYROID CARCINOMA;THYROIDECTOMY;TITER;TOPIRAMATE;TRANSCRIPTION FACTOR;TRANSEPIDERMAL WATER LOSS;VASCULAR ENDOTHELIAL GROWTH FACTOR;VULVAR NEOPLASM;WALDENSTROM MACROGLOBULINEMIA;WHITE ADIPOSE TISSUE;WNT SIGNALING PATHWAY","5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CERVICAL INTRAEPITHELIAL NEOPLASIA;HPV INFECTION;ANTIRETROVIRAL THERAPY;DNA METHYLATION;INTRAEPITHELIAL NEOPLASIA;ALLELE FREQUENCY;CATENIN;CAUDATE LOBE;CUTANEOUS LYMPHOMA;CUTANEOUS T-CELL LYMPHOMA;CYSTECTOMY;DEBULKING;ERYTHROPOIETIC PROTOPORPHYRIA;FERROCHELATASE;FIBROBLAST GROWTH FACTOR RECEPTOR 1;GENE EXPRESSION PROFILING;GENITAL WARTS;GLUCAGONOMA;KERATINOCYTE GROWTH FACTOR;KRAS;LYMPHOPLASMACYTIC LYMPHOMA;MAMMARY GLAND;MISSENSE MUTATION;OXCARBAZEPINE;PAPILLOMAVIRIDAE;PERIPHERAL T-CELL LYMPHOMA;POLYCYSTIC OVARY;POLYMORPHISM (COMPUTER SCIENCE);RESTRICTION FRAGMENT LENGTH POLYMORPHISM;RETINOBLASTOMA PROTEIN;SENTINEL LYMPH NODE;SINGLE-NUCLEOTIDE POLYMORPHISM;STAT PROTEIN;TRASTUZUMAB","3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MIDDLE AGED;SKIN NEOPLASMS;AGED;MALE;MELANOMA;UTERINE CERVICAL NEOPLASMS;;BIOMARKERS, TUMOR;BREAST NEOPLASMS;PAPILLOMAVIRUS INFECTIONS;ADENOCARCINOMA;AGED, 80 AND OVER;CARCINOMA, SQUAMOUS CELL;CERVICAL INTRAEPITHELIAL NEOPLASIA;CERVIX UTERI;ADOLESCENT;COLORECTAL NEOPLASMS","38;24;20;20;18;15;15;12;12;11;10;10;10;8;8;8;8;8;7;7","BODY CONTOURING TECHNIQUES AND PROCEDURES;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;MELANIN PIGMENTATION IN MAMMALIAN SKIN;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;INTEGRIN SIGNALING IN INFLAMMATION AND CANCER;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MOLECULAR MECHANISMS OF HEME BIOSYNTHESIS AND RELATED DISORDERS;BIOLOGICAL AND CLINICAL EFFECTS OF IONIZING RADIATION;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;CLINICAL AND MOLECULAR CHARACTERISTICS OF GLOMUS TUMORS;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL SKIN INFECTIONS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEPATOCELLULAR CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT","3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CELLULITE;HPV VACCINATION;TOLERABILITY;BREAST CANCER;DERMAL REMODELING;DIFFERENTIATED THYROID CANCER;ERYTHEMA;LIPODYSTROPHY;MELANOCYTE;MELANOMA;MELASMA;NODULE (GEOLOGY);PYRUVIC ACID;RADIOTHERAPY;THYROID NODULES;ALCOHOL OXIDATION;ALLERGIC CONTACT DERMATITIS;ANTIBODY ENGINEERING;ANTIGEN PRESENTATION;AVIDITY","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","INSTRUMENTAL EVALUATION;ACID PEEL;BREAST CANCER;CERVICAL CANCER;CERVICAL INTRAEPITHELIAL;GROWTH FACTOR;HUMAN PAPILLOMAVIRUS;INTRAEPITHELIAL NEOPLASIA;MALIGNANT MELANOMA;MYCOSIS FUNGOIDES;PYRUVIC ACID;SKIN IMPROVEMENT;WEEKLY PACLITAXEL;A-INDUCED INHIBITION;ACID-BASED FORMULATION;ACNE VULGARIS;ACTIVATING PTPN;ADULT SOLID;ADVANCED BREAST;ADVANCED NECK;ANDIΒI-CATENIN ACCUMULATION;ANGIOGENIC FACTORS;ANTIBODY RESPONSE;ANTICELLULITE PRODUCTS;ARGPRO POLYMORPHISM;ARTERYNEOBLADDER FISTULA;BEADED LINES;BRAIN TUMOURS;BRESLOW THICKNESS;BSMI POLYMORPHISM","3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CERVICAL CANCER;MELANOMA CELLS;NORMAL MELANOCYTES;CELL CYCLE;CIN CIN;HPV PROTEINS;HUMAN PAPILLOMAVIRUS;INFLAMMATORY PROCESS;NM-H EXPRESSION;PIROXICAM TREATMENT;STATISTICALLY SIGNIFICANT;WEEKLY PACLITAXEL;WOMEN INFECTED;ABERRANT DOWNREGULATION;ABERRANT PROCESSES;ACTIVE GTPASE;ADVANCED BREAST;BISULFITE-MODIFIED DNA;BRAIN LYMPHOCYTES;BRAIN RABA;BREAST CANCER;CA FIELDS;CELLS RECAPITULATES;CIN LESIONS;CONGENITAL NEVI;CONSTITUTIVELY ACTIVE;CONTROL SILENCING;CYCLE ANALYSIS;DENATURED HPV;DISORDERS INVOLVING","5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",2,0.04,5.25,5.5,0,0,0,0,5.5,0,0,5.5,0,0,0,0,0,0,0,0,0,0,0,78.5,78.5,2,0,1,0,0,0,0,0,1,0,0,0,2,0,0,0,5,7.41,4,0,2,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CITRO GENNARO;PUCCI SABINA;SPAGNOLI LUIGI GIUSTO;BONANNO ELENA;CONTINO GIANMARCO;NOVELLI GIUSEPPE;PICHIORRI FLAVIA","2;2;2;1;1;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA;UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA;IST FISIOTERAP OSPITALROMA;ISTITUTI FISIOTERAPICI OSPITALIERI (IFO) ISTITUTOREGINA ELENE","2;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","4;1;1",NA,NA,"4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","2","G01N33/574;A61P35/00;C07K14/755;C07K16/00;C07K16/18;C07K16/30;C07K16/40;C12N15/12;G01N33/577;G01N33/58","2;1;1;1;1;1;1;1;1;1","A61P35/00;C07K16/30;C07K16/40;C07K2317/34;G01N2333/9015;G01N33/57407;G01N33/6896","1;1;1;1;1;1;1",9,6.5,579.5,12.86,0,0,17.78,0,0,5,0,4,0,0,0,0,2,0,0,0,0,0,0,0,8,1,0,2,7,0,0,0,0,0,0,0,0,"Canada;Italy","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3203 DENTISTRY;3215 REPRODUCTIVE MEDICINE","9;6;4;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LUNG;LUNG CANCER;LYMPHOMA;RARE DISEASES;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","2;2;2;1;1;1;1;1;1;1;1","CANCER","7","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","5;1","LUNG CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BRAIN TUMOR;COLON AND RECTAL CANCER;GASTROINTESTINAL TRACT;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER;RESPIRATORY SYSTEM;SARCOMA","2;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","6",2,80000,80000,2.5,1,1,0,19,435749.474025974,0.114744831561219,"ISTITUTI FISIOTERAPICI OSPITALIERI","2","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP6-2004-MOBILITY-12 (CALL FOR PROPOSAL);FP6-MOBILITY - HUMAN RESOURCES AND MOBILITY IN THE SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ""STRUCTURING THE EUROPEAN RESEARCH AREA"" UNDER THE SIXTH FRAMEWORK PROGRAMME 2002-2006 (PROGRAMME);EIF - MARIE CURIE ACTIONS-INTRA-EUROPEAN FELLOWSHIPS (FUNDING SCHEME);IRG - MARIE CURIE ACTIONS-INTERNATIONAL RE-INTEGRATION GRANTS (FUNDING SCHEME)","2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4203 HEALTH SERVICES AND SYSTEMS","2;2;1;1;1","AGING;BREAST CANCER;CANCER;CLINICAL RESEARCH;DIABETES;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD);NUTRITION;OBESITY;PREVENTION","1;1;1;1;1;1;1;1;1","CANCER","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;8.1 ORGANISATION AND DELIVERY OF SERVICES","1;1","BREAST CANCER","1","2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER","1;1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","2",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IFO",2007,54,7.66666666666667,2.27777777777778,0.462962962962963,0.351851851851852,0.5,1.58441558441558,1.13636363636364,2.11111111111111,1.17391304347826,0.203703703703704,1,20,14,5,12,0.37,0.26,0.09,0.22,49.54,0.938628269308596,NA,0.407407407407407,0.833333333333333,0.489,0.336,0.422,0.443,"MAURO PICARDO;ENZO BERARDESCA;MARCO ARDIGÒ;ANTONIO CRISTAUDO;GIOVANNI LEONE;NICAELA ASPITE;MARIA ROSARIA TORRISI;ALDO MORRONE;CARLO COTA;GIORGIA CARDINALI;VALENTINA BORDIGNON;FRANCESCO PETRUCCI;ALESSIA PACIFICO;GIOVANNI FORTE;ANDREA PARO VIDOLIN;MONICA OTTAVIANI;GIOVANNI REZZA;O. SENOFONTE;STEFANIA BRIGANTI;C. FERRARO","13;7;6;5;5;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2","MAURO PICARDO;ALDO MORRONE;ENZO BERARDESCA;GIOVANNI LEONE;MARCO ARDIGÒ;ALESSIA PACIFICO;ANTONIO CRISTAUDO;CARLO COTA;NICAELA ASPITE;FRANCESCO PETRUCCI;ALAIN TAÏEB;GIOVANNI FORTE;STEFANIA BRIGANTI;MARIA ROSARIA TORRISI;GEORGIANA CLARE MARULLI;S. BUCHER;GIORGIA CARDINALI;VALENTINA BORDIGNON;ANDREA PARO VIDOLIN;BEATRICE BOCCA","2.43;1.38;1.3;1.04;1.03;0.83;0.81;0.68;0.57;0.5;0.5;0.5;0.48;0.45;0.45;0.45;0.43;0.4;0.38;0.38","MAURO PICARDO;ENZO BERARDESCA;MARCO ARDIGÒ;ANTONIO CRISTAUDO;GIOVANNI LEONE;NICAELA ASPITE;MARIA ROSARIA TORRISI;ALDO MORRONE;CARLO COTA;GIORGIA CARDINALI;VALENTINA BORDIGNON;ALESSIA PACIFICO;ANDREA PARO VIDOLIN;MONICA OTTAVIANI;STEFANIA BRIGANTI;C. FERRARO;GIULIA BOLASCO;ALON SCOPE;MASSIMO GIULIANI;CATERINA CATRICALÀ","13;7;6;5;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2","MAURO PICARDO;ALDO MORRONE;ENZO BERARDESCA;GIOVANNI LEONE;MARCO ARDIGÒ;ALESSIA PACIFICO;ANTONIO CRISTAUDO;CARLO COTA;NICAELA ASPITE;STEFANIA BRIGANTI;MARIA ROSARIA TORRISI;S. BUCHER;GIORGIA CARDINALI;VALENTINA BORDIGNON;ANDREA PARO VIDOLIN;PIETRO DONATI;A. AMANTEA;NORMA CAMELI;ANTONIO MASTROIANNI;GIULIA BOLASCO","2.43;1.38;1.3;1.04;1.03;0.83;0.81;0.68;0.57;0.48;0.45;0.45;0.43;0.4;0.38;0.33;0.33;0.33;0.29;0.29","MAURO PICARDO;GIOVANNI LEONE;ALAIN TAÏEB;ANDREA PARO VIDOLIN;MARIA LUCIA DELL’ANNA;MONICA OTTAVIANI;MARCO ARDIGÒ;ENZO BERARDESCA;ARIANNA MASTROFRANCESCO;ANTONIO CRISTAUDO;ALESSIA PACIFICO;MARINA VENTURINI;NICAELA ASPITE;P. CALZAVARA;R. SALA;W. WESTERHOF;GIORGIA CARDINALI;MARIA ROSARIA TORRISI;ALON SCOPE;ANNA DI NARDO","1132;473;454;401;283;283;282;256;210;197;190;185;185;185;185;185;160;157;153;151","MAURO PICARDO;GIOVANNI LEONE;ANDREA PARO VIDOLIN;MARCO ARDIGÒ;ENZO BERARDESCA;ARIANNA MASTROFRANCESCO;ALESSIA PACIFICO;MARIA LUCIA DELL’ANNA;MARINA VENTURINI;MONICA OTTAVIANI;NICAELA ASPITE;P. CALZAVARA;R. SALA;W. WESTERHOF;GIORGIA CARDINALI;ANNA DI NARDO;PAOLA MUTI;ANTONIO CRISTAUDO;CARLO COTA;GIULIA BOLASCO","1034;333;303;280;254;210;190;185;185;185;185;185;185;185;160;151;141;126;125;120","MAURO PICARDO;ENZO BERARDESCA;MARCO ARDIGÒ;NICAELA ASPITE;ALDO MORRONE;ANTONIO CRISTAUDO;CARLO COTA;ALESSIA PACIFICO;GIOVANNI LEONE;GIORGIA CARDINALI;A. DI CARLO;ANDREA PARO VIDOLIN;ARIANNA MASTROFRANCESCO;GIULIA BOLASCO;GUIDO PALAMARA;MARIA ROSARIA TORRISI;MASSIMO GIULIANI;S. BUCHER;STEFANIA BRIGANTI;VALENTINA BORDIGNON","12;6;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;POLITICAL SCIENCE;MATERIALS SCIENCE;MATHEMATICS;PSYCHOLOGY;ART;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;PHILOSOPHY","39;26;16;5;4;3;3;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;PATHOLOGY;BIOCHEMISTRY;DERMATOLOGY;CELL BIOLOGY;GENETICS;CANCER RESEARCH;SURGERY;CHROMATOGRAPHY;GASTROENTEROLOGY;NURSING;OPTICS;PALEONTOLOGY;RADIOLOGY;VIROLOGY;BIOTECHNOLOGY;DEMOGRAPHY;ENVIRONMENTAL HEALTH;FOOD SCIENCE;INTENSIVE CARE MEDICINE;NUCLEAR CHEMISTRY;ONCOLOGY;ORGANIC CHEMISTRY","19;18;16;14;12;10;10;9;9;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","GENE;CANCER;MELANOMA;ANTIBODY;DISEASE;RECEPTOR;VITILIGO;CELL CULTURE;STAGE (STRATIGRAPHY);ALLERGY;BIOPSY;CONFOCAL MICROSCOPY;ENZYME;IN VIVO;INTERFERON;MASS SPECTROMETRY;MEMBRANE;OXIDATIVE STRESS;PSORIASIS;QUALITY OF LIFE (HEALTHCARE);SIGNAL TRANSDUCTION","9;8;6;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;KERATINOCYTE;CARCINOGENESIS;INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY;SKIN CANCER;ALLELE;ALPHA INTERFERON;BASAL CELL CARCINOMA;CDKN2A;COELIAC DISEASE;GENOTYPE;INFLIXIMAB;MAPK/ERK PATHWAY;MELANOCYTE;MUTATION;PHOSPHOLIPID;TRANSCRIPTION FACTOR;TRANSEPIDERMAL WATER LOSS;VIRAL DISEASE;ACRIDINE ORANGE;ADALIMUMAB;ADJUVANT THERAPY;ALLERGEN;ANAPLASTIC LARGE-CELL LYMPHOMA;ANTIMICROBIAL PEPTIDES;ATOPY;BARTHEL INDEX;BASAL (MEDICINE);BULLA (SEAL);CATALASE;CD8;CELL CYCLE;CELL MIGRATION;CELLULAR DIFFERENTIATION;CELLULAR RESPIRATION;CERVICAL CANCER;COMPLETE REMISSION;CONCHA BULLOSA;CONTACT DERMATITIS;CRYOGLOBULINS;CYCLOOXYGENASE;CYTOCHROME C;CYTOSKELETON;DERMATITIS HERPETIFORMIS;DERMATOSCOPY;DNA DAMAGE;DOWNREGULATION AND UPREGULATION;DRUG ABUSER;ERBB;ESSENTIAL THROMBOCYTHEMIA;ETANERCEPT;EXCIMER;EXON;FIBROBLAST GROWTH FACTOR;FOOD ALLERGY;GENE SILENCING;GIST;GLIADIN;GONORRHEA;GROWTH FACTOR;HACAT;HEPATECTOMY;HEPATITIS C VIRUS;HEPATOCYTE GROWTH FACTOR;HETEROSEXUALITY;HORSERADISH PEROXIDASE;HYPERPHOSPHORYLATION;IMATINIB;IMMUNOGENICITY;IMMUNOSTAINING;INNATE IMMUNE SYSTEM;IRIDIUM;LEACHING (PEDOLOGY);LINOLEIC ACID;LIPID PEROXIDATION;LIPOIC ACID;LIVER TRANSPLANTATION;LUPUS ERYTHEMATOSUS;LYMPHADENECTOMY;MANNAN-BINDING LECTIN;MELANOSOME;MICROWAVE DIGESTION;MONOCLONAL ANTIBODY;MYCOSIS FUNGOIDES;NEUROREHABILITATION;PAPILLARY DERMIS;PARACRINE SIGNALLING;PATCH TEST;PERIPHERAL BLOOD MONONUCLEAR CELL;PERMEABILITY (ELECTROMAGNETISM);PERMEATION;PHYLOGENETIC TREE;PI3K/AKT/MTOR PATHWAY;PLACEBO;PLATINUM;POLYMERASE CHAIN REACTION;POSITIVE PREDICATIVE VALUE;PROGRAMMED CELL DEATH;PROINFLAMMATORY CYTOKINE;PROTEIN KINASE A;PROTEIN KINASE B;PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC;PROVOCATION TEST;PSORALEN;PSORIATIC ARTHRITIS;RECEPTOR TYROSINE KINASE;RHODIUM;RIGHT TO HEALTH;RITUXIMAB;RNA;SEROCONVERSION;SEROLOGY;SUPEROXIDE;SUPEROXIDE DISMUTASE;SUPPRESSOR;SYPHILIS;TELOMERE;TISSUE TRANSGLUTAMINASE;TLR4;TOLERABILITY;TYROSINE KINASE;TYROSINE PHOSPHORYLATION;UBIQUITIN;VASCULAR ENDOTHELIAL GROWTH FACTOR;VASCULITIS;VIRAL LOAD;VULVAR CANCER;WW DOMAIN","4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TUMOR SUPPRESSOR GENE;CARDIOLIPIN;KERATINOCYTE GROWTH FACTOR;ACTIN CYTOSKELETON;ANTIRETROVIRAL THERAPY;ATAXIA-TELANGIECTASIA;CATHELICIDIN;CLADE;CONTACT ALLERGY;CORTACTIN;CRYOGLOBULINEMIA;CUTANEOUS T-CELL LYMPHOMA;DISCOID LUPUS ERYTHEMATOSUS;EFALIZUMAB;ELIMINATION DIET;ELISPOT;FGF10;GENE MUTATION;HAPLOTYPE;HORMONE RECEPTOR;HPV INFECTION;IMATINIB MESYLATE;INTERFERON ALFA;LAMELLIPODIUM;LENTIVIRUS;MAMMARY GLAND;MELANOCORTIN 1 RECEPTOR;MEN WHO HAVE SEX WITH MEN;MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;MILK ALLERGY;MOLECULAR EPIDEMIOLOGY;NUCLEAR RECEPTOR;NUCLEOTIDYLTRANSFERASE;ONCOGENE;ORTHOTOPIC LIVER TRANSPLANTATION;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PEROXYNITRITE;PLATINUM GROUP;PROPIDIUM IODIDE;RADICAL VULVECTOMY;RADIOALLERGOSORBENT TEST;REVERSE TRANSCRIPTASE;SENTINEL LYMPH NODE;SENTINEL NODE;SEROPREVALENCE;SEXUAL PARTNER;SIDA;SYSTEMIC THERAPY;TLR2;TRICHOEPITHELIOMA;UBIQUITIN LIGASE;VULVECTOMY;ZIDOVUDINE","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;VITILIGO;KERATINOCYTES;SKIN;AGED;BREAST NEOPLASMS;SKIN NEOPLASMS;DERMATITIS, ALLERGIC CONTACT;FIBROBLAST GROWTH FACTOR 7;MELANOCYTES;CARCINOMA, BASAL CELL;EPIDERMIS;MICROSCOPY, CONFOCAL;ADOLESCENT;;CARCINOMA, SQUAMOUS CELL","47;31;24;22;19;16;15;14;13;11;10;9;9;9;8;8;8;7;6;6","MELANIN PIGMENTATION IN MAMMALIAN SKIN;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;HEPATITIS C INFECTION AND TREATMENT;INNOVATIONS IN TRANSDERMAL DRUG DELIVERY SYSTEMS;MELANOMA;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;SKIN SENSITIZATION AND CONTACT ALLERGY RESEARCH;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;ATOPIC DERMATITIS AND SKIN MICROBIOME;CHRONIC RHINOSINUSITIS AND NASAL POLYPS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;DIAGNOSIS AND MANAGEMENT OF URTICARIA;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER","7;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","VITILIGO;MELANIN;MELANOCYTE;NONMELANOMA SKIN CANCER;UV RADIATION;ALLERGIC CONTACT DERMATITIS;CANCER THERAPY;CLINICAL PRACTICE;CONCOMITANT;CONTACT ALLERGY;FIBROBLAST GROWTH FACTOR;HIV;KERATINOCYTE GROWTH FACTOR;MELANOMA;PIGMENTATION;PIGMENTATION DISORDER;SKIN CANCERS;SKIN PENETRATION ENHANCERS;SKIN PERMEATION ENHANCEMENT;SKIN SENSITIZATION","5;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GROWTH FACTOR;BREAST CANCER;REFLECTANCE CONFOCAL;ALLERGENIC METALS;CELL CARCINOMA;CONFOCAL MICROSCOPY;HUMAN KERATINOCYTES;KERATINOCYTE GROWTH;PRELIMINARY EVALUATION;SQUAMOUS CELL;ACID ISOLATION;ACID METABOLITE;ACTIN ASSEMBLY;AIPITCH UBIQUITINATES;ALLERGIC CONTACT;ALLERGOLOGICAL BIOMONITORING;AMPUTATION ARISING;ANATOMIC VARIANTS;ANGIOGENIC CYTOKINES;ANTIMICROBIAL PEPTIDES;APPLYING QUALITY-OF-LIFE;ATAXIA TELANGIECTASIA;ATOPIC DERMATITIS;ATOPIC DIATHESIS;AUTOIMMUNE PROGESTERONE;BARRIER PROPERTIES;BASAL CELL;BI-LAYER COMPOSITE;BIOLOGICAL MARKERS;BIOMIMETIC NITRATION","4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PUBMED SCOPUS;CROSSREF PUBMED;MELANOMA CELLS;MET EXPRESSION;MET PROMOTER;CLINICAL SETTING;HUMAN MELANOCYTES;PUBMED GOOGLE;BREAST CANCER;QOL DATA;JP BALLOTTI;ORTONNE JP;FISHER DE;GROUP-LEVEL DATA;MITF EXPRESSION;BIOL -CROSSREF;CELL BIOL;CAMP PATHWAY;CLINICAL SIGNIFICANCE;HUMAN MET;PATIENT CARE;QOL ASSESSMENT;CELLS EXPOSED;CLINICAL TRIALS;GROWTH FACTOR;HUMAN MELANOMA;MOUSE MITF;PRIMARY CARE;QOL QUESTIONNAIRES;RES -CROSSREF","81;55;44;35;20;16;14;14;13;11;10;10;9;9;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6",2,0.04,8.56,2.5,0,1,0,0,0,0,2,2.5,0,0,1,0,0,0,0,1,0,0,0,81.75,81.75,2,0,1,0,0,0,2,0,0,0,0,0,1,2,0,1,6.66666666666667,16.39,2.33333333333333,0,2,1,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"ACCARDI LUISA;BITTI ORSOLA;DI BONITO PAOLA;DIBELLO FRANCESCO;FRANCONI ROSELLA;GIORGI COLOMBA;MARCANTE MARIA-LUISA;VENUTI ALDO;BLANDINO GIOVANNI;CITRO GENNARO","2;2;2;2;2;2;2;2;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;AGENZIA NAZIONALE PER LE NUOVE TECNOLOGIE LENERGIA E LO SVILUPPO ECONOMICO SOSTENIBILE ENEA;ISTITUTO SUPERIORE DI SANITA ISS","3;2;2","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES","5;3;1","COMPLEMENTARY AND INTEGRATIVE HEALTH;IMMUNIZATION;VACCINE RELATED;CANCER","2;2;2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","1;1","A01H5/00;A61K36/81;A61K39/12;A61K39/39;A61P31/00;C07K14/025;C12N15/82;A61K38/04;C07K14/47","2;2;2;2;2;2;2;1;1","A61K39/39;A61P31/00;C07K14/005;C12N15/8258;C12N2710/20022;A61K38/00;A61P35/00;A61P43/00;C07K14/4746","2;2;2;2;2;1;1;1;1",13,8.7,933.2,16.88,2,0.15,50.62,0,0,5,0,6,0,0,2,0,8,2,0,0,0,0,0,0,9,3,1,10,3,0,0,0,0,0,0,0,0,"Germany","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;40 ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","12;9;7;3;2;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BREAST CANCER;AGING;PATIENT SAFETY;RARE DISEASES;AUTOIMMUNE DISEASE;ESTROGEN;HEMATOLOGY;LUNG;LUNG CANCER","9;7;7;3;2;2;2;1;1;1;1;1","CANCER;MUSCULOSKELETAL;SKIN","7;1;1","6.1 PHARMACEUTICALS","8","BREAST CANCER;BLOOD CANCER;BRAIN TUMOR;LEUKEMIA / LEUKAEMIA;LUNG CANCER;MELANOMA;PROSTATE CANCER;SARCOMA","4;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;1.4 CANCER PROGRESSION AND METASTASIS","7;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"PUBLIC LIBRARY OF SCIENCE","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","2;1;1","EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;INFLUENZA;PNEUMONIA & INFLUENZA;PREVENTION;VACCINE RELATED","1;1;1;1;1;1","INFECTION","1",NA,NA,"HEALTH SERVICES & SYSTEMS","1","CLINICAL MEDICINE AND SCIENCE","1",NA,NA,NA,NA
"IRCCS_IFO",2008,57,8.57894736842105,2.50877192982456,0.43859649122807,0.350877192982456,0.473684210526316,1.50526315789474,1.04166666666667,1.33333333333333,1.08,0.368421052631579,1,19,15,8,5,0.33,0.26,0.14,0.09,41.79,0.761582813931345,NA,0.385964912280702,0.807017543859649,0.436,0.377,0.45,0.368,"MAURO PICARDO;ENZO BERARDESCA;CATERINA CATRICALÀ;MARCO ARDIGÒ;ENRICA FLORI;ALDO MORRONE;ANGELA FERRARI;VIRGINIA FERRARESI;CLAUDIA FABBRI;ARIANNA MASTROFRANCESCO;ANTONIO CRISTAUDO;LAURA EIBENSCHUTZ;F SOCCORSI;GIOVANNI REZZA;ADRIANO PELLICELLI;STEFANIA BRIGANTI;ALFONSO BALDI;GIUSTINO MARIANI;VITTORIA MARESCA;ANTONELLA VENTO","10;8;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","ENZO BERARDESCA;MAURO PICARDO;ALDO MORRONE;MARCO ARDIGÒ;CATERINA CATRICALÀ;MARIA LUCIA DELL’ANNA;ENRICA FLORI;CATIA DE FELIPE;SERGIO CHIMENTI;CLAUDIA RONA;ANGELA FERRARI;ARIANNA MASTROFRANCESCO;NORMA CAMELI;UGO FORNARI;CLAUDIA FABBRI;VIRGINIA FERRARESI;PIETRO DONATI;NANCY SANTESSO;JOACHIM W. FLUHR;BRITTA LANG","1.95;1.65;1.39;0.73;0.56;0.55;0.54;0.5;0.5;0.5;0.44;0.43;0.42;0.39;0.38;0.37;0.37;0.33;0.33;0.33","MAURO PICARDO;ENZO BERARDESCA;CATERINA CATRICALÀ;MARCO ARDIGÒ;ENRICA FLORI;ALDO MORRONE;ANGELA FERRARI;VIRGINIA FERRARESI;CLAUDIA FABBRI;ARIANNA MASTROFRANCESCO;ANTONIO CRISTAUDO;LAURA EIBENSCHUTZ;STEFANIA BRIGANTI;VITTORIA MARESCA;ANTONELLA VENTO;FABRIZIO ENSOLI;EMANUELA CAMERA;VALENTINA BORDIGNON;PAOLA DE SIMONE;PAOLA CORDIALI‐FEI","10;8;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","ENZO BERARDESCA;MAURO PICARDO;ALDO MORRONE;MARCO ARDIGÒ;CATERINA CATRICALÀ;MARIA LUCIA DELL’ANNA;ENRICA FLORI;CATIA DE FELIPE;ANGELA FERRARI;ARIANNA MASTROFRANCESCO;NORMA CAMELI;UGO FORNARI;CLAUDIA FABBRI;VIRGINIA FERRARESI;PIETRO DONATI;NANCY SANTESSO;VITTORIA MARESCA;MARIA CECILIA CERCATO;ALESSIA GIULIANI;ANTONIO MASTROIANNI","1.95;1.65;1.39;0.73;0.56;0.55;0.54;0.5;0.44;0.43;0.42;0.39;0.38;0.37;0.37;0.33;0.32;0.32;0.31;0.31","MAURO PICARDO;CLAUDIA FABBRI;ENRICA FLORI;EMANUELA CAMERA;PHILIPPE BAHADORAN;ARIANNA MASTROFRANCESCO;ALBERTO GIANNETTI;ANTONIO ADDIS;CARLO TOMINO;EUGENIA CAGGESE;LILIANE CHATENOUD;LUIGI NALDI;MARA MACCARONE;PAOLA BERTUCCIO;ROSANNA CUSCITO;SERGIO CHIMENTI;ANDRZEJ SŁOMIŃSKI;CLAUDIA GIACHINO;E. HELEN KEMP;HÜSEYIN ÖNAY","1017;405;345;318;309;236;208;208;208;208;208;208;208;208;208;208;199;199;199;199","MAURO PICARDO;CLAUDIA FABBRI;ENRICA FLORI;EMANUELA CAMERA;ARIANNA MASTROFRANCESCO;MARIA LUCIA DELL’ANNA;VITTORIA MARESCA;ENZO BERARDESCA;CATERINA CATRICALÀ;BARBARA BELLEI;STEFANIA BRIGANTI;ANTONIO CRISTAUDO;ENZO IZZO;FABRIZIO ENSOLI;GIANLUCA BOSSI;A. AMANTEA;MASSIMO GIULIANI;PIETRO DONATI;ANTONELLA VENTO;PAOLA CORDIALI‐FEI","1017;405;345;318;236;199;196;164;149;148;126;111;109;94;88;86;67;67;63;63","MAURO PICARDO;ENZO BERARDESCA;CATERINA CATRICALÀ;ENRICA FLORI;MARCO ARDIGÒ;ALDO MORRONE;ARIANNA MASTROFRANCESCO;CLAUDIA FABBRI;A. DI CARLO;ANGELA FERRARI;ANTONELLA VENTO;ANTONIO CRISTAUDO;BARBARA BELLEI;EMANUELA CAMERA;FABRIZIO ENSOLI;LAURA EIBENSCHUTZ;MARIA LUCIA DELL’ANNA;MASSIMO GIULIANI;NORMA CAMELI;PAOLA CORDIALI‐FEI","10;8;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;ECONOMICS;ENGINEERING;GEOLOGY;HISTORY","48;21;7;5;3;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;DERMATOLOGY;PATHOLOGY;GENETICS;IMMUNOLOGY;BIOCHEMISTRY;CANCER RESEARCH;VIROLOGY;SURGERY;CELL BIOLOGY;RADIOLOGY;GASTROENTEROLOGY;NURSING;ONCOLOGY;OPTICS;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;ANATOMY;ASTRONOMY;LAW","23;21;14;12;11;10;9;9;7;6;6;4;4;4;4;3;3;3;2;2;2","GENE;CANCER;MELANOMA;IN VITRO;VIRUS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;DISEASE;ENZYME;PSORIASIS;ANTIOXIDANT;BASAL CELL;BIOPSY;CARCINOMA;CHEMOTHERAPY;CYTOKINE;LESION;MELANIN;OXIDATIVE STRESS;POPULATION;REACTIVE OXYGEN SPECIES","9;8;8;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","GENE EXPRESSION;MELANOCYTE;BASAL CELL CARCINOMA;CD8;PLAQUE PSORIASIS;ALLERGIC CONTACT DERMATITIS;BREAST CANCER;CATALASE;CHRONIC HEPATITIS;CONTACT DERMATITIS;GENE SILENCING;HEPATITIS B VIRUS;PERIPHERAL BLOOD MONONUCLEAR CELL;PROINFLAMMATORY CYTOKINE;PSORIATIC ARTHRITIS;REGULATION OF GENE EXPRESSION;SKIN CANCER;T CELL;TRANSCRIPTION FACTOR;ACITRETIN;ADALIMUMAB;ADENOCARCINOMA;ASPERGILLUS PARASITICUS;ASTAXANTHIN;ASTROPHYSICAL PLASMA;AUTOANTIBODY;AVIDITY;BIOSYNTHESIS;BIRT–HOGG–DUBÉ SYNDROME;BONE BIOPSY;BRACHYTHERAPY;CISPLATIN;DACARBAZINE;DNA DAMAGE;DOWNREGULATION AND UPREGULATION;DRUG REACTION;ENTEROPATHY;EPIDERMODYSPLASIA VERRUCIFORMIS;ETANERCEPT;EVIDENCE-BASED MEDICINE;EVIDENCE-BASED PRACTICE;EXON;FACTOR V;FIBROBLAST;FOLLICULIN;GEMCITABINE;GENOTYPE;GERMLINE;GLIADIN;GLUTATHIONE;GSK-3;HEPATITIS C VIRUS;HUMAN LEUKOCYTE ANTIGEN;IMAGING SPECTROMETER;IMMUNOGENICITY;IMMUNOGLOBULIN E;IMMUNOTHERAPY;INTERFERON GAMMA;INTERLEUKIN 2;INTRON;LABIA MAJORA;LABIA MINORA;LUPUS VULGARIS;LYMPHADENECTOMY;MELANOSIS;MELANOSOME;MICROPHTHALMIA;MULTICENTER STUDY;MUTANT;MUTATION;ORBITAL MECHANICS;OVERWEIGHT;PATCH TEST;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PHOTOPROTECTION;PLACEBO;PROSTATE;PROSTATE CANCER;PROTEASE;PSORIASIS AREA AND SEVERITY INDEX;REAL-TIME POLYMERASE CHAIN REACTION;RECOMBINANT DNA;RHEUMATOID FACTOR;RNA;ROSACEA;SOFT TISSUE SARCOMA;SOLAR WIND;SUPEROXIDE DISMUTASE;SYPHILIS;SYSTEMATIC REVIEW;TENOFOVIR;TRIPEPTIDE;TUMOR PROGRESSION;TYROSINASE;VACCINE TRIAL;VASCULITIS;VENOUS THROMBOSIS;VIRAL LOAD;VULVAR CANCER;WNT SIGNALING PATHWAY","4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;ANTI-NUCLEAR ANTIBODY;ANTIRETROVIRAL THERAPY;ANTIVIRAL THERAPY;ANTIVIRAL TREATMENT;BETA-CATENIN;CANTHAXANTHIN;CARBOPLATIN;CATENIN;CONTACT ALLERGY;DERMAL FIBROBLAST;DKK1;DOUBLE BLIND;ELISPOT;FACTOR V LEIDEN;FRAMESHIFT MUTATION;GAIN OF FUNCTION;GERMLINE MUTATION;GSK3B;HBSAG;HIV VACCINE;LAMIVUDINE;MAMMOGRAPHY;MELANOCORTIN 1 RECEPTOR;MEN WHO HAVE SEX WITH MEN;MICROARRAY ANALYSIS TECHNIQUES;PROMOTER;RADICAL VULVECTOMY;REPORTER GENE;RIBAVIRIN;RNA INTERFERENCE;SENTINEL LYMPH NODE;SERINE PROTEASE;TAQMAN;TRANSCRIPTIONAL REGULATION;USTEKINUMAB;VULVECTOMY","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;AGED;MELANOCYTES;HIV INFECTIONS;SKIN;OXIDATIVE STRESS;SKIN NEOPLASMS;;MELANOMA;PSORIASIS;REACTIVE OXYGEN SPECIES;HIV-1;CARCINOMA, BASAL CELL;MESOTHELIOMA;APOPTOSIS;ANTIOXIDANTS","44;27;25;19;19;15;14;13;12;11;11;10;10;10;10;9;8;8;7;6","MELANIN PIGMENTATION IN MAMMALIAN SKIN;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;HEPATITIS B INFECTION AND TREATMENT;HEPATITIS C INFECTION AND TREATMENT;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;ATOPIC DERMATITIS AND SKIN MICROBIOME;BREAST CANCER SCREENING TECHNOLOGY;CLINICAL AND MOLECULAR ASPECTS OF NOCARDIOSIS;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES;DIAGNOSIS AND MANAGEMENT OF ABDOMINAL TUBERCULOSIS;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;ECTOPARASITIC DISEASES IN HUMANS AND ANIMALS;EPIDEMIOLOGY AND PATHOBIOLOGY OF MONKEYPOX VIRUS INFECTION;EPIDEMIOLOGY OF MULTIPLE PRIMARY CANCERS;GENE THERAPY TECHNIQUES AND APPLICATIONS;HEPATOCELLULAR CARCINOMA","6;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MELANIN;HIV;MELANOCYTE;ANTIVIRAL THERAPY;MELANOMA;PSORIASIS;TREATMENT;BASAL CELL CARCINOMA;MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;PROINFLAMMATORY CYTOKINE;SKIN AGING;SKIN SENSITIZATION;SUNSCREEN USE;VITILIGO;ABACAVIR;ACITRETIN;ADEFOVIR;AFLATOXIN;AGING;AIDS","6;4;4;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1","CELL CARCINOMA;HUMAN MELANOCYTES;OXIDATIVE STRESS;PLAQUE PSORIASIS;TH-TYPE RESPONSE;ABBOTT REALTIME;ACQUIRED THROMBOPHILIC;ADEFOVIR MONOTHERAPY;ADVANCED MESOTHELIOMA;ADVANCED SOFT;AFFECT UVA-INDUCED;AFFECTS HUMAN;AFLATOXIN BIOSYNTHESIS;AFRICAN INDIVIDUALS;AGING SKIN;ALPHAMSH EMERGING;ALTERNATIVE TREATMENT;AMPLIPREPCOBAS TAQMAN;ANTIBODY AVIDITY;ANTIINFLAMMATORY FUTURE;ANTIOXIDANT DEFENSE;ANTIOXIDANTS EFFECTIVELY;ANTITUMOR IMMUNITY;ANTIVIRAL TREATMENT;AP IYAPAI;ASTAXANTHIN CANTHAXANTHIN;ATOPIC DERMATITIS;AUTOCHTHONOUS CREEPING;AUTOIMMUNE DISEASE;BASAL CELL","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PEGYLATED INTERFERON;CONCURRENT ABACAVIR;EV PATIENTS;HIV INFECTED;IMMUNE RESPONSE;MIXED CRYOGLOBULINAEMIA;OXIDATIVE STRESS;AFLATOXIN BIOSYNTHESIS;ANTI HCV;CI -P;EYEBROW HAIRS;FATTY ACIDS;HIV- NON-B;INTERFERON ALFA;INTRACELLULAR PHOSPHORILATION;LOAD ANALYSIS;NON-B SUBTYPE;RABA EXPRESSION;VIRAL DECAY;VIRAL LOAD;Β-HPV TYPES;ABBOTT REALTIME;CELL PROLIFERATION;CHOLESTEROL CONTENT;CHRONIC HEPATITIS;CYTOKINE PROFILES;DNA FRAGMENT;EPIDERMODYSPLASIA VERRUCIFORMIS;HUMAN PAPILLOMAVIRUS;INCREASED SUSCEPTIBILITY","8;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3",1,0.02,1,1,0,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,0,0,1,19,20,4,1,2,2,0,1,1,0,0,0,0,0,5,2,0,9.5,4.28571428571429,20.98,3,0,4,5,0,1,1,0,0,2,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CITRO GENNARO;CONDEELIS JOHN S;GERTLER FRANK;GOSWAMI SUMANTA;NISTICO PAOLA;BLANDINO GIOVANNI;GALATI ROSSELLA MARIA;VERDINA ALESSANDRA;BONANNO ELENA;GENNARO CITRO","3;3;3;3;3;2;2;2;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;CONDEELIS JOHN S;EINSTEIN COLL MED;GERTLER FRANK;GOSWAMI SUMANTA;IFO REGINA ELENA CANCER INST;MASSACHUSETTS INST TECHNOLOGY;NISTICO PAOLA;INDIVIDUAL;INSTITUTE FISIOTERAPICI OSPITALIERI","3;2;2;2;2;2;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES","12;4;2;2;1","CANCER;GENETICS","3;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","2;2;1","G01N33/574;G01N33/53;G01N33/567;A61K38/04;C07K14/47;C07K16/18;A61K39/00;C07K14/755;C07K16/00;C07K16/30","5;3;3;2;2;2;1;1;1;1","A61P35/00;A61K31/713;C12Q1/6886;C12Q2600/106;C12Q2600/112;C12Q2600/136;G01N33/5011;G01N33/57415;G01N33/57419;G01N33/57434","6;3;3;3;3;3;3;3;3;3",12,5.55,739.9,13.04,3,0.25,102.75,0,0,6,1,5,0,0,0,0,10,0,0,0,0,0,0,0,8,4,0,10,2,0,0,0,0,0,0,0,0,"United States;Italy;France;Germany;United Kingdom","4;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","12;10;4;4;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;TRANSPLANTATION;BREAST CANCER;DIGESTIVE DISEASES;LYMPHOMA;AGING;BIOMEDICAL IMAGING;CARDIOVASCULAR;DENTAL/ORAL AND CRANIOFACIAL DISEASE;ESTROGEN;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HODGKIN'S DISEASE;LIVER DISEASE;PATIENT SAFETY;PEDIATRIC","11;8;7;6;4;4;3;3;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;BLOOD;CARDIOVASCULAR","8;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","11;2;1;1","BREAST CANCER;HODGKIN'S DISEASE;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;COLON AND RECTAL CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LIVER CANCER;MYELOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","4;2;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","10;1",1,2896600,362075,4,8,5,1,1,460018.224025974,0.123908134554212,"FRAUNHOFER SOCIETY;ISTITUTI FISIOTERAPICI OSPITALIERI;LINK CONSULTING;OSPEDALE DI PARMA;PLANET;STMICROELECTRONICS (ITALY);TECHNICAL UNIVERSITY OF MADRID;UNIVERSITY OF IOANNINA","1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP - COLLABORATIVE PROJECT (GENERIC) (FUNDING SCHEME);FP7-ICT - SPECIFIC PROGRAMME ""COOPERATION"": INFORMATION AND COMMUNICATION TECHNOLOGIES (PROGRAMME);FP7-ICT-2007-2 (CALL FOR PROPOSAL)","1;1;1","31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS","1;1;1","BIOENGINEERING;BIOTECHNOLOGY;CANCER;GENETIC TESTING;GENETICS;HUMAN GENOME","1;1;1;1;1;1","CANCER","1","2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1;1","NOT SITE-SPECIFIC CANCER","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS","1;1","A01 CLINICAL MEDICINE","1",NA,NA,10,"PUBLIC LIBRARY OF SCIENCE","10","32 BIOMEDICAL AND CLINICAL SCIENCES;38 ECONOMICS;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3801 APPLIED ECONOMICS;4203 HEALTH SERVICES AND SYSTEMS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES;40 ENGINEERING;4202 EPIDEMIOLOGY;48 LAW AND LEGAL STUDIES;4806 PRIVATE LAW AND CIVIL OBLIGATIONS","8;4;4;3;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;BREAST CANCER;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PREVENTION","2;1;1;1;1","CANCER;CARDIOVASCULAR","3;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","2;1;1","BIOMEDICAL;CLINICAL","1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","4;1;1","BREAST CANCER","3",NA,NA
"IRCCS_IFO",2009,65,9.36923076923077,2.47692307692308,0.430769230769231,0.261538461538462,0.415384615384615,1.86046511627907,1.21739130434783,1.13333333333333,1.28571428571429,0.215384615384615,0,24,11,10,13,0.37,0.17,0.15,0.2,37.38,0.808189804502692,NA,0.384615384615385,0.846153846153846,0.418,0.412,0.414,0.417,"MAURO PICARDO;ENZO BERARDESCA;ALDO MORRONE;CARLO COTA;FABRIZIO ENSOLI;VALENTINA BORDIGNON;L. NOSOTTI;CATERINA CATRICALÀ;A. DI CARLO;G. BIOLCATI;BARBARA ENSOLI;A. AMANTEA;DANIELA KOVACS;STEFANIA BELLINO;LUIGI TOMA;FULVIA PIMPINELLI;VALERIA FIORELLI;ANTONELLA TRIPICIANO;STEFANIA BRIGANTI;VITTORIA MARESCA","13;8;6;5;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3","ENZO BERARDESCA;MAURO PICARDO;CARLO COTA;ALDO MORRONE;MARCO ARDIGÒ;CATERINA CATRICALÀ;A. AMANTEA;DANIELA KOVACS;PIETRO DONATI;VALENTINA BORDIGNON;GIORGIA CARDINALI;MANUELA CARRERA;NICAELA ASPITE;L. NOSOTTI;LUIGI TOMA;GEBRE AB BARNABAS;G. BIOLCATI;UMBERTO PRENCIPE;CARMINE ZOCCALI;ENRICA FLORI","2.03;1.93;0.9;0.79;0.69;0.63;0.62;0.56;0.56;0.51;0.5;0.5;0.5;0.48;0.47;0.47;0.47;0.45;0.45;0.41","MAURO PICARDO;ENZO BERARDESCA;CARLO COTA;FABRIZIO ENSOLI;VALENTINA BORDIGNON;L. NOSOTTI;CATERINA CATRICALÀ;A. DI CARLO;G. BIOLCATI;A. AMANTEA;DANIELA KOVACS;LUIGI TOMA;FULVIA PIMPINELLI;ANTONELLA TRIPICIANO;STEFANIA BRIGANTI;VITTORIA MARESCA;GIORGIA CARDINALI;VIRGINIA FERRARESI;FRANCO DI FILIPPO;MARCO ARDIGÒ","13;8;5;5;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3","ENZO BERARDESCA;MAURO PICARDO;CARLO COTA;MARCO ARDIGÒ;CATERINA CATRICALÀ;A. AMANTEA;DANIELA KOVACS;PIETRO DONATI;VALENTINA BORDIGNON;GIORGIA CARDINALI;NICAELA ASPITE;L. NOSOTTI;LUIGI TOMA;G. BIOLCATI;UMBERTO PRENCIPE;CARMINE ZOCCALI;ENRICA FLORI;LUCA BARBIERI;ARIANNA MASTROFRANCESCO;FULVIA PIMPINELLI","2.03;1.93;0.9;0.69;0.63;0.62;0.56;0.56;0.51;0.5;0.5;0.48;0.47;0.47;0.45;0.45;0.41;0.4;0.39;0.39","MAURO PICARDO;EMANUELA CAMERA;ARIANNA MASTROFRANCESCO;MONICA OTTAVIANI;ENZO BERARDESCA;AMIT G. PANDYA;DÓRIS HEXSEL;HENRY H. CHAN;I. REIG RINCÓN DE ARELLANO;JPW VAN DER VEEN;JUNWOO LIM;LUI H;MARK BERNEBURG;MARTA I. RENDON;ORTONNE JP;PEARL E. GRIMES;SIN‐HYEOG IM;SUSAN C. TAYLOR;TÂNIA FERREIRA CESTARI;W. WESTERHOF","804;366;327;297;266;240;240;240;240;240;240;240;240;240;240;240;240;240;240;240","MAURO PICARDO;ARIANNA MASTROFRANCESCO;ENZO BERARDESCA;CARLO COTA;FABRIZIO ENSOLI;ANTONIO CRISTAUDO;MARCO ARDIGÒ;DANIELA KOVACS;A. DI CARLO;A. AMANTEA;MASSIMO GIULIANI;MARISTELLA GUERRA;VITTORIO FRANCAVILLA;LUIGI TOMA;ANGELA ARANCIO;GUIDO PALAMARA;ANTONINO GUERRISI;GIORGIA CARDINALI;CATERINA CATRICALÀ;ENRICA FLORI","804;327;243;232;182;157;155;153;141;136;135;127;108;103;102;102;98;93;92;91","MAURO PICARDO;ENZO BERARDESCA;CARLO COTA;A. AMANTEA;A. DI CARLO;CATERINA CATRICALÀ;FABRIZIO ENSOLI;DANIELA KOVACS;ENRICA FLORI;LUCA BARBIERI;MARCO ARDIGÒ;FRANCO DI FILIPPO;GIORGIA CARDINALI;L. NOSOTTI;MASSIMO GIULIANI;PIETRO DONATI;STEFANIA BRIGANTI;VALENTINA BORDIGNON;LUIGI TOMA;VITTORIA MARESCA","13;7;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATERIALS SCIENCE;PHYSICS;PSYCHOLOGY;ENGINEERING;BUSINESS;ECONOMICS;HISTORY;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY","54;26;11;6;3;3;3;2;1;1;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;DERMATOLOGY;IMMUNOLOGY;SURGERY;BIOCHEMISTRY;GENETICS;CANCER RESEARCH;RADIOLOGY;VIROLOGY;CELL BIOLOGY;GASTROENTEROLOGY;ANATOMY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;PALEONTOLOGY;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;UROLOGY","30;22;18;16;14;13;13;11;11;8;6;5;4;4;4;4;4;3;3;3","GENE;CANCER;MELANOMA;VIRUS;CHEMOTHERAPY;DISEASE;IMMUNE SYSTEM;ALTERNATIVE MEDICINE;CELL CULTURE;ORTHOPEDIC SURGERY;POPULATION;PSORIASIS;TUMOR NECROSIS FACTOR ALPHA;COMPUTED TOMOGRAPHY;DERMIS;ENZYME;EPIDERMIS (ZOOLOGY);HEPATITIS C;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IN VITRO;LUNG CANCER;MELANIN;RECEPTOR","12;8;7;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","KERATINOCYTE;BREAST CANCER;GENE EXPRESSION;HACAT;HEPATITIS C VIRUS;PLACEBO;VIRAL LOAD;CATALASE;COMPUTED TOMOGRAPHIC;COMPUTED TOMOGRAPHIC ANGIOGRAPHY;COMPUTED TOMOGRAPHY ANGIOGRAPHY;GENE KNOCKDOWN;GENOTYPE;GROWTH FACTOR;HEPATITIS B VIRUS;METASTASIS;MUTANT;ACQUIRED IMMUNE SYSTEM;ADALIMUMAB;ANTIBODY RESPONSE;ASPERGILLUS PARASITICUS;BASAL (MEDICINE);BETA THALASSEMIA;BIOLOGIC AGENTS;BIOSYNTHESIS;BLOOD LIPIDS;CALCINEURIN;CD19;CD8;CDKN2A;CELL CYCLE;CELL MIGRATION;CERVICAL CANCER;CHELATION THERAPY;CHRONIC HEPATITIS;CHRONIC LIVER DISEASE;COLOSTRUM;COMPLEMENTARY DNA;CONTRAST-ENHANCED ULTRASOUND;CUTANEOUS LEISHMANIASIS;DERMATOSCOPY;DICHLOROFLUORESCEIN;DOWNREGULATION AND UPREGULATION;DOXORUBICIN;ENDOCRINE SYSTEM;EOSIN;EPIGENETICS;ETANERCEPT;EX VIVO;FIBROBLAST;GENE SILENCING;GENE TRANSFER;GLUTATHIONE;H&E STAIN;HAILEY–HAILEY DISEASE;HEAD AND NECK CANCER;IMMUNITY;IMMUNOGENICITY;IMMUNOTHERAPY;INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY;INFLIXIMAB;INNATE IMMUNE SYSTEM;INSULIN RESISTANCE;LIMB PERFUSION;MEGLUMINE;MELANOCYTE;MELANOSOME;MELPHALAN;MESSENGER RNA;METABOLIC SYNDROME;MUCOCUTANEOUS ZONE;MUTATION;NECK DISSECTION;NEPHRECTOMY;OCCULT;OCHRATOXIN A;OVARIAN CANCER;OVERWEIGHT;PAPILLARY DERMIS;PATHOGNOMONIC;PENTAMIDINE;PERIPHERAL BLOOD MONONUCLEAR CELL;PERONEAL ARTERY;PHENOTYPE;PHOTOCATALYSIS;PHOTOPROTECTION;PLAQUE PSORIASIS;PLASMODIUM FALCIPARUM;POLYMERASE CHAIN REACTION;PROINFLAMMATORY CYTOKINE;PROSTATE;PROSTATE CANCER;PSORIATIC ARTHRITIS;RAPID DIAGNOSTIC TEST;REAL-TIME POLYMERASE CHAIN REACTION;RETICULAR DERMIS;RISK PERCEPTION;RNA;SKIN CANCER;SOFT TISSUE SARCOMA;SYNOVITIS;SYPHILIS;T CELL;TACROLIMUS;THYROID CANCER;THYROID CARCINOMA;THYROIDECTOMY;TOMOGRAPHIC RECONSTRUCTION;TRANSCRIPTION FACTOR;TRANSEPIDERMAL WATER LOSS;TUMOR MICROENVIRONMENT;TUMOR PROGRESSION;TYROSINASE;TYROSINE KINASE;TYROSINE PHOSPHORYLATION;VACCINE TRIAL;VIRAL DISEASE;WAIST;WESTERN BLOT","4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","KERATINOCYTE GROWTH FACTOR;REVERSE TRANSCRIPTASE;RIBAVIRIN;TRANSACTIVATION;ADJUVANT CHEMOTHERAPY;ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;ARTEMISININ;ASPERGILLUS NIDULANS;ASPERGILLUS OCHRACEUS;CD81;CDKN2B;DERMAL FIBROBLAST;DNA METHYLATION;EFALIZUMAB;ELISPOT;EOSIN Y;FRAMESHIFT MUTATION;GENE MUTATION;GLUTATHIONE S-TRANSFERASE;GSTP1;HBSAG;HIV VACCINE;LAMIVUDINE;LASER CAPTURE MICRODISSECTION;LOSS FUNCTION;LYMPHOVASCULAR INVASION;MEGLUMINE ANTIMONIATE;METASTATIC BREAST CANCER;MISSENSE MUTATION;OCHRATOXIN;PAPILLOMAVIRIDAE;PCA3;PIMECROLIMUS;REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;RNA EXTRACTION;SECONDARY METABOLISM;SIDA;SYPHILIS SERODIAGNOSIS;TRASTUZUMAB;TREPONEMA","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;MELANOMA;SKIN NEOPLASMS;HIV INFECTIONS;KERATINOCYTES;T-LYMPHOCYTES;;ADOLESCENT;AIDS VACCINES;PSORIASIS;YOUNG ADULT;AGED, 80 AND OVER;HEPATITIS C;HIV-1;INTERFERON-GAMMA","51;40;36;32;29;24;18;17;14;12;12;11;11;9;9;9;8;8;8;8","RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES;HEPATITIS C INFECTION AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MELANIN PIGMENTATION IN MAMMALIAN SKIN;GLOBAL BURDEN OF LEISHMANIASIS INCIDENCE AND TREATMENT;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;MICROSURGICAL RECONSTRUCTION TECHNIQUES;MOLECULAR MECHANISMS OF HEME BIOSYNTHESIS AND RELATED DISORDERS;SARCOMA RESEARCH AND TREATMENT;ADAPTATION OF TENDON AND SKELETAL MUSCLE TO MECHANICAL LOADING;ATOPIC DERMATITIS AND SKIN MICROBIOME;BIOLOGICAL BASIS AND CLINICAL MANAGEMENT OF SYPHILIS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BODY ART AND MODIFICATION PRACTICES IN SOCIETY;CANCER IMMUNOTHERAPY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS","4;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","HIV;TREATMENT;EPIDERMIS (ZOOLOGY);HACAT;HEPATITIS C;PSORIASIS;BREAST CANCER;COMPUTED TOMOGRAPHIC ANGIOGRAPHY;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CONCORDANCE;DOSE;GOLD STANDARD (TEST);KERATINOCYTE GROWTH FACTOR;PEGYLATED INTERFERON;PERFORATOR FLAP;ACNE VULGARIS;ADJUVANT CHEMOTHERAPY;ALANINE AMINOTRANSFERASE;ANTIBACTERIAL PROPERTIES;ANTIBODY RESPONSE","4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1","CLINICAL ASPECTS;COMPUTED TOMOGRAPHIC;CONFOCAL MICROSCOPY;ETHIOPIA CLINICAL;HIV- TAT;MELANOMA PATIENTS;MUCOCUTANEOUS LEISHMANIASIS;NORTHERN ETHIOPIA;PROGNOSTIC FACTORS;TAT PROTEIN;THERAPEUTIC CONCERNS;TIGRAY NORTHERN;TOMOGRAPHIC ANGIOGRAPHY;ABSOLUTE QUANTITATIVE;ACIDIC CATALASE;ACTIVATION PRELIMINARY;ACTIVITY REPORT;ADAPTIVE IMMUNE;ADDRESSES DENDRITIC;ADVANCED EXTERNAL;ADVANCED HEADNECK;AFFECTS OCHRATOXIN;ALANINE AMINOTRANSFERASE;AMINOTRANSFERASE LEVELS;ANATOMICAL CONSIDERATIONS;ANDOR OVARIAN;ANGIOGRAPHY IMPLICATIONS;ANGIOMATOUS REACTION;ANTHRACYCLINE-BASED CHEMOTHERAPY;ANTIRETROVIRAL DRUGS","2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CELL-CYCLE INHIBITOR;GENE EXPRESSION;NEWLY DIAGNOSED;TUMOR CELLS;BIOLOGICAL FLUIDS;BLASTIC PLASMACYTOID;CANCER CELLS;CELL NEOPLASM;CELL RESPONSE;CLINICAL SYMPTOMS;COMPARATIVE GENOMIC;CORTICOSTEROID THERAPY;DENDRITIC CELL;DENTAL PROSTHESES;DIAGNOSED HIV-;DRUG RESISTANCE;DRUG RESISTANT;ECCRINE POROMA;GENETIC RISK;GENOMIC HYBRIDIZATION;HIV- INFECTED;HIV- STRAINS;IMMUNE RESPONSE;IRREGULAR VESSELS;LINEAR IRREGULAR;MALIGNANT TRANSFORMATION;OBJECTIVE RISK;PATCH TESTING;PLASMACYTOID DENDRITIC;RESISTANCE MUTATION","4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",3,0.05,6,2.5,0,0,0,0,2.5,0,0,2.5,0,0,0,0,0,0,0,0,0,1,0,27.5,27.5,3,1,2,0,0,0,0,0,0,0,0,0,3,0,0,0,3.66666666666667,6.88,2,0,1,3,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"NISTICO PAOLA;BLANDINO GIOVANNI;CITRO GENNARO;CONDEELIS JOHN S;DI MODUGNO FRANCESCA;GALATI ROSSELLA MARIA;GERTLER FRANK;GOSWAMI SUMANTA;PINO MARIA SIMONA;VERDINA ALESSANDRA","2;1;1;1;1;1;1;1;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;ALBERT EINSTEIN COLLEGE OF MEDICINE;IFO REGINA ELENA CANCER INST;IFO-REGINA ELENA CANCER INSTITUTE;MASSACHUSETTS INSTITUTE OF TECHNOLOGY","2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES","5;2;1;1;1","CANCER","1","5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","2;1;1","C12Q1/68;A61K31/713;C07K7/06;C07K7/08;C12Q1/02;G01N33/50;G01N33/574","2;1;1;1;1;1;1","A61P35/00;C12Q1/6886;C12Q2600/106;C12Q2600/112;A61K31/713;A61K38/00;A61P43/00;C07K14/4746;C12Q2600/136;G01N33/5011","2;2;2;2;1;1;1;1;1;1",12,9.2,582.5,15.79,6,0.5,97.42,0,0,4,0,7,0,0,1,0,9,1,0,0,0,0,0,0,5,5,2,10,2,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","12;12;4;3;3;3","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LYMPHOMA;BREAST CANCER;DIGESTIVE DISEASES;ORPHAN DRUG;STEM CELL RESEARCH;TRANSPLANTATION;BIOENGINEERING;CERVICAL CANCER;COLO-RECTAL CANCER;OVARIAN CANCER;PANCREATIC CANCER;PATIENT SAFETY;PEDIATRIC;PEDIATRIC RESEARCH INITIATIVE;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","10;9;8;7;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER","12","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;3.3 NUTRITION AND CHEMOPREVENTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION)","10;2;2;2;1;1;1","BREAST CANCER;NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;CERVICAL CANCER;GASTROINTESTINAL TRACT;GENITAL SYSTEM, MALE;HODGKIN'S DISEASE;OVARIAN CANCER;PANCREATIC CANCER;PROSTATE CANCER","3;3;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;3.3 CHEMOPREVENTION;3.6 RESOURCES AND INFRASTRUCTURE RELATED TO PREVENTION;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","8;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,"PUBLIC LIBRARY OF SCIENCE","20","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;49 MATHEMATICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;38 ECONOMICS;3103 ECOLOGY;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;3801 APPLIED ECONOMICS;40 ENGINEERING;4006 COMMUNICATIONS ENGINEERING;4202 EPIDEMIOLOGY;4206 PUBLIC HEALTH;46 INFORMATION AND COMPUTING SCIENCES;4905 STATISTICS","15;5;5;4;4;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;PREVENTION;BIOTECHNOLOGY;CANCER;CERVICAL CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;INFECTIOUS DISEASES;SEXUALLY TRANSMITTED INFECTIONS;CARDIOVASCULAR;GENETIC TESTING;GENETICS;HEART DISEASE;HIV/AIDS;LUNG;PATIENT SAFETY;RARE DISEASES","3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","3;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","2;1;1;1;1;1;1","BIOMEDICAL;CLINICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","3;2;1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;HEALTH SERVICES RESEARCH","4;3;1","CERVICAL CANCER;LUNG CANCER;GENITAL SYSTEM, FEMALE;NOT SITE-SPECIFIC CANCER","2;2;1;1",NA,NA
"IRCCS_IFO",2010,56,10.6964285714286,2.80357142857143,0.321428571428571,0.267857142857143,0.553571428571429,1.56,1,1.875,1.03333333333333,0.464285714285714,0,27,10,8,5,0.48,0.18,0.14,0.09,54.11,1.19730984965717,NA,0.410714285714286,0.946428571428571,0.444,0.296,0.503,0.265,"MAURO PICARDO;CATERINA CATRICALÀ;BARBARA BELLEI;L. NOSOTTI;A. DI CARLO;GUIDO PALAMARA;CHRISTOS C. ZOUBOULIS;GIORGIA CARDINALI;CARLO LEONETTI;ALESSANDRA LATINI;ENZO BERARDESCA;MARCO ARDIGÒ;NICAELA ASPITE;GIUSEPPE ARGENZIANO;A. AMANTEA;VITALIANO SILIPO;IRIS ZALAUDEK;GRAZIA PRIGNANO;DANIELA KOVACS;ANTONIO CRISTAUDO","13;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2","MAURO PICARDO;A. DI CARLO;CATERINA CATRICALÀ;BARBARA BELLEI;MARCO ARDIGÒ;LUIGI LAINO;DANIELA KOVACS;GIUSEPPE ARGENZIANO;IRIS ZALAUDEK;GIORGIA CARDINALI;ENZO BERARDESCA;CHRISTOS C. ZOUBOULIS;NICAELA ASPITE;JO LINDA SINAGRA;ANGELA PITISCI;LIONEL LARUE;A. AMANTEA;VITTORIA MARESCA;ENRICA FLORI;GRAZIA PRIGNANO","1.81;0.93;0.85;0.78;0.51;0.5;0.47;0.47;0.47;0.41;0.4;0.38;0.38;0.37;0.37;0.37;0.35;0.33;0.33;0.32","MAURO PICARDO;CATERINA CATRICALÀ;BARBARA BELLEI;L. NOSOTTI;A. DI CARLO;GUIDO PALAMARA;GIORGIA CARDINALI;CARLO LEONETTI;ALESSANDRA LATINI;ENZO BERARDESCA;MARCO ARDIGÒ;NICAELA ASPITE;A. AMANTEA;VITALIANO SILIPO;IRIS ZALAUDEK;GRAZIA PRIGNANO;DANIELA KOVACS;ANTONIO CRISTAUDO;MONICA OTTAVIANI;JO LINDA SINAGRA","13;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2","MAURO PICARDO;A. DI CARLO;CATERINA CATRICALÀ;BARBARA BELLEI;MARCO ARDIGÒ;LUIGI LAINO;DANIELA KOVACS;IRIS ZALAUDEK;GIORGIA CARDINALI;ENZO BERARDESCA;NICAELA ASPITE;JO LINDA SINAGRA;ANGELA PITISCI;A. AMANTEA;VITTORIA MARESCA;ENRICA FLORI;GRAZIA PRIGNANO;VITALIANO SILIPO;EMANUELA CAMERA;ALESSANDRA LATINI","1.81;0.93;0.85;0.78;0.51;0.5;0.47;0.47;0.41;0.4;0.38;0.37;0.37;0.35;0.33;0.33;0.32;0.32;0.31;0.3","MAURO PICARDO;CATERINA CATRICALÀ;ALAIN TAÏEB;ANDREAS OVERBECK;ANTHONY P. WEETMAN;CHRISTINA M. MAILLOUX;DAVID J. GAWKRODGER;DOROTHY C. BENNETT;E. HELEN KEMP;GIOVANNI LEONE;JO LAMBERT;KATHERINE GOWAN;KHALED EZZEDINE;MARGARET R. WALLACE;N. VAN GEEL;PAMELA R. FAIN;PAULENE J. HOLLAND;RICHARD A. SPRITZ;SHERI L. RICCARDI;STANCA A. BIRLEA","1488;464;452;452;452;452;452;452;452;452;452;452;452;452;452;452;452;452;452;452","MAURO PICARDO;GIOVANNI LEONE;BARBARA BELLEI;JO LINDA SINAGRA;EMANUELA CAMERA;CATERINA CATRICALÀ;NICAELA ASPITE;ANTONINO GUERRISI;GIORGIA CARDINALI;MARCO ARDIGÒ;ANGELA PITISCI;A. AMANTEA;MONICA OTTAVIANI;ENZO BERARDESCA;M CORDERO GALANTE;MATTEO LUDOVICI;DANIELA KOVACS;ENRICA FLORI;VITTORIA MARESCA;B. CAPITANIO","1488;452;407;282;263;255;252;251;223;210;195;177;170;167;158;158;157;147;147;124","MAURO PICARDO;BARBARA BELLEI;A. DI CARLO;A. AMANTEA;CATERINA CATRICALÀ;DANIELA KOVACS;ENZO BERARDESCA;GIORGIA CARDINALI;GRAZIA PRIGNANO;GUIDO PALAMARA;L. NOSOTTI;MARCO ARDIGÒ;NICAELA ASPITE;ALESSANDRA LATINI;ANGELA PITISCI;ANTONIO CRISTAUDO;ANTONIO SPADEA;CARLO COTA;CARLO LEONETTI;EMANUELA CAMERA","13;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY","38;31;11;4;2;2;2;1;1","INTERNAL MEDICINE;BIOCHEMISTRY;IMMUNOLOGY;GENETICS;CELL BIOLOGY;DERMATOLOGY;PATHOLOGY;SURGERY;CANCER RESEARCH;GASTROENTEROLOGY;ENDOCRINOLOGY;VIROLOGY;ANATOMY;MICROBIOLOGY;RADIOLOGY;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;OPTICS;BIOTECHNOLOGY;CHROMATOGRAPHY;NURSING;ORGANIC CHEMISTRY;PHARMACOLOGY;PHYSICAL THERAPY;RISK ANALYSIS (ENGINEERING)","22;18;17;15;14;14;9;9;8;8;7;5;4;4;4;3;3;3;2;2;2;2;2;2;2","GENE;IN VITRO;MELANOMA;VIRUS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;CYTOKINE;RECEPTOR;SIGNAL TRANSDUCTION;STEM CELL;CANCER;CELL CULTURE;DNA;ENZYME;OXIDATIVE STRESS;PSORIASIS;TUMOR NECROSIS FACTOR ALPHA;VITILIGO;ACNE;ADIPOSE TISSUE;ALLERGY;ANTIBIOTICS;BACTERIA;CARCINOMA;COHORT;CONFOCAL;COST EFFECTIVENESS;DERMIS;EPIDEMIOLOGY;HEPATOCELLULAR CARCINOMA;HISTOPATHOLOGY;HORMONE;IN VIVO;INCIDENCE (GEOMETRY);INFLAMMATION;INTERFERON;KINASE;MELASMA;NEISSERIA GONORRHOEAE;POPULATION;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;REACTIVE OXYGEN SPECIES;SARCOIDOSIS;STROMAL CELL;TOXICITY","13;6;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GENOTYPE;HEPATITIS C VIRUS;VIRAL LOAD;CD34;KERATINOCYTE;MELANOCYTE-STIMULATING HORMONE;MUTATION;NEVUS;ADIPOGENESIS;CD44;CONTACT DERMATITIS;DERMATOLOGY LIFE QUALITY INDEX;ENDOTHELIAL STEM CELL;GONORRHEA;GROWTH FACTOR;INFLIXIMAB;MELANOCYTE;PERIPHERAL BLOOD MONONUCLEAR CELL;PROTEIN KINASE A;PSORIATIC ARTHRITIS;SYPHILIS;TRANSCRIPTION FACTOR","4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","RIBAVIRIN;ADULT STEM CELL;CD90;KERATINOCYTE GROWTH FACTOR;MEN WHO HAVE SEX WITH MEN;MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;SINGLE-NUCLEOTIDE POLYMORPHISM;ANTIRETROVIRAL THERAPY;BETA-CATENIN;CARDIOLIPIN;CATENIN;CATHELICIDIN;CATHEPSIN L;CD38;CHOCOLATE AGAR;COALESCENT THEORY;DERMAL FIBROBLAST;GLUTATHIONE S-TRANSFERASE;HAPLOTYPE;HBSAG;IMATINIB MESYLATE;INTERFERON ALFA;MAMMOGRAPHY;MELANOCORTIN 1 RECEPTOR;MELANOCYTIC NEVUS;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MG132;MOLECULAR EPIDEMIOLOGY;MULTILOCUS SEQUENCE TYPING;NICKEL ALLERGY;NOCARDIOSIS;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PATCH TESTING;PEPSTATIN;POLY ADP RIBOSE POLYMERASE;SMALL INTERFERING RNA;SPHEROPLAST;STEM CELL FACTOR;V600E;VIRAL QUASISPECIES","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;ADULT;FEMALE;MIDDLE AGED;MALE;MELANOMA;SKIN NEOPLASMS;AGED;;YOUNG ADULT;HIV INFECTIONS;HEPACIVIRUS;VITILIGO;ALPHA-MSH;ITALY;ANTIVIRAL AGENTS;GENOTYPE;HIV-1;MONOPHENOL MONOOXYGENASE;RIBAVIRIN","42;24;23;23;22;20;15;14;13;11;10;9;9;8;8;7;7;7;7;7","MELANIN PIGMENTATION IN MAMMALIAN SKIN;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;HEPATITIS C INFECTION AND TREATMENT;MELANOMA;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;CLINICAL CHARACTERISTICS AND MANAGEMENT OF SARCOIDOSIS;HEPATOCELLULAR CARCINOMA;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MULTIPOTENT MESENCHYMAL STEM CELLS;SKIN SENSITIZATION AND CONTACT ALLERGY RESEARCH;ADVANCES IN ULTRASOUND ELASTOGRAPHY IMAGING TECHNIQUES;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;BIOLOGICAL ACTIVITIES OF TRITERPENOIDS AND SAPONINS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CLINICAL AND MOLECULAR ASPECTS OF NOCARDIOSIS;COLORECTAL CANCER RESEARCH AND TREATMENT;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS","7;4;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","MELANIN;TREATMENT;DERMOSCOPY;HIV;MELANOCYTE;MELANOCYTE-STIMULATING HORMONE;MELANOMA;SKIN CANCERS;VITILIGO;ANTIVIRAL THERAPY;CD90;CONTACT ALLERGY;HEPATOCELLULAR CARCINOMA;HISTOPATHOLOGY;KERATINOCYTE GROWTH FACTOR;MELASMA;MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;NEISSERIA GONORRHOEAE;PIGMENTATION;SKIN SENSITIZATION","4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","VIROLOGICAL RESPONSE;ADIPOSE-DERIVED STEM;CLINICAL FEATURES;CONFOCAL MICROSCOPY;COST-EFFECTIVENESS ANALYSIS;GENERALIZED VITILIGO;HEPATOCELLULAR CARCINOMA;HUMAN KERATINOCYTES;LIPOASPIRATE TRANSPLANT;MULTICENTER STUDY;NORMAL HUMAN;REFLECTANCE CONFOCAL;STEM CELLS;ACID MODULATES;ACTINIC KERATOSIS;ACTIVITY CLINICAL;ADVANCED HEPATOCELLULAR;ALANINE AMINOTRANSFERASE;AMINOTRANSFERASE LEVELS;ANTI-HB CORE;ANTI-HBC POSITIVE;ANTIGEN ANTI-HBC;AUTOIMMUNITY SUSCEPTIBILITY;AZELAIC ACID;BLOOD MONONUCLEAR;BRAF MUTATIONS;BREAST CANCER;CANCER RISK;CARCINOMA MICROENVIRONMENT;CARE DATABASE","3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","STEM CELLS;CD CD;ADIPOSE-DERIVED STEM;HCV GENOTYPE;MELANOMA CELLS;VITRO CULTURE;CELL LINES;DIAGNOSTIC ACCURACY;VIROLOGICAL RESPONSE;ADIPOCYTIC DIFFERENTIATION;ADIPOGENIC LINEAGE;ADIPOSE STEM;GADOXETATE DISODIUMENHANCED;LIPOASPIRATE TRANSPLANT;MELANOMA CELL;TISSUE REGENERATION;TRANSCRIPTION FACTOR;AVERAGE DIAGNOSTIC;COMBINATION THERAPY;ERYTHROCYTE RIBAVIRIN;GENERALIZED VITILIGO;GENOTYPE PATIENTS;HCV RNA;HIV- SUBTYPE;HUMAN MELANOMA;MCF CELLS;MICROM NA;MULTIDETECTOR CT;MULTIPHASIC -SECTION;NOCARDIA SPP","14;10;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3",3,0.05,7.42,3,0,0,0,1,1,0,0,4.5,0,1,1.5,0,0,0,1,1,1,1,0,85,85,1,0,2,0,0,0,0,0,0,0,0,0,2,0,0,5,4,5.13,2,0,1,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"CONDEELIS JOHN S;GERTLER FRANK;GOSWAMI SUMANTA;NISTICO PAOLA","2;2;2;2","ALBERT EINSTEIN COLLEGE OF MEDICINE;IFO REGINA ELENA CANCER INST;INDIVIDUAL;MASSACHUSETTS INSTITUTE OF TECHNOLOGY","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","4;2","BRAIN DISORDERS;CANCER;GENETICS","1;1;1",NA,NA,"G01N33/53;A61K39/395;C07K5/10;C12Q1/68;G01N33/567;G01N33/574","2;1;1;1;1;1","A61K31/713;A61P35/00;C12Q1/6886;C12Q2600/106;C12Q2600/112;C12Q2600/136;G01N33/5011;G01N33/57415;G01N33/57419;G01N33/57434","2;2;2;2;2;2;2;2;2;2",12,4.7,237.64,12.9,3,0.25,46.17,0,0,4,0,4,0,0,4,0,9,2,0,0,0,0,0,0,11,1,0,11,1,0,0,0,0,0,0,0,0,"France;Italy;United States","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","12;7;4;4;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;CHILDHOOD LEUKEMIA;LYMPHOMA;PEDIATRIC;PEDIATRIC CANCER;AGING;ORPHAN DRUG;AUTOIMMUNE DISEASE;BREAST CANCER;CARDIOVASCULAR;COMPLEMENTARY AND INTEGRATIVE HEALTH;DIGESTIVE DISEASES;FOODBORNE ILLNESS;INFECTIOUS DISEASES;NUTRITION;PATIENT SAFETY","11;9;7;7;6;3;3;3;3;2;2;1;1;1;1;1;1;1;1;1","CANCER;INFECTION;ORAL AND GASTROINTESTINAL;SKIN","8;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","9;2;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;HODGKIN'S DISEASE;NOT SITE-SPECIFIC CANCER;SMALL INTESTINE CANCER;STOMACH CANCER","4;3;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD","4;2;2;2;1;1",1,398600,199300,4,2,1,1,13,140343.75,0.399020262747718,"IRCCS OSPEDALE SAN RAFFAELE;ISTITUTI FISIOTERAPICI OSPITALIERI","1;1","TELETHON FOUNDATION","1",NA,NA,"TELETHON GRANT PROJECTS - 2010 (PROGRAM)","1","31 BIOLOGICAL SCIENCES;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES","1;1;1","BRAIN DISORDERS;EPILEPSY;GENETICS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MENTAL HEALTH;NEURODEGENERATIVE;NEUROSCIENCES;PEDIATRIC;RARE DISEASES;RETT SYNDROME","1;1;1;1;1;1;1;1;1;1","CONGENITAL;NEUROLOGICAL","1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,10,"PUBLIC LIBRARY OF SCIENCE","10","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;3103 ECOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;38 ECONOMICS;3801 APPLIED ECONOMICS;4206 PUBLIC HEALTH;46 INFORMATION AND COMPUTING SCIENCES;49 MATHEMATICAL SCIENCES","6;6;3;3;2;1;1;1;1;1;1;1","CANCER;GENETICS;AGING;BREAST CANCER;CARDIOVASCULAR;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;HYPERTENSION;PATIENT SAFETY;PREVENTION","3;2;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","3;2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;6.1 PHARMACEUTICALS","2;1;1","BIOMEDICAL;CLINICAL;POPULATION & SOCIETY","3;1;1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;HEALTH SERVICES RESEARCH","2;2;2;1","MELANOMA;BREAST CANCER;NOT SITE-SPECIFIC CANCER","2;1;1","4 QUALITY EDUCATION","1"
"IRCCS_IFO",2011,94,11.2872340425532,2.34042553191489,0.319148936170213,0.276595744680851,0.393617021276596,1.99090909090909,1.25,1.36842105263158,1.42307692307692,0.329787234042553,2,39,12,15,13,0.41,0.13,0.16,0.14,34.82,0.8186136740441,NA,0.436170212765957,0.861702127659574,0.504,0.358,0.396,0.341,"CATERINA CATRICALÀ;ROBERTO LATAGLIATA;MASSIMO BRECCIA;ENZO BERARDESCA;ANTONIO SPADEA;GIUSEPPE ARGENZIANO;IRIS ZALAUDEK;ELVIRA MOSCARELLA;MAURO PICARDO;GIULIANA ALIMENA;MARIA CONCETTA PETTI;CARLO COTA;MICHELE CEDRONE;GIOVANNI PELLACANI;ANTONIO CRISTAUDO;GIUSEPPE AVVISATI;GABRIELLA FABBROCINI;FABRIZIO ENSOLI;CHIARA PANETTA;MARCO ARDIGÒ","11;9;9;8;8;8;8;7;7;7;6;6;6;5;5;5;5;5;5;5","A. DI CARLO;ENZO BERARDESCA;MAURO PICARDO;MARIA GABRIELLA DONÀ;CARLO COTA;CATERINA CATRICALÀ;MARCO ARDIGÒ;GIOVANNI LEONE;ALESSIA PACIFICO;ELVIRA MOSCARELLA;GIUSEPPE ARGENZIANO;IRIS ZALAUDEK;S. BUCHER;GERARDO FERRARA;CLAUDIO BONIFATI;NORMA CAMELI;A. AMANTEA;ANTONELLÁ TOSTI;ANTONIO CRISTAUDO;DIEGO RIBUFFO","1.77;1.42;1.3;1.18;1.12;1;0.99;0.94;0.9;0.8;0.73;0.73;0.7;0.69;0.69;0.63;0.61;0.55;0.54;0.53","CATERINA CATRICALÀ;ENZO BERARDESCA;ANTONIO SPADEA;ELVIRA MOSCARELLA;MAURO PICARDO;MARIA CONCETTA PETTI;CARLO COTA;GIOVANNI PELLACANI;ANTONIO CRISTAUDO;FABRIZIO ENSOLI;CHIARA PANETTA;MARCO ARDIGÒ;ISABELLA SPERDUTI;NORMA CAMELI;LAURA EIBENSCHUTZ;FULVIA PIMPINELLI;GIOVANNI LEONE;A. AMANTEA;GRAZIA PRIGNANO;A. DI CARLO","11;8;8;7;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4","A. DI CARLO;ENZO BERARDESCA;MAURO PICARDO;MARIA GABRIELLA DONÀ;CARLO COTA;CATERINA CATRICALÀ;MARCO ARDIGÒ;GIOVANNI LEONE;ALESSIA PACIFICO;ELVIRA MOSCARELLA;S. BUCHER;GERARDO FERRARA;CLAUDIO BONIFATI;NORMA CAMELI;A. AMANTEA;ANTONIO CRISTAUDO;GIOVANNI PELLACANI;RENATO COVELLO;LUIGI LAINO;ALESSANDRA D’ADDIO","1.77;1.42;1.3;1.18;1.12;1;0.99;0.94;0.9;0.8;0.7;0.69;0.69;0.63;0.61;0.54;0.52;0.51;0.5;0.5","GIUSEPPE ARGENZIANO;IRIS ZALAUDEK;ALBERTA CAPPELLI;ALESSANDRO VIT;BRUNO SANGRO;C.L. MAINI;CARLO URIGO;DANIELE GASPARINI;EMANUELA GIAMPALMA;FRANCESCO FIORE;FRANCESCO IZZO;GIUSEPPE MARIA ETTORRE;HOJJAT AHMADZADEHFAR;JOSÉ IGNACIO BILBAO;KAI WILHELM;L CARPANESE;MARK VAN BUSKIRK;MERCEDES IÑARRAIRAEGUI;ONELIO GEATTI;PHILIPP M. PAPROTTKA","606;606;603;603;603;603;603;603;603;603;603;603;603;603;603;603;603;603;603;603","C.L. MAINI;L CARPANESE;CATERINA CATRICALÀ;LAURA EIBENSCHUTZ;ENZO BERARDESCA;NORMA CAMELI;MAURO PICARDO;MARCO ARDIGÒ;MARINA AGOZZINO;CARLO COTA;ELVIRA MOSCARELLA;MICHÈLE MILELLA;ANNA DI BENEDETTO;MARCELLA MOTTOLESE;CHIARA PANETTA;VITALIANO SILIPO;FABRIZIO ENSOLI;GRAZIA PRIGNANO;ISABELLA SPERDUTI;GIOVANNI LEONE","603;603;574;337;254;213;192;171;148;147;142;134;124;124;122;118;100;100;98;93","CATERINA CATRICALÀ;ENZO BERARDESCA;ANTONIO SPADEA;MAURO PICARDO;CARLO COTA;FABRIZIO ENSOLI;ANTONIO CRISTAUDO;CHIARA PANETTA;ELVIRA MOSCARELLA;NORMA CAMELI;MARCO ARDIGÒ;A. AMANTEA;A. DI CARLO;GRAZIA PRIGNANO;LAURA EIBENSCHUTZ;FULVIA PIMPINELLI;GIOVANNI LEONE;ALESSIA PACIFICO;CLAUDIO BONIFATI;F. M. SOLIVETTI","10;8;7;7;6;5;5;5;5;5;5;4;4;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;BUSINESS;SOCIOLOGY;ENGINEERING;POLITICAL SCIENCE;MATERIALS SCIENCE;ECONOMICS;MATHEMATICS;PSYCHOLOGY","80;34;14;14;7;4;4;3;3;2;1;1;1","INTERNAL MEDICINE;DERMATOLOGY;PATHOLOGY;GENETICS;CANCER RESEARCH;IMMUNOLOGY;SURGERY;OPTICS;GASTROENTEROLOGY;ONCOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;RADIOLOGY;VIROLOGY;CELL BIOLOGY;ANATOMY;DEMOGRAPHY;ENDOCRINOLOGY;MICROBIOLOGY;MOLECULAR BIOLOGY;NURSING","50;32;25;22;20;20;19;12;11;9;8;8;8;8;7;4;4;4;4;4;4","CANCER;GENE;DISEASE;MELANOMA;INCIDENCE (GEOMETRY);POPULATION;PSORIASIS;APOPTOSIS;BIOPSY;DNA;ERYTHEMA;IMMUNE SYSTEM;RETROSPECTIVE COHORT STUDY;VIRUS;ANTIBODY;ANTIGEN;ARTHRITIS;CHEMOTHERAPY;CONFOCAL;MYELOID LEUKEMIA;QUALITY OF LIFE (HEALTHCARE);TUMOR NECROSIS FACTOR ALPHA","16;13;11;11;8;8;7;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4","BREAST CANCER;MUTATION;NEVUS;PSORIATIC ARTHRITIS;SKIN CANCER;CD8;DERMATOLOGY LIFE QUALITY INDEX;DERMATOSCOPY;DNA DAMAGE;GENOTYPE;IMATINIB;POLYMERASE CHAIN REACTION;TOLERABILITY;ACTINIC KERATOSIS;ACUPUNCTURE;CATALASE;CDKN2A;CELL CYCLE;DNA REPAIR;ESSENTIAL THROMBOCYTHEMIA;GENOME;GLUTATHIONE;HAEMATOPOIESIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS C VIRUS;LENTIGO MALIGNA;LENTIGO MALIGNA MELANOMA;MELANOCYTE;PHOTOPROTECTION;RETINOIC ACID;RHEUMATOID FACTOR;RITUXIMAB;SEROLOGY;STAPHYLOCOCCUS AUREUS;T CELL;TRANSCRIPTION FACTOR;VIRAL DISEASE","5;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IMATINIB MESYLATE;ACUTE PROMYELOCYTIC LEUKEMIA;DRY NEEDLING;GERMLINE MUTATION;MELANOCYTIC NEVUS;SENTINEL LYMPH NODE;AGAR DILUTION;ANAGRELIDE;BK VIRUS;BREAST RECONSTRUCTION;BUSULFAN;CANCER CACHEXIA;CEFIXIME;CEFPODOXIME;CONDITIONING REGIMEN;CYTOMEGALOVIRUS INFECTION;DASATINIB;DEEP SEQUENCING;DISCOID LUPUS ERYTHEMATOSUS;DNA EXTRACTION;ELISPOT;ENTHESITIS;EQ-5D;GENOTYPING;GLUTATHIONE PEROXIDASE;HEMATOPOIETIC CELL;HERPESVIRIDAE;HIV VACCINE;INTRAVENOUS DRUG;KAPOSI'S SARCOMA;LATENT TUBERCULOSIS;MALE BREAST CANCER;MEK INHIBITOR;MEN WHO HAVE SEX WITH MEN;MERKEL CELL;MERKEL CELL POLYOMAVIRUS;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;MISSENSE MUTATION;NICKEL ALLERGY;NUCLEAR EXPORT SIGNAL;NUCLEAR PROTEIN;NUCLEAR TRANSPORT;ONCOGENE;OXCARBAZEPINE;PHOTOLYASE;POINT MUTATION;PULSED-FIELD GEL ELECTROPHORESIS;PYRIMIDINE DIMER;RETINOBLASTOMA PROTEIN;REVERSE TRANSCRIPTASE;SENTINEL NODE;SEROPREVALENCE;SINGLE-NUCLEOTIDE POLYMORPHISM;SINGLE-STRAND CONFORMATION POLYMORPHISM;SPITZ NEVUS;STAPHYLOCOCCAL INFECTIONS;T-CELL RECEPTOR;TLR2;TRETINOIN;UBIQUITIN LIGASE;UNDERWEIGHT;USTEKINUMAB","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;SKIN NEOPLASMS;ADULT;;AGED;PSORIASIS;MELANOMA;ITALY;HIV INFECTIONS;DERMOSCOPY;AGED, 80 AND OVER;BREAST NEOPLASMS;YOUNG ADULT;ADOLESCENT;MICROSCOPY, CONFOCAL;DERMATOLOGIC AGENTS;HIV-1","66;51;46;39;38;36;26;23;21;18;17;13;12;11;11;11;10;10;9;9","MELANOMA;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;MELANIN PIGMENTATION IN MAMMALIAN SKIN;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ATOPIC DERMATITIS AND SKIN MICROBIOME;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC REARRANGEMENT DISORDERS IN SKIN DISEASES;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;SKIN SCARRING AND REMODELING MECHANISMS;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;HEPATITIS C INFECTION AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;IMPACT OF HEALTH LITERACY ON HEALTH OUTCOMES;REGULATION AND FUNCTION OF HAIR FOLLICLE STEM CELLS;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES;SKIN SENSITIZATION AND CONTACT ALLERGY RESEARCH;ADVANCES IN ULTRASOUND ELASTOGRAPHY IMAGING TECHNIQUES;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;BRAIN FLUID DYNAMICS AND WASTE CLEARANCE MECHANISMS;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES","8;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1","SKIN CANCERS;PSORIASIS;DERMOSCOPY;ERYTHEMA;MELANOMA;NONMELANOMA SKIN CANCER;DERMAL REMODELING;DERMATOSCOPY;DISCONTINUATION;HIV;IMATINIB MESYLATE;PATHOGENESIS;PHOTOAGING;SUNSCREEN USE;TOLERABILITY;VITILIGO;ACTINIC KERATOSIS;ACUTE PROMYELOCYTIC LEUKEMIA;ANTIGEN PRESENTATION;CANCER COMMUNICATION","8;6;5;5;5;5;4;3;3;3;3;3;3;3;3;3;2;2;2;2","CONFOCAL MICROSCOPY;CELL CARCINOMA;CEMENT SCAFFOLD;ITALIAN PATIENTS;RISK FACTORS;SKIN CANCER;ACUTE PROMYELOCYTIC;AIDA PROTOCOLS;ANTIOXIDANT DEFENCE;ARTRITE REUMATOIDE;BREAST CANCER;CANCER INFORMATION;CANCER PATIENTS;CELL TRANSPLANTATION;CHRONIC HAND;CHRONIC MYELOID;CLINICAL FEATURES;CML PATIENTS;CUTANEOUS MELANOMA;DIFFERENTIATION SYNDROME;DISEASE RELAPSE;FAMILIAL CUTANEOUS;GRANULOMA ANNULARE;HAND ECZEMA;HEMATOPOIETIC STEM;HUMAN SKIN;IMMUNE RESPONSES;INFORMATION SERVICE;LEUKEMIA TREATED;LIGHT ERUPTION","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GENERALIZED VITILIGO;VITILIGO AGE;VITILIGO SUSCEPTIBILITY;COST PATIENT-MONTH;DEPIGMENTING SERUM;EQ-D VAS;GENES INVOLVED;HIGH-DOSE MEL;PSORIATIC ARTHRITIS;SOOT PARTICLES;SUMMARY SCORE;CMV INFECTION;LINEAR ARRAY;CELL TRANSPLANTATION;COLOR DOPPLER;CONDITIONING REGIMEN;DLQI SUMMARY;HUMAN SKIN;INDEPENDENT PREDICTOR;MUCOCUTANEOUS TOXICITY;NEUROENDOSCOPIC BIOPSY;NEWLY DIAGNOSED;SKIN NEEDLING;STEM CELL;AML PATIENTS;BETA HPV;CLINICALLY RELEVANT;CONDITIONING REGIMENS;DIESEL ENGINE;DIFFERENTIATION SYNDROME","8;8;8;7;6;6;6;6;6;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3",4,0.04,5.88,4,0,0,0,0,1,0,1.75,4.75,0,1,3,0,0,0,0,3,0,0,0,112.25,112.25,3,1,1,0,0,0,0,1,1,0,0,0,3,1,0,1,4.75,8.68,1.75,0,3,2,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CIANA PAOLO;GOEMAN FRAUKE;MAGGI ADRIANA;PIAGGIO GIULIA;SACCHI ADA;TIVERON CECILIA;BLANDINO GIOVANNI;CITRO GENNARO;DI MODUGNO FRANCESCA;GALATI ROSSELLA MARIA","2;2;2;2;2;2;1;1;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;TOP (TRANSGENIC OPERATIVE PRODUCTS) SRL;INSTITUTI FISIOTERAPICI OSPITALIERI;IST FISIOTERAP OSPITALROMA","3;2;1;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","5;3;2;1;1;1","CANCER;GENETICS;PREVENTION","3;2;1","5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","4;1;1","A01K67/027;C12Q1/68;A61K38/04;A61K38/06;C07K14/00;C07K16/00;C07K17/00;C07K5/00;C07K7/00;C12N15/85","2;2;1;1;1;1;1;1;1;1","A01K2267/0331;A01K2267/0393;A01K67/0275;C12N15/8509;C12N2830/40;A61K38/00;A61P35/00;A61P43/00;C07K14/4746;C12Q1/6886","2;2;2;2;2;1;1;1;1;1",13,7.15,639.23,12.62,4,0.31,98.23,1,0,7,0,4,0,0,1,0,12,1,0,0,0,0,0,0,11,1,1,13,0,0,0,0,0,0,0,0,0,"Switzerland;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","13;10;6;2;1;1","CLINICAL RESEARCH;CANCER;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;HEMATOLOGY;ORPHAN DRUG;AGING;GENETICS;LUNG;LUNG CANCER;PEDIATRIC;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;BIOTECHNOLOGY;BREAST CANCER;CHILDHOOD LEUKEMIA;DIGESTIVE DISEASES;HIV/AIDS;IMMUNIZATION","13;12;9;7;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1","CANCER;BLOOD;INFECTION","9;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.4 VACCINES;6.2 CELLULAR AND GENE THERAPIES","12;2;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;SARCOMA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BREAST CANCER;GALLBLADDER CANCER;LIVER CANCER;MELANOMA;PROSTATE CANCER;SKIN CANCER","2;2;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","9;2;2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;AMERICAN ASSOCIATION FOR CANCER RESEARCH","8;5;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3206 MEDICAL BIOTECHNOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;49 MATHEMATICAL SCIENCES;4905 STATISTICS","20;10;7;6;6;2;2;1;1;1;1;1;1","CANCER;GENETICS;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;BREAST CANCER;CARDIOVASCULAR;CLINICAL RESEARCH;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;LUNG;LUNG CANCER;ORPHAN DRUG;PREVENTION;RARE DISEASES;REGENERATIVE MEDICINE;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;STEM CELL RESEARCH - UMBILICAL CORD BLOOD/ PLACENTA;STEM CELL RESEARCH - UMBILICAL CORD BLOOD/ PLACENTA - HUMAN;TRANSPLANTATION","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","8;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","1;1;1","BIOMEDICAL","3","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","5;2","BREAST CANCER;NOT SITE-SPECIFIC CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER","6;2;1;1",NA,NA
"IRCCS_IFO",2012,67,10.3731343283582,2.94029850746269,0.462686567164179,0.26865671641791,0.656716417910448,2,1.34782608695652,1.63636363636364,1.33333333333333,0.373134328358209,1,33,11,3,8,0.49,0.16,0.04,0.12,38.85,0.930148315224229,4.28018223234624,0.358208955223881,0.805970149253731,0.421,0.373,0.381,0.378,"CARLO COTA;MAURO PICARDO;CATERINA CATRICALÀ;AMINA VOCATURO;GIUSEPPE ARGENZIANO;IRIS ZALAUDEK;A. DI CARLO;ELVIRA MOSCARELLA;FABRIZIO ENSOLI;ENZO BERARDESCA;GUIDO PALAMARA;ROBERTO LATAGLIATA;ALESSANDRA LATINI;F. M. SOLIVETTI;MARCO ARDIGÒ;ANTONIO SPADEA;MASSIMO GIULIANI;MARIA GABRIELLA DONÀ;MARIA BENEVOLO;ROBERTO CIANNI","9;9;8;7;7;7;7;6;5;5;5;4;4;4;4;4;4;4;4;3","A. DI CARLO;CARLO COTA;MAURO PICARDO;ENZO BERARDESCA;IRIS ZALAUDEK;GIUSEPPE ARGENZIANO;CATERINA CATRICALÀ;AMINA VOCATURO;ELVIRA MOSCARELLA;F. M. SOLIVETTI;CARMINE ZOCCALI;FULVIA ELIA;BARBARA BELLEI;DARIO GRACEFFA;MARCO ARDIGÒ;FABRIZIO ENSOLI;GIOVANNI ZOCCALI;MARIANTONIA CAROSI;MARIA GABRIELLA DONÀ;MARIA BENEVOLO","1.79;1.15;1.01;0.9;0.89;0.86;0.85;0.79;0.76;0.63;0.62;0.56;0.49;0.48;0.47;0.44;0.42;0.41;0.38;0.38","CARLO COTA;MAURO PICARDO;CATERINA CATRICALÀ;AMINA VOCATURO;IRIS ZALAUDEK;A. DI CARLO;ELVIRA MOSCARELLA;FABRIZIO ENSOLI;ENZO BERARDESCA;GUIDO PALAMARA;ALESSANDRA LATINI;F. M. SOLIVETTI;MARCO ARDIGÒ;ANTONIO SPADEA;MASSIMO GIULIANI;MARIA GABRIELLA DONÀ;FULVIA ELIA;MATTEO LUDOVICI;DARIO GRACEFFA;GIORGIA CARDINALI","9;9;8;7;7;7;6;5;5;5;4;4;4;4;4;4;3;3;3;3","A. DI CARLO;CARLO COTA;MAURO PICARDO;ENZO BERARDESCA;IRIS ZALAUDEK;CATERINA CATRICALÀ;AMINA VOCATURO;ELVIRA MOSCARELLA;F. M. SOLIVETTI;CARMINE ZOCCALI;FULVIA ELIA;BARBARA BELLEI;DARIO GRACEFFA;MARCO ARDIGÒ;FABRIZIO ENSOLI;GIOVANNI ZOCCALI;MARIANTONIA CAROSI;MARIA GABRIELLA DONÀ;S. BUCHER;ANGELA PITISCI","1.79;1.15;1.01;0.9;0.89;0.85;0.79;0.76;0.63;0.62;0.56;0.49;0.48;0.47;0.44;0.42;0.41;0.38;0.38;0.38","MAURO PICARDO;ALAIN TAÏEB;DAVINDER PARSAD;KHALED EZZEDINE;NANJA VAN GEEL;YVON GAUTHIER;AZALEA LEE;B. K. GOH;C. LAN;C. SILVA DE CASTRO;HENRY W. LIM;I. CAROLINE LE POOLE;ICHIRO KATAYAMA;ILTEFAT HAMZAVI;LAÏLA BENZEKRI;NAOKI OISO;RICHARD A. SPRITZ;SEUNG KYUNG HANN;TAG S. ANBAR;TAMIO SUZUKI","1217;963;963;963;963;963;575;575;575;575;575;575;575;575;575;575;575;575;575;575","MAURO PICARDO;MARIA LUCIA DELL’ANNA;GIOVANNI LEONE;CATERINA CATRICALÀ;ANDREA RUSSO;MASSIMO GIULIANI;MARIA GABRIELLA DONÀ;CARLO COTA;A. DI CARLO;GUIDO PALAMARA;ENZO BERARDESCA;NICAELA ASPITE;GIORGIA CARDINALI;ALESSANDRA LATINI;FABRIZIO ENSOLI;ELVIRA MOSCARELLA;ENRICA FLORI;DANIELA KOVACS;VITALIANO SILIPO;MARCO ARDIGÒ","1217;439;388;217;197;189;174;171;166;159;148;146;143;124;124;123;123;97;95;91","MAURO PICARDO;CARLO COTA;CATERINA CATRICALÀ;A. DI CARLO;ENZO BERARDESCA;FABRIZIO ENSOLI;GUIDO PALAMARA;ALESSANDRA LATINI;ANTONIO SPADEA;ELVIRA MOSCARELLA;MARIA GABRIELLA DONÀ;MASSIMO GIULIANI;F. M. SOLIVETTI;S. BUCHER;DARIO GRACEFFA;ENRICA FLORI;FULVIA ELIA;GIORGIA CARDINALI;MARCO ARDIGÒ;MARIA LUCIA DELL’ANNA","9;8;8;7;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATHEMATICS;ENGINEERING;COMPUTER SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;POLITICAL SCIENCE;PSYCHOLOGY;GEOGRAPHY","58;27;9;6;6;4;3;3;2;2;2;1","INTERNAL MEDICINE;PATHOLOGY;SURGERY;DERMATOLOGY;CANCER RESEARCH;BIOCHEMISTRY;IMMUNOLOGY;GASTROENTEROLOGY;GENETICS;CELL BIOLOGY;OPTICS;RADIOLOGY;MICROBIOLOGY;ENDOCRINOLOGY;GYNECOLOGY;ONCOLOGY;VIROLOGY;DEMOGRAPHY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;MOLECULAR BIOLOGY;PALEONTOLOGY;PSYCHIATRY","33;22;22;21;15;14;13;11;11;8;7;6;5;4;4;4;4;3;3;3;3;3;3","GENE;MELANOMA;CANCER;INCIDENCE (GEOMETRY);CHEMOTHERAPY;COHORT;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;ENZYME;HUMAN IMMUNODEFICIENCY VIRUS (HIV);PSORIASIS;SIGNAL TRANSDUCTION;VIRUS;ANTIBODY;BIOPSY;CONFOCAL;CONFOCAL MICROSCOPY;DISEASE;HEPATOCELLULAR CARCINOMA;IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;PLATELET;POPULATION;RECEPTOR;RHEUMATOID ARTHRITIS;THROMBOSIS;VITILIGO","13;10;9;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","GENOTYPE;CERVICAL CANCER;TOLERABILITY;CD8;DERMATOSCOPY;NEVUS;PSORIATIC ARTHRITIS;VIRAL LOAD;ADALIMUMAB;ANAL CANCER;CARCINOGENESIS;CLINICAL ENDPOINT;COLORECTAL CANCER;CUMULATIVE INCIDENCE;CYTOTOXIC T CELL;DEEP VEIN;DERMATOFIBROMA;EPITOPE;ETANERCEPT;IMMUNOTHERAPY;MAPK/ERK PATHWAY;PSORIASIS AREA AND SEVERITY INDEX;SYPHILIS;TRANSCRIPTION FACTOR;VASCULAR ENDOTHELIAL GROWTH FACTOR","6;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;COLPOSCOPY;GENOTYPING;HPV INFECTION;MEN WHO HAVE SEX WITH MEN;ASPARTATE TRANSAMINASE;AXIN2;AZOXYMETHANE;BETA-CATENIN;CATENIN;CD28;CD3;CELLULAR SENESCENCE;CERVICAL INTRAEPITHELIAL NEOPLASIA;COLONIC DISEASE;COLOR IMAGE;CONDOM;CREB;CYANOACRYLATE;ELECTROCHEMOTHERAPY;ELISPOT;FOLINIC ACID;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;LENTIVIRUS;LEUKAPHERESIS;LYMPHANGIOGENESIS;MELANOCYTIC NEVUS;MULTILOCUS SEQUENCE TYPING;NUCLEAR RECEPTOR;OCCUPATIONAL BURNOUT;OXALIPLATIN;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;PULSED-FIELD GEL ELECTROPHORESIS;REVERSE TRANSCRIPTASE;SIDA;SMALL INTERFERING RNA;T-CELL RECEPTOR;TISSUE TROPISM;V3 LOOP;VASCULAR ENDOTHELIAL GROWTH FACTOR A;VIRAL ENTRY;ZIDOVUDINE","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;;SKIN NEOPLASMS;PAPILLOMAVIRUS INFECTIONS;MELANOMA;AGED;ITALY;YOUNG ADULT;UTERINE CERVICAL NEOPLASMS;ADOLESCENT;HIV INFECTIONS;BONE NEOPLASMS;IMMUNOSUPPRESSIVE AGENTS;TREATMENT OUTCOME;AGED, 80 AND OVER;ARTHRITIS, PSORIATIC","46;30;30;26;22;17;17;14;13;12;12;12;11;10;9;8;8;8;7;7","MELANOMA;MELANIN PIGMENTATION IN MAMMALIAN SKIN;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;HEPATOCELLULAR CARCINOMA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ATOPIC DERMATITIS AND SKIN MICROBIOME;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;IMMUNOBIOLOGY OF DENDRITIC CELLS;LYMPHANGIOGENESIS IN CANCER METASTASIS AND DISEASE;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;ACUTE MYELOID LEUKEMIA;ALLELOPATHY AND PLANT INTERACTIONS;ANORECTAL SURGICAL PROCEDURES;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;BODY ART AND MODIFICATION PRACTICES IN SOCIETY;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;CHEMOTHERAPY-INDUCED DERMATOLOGICAL TOXICITY;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;COPPER AND ZINC IN HEALTH AND DISEASE","7;6;5;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","TREATMENT;MELANOMA;HPV VACCINATION;TOLERABILITY;CYTOLOGY SCREENING;DERMATOSCOPY;DERMOSCOPY;VITILIGO;ANAL SEX;CANCER SURVIVORSHIP;CLINICAL ENDPOINT;CUMULATIVE INCIDENCE;DERMAL REMODELING;DERMATOFIBROMA;ERYTHROCYTE SEDIMENTATION RATE;HIV;MELANIN;MICROVASCULATURE DETECTION;NEISSERIA GONORRHOEAE;NODULE (GEOLOGY)","6;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","CONFOCAL MICROSCOPY;HEPATOCELLULAR CARCINOMA;PSORIATIC ARTHRITIS;REFLECTANCE CONFOCAL;CARCINOMA HCC;CYTO-PV TRIAL;FOLINIC ACID;HPV INFECTION;POLYCYTHEMIA VERA;PROSPECTIVE COHORT;ABSTRACT CLINICAL;ACID -FLUOROURACIL;ACID REDUCED;ACTIVATES AKT;ADOPTIVE IMMUNOTHERAPY;AFFECT AFLATOXIN;AFLATOXIN BIOSYNTHESIS;AKT PATHWAY;ANAL CYTOLOGICAL;ANAL HPV;ANAPLASTIC OLIGODENDROGLIOMA;ANTI-HIV ANTIBODIES;ANTI-TNF TREATMENT;ANTIGEN SPECIFIC;ANTIMICROBIAL SUSCEPTIBILITY;APPROACH URETHRAL;ARTHRITIS PATIENTS;ARTHROSCOPIC GUIDED;ASPERGILLUS FLAVUS;ASSESSMENT RANDOMIZED","4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CLASPIN EXPRESSION;SENSITIVE SKIN;BREAST CANCER;LYMPH NODES;DOPACHROME TAUTOMERASE;FATTY ACIDS;PATIENTS AFFECTED;PATIENTS INFECTED;SEBORRHEIC KERATOSIS;ANAL CANCER;ANAL CYTOLOGICAL;ANTIVIRAL TREATMENT;CD CELL;CELL COUNT;CHINESE WOMEN;CYTOLOGICAL ABNORMALITIES;DERMOSCOPIC FEATURES;DIHYDROXYINDOLE--CARBOXYLIC ACID;DRUG RESISTANCE;GENOTYPE HCV-POSITIVE;HCV-POSITIVE LIVER;HPV GENOTYPING;HPV INFECTION;HUMAN KERATINOCYTES;IMMUNE RESPONSE;LIVER TRANSPLANT;NORMAL TISSUES;PEROXISOME PROLIFERATION;SIGNALING PATHWAY;SKIN LESIONS","7;7;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",2,0.03,11.48,7.75,1,1,0,1,0,0,0,9.5,0,0,8,0,0,0,2,6,0,0,0,102.75,102.75,6,2,3,0,0,0,1,0,1,0,0,0,6,1,0,7,3.71428571428571,13.27,2.14285714285714,0,3,3,0,1,4,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CITRO GENNARO;BLANDINO GIOVANNI;DI AGOSTINO SILVIA;DI MODUGNO FRANCESCA;STRANO SABRINA;BONANNO ELENA;CHESSA LUCIANA;CUNDARI ENRICO;FRANCONI ROSELLA;MASSA SILVIA","3;2;2;2;2;1;1;1;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA;AGENZIA NAZIONALE PER LE NUOVE TECNOLOGIE LENERGIA E LO SVILUPPO ECONOMICO SOSTENIBILE ENEA;CONSIGLIO NAZIONALE DELLE RICHERCHE CNR;UNI DEGLI STUDI DI L AQUILA;UNIVERSITA DEGLI STUDI DELL'AQUILA;UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA;VENUTI AIDO","7;2;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY","9;7;3;3;2;1","ATAXIA TELANGIECTASIA;BIOTECHNOLOGY;GENETICS;IMMUNIZATION;INFECTIOUS DISEASES;NEURODEGENERATIVE;PREVENTION;RARE DISEASES;SEXUALLY TRANSMITTED INFECTIONS;VACCINE RELATED","1;1;1;1;1;1;1;1;1;1","5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","3;2;2","A61K33/243;A61K38/10;A61P35/00;C07K16/18;C12Q1/68;G01N33/574;A61K31/713;A61K38/08;A61K38/16;A61K38/17","2;2;2;2;2;2;1;1;1;1","A61K31/513;A61K31/592;A61K31/704;A61K33/243;A61K38/10;A61K38/1758;A61K45/06;A61P35/00;C07K14/4746;C12Q1/6886","2;2;2;2;2;2;2;2;2;2",15,8.23,507.36,15.96,6,0.4,80.53,0,0,4,0,5,0,1,5,0,11,3,0,0,0,0,0,0,12,3,0,14,1,0,0,0,0,0,0,0,0,"Italy;United States","2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;44 HUMAN SOCIETY;4403 DEMOGRAPHY","15;10;6;4;1;1;1;1","CLINICAL RESEARCH;CANCER;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;PREVENTION;BREAST CANCER;CHILDHOOD LEUKEMIA;GENETICS;OVARIAN CANCER;PATIENT SAFETY;PEDIATRIC;PEDIATRIC CANCER;TRANSPLANTATION;AGING;BIOMEDICAL IMAGING;CONTRACEPTION/REPRODUCTION;HODGKIN'S DISEASE;HUMAN GENOME","13;12;8;7;5;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1","CANCER;INFECTION;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","10;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","10;5;1;1","NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LEUKEMIA / LEUKAEMIA;MELANOMA;OVARIAN CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;LIVER CANCER;LUNG CANCER;THYROID CANCER","3;2;2;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","10;2;2;1",1,252600,126300,4,2,1,1,6,81400,0.823095823095823,"ISTITUTI FISIOTERAPICI OSPITALIERI;SAPIENZA UNIVERSITY OF ROME","1;1","TELETHON FOUNDATION","1",NA,NA,"TELETHON GRANT PROJECTS - 2012 (PROGRAM)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY","1;1","CLINICAL RESEARCH;PREVENTION","1;1",NA,NA,"2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,10,"PUBLIC LIBRARY OF SCIENCE","10","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3107 MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3001 AGRICULTURAL BIOTECHNOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3204 IMMUNOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","8;5;2;2;2;1;1;1;1;1;1","RARE DISEASES;CANCER;GENETICS;BIOTECHNOLOGY;STEM CELL RESEARCH;NEUROBLASTOMA;NEUROSCIENCES;PEDIATRIC;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;AGING;CARDIOVASCULAR;CLINICAL RESEARCH;HEART DISEASE;NUTRITION;PEDIATRIC CANCER;PROSTATE CANCER;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;UROLOGIC DISEASES","5;4;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM","3;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.1 PHARMACEUTICALS","4;2;1","BIOMEDICAL","6","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","5;1","NEUROBLASTOMA;PROSTATE CANCER;SARCOMA","2;1;1",NA,NA
"IRCCS_IFO",2013,73,10.972602739726,2.61643835616438,0.410958904109589,0.342465753424658,0.438356164383562,2.22093023255814,1.2,1.38888888888889,1.28,0.438356164383562,2,27,16,9,8,0.37,0.22,0.12,0.11,24.4,0.699210863128018,4.28600823045267,0.328767123287671,0.835616438356164,0.457,0.369,0.245,0.375,"CARLO COTA;MAURO PICARDO;ELVIRA MOSCARELLA;MARCO ARDIGÒ;ANTONIO SPADEA;PIETRO DONATI;MASSIMO GIULIANI;GIOVANNI PAOLINO;ALESSANDRA LATINI;MARINA AGOZZINO;CATERINA CATRICALÀ;LUCA MUSCARDIN;ANTONIO CRISTAUDO;ROBERTO LATAGLIATA;CATERINA LONGO;MARIA MERCEDES SANTORO;EMANUELA CAMERA;CHIARA PANETTA;ENZO BERARDESCA;MICHELE CEDRONE","12;8;7;7;7;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4","MARCO ARDIGÒ;CARLO COTA;ENZO BERARDESCA;PIETRO DONATI;MARINA AGOZZINO;LUCA MUSCARDIN;ELVIRA MOSCARELLA;GIOVANNI PAOLINO;MAURO PICARDO;CHIARA PANETTA;CATERINA CATRICALÀ;MASSIMO GIULIANI;A. DI CARLO;CARMINE ZOCCALI;SUSAN COZZOLINO;FELICE MUSICCO;PAOLA CORDIALI‐FEI;ISABELLA SPERDUTI;ANTONIO SPADEA;ANTONIO CRISTAUDO","2.12;1.68;1.54;1.17;0.95;0.9;0.85;0.84;0.76;0.7;0.67;0.63;0.53;0.53;0.5;0.5;0.48;0.48;0.43;0.42","CARLO COTA;MAURO PICARDO;ELVIRA MOSCARELLA;MARCO ARDIGÒ;ANTONIO SPADEA;PIETRO DONATI;MASSIMO GIULIANI;GIOVANNI PAOLINO;ALESSANDRA LATINI;MARINA AGOZZINO;CATERINA CATRICALÀ;LUCA MUSCARDIN;ANTONIO CRISTAUDO;EMANUELA CAMERA;CHIARA PANETTA;ENZO BERARDESCA;A. DI CARLO;GUIDO PALAMARA;FABRIZIO ENSOLI;PAOLA CORDIALI‐FEI","12;8;7;7;7;7;6;5;5;5;5;5;4;4;4;4;4;4;3;3","MARCO ARDIGÒ;CARLO COTA;ENZO BERARDESCA;PIETRO DONATI;MARINA AGOZZINO;LUCA MUSCARDIN;ELVIRA MOSCARELLA;GIOVANNI PAOLINO;MAURO PICARDO;CHIARA PANETTA;CATERINA CATRICALÀ;MASSIMO GIULIANI;A. DI CARLO;CARMINE ZOCCALI;SUSAN COZZOLINO;FELICE MUSICCO;PAOLA CORDIALI‐FEI;ANTONIO SPADEA;ANTONIO CRISTAUDO;EMANUELA CAMERA","2.12;1.68;1.54;1.17;0.95;0.9;0.85;0.84;0.76;0.7;0.67;0.63;0.53;0.53;0.5;0.5;0.48;0.43;0.42;0.4","MAURO PICARDO;CARLO COTA;EMANUELA CAMERA;CATERINA CATRICALÀ;ELVIRA MOSCARELLA;PAOLA GRAMMATICO;CHRISTOS C. ZOUBOULIS;CATERINA LONGO;L. THOMAS;AIJA OZOLA;ALEXANDER J. STRATIGOS;ALISA M. GOLDSTEIN;ANDERS MOLVEN;ANNE BÉNÉDICTE DUVAL‐MODESTE;BRIGITTE BRESSAC–DE PAILLERETS;DACE PJANOVA;HANNE PUNTERVOLL;HENSIN TSAO;HILDEGUNN HØBERG‐VETTI;HUI-HAN HU","487;248;207;172;172;150;141;135;130;125;125;125;125;125;125;125;125;125;125;125","MAURO PICARDO;CARLO COTA;EMANUELA CAMERA;CATERINA CATRICALÀ;ANTONIO CRISTAUDO;MARIA ROSARIA TORRISI;MATTEO LUDOVICI;BARBARA BELLEI;MARIA LUCIA DELL’ANNA;MARCO ARDIGÒ;MARINA AGOZZINO;MASSIMO GIULIANI;ANGELA PITISCI;FABIOLA LUZI;MONICA OTTAVIANI;MARIALUISA APPETECCHIA;S. BUCHER;FABRIZIO ENSOLI;DIANA GIANNARELLI;MARISTELLA GUERRA","487;242;207;172;111;111;107;104;104;103;97;93;89;89;89;85;82;78;77;76","CARLO COTA;MAURO PICARDO;MARCO ARDIGÒ;PIETRO DONATI;ANTONIO SPADEA;MASSIMO GIULIANI;CATERINA CATRICALÀ;GIOVANNI PAOLINO;MARINA AGOZZINO;ALESSANDRA LATINI;LUCA MUSCARDIN;A. DI CARLO;ANTONIO CRISTAUDO;CHIARA PANETTA;EMANUELA CAMERA;ENZO BERARDESCA;GUIDO PALAMARA;BARBARA BELLEI;CARMINE ZOCCALI;FABRIZIO ENSOLI","11;8;7;7;6;6;5;5;5;5;5;4;4;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;GEOGRAPHY;PSYCHOLOGY;SOCIOLOGY;BUSINESS;ECONOMICS;ENGINEERING;POLITICAL SCIENCE","62;29;11;7;3;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;SURGERY;DERMATOLOGY;CANCER RESEARCH;IMMUNOLOGY;GENETICS;BIOCHEMISTRY;CELL BIOLOGY;GASTROENTEROLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;OPTICS;VIROLOGY;ENDOCRINOLOGY;ANATOMY;BIOTECHNOLOGY;MICROBIOLOGY;PEDIATRICS;FAMILY MEDICINE;RADIOLOGY","40;28;19;18;14;14;10;9;9;9;9;7;7;7;5;4;4;4;4;3;3","CANCER;GENE;MELANOMA;DISEASE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);CONFOCAL MICROSCOPY;POPULATION;PSORIASIS;HISTOPATHOLOGY;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;BIOPSY;CHEMOTHERAPY;CONFOCAL;IMMUNOHISTOCHEMISTRY;IN VIVO;RADIATION THERAPY;ANTIBIOTICS;ANTIBODY;BONE MARROW;ENZYME;EPIDEMIOLOGY;HISTOLOGY;INCIDENCE (GEOMETRY);LESION;MICROSCOPY;POLYCYTHEMIA VERA;TUMOR NECROSIS FACTOR ALPHA","13;10;10;7;7;6;6;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","GENOTYPE;NEVUS;BREAST CANCER;MYELOFIBROSIS;POLYMERASE CHAIN REACTION;VIRAL LOAD;ALLERGIC CONTACT DERMATITIS;CERVICAL CANCER;CONTACT DERMATITIS;DOWNREGULATION AND UPREGULATION;ESSENTIAL THROMBOCYTHEMIA;HAZARD RATIO;KERATINOCYTE;MELANOCYTE;MUTATION;PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR;SKIN CANCER;SYPHILIS;TOLERABILITY;ACANTHOSIS;ADALIMUMAB;ADIPOCYTE;ADIPOGENESIS;ALLELE;ALLERGEN;ANAL CANCER;ANTIBACTERIAL AGENT;ARACHIDONIC ACID;AUTOANTIBODY;AUTOIMMUNE DISEASE;AUTOIMMUNITY;BACTEREMIA;BASAL (MEDICINE);BETAMETHASONE DIPROPIONATE;BIOSTATISTICS;BIOSYNTHESIS;BISPHOSPHONATE;BLADDER CANCER;BRACHYTHERAPY;BULLOUS PEMPHIGOID;CALCIPOTRIOL;CARCINOGENESIS;CELLULAR DIFFERENTIATION;CLOSTRIDIUM DIFFICILE;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;DEFERASIROX;DENOSUMAB;DERMATOLOGY LIFE QUALITY INDEX;DNA DAMAGE;DNA REPAIR;DOCETAXEL;ENDOCYTOSIS;ENDOMETRIAL CANCER;ENDONUCLEASE;EXON;EXTERNAL ILIAC VEIN;FUMONISIN;FUMONISIN B1;GALACTOMANNAN;GENE SILENCING;GERMLINE;GIANT-CELL TUMOR OF BONE;GROWTH HORMONE;HEMIPELVECTOMY;HEPATITIS B VIRUS;HETERODUPLEX;HUMAN LEUKOCYTE ANTIGEN;HYDROXYCARBAMIDE;IMAGING SPECTROMETER;IMATINIB;IMMUNOTHERAPY;INFRARED TELESCOPE;INSULIN RESISTANCE;INTERLEUKIN 17;INTERLEUKIN 6;INTERTRIGINOUS;LEISHMANIA;LENTIGO;LENTIGO MALIGNA;LIDOCAINE HYDROCHLORIDE;LIPOGENESIS;LIPOXYGENASE;LISTERIA MONOCYTOGENES;LYMPHADENECTOMY;MAINTENANCE THERAPY;MANDIBLE (ARTHROPOD MOUTHPART);MAPK/ERK PATHWAY;MELANOCORTIN;MENDELIAN INHERITANCE;METASTASIS;METASTATIC MELANOMA;MIXED CONNECTIVE TISSUE DISEASE;MUTANT;MYCOSIS FUNGOIDES;MYELODYSPLASTIC SYNDROMES;NF-ΚB;NILE RED;OVARIAN CANCER;OXYLIPIN;PAGETOID;PARATHYROID ADENOMA;PARATHYROID HORMONE;PATCH TEST;PHARMACIST;PHARMACODYNAMICS;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PHYLOGENETIC TREE;PHYLOGENETICS;PI3K/AKT/MTOR PATHWAY;PLACEBO;PRILOCAINE;PROLIFERATION INDEX;PROSTATE CANCER;PROTEIN KINASE A;PSORIASIS AREA AND SEVERITY INDEX;PSORIATIC ARTHRITIS;PYROSEQUENCING;QUALITY-ADJUSTED LIFE YEAR;RENAL TRANSPLANT;SKIN BIOPSY;SUPERFICIAL SPREADING MELANOMA;TELOMERE;TOPICAL ANESTHETIC;TRANSCRIPTION FACTOR;TRANSFECTION;TROPISM;UNIVARIATE ANALYSIS;VENOUS THROMBOSIS;VIRAL DISEASE;VIREMIA;VISCERAL LEISHMANIASIS;WEIGHT LOSS","4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANAGRELIDE;ANTIRETROVIRAL THERAPY;MELANOCYTIC NEVUS;MEN WHO HAVE SEX WITH MEN;SPITZ NEVUS;ABSCOPAL EFFECT;ACANTHOSIS NIGRICANS;ACROMEGALY;AMASTIGOTE;ANDROGEN DEPRIVATION THERAPY;BREAST RECONSTRUCTION;CLADE;CONNECTIVE TISSUE DISEASE;CUTANEOUS T-CELL LYMPHOMA;CYSTECTOMY;CYTOREDUCTIVE SURGERY;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DNA EXTRACTION;GENITAL WARTS;GENOTYPING;GERMLINE MUTATION;HPV INFECTION;HUMAN PAPILLOMA VIRUS;IMATINIB MESYLATE;INTERLEUKIN 23;IPILIMUMAB;LAMIVUDINE;LEISHMANIA INFANTUM;LYMPHOMATOID PAPULOSIS;MASTECTOMY;MICROMETASTASIS;MOLECULAR CLOCK;MOLECULAR EPIDEMIOLOGY;MORBID OBESITY;MYELOPROLIFERATIVE NEOPLASM;NUCLEAR RECEPTOR;OIL RED O;OSTEONECROSIS OF THE JAW;PAPILLOMAVIRIDAE;PEMPHIGOID;PERILIPIN;PERITONEAL CARCINOMATOSIS;PHOTOLYASE;PROTEIN SYNTHESIS INHIBITOR;REVERSE TRANSCRIPTASE;SECONDARY HYPERPARATHYROIDISM;SECONDARY METABOLISM;SENTINEL LYMPH NODE;SIDA;TAXANE;TISSUE TROPISM;TNF INHIBITOR;ZIDOVUDINE","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;SKIN NEOPLASMS;AGED;;MELANOMA;SKIN;HIV INFECTIONS;YOUNG ADULT;ADOLESCENT;PSORIASIS;DERMOSCOPY;AGED, 80 AND OVER;HIV-1;KERATINOCYTES;CARCINOMA;CARCINOMA, SQUAMOUS CELL","55;44;41;36;31;28;20;18;18;18;17;15;13;13;12;11;11;11;10;9","MELANOMA;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;MALE CIRCUMCISION FOR HIV PREVENTION AND PENILE HEALTH;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;MELANIN PIGMENTATION IN MAMMALIAN SKIN;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;SKIN SENSITIZATION AND CONTACT ALLERGY RESEARCH;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES;CHEMOTHERAPY-INDUCED DERMATOLOGICAL TOXICITY;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;CLOSTRIDIUM DIFFICILE INFECTION AND TREATMENT;DENTAL ANXIETY AND ANESTHETIC MANAGEMENT IN DENTISTRY","7;4;4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MELANOMA;HISTOPATHOLOGY;HIV;DERMOSCOPY;HISTOLOGY;MELANIN;MELANOCYTE;PSORIASIS;ANAGRELIDE;ANTIRETROVIRAL THERAPY;CHONDROSARCOMA;CYTOLOGY SCREENING;DISCONTINUATION;EPIDERMIS (ZOOLOGY);HPV VACCINATION;INTERQUARTILE RANGE;LIPID DROPLET;MEDICAL MICROBIOLOGY;MELANOCYTIC NEVUS;MYELOFIBROSIS","7;5;5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","CONFOCAL MICROSCOPY;REFLECTANCE CONFOCAL;MYELOPROLIFERATIVE NEOPLASMS;RETROSPECTIVE STUDY;CELL CARCINOMA;DIFFERENTIAL DIAGNOSIS;IIN VIVOI;PILOT STUDY;PSORIASIS RESULTS;RHEUMATOID ARTHRITIS;SQUAMOUS CELL;VIVOI REFLECTANCE;ABSCOPAL EFFECT;ACCEPTOR KERATINOCYTES;ACID PEEL;ACIDDEPENDENT SIGNALING;ALTERED EXPRESSION;ANAL SAMPLES;ANALOG-REFRACTORY GROWTH;ANALOGUE NLEDPHEΑMELANOCYTESTIMULATING;ANTI-TNFΑ THERAPY;ANTIRETROVIRAL THERAPY;ARACHIDONIC ACIDDEPENDENT;ARRAY HPV;ASPERGILLUS GALACTOMANNAN;ASSOCIATIONS WITHIMCRIVARIANTS;ATYPICAL LENTIGINOUS;BALANCED INHALATION;BASAL CELL;BEA- ONLINE","6;4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LINEAR ARRAY;ARRAY TEST;FFPE SAMPLES;HPV GENOTYPING;PUBMED SCOPUS;BIOPSY SPECIMENS;HPV DETECTION;CYTOLOGIC SAMPLES;HPV GENOTYPE;HPV GENOTYPES;ATYPICAL SQUAMOUS;CONE BIOPSY;CROSSREF PUBMED;INNO-LIPA ASSAY;SQUAMOUS CELLS;TNF-ALFA INHIBITOR;DNA EXTRACTION;SQUAMOUS INTRAEPITHELIAL;TEST RESULTS;ARRAY HPV;CDI EPISODES;HUMAN PAPILLOMAVIRUS;IL- IL-;INDICATOR DISEASE;NUCLEIC ACIDS;PAIRED CYTOLOGIC;PRE-HAART VIRAEMIA;TEST RESULT;VIROLOGICAL SUCCESS;BIOPSY SAMPLES","60;45;26;19;16;14;13;12;11;11;10;10;10;10;10;10;9;9;9;8;8;8;8;8;8;8;8;8;8;7",2,0.03,0.88,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,35,35,6,3,3,0,0,2,0,0,1,0,0,0,7,2,0,4.33333333333333,3.33333333333333,15.71,2.22222222222222,0,6,3,1,0,3,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,7,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"DI MODUGNO FRANCESCA;BON GIULIA;DI CARLO SELENE ELEONORA;FALCIONI RITA;FOLGIERO VALENTINA;NISTICO PAOLA;NISTICO' PAOLA;BONANNO ELENA;CHESSA LUCIANA;CITRO GENNARO","3;2;2;2;2;2;2;1;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;IST FISIOTERAP OSPITALROMA;ALBERT EINSTEIN COLLEGE OF MEDICINE;CARAGLIA MICHELE;CONSIGLIO NAZIONALE DELLE RICHERCHE CNR;DE ROSA GIUSEPPE;IFO REGINA ELENA CANCER INST;INSTITUTE FISIOTERAPICI OSPITALIERI;LA ROTONDA MARIA IMMACOLATA;MASSACHUSETTS INSTITUTE OF TECHNOLOGY","7;2;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY","13;5;4;3;1;1","CANCER;BREAST CANCER;RARE DISEASES;ATAXIA TELANGIECTASIA;BIOENGINEERING;BRAIN DISORDERS;GENETICS;NANOTECHNOLOGY;NEURODEGENERATIVE;UROLOGIC DISEASES","4;2;2;1;1;1;1;1;1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1","C12Q1/68;G01N33/574;A61K39/395;C07K14/435;A61K38/10;A61K38/18;A61P35/00;C07K7/08;G01N33/53;G01N33/68","4;4;3;3;2;2;2;2;2;2","A61P35/00;C12Q1/6886;C12Q2600/136;G01N33/5011;G01N33/57407;G01N33/57415;G01N33/57419;G01N33/57434;G01N33/57438;C07K14/435","4;4;4;4;4;4;4;4;4;3",32,6.86,2906.21,38.55,16,0.5,81.78,1,2,5,1,12,0,1,10,0,25,4,0,0,0,0,0,0,20,11,1,29,3,0,0,0,0,0,0,0,0,"United States;Italy;United Kingdom;Japan;Switzerland","9;5;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE;3204 IMMUNOLOGY","32;24;10;2;2;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;BREAST CANCER;HEMATOLOGY;AGING;LUNG;OVARIAN CANCER;BRAIN CANCER;BRAIN DISORDERS;DIGESTIVE DISEASES;ESTROGEN;GENETICS;LUNG CANCER;LYMPHOMA;NEUROSCIENCES;PREVENTION;ACUTE RESPIRATORY DISTRESS SYNDROME","28;25;23;13;7;6;4;3;3;3;2;2;2;2;2;2;2;2;2;1","CANCER;INFECTION;MUSCULOSKELETAL;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","20;1;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING","22;4;2;1;1;1","BREAST CANCER;BRAIN TUMOR;MELANOMA;OVARIAN CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;CERVICAL CANCER;GENITAL SYSTEM, FEMALE;LIVER CANCER;NOT SITE-SPECIFIC CANCER;PROSTATE CANCER;THYROID CANCER","6;3;3;3;2;2;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","20;3;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,53,"PUBLIC LIBRARY OF SCIENCE","53","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3215 REPRODUCTIVE MEDICINE;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;34 CHEMICAL SCIENCES;49 MATHEMATICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3103 ECOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3207 MEDICAL MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;3401 ANALYTICAL CHEMISTRY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","65;21;17;9;8;7;4;4;4;4;3;2;2;1;1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;GENETICS;BIOTECHNOLOGY;BRAIN DISORDERS;NEUROSCIENCES;AGING;AUTOIMMUNE DISEASE;INFECTIOUS DISEASES;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;PROSTATE CANCER;RARE DISEASES;SEXUALLY TRANSMITTED INFECTIONS;UROLOGIC DISEASES;BIOMEDICAL IMAGING;BRAIN CANCER;CERVICAL CANCER;COLO-RECTAL CANCER;DIGESTIVE DISEASES","8;5;5;4;4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1","CANCER;NEUROLOGICAL;GENERIC HEALTH RELEVANCE;INFECTION","7;3;2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.1 PHARMACEUTICALS;3.4 VACCINES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)","5;2;2;1;1;1;1","BIOMEDICAL;CLINICAL;POPULATION & SOCIETY","8;3;3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","17;11;1","COLON AND RECTAL CANCER;BRAIN TUMOR;BREAST CANCER;PROSTATE CANCER;ANAL CANCER;CERVICAL CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;THYROID CANCER","3;2;2;2;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING;4 QUALITY EDUCATION","2;1"
"IRCCS_IFO",2014,102,10.9117647058824,2.62745098039216,0.392156862745098,0.264705882352941,0.401960784313726,2.07751937984496,1.11111111111111,1.22727272727273,1.10810810810811,0.480392156862745,0,43,22,16,7,0.42,0.22,0.16,0.07,24.96,0.660483217338763,4.48015122873346,0.313725490196078,0.872549019607843,0.388,0.383,0.399,0.38,"CARLO COTA;MAURO PICARDO;ALESSANDRA LATINI;ENZO BERARDESCA;FABRIZIO ENSOLI;ELVIRA MOSCARELLA;ANDREA ANTINORI;MARCO ARDIGÒ;ISABELLA SPERDUTI;MARIA GABRIELLA DONÀ;A. DI CARLO;ANTONIO CRISTAUDO;EMANUELA CAMERA;VIRGINIA FERRARESI;MASSIMO GIULIANI;GIUSEPPE ARGENZIANO;CATERINA CATRICALÀ;IRIS ZALAUDEK;JO LINDA SINAGRA;GIOVANNA D’AGOSTO","11;11;9;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;4;4","CARLO COTA;MAURO PICARDO;MARCO ARDIGÒ;ENZO BERARDESCA;ISABELLA SPERDUTI;VIVIANA LORA;BARBARA BELLEI;A. DI CARLO;ALESSANDRA LATINI;MARIA MARIANO;NORMA CAMELI;LORENZO CERRONI;FABRIZIO ENSOLI;CATERINA CATRICALÀ;GIOVANNA D’AGOSTO;PAOLA CORDIALI‐FEI;MARIA GABRIELLA DONÀ;F. M. SOLIVETTI;FRANCESCO FACCIOLO;TATIANA KOUDRIAVTSEVA","1.59;1.45;1.03;1.01;0.84;0.79;0.73;0.66;0.65;0.62;0.62;0.62;0.61;0.6;0.59;0.59;0.58;0.56;0.54;0.53","CARLO COTA;MAURO PICARDO;ALESSANDRA LATINI;ENZO BERARDESCA;FABRIZIO ENSOLI;MARCO ARDIGÒ;ISABELLA SPERDUTI;MARIA GABRIELLA DONÀ;A. DI CARLO;ANTONIO CRISTAUDO;EMANUELA CAMERA;VIRGINIA FERRARESI;MASSIMO GIULIANI;CATERINA CATRICALÀ;JO LINDA SINAGRA;GIOVANNA D’AGOSTO;MATTEO LUDOVICI;MANUELA COLAFIGLI;F. M. SOLIVETTI;PAOLA DE SIMONE","11;11;9;7;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4","CARLO COTA;MAURO PICARDO;MARCO ARDIGÒ;ENZO BERARDESCA;ISABELLA SPERDUTI;VIVIANA LORA;BARBARA BELLEI;A. DI CARLO;ALESSANDRA LATINI;MARIA MARIANO;NORMA CAMELI;FABRIZIO ENSOLI;CATERINA CATRICALÀ;GIOVANNA D’AGOSTO;PAOLA CORDIALI‐FEI;MARIA GABRIELLA DONÀ;F. M. SOLIVETTI;FRANCESCO FACCIOLO;TATIANA KOUDRIAVTSEVA;VIRGINIA FERRARESI","1.59;1.45;1.03;1.01;0.84;0.79;0.73;0.66;0.65;0.62;0.62;0.61;0.6;0.59;0.59;0.58;0.56;0.54;0.53;0.52","MAURO PICARDO;EMANUELA CAMERA;MATTEO LUDOVICI;CHRISTOS C. ZOUBOULIS;CARLO COTA;ISABELLA SPERDUTI;ATTILA GÁBOR SZÖLLŐSI;ATTILA OLÁH;BALÁZS I. TÓTH;BALÁZS PÁL;GABRIELLA CZIFRA;ISTVÁN BORBÍRÓ;JENNIFER E. KLOEPPER;KOJI SUGAWARA;LÍDIA AMBRUS;RALF PAUS;TAMÁS BÍRÓ;THOMAS VOETS;ALESSANDRA LATINI;MARCO ARDIGÒ","519;379;334;276;246;238;231;231;231;231;231;231;231;231;231;231;231;231;215;206","MAURO PICARDO;EMANUELA CAMERA;MATTEO LUDOVICI;CARLO COTA;MARCO ARDIGÒ;ISABELLA SPERDUTI;ALESSANDRA LATINI;MARIA GABRIELLA DONÀ;BARBARA BELLEI;ENZO BERARDESCA;GIOVANNI BLANDINO;SILVIA DI AGOSTINO;G. BIOLCATI;ARIANNA MASTROFRANCESCO;ANTONIO CRISTAUDO;FABRIZIO ENSOLI;DANIELA KOVACS;VIRGINIA FERRARESI;CATERINA CATRICALÀ;ALINE MARTAYAN","519;379;334;246;206;198;175;158;145;139;138;138;133;122;121;116;107;104;97;91","MAURO PICARDO;CARLO COTA;ALESSANDRA LATINI;ENZO BERARDESCA;FABRIZIO ENSOLI;MARCO ARDIGÒ;MARIA GABRIELLA DONÀ;CATERINA CATRICALÀ;EMANUELA CAMERA;ANTONIO CRISTAUDO;ISABELLA SPERDUTI;MASSIMO GIULIANI;VIRGINIA FERRARESI;A. DI CARLO;BARBARA BELLEI;GRAZIA PRIGNANO;JO LINDA SINAGRA;MANUELA COLAFIGLI;MATTEO LUDOVICI;PAOLA DE SIMONE","11;11;8;7;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;MATHEMATICS;ENGINEERING;ECONOMICS;MATERIALS SCIENCE;PSYCHOLOGY;ART;BUSINESS;POLITICAL SCIENCE","91;37;18;12;7;7;5;4;3;3;2;1;1;1","INTERNAL MEDICINE;PATHOLOGY;DERMATOLOGY;SURGERY;IMMUNOLOGY;CANCER RESEARCH;BIOCHEMISTRY;GENETICS;GASTROENTEROLOGY;VIROLOGY;CELL BIOLOGY;OPTICS;RADIOLOGY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;ONCOLOGY;ORGANIC CHEMISTRY;PSYCHIATRY;DEMOGRAPHY;NURSING;PEDIATRICS","54;36;34;25;21;18;17;14;13;11;10;10;9;8;7;7;7;7;6;6;6","CANCER;GENE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);MELANOMA;IMMUNE SYSTEM;DISEASE;POPULATION;PSORIASIS;BASAL CELL;CHEMOTHERAPY;ADVERSE EFFECT;BIOPSY;HUMAN PAPILLOMAVIRUS;INCIDENCE (GEOMETRY);PUBLIC HEALTH;VIRUS;ANTIBODY;CONFIDENCE INTERVAL;CONFOCAL;CONFOCAL MICROSCOPY;ENZYME;QUALITY OF LIFE (HEALTHCARE)","19;16;14;12;8;7;7;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4","VIRAL LOAD;CERVICAL CANCER;BASAL CELL CARCINOMA;SKIN CANCER;SYPHILIS;ACTINIC KERATOSIS;CD8;ETANERCEPT;GENOTYPE;IMMUNOTHERAPY;INFLIXIMAB;MUTANT;NEVUS;PHENOTYPE;PLACEBO;PROINFLAMMATORY CYTOKINE;PROTOPORPHYRIN;TOLERABILITY;ADALIMUMAB;ADIPOCYTE;ANTIPHOSPHOLIPID SYNDROME;AUTOANTIBODY;CLINICAL ENDPOINT;CONTACT DERMATITIS;COST-EFFECTIVENESS ANALYSIS;CYTARABINE;DERMATOSCOPY;DIESEL EXHAUST;DOWNREGULATION AND UPREGULATION;GENE EXPRESSION;HAZARD RATIO;HEAD AND NECK CANCER;HERD IMMUNITY;IMMUNIZATION;MARAVIROC;MELANOCYTE;MELANOMA DIAGNOSIS;MYCOBACTERIUM;PSORIATIC ARTHRITIS;RETINOIC ACID;SUPPRESSOR;TYROSINASE","7;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;HPV INFECTION;ERYTHROPOIETIC PROTOPORPHYRIA;GENOTYPING;IPILIMUMAB;MEN WHO HAVE SEX WITH MEN;ACUTE PROMYELOCYTIC LEUKEMIA;GENITAL WARTS;LAMIVUDINE;MELANOCYTIC NEVUS;MYCOBACTERIUM ABSCESSUS;AGGRESSIVE LYMPHOMA;AMYLOID FIBRIL;BENZOYL PEROXIDE;CANNABINOID RECEPTOR;CARBON DIOXIDE LASER;CHEMOKINE RECEPTOR;COMPARATIVE GENOMIC HYBRIDIZATION;CONDOM;CUTANEOUS LYMPHOMA;CUTANEOUS MASTOCYTOSIS;CUTANEOUS T-CELL LYMPHOMA;CYANOACRYLATE;DECORIN;DIFFUSING CAPACITY;DNA MISMATCH REPAIR;ELECTROCHEMOTHERAPY;FERROCHELATASE;GENE EXPRESSION PROFILING;GENETIC HETEROGENEITY;GP41;HAND ECZEMA;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HEMIN;HERPESVIRIDAE;HORMONAL THERAPY;IDARUBICIN;IL-2 RECEPTOR;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRRITANT CONTACT DERMATITIS;LATENT TUBERCULOSIS;METASTATIC BREAST CANCER;MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;MICROSATELLITE;MUTANT PROTEIN;MYCOBACTERIUM CHELONAE;OCCUPATIONAL DERMATITIS;PAPILLOMAVIRIDAE;PARANEOPLASTIC PEMPHIGUS;PAZOPANIB;PENETRANCE;PHOTOLYASE;SEXUAL TRANSMISSION;SKIN INFECTION;STAT PROTEIN;STREPTOCOCCUS UBERIS;TRANSSPHENOIDAL SURGERY;TRASTUZUMAB;USTEKINUMAB;VIRAL QUASISPECIES;XERODERMA PIGMENTOSUM","5;5;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;SKIN NEOPLASMS;ADULT;MIDDLE AGED;;ITALY;MELANOMA;AGED;SKIN;PSORIASIS;CARCINOMA, BASAL CELL;ADOLESCENT;YOUNG ADULT;NEVUS, PIGMENTED;HIV INFECTIONS;KERATOSIS, ACTINIC;HIV-1;MELANOCYTES","73;53;49;41;39;38;29;26;20;19;18;17;16;15;14;13;12;12;11;11","EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MELANIN PIGMENTATION IN MAMMALIAN SKIN;MELANOMA;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MOLECULAR MECHANISMS OF HEME BIOSYNTHESIS AND RELATED DISORDERS;SKIN SENSITIZATION AND CONTACT ALLERGY RESEARCH;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;MYCOTOXINS AND THEIR IMPACT;PATHOGENESIS AND TREATMENT OF PEMPHIGOID DISEASES;SKIN SCARRING AND REMODELING MECHANISMS;THE P53 SIGNALING NETWORK IN CANCER RESEARCH","5;4;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MELANOMA;SKIN CANCERS;NONMELANOMA SKIN CANCER;ANTIRETROVIRAL THERAPY;DERMOSCOPY;HIV;HPV VACCINATION;MELANOCYTE;PHOTODYNAMIC THERAPY;TREATMENT;ACTINIC KERATOSIS;DISCONTINUATION;ERYTHEMA;ERYTHROPOIETIC PROTOPORPHYRIA;PROINFLAMMATORY CYTOKINE;REGIMEN;RITONAVIR;TOLERABILITY;TUMOR STAGING;ACTINIC KERATOSES","8;7;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2","HUMAN PAPILLOMAVIRUS;CONFOCAL MICROSCOPY;COMPLETE RESECTION;EORTC PHASE;III MELANOMA;III TRIAL;MULTICENTRE STUDY;MULTIPLE SCLEROSIS;PHASE III;PLAQUE PSORIASIS;REFLECTANCE CONFOCAL;STAGE III;VERSUS PLACEBO;ACTINIC KERATOSIS;ACUTE PROMYELOCYTIC;ANAL HUMAN;ANTIPHOSPHOLIPID ANTIBODIES;BASAL CELL;CELL CARCINOMA;CHRONIC PLAQUE;COHORT STUDY;DIESEL EXHAUST;ECONOMIC EVALUATION;ERYTHROPOIETIC PROTOPORPHYRIA;FRACTIONAL LASER;HERD IMMUNITY;II STUDY;INITIAL EFFICACY;IPILIMUMAB VERSUS;MELANOMA INITIAL","6;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BRISTOL-MYERS SQUIBB;REGGIO EMILIA;SKIN CANCER;ARCISPEDALE SANTA;CANCER UNIT;MARIA NUOVA-IRCCS;NUOVA-IRCCS REGGIO;SANTA MARIA;UNIT ARCISPEDALE;EMILIA ITALYSEARCH;UNIVERSAL VACCINATION;CD T-CELL;ADVISORY ROLE;DERMATOLOGY UNIT;UNIT UNIVERSITY;HORMONAL RECURRENCE;HPV INFECTION;ROLE BRISTOL-MYERS;EMILIA MODENA;HONORARIA BRISTOL-MYERS;LUNG METASTASES;MEDIAN AGE;MODENA ITALYSEARCH;MSI ANALYSIS;PATHOLOGY UNIT;BIOLOGIC THERAPIES;CELL CARCINOMA;COPPER DEFICIENCY;DNA REPAIR;FAMILY HISTORY","29;18;18;12;12;12;12;12;12;10;10;9;8;8;8;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5",7,0.07,4.5,3.5,1.75,1.75,0,0,0,0,0,5,0,0,4,0,0,1,0,3.5,1,0,0,39,39,5,0,2,0,0,0,2,0,0,1,0,0,2,3,0,4,4.4,8.21,2.4,0,3,3,1,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BLANDINO GIOVANNI;CARAGLIA MICHELE;CITRO GENNARO;CONDEELIS JOHN S;DE ROSA GIUSEPPE;DI AGOSTINO SILVIA;DI MODUGNO FRANCESCA;FRANCONI ROSELLA;GERTLER FRANK;GOSWAMI SUMANTA","1;1;1;1;1;1;1;1;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;AGENZIA NAZIONALE PER LE NUOVE TECNOLOGIE LENERGIA E LO SVILUPPO ECONOMICO SOSTENIBILE ENEA;ALBERT EINSTEIN COLLEGE OF MEDICINE;IFO-REGINA ELENA CANCER INSTITUTE;IST FISIOTERAP OSPITALROMA;MASSACHUSETTS INSTITUTE OF TECHNOLOGY;ST FISIOTERAPICI OSPITALIERI IFO ST REGINA ELENA PER LO STUDIO E LA CURA DEI TUMORI;UNIVERSITA DEGLI STUDI DELL'AQUILA;VENUTI AIDO","4;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3206 MEDICAL BIOTECHNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","5;3;2;1;1","CANCER;BIOENGINEERING;BRAIN DISORDERS;GENETICS;NANOTECHNOLOGY;UROLOGIC DISEASES","2;1;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","A61K38/17;C12Q1/68;G01N33/574;A61K31/713;A61K33/243;A61K38/08;A61K38/10;A61K38/16;A61K9/127;A61P35/00","2;2;2;1;1;1;1;1;1;1","A61P35/00;C12Q1/6886;C12Q2600/136;G01N33/5011;G01N33/57415;G01N33/57419;G01N33/57434;G01N33/57438;A61K2039/53;A61K2039/585","3;2;2;2;2;2;2;2;1;1",25,6.12,399.17,20.16,14,0.56,64.92,0,1,8,0,6,0,1,9,0,20,5,0,0,0,0,0,0,19,6,0,24,0,0,1,0,0,0,0,0,0,"Italy;United States;Belgium;Germany","5;5;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE","25;17;11;4;2;2;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;BREAST CANCER;PATIENT SAFETY;TRANSPLANTATION;GENETICS;ORPHAN DRUG;PEDIATRIC;CHILDHOOD LEUKEMIA;LYMPHOMA;PEDIATRIC CANCER;PREVENTION;REGENERATIVE MEDICINE;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIGESTIVE DISEASES;LUNG;LUNG CANCER","23;22;18;12;7;6;5;5;4;4;4;3;3;3;3;3;2;2;2;2","CANCER;INFECTION;REPRODUCTIVE HEALTH AND CHILDBIRTH","17;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","15;6;4;1;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;HEAD AND NECK CANCER;LUNG CANCER;ORAL CAVITY AND LIP CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;SKIN CANCER;CERVICAL CANCER;ENDOMETRIAL CANCER;LARYNGEAL CANCER;MELANOMA;NOT SITE-SPECIFIC CANCER;SALIVARY GLAND CANCER","6;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;6.2 SURVEILLANCE","17;5;3;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH","7;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;42 HEALTH SCIENCES;3107 MICROBIOLOGY;3202 CLINICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4203 HEALTH SERVICES AND SYSTEMS","5;2;2;2;2;1;1;1;1","BIOTECHNOLOGY;GENETICS","1;1","CANCER","2","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1","POPULATION & SOCIETY","1","CLINICAL MEDICINE AND SCIENCE","2","BREAST CANCER","2",NA,NA
"IRCCS_IFO",2015,87,10.2183908045977,2.41379310344828,0.459770114942529,0.264367816091954,0.471264367816092,1.94444444444444,1.42857142857143,1.64285714285714,1.41379310344828,0.494252873563218,3,29,17,10,15,0.33,0.2,0.11,0.17,24.32,0.652616277174014,3.88743882544861,0.310344827586207,0.793103448275862,0.54,0.374,0.462,0.369,"GIOVANNI LEUZZI;FRANCESCO FACCIOLO;ISABELLA SPERDUTI;DANIELE FORCELLA;TATIANA KOUDRIAVTSEVA;ANTONIO CRISTAUDO;DOMENICO PLANTONE;CARLO COTA;ROSARIA RENNA;MASSIMO GIULIANI;MAURO PICARDO;MIRELLA MARINO;ALESSANDRA LATINI;ENZO BERARDESCA;MARCO ARDIGÒ;CHIARA MANDOJ;GABRIELE ALESSANDRINI;DIANA GIANNARELLI;EDOARDO PESCARMONA;FULVIA ELIA","13;9;8;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;3","GIOVANNI LEUZZI;FRANCESCO FACCIOLO;DANIELE FORCELLA;TATIANA KOUDRIAVTSEVA;ENZO BERARDESCA;DOMENICO PLANTONE;ROSARIA RENNA;ROSARIA R ENNA;ISABELLA SPERDUTI;GABRIELE ALESSANDRINI;CARLO COTA;GIOVANNI PAOLINO;CATERINA MAINERO;ENRICO MELIS;MICHELE DONATI;CHIARA MANDOJ;MARCO ARDIGÒ;DARIO GRACEFFA;KENJI KAWAMUKAI;DIANA GIANNARELLI","3.61;2.03;1.43;1.34;1.34;1.01;1.01;1;0.89;0.73;0.73;0.7;0.7;0.7;0.7;0.68;0.66;0.61;0.58;0.57","GIOVANNI LEUZZI;FRANCESCO FACCIOLO;ISABELLA SPERDUTI;DANIELE FORCELLA;TATIANA KOUDRIAVTSEVA;ANTONIO CRISTAUDO;DOMENICO PLANTONE;CARLO COTA;ROSARIA RENNA;MASSIMO GIULIANI;MAURO PICARDO;MIRELLA MARINO;ALESSANDRA LATINI;ENZO BERARDESCA;MARCO ARDIGÒ;CHIARA MANDOJ;GABRIELE ALESSANDRINI;DIANA GIANNARELLI;EDOARDO PESCARMONA;FULVIA ELIA","13;9;8;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;3","GIOVANNI LEUZZI;FRANCESCO FACCIOLO;DANIELE FORCELLA;TATIANA KOUDRIAVTSEVA;ENZO BERARDESCA;DOMENICO PLANTONE;ROSARIA RENNA;ROSARIA R ENNA;ISABELLA SPERDUTI;GABRIELE ALESSANDRINI;CARLO COTA;GIOVANNI PAOLINO;ENRICO MELIS;MICHELE DONATI;CHIARA MANDOJ;MARCO ARDIGÒ;DARIO GRACEFFA;DIANA GIANNARELLI;FULVIA ELIA;MIRELLA MARINO","3.61;2.03;1.43;1.34;1.34;1.01;1.01;1;0.89;0.73;0.73;0.7;0.7;0.7;0.68;0.66;0.61;0.57;0.56;0.56","DANIELA POZZI;GIULIO CARACCIOLO;LUCA DIGIACOMO;SARA PALCHETTI;VALENTINA COLAPICCHIONI;ALDO LAGANÀ;ANNA LAURA CAPRIOTTI;ISABELLA SPERDUTI;MASSIMO GIULIANI;MAURO PICARDO;ANTONIO CRISTAUDO;ALESSANDRA LATINI;CARLO COTA;FABRIZIO ENSOLI;GIORGIA LA BARBERA;PAOLA CORDIALI‐FEI;VALENTINA BORDIGNON;ALESSANDRA LO PRESTI;ANTONELLA VENTO;C. FERRARO","457;457;457;457;457;335;335;304;254;246;245;232;213;207;198;160;160;150;150;150","DANIELA POZZI;MASSIMO GIULIANI;MAURO PICARDO;ANTONIO CRISTAUDO;ALESSANDRA LATINI;FABRIZIO ENSOLI;CARLO COTA;PAOLA CORDIALI‐FEI;VALENTINA BORDIGNON;ANTONELLA VENTO;C. FERRARO;ELISABETTA TRENTO;GIOVANNA D’AGOSTO;ILARIA LESNONI LA PAROLA;CATERINA AURIZI;FIAMMETTA SORGE;G. BIOLCATI;ARIANNA MASTROFRANCESCO;MARIA GABRIELLA DONÀ;ISABELLA SPERDUTI","457;254;246;245;232;207;194;160;160;150;150;150;150;150;126;126;126;119;117;116","GIOVANNI LEUZZI;FRANCESCO FACCIOLO;DANIELE FORCELLA;ISABELLA SPERDUTI;MASSIMO GIULIANI;TATIANA KOUDRIAVTSEVA;ANTONIO CRISTAUDO;MAURO PICARDO;ALESSANDRA LATINI;CARLO COTA;DOMENICO PLANTONE;ENZO BERARDESCA;GABRIELE ALESSANDRINI;MARCO ARDIGÒ;MARINA AGOZZINO;A BONADIES;EDOARDO PESCARMONA;F. M. SOLIVETTI;FABRIZIO ENSOLI;MARIA GABRIELLA DONÀ","11;9;7;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;SOCIOLOGY;ENGINEERING;MATERIALS SCIENCE;MATHEMATICS;ART;BUSINESS;ECONOMICS;GEOLOGY;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY","77;32;13;8;7;5;3;2;2;1;1;1;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;SURGERY;IMMUNOLOGY;DERMATOLOGY;ONCOLOGY;BIOCHEMISTRY;GENETICS;CANCER RESEARCH;RADIOLOGY;GASTROENTEROLOGY;VIROLOGY;CELL BIOLOGY;OPTICS;PALEONTOLOGY;GENERAL SURGERY;NUCLEAR MEDICINE;PSYCHIATRY;ANATOMY;ARTIFICIAL INTELLIGENCE;DEMOGRAPHY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;MICROBIOLOGY;NURSING;ORGANIC CHEMISTRY;PHYSICAL THERAPY;PROGRAMMING LANGUAGE","55;24;21;19;17;15;14;14;12;12;9;7;6;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3","CANCER;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;HUMAN IMMUNODEFICIENCY VIRUS (HIV);DISEASE;IN VITRO;MELANOMA;MULTIPLE SCLEROSIS;MULTIVARIATE ANALYSIS;ADVERSE EFFECT;ANTIBODY;COHORT;HUMAN PAPILLOMAVIRUS;IMMUNE SYSTEM;LUNG;LUNG CANCER;ANTIMICROBIAL;CLINICAL TRIAL;CONFOCAL;CONFOCAL MICROSCOPY;DNA;INFLAMMATION;LESION;LYMPHOMA;MAGNETIC RESONANCE IMAGING;NEUROLOGY;ODDS RATIO;PROSPECTIVE COHORT STUDY;PSORIASIS;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;RETROSPECTIVE COHORT STUDY;SARCOMA;STAGE (STRATIGRAPHY);TOXICITY","26;11;9;7;7;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;GENOTYPE;CERVICAL CANCER;HAZARD RATIO;VIRAL LOAD;ADALIMUMAB;ADENOCARCINOMA;BLEOMYCIN;COLORECTAL CANCER;SYPHILIS;UNIVARIATE ANALYSIS;ADJUVANT THERAPY;ANAL CANAL;AUTOANTIBODY;CD8;CORONA (PLANETARY GEOLOGY);IMAGE SEGMENTATION;IMMUNIZATION;LYMPHOPROLIFERATIVE DISORDERS;PANCREATIC CANCER;TOLERABILITY;TRANSCRIPTION FACTOR;TRANSEPIDERMAL WATER LOSS","6;6;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","HPV INFECTION;ANTIRETROVIRAL THERAPY;ELECTROCHEMOTHERAPY;GENOTYPING;MEN WHO HAVE SEX WITH MEN;BREAST RECONSTRUCTION;GROUND-GLASS OPACITY;MASTECTOMY;PAPILLOMAVIRIDAE;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ALPHA (FINANCE);BENZOYL PEROXIDE;BRONCHOPLEURAL FISTULA;BRONCHUS;CATHELICIDIN;CEFIXIME;CERVICAL INTRAEPITHELIAL NEOPLASIA;DNA MISMATCH REPAIR;ELISPOT;ERBB3;GENETIC HETEROGENEITY;GENITAL WARTS;GLYCOLIC ACID;HAMP;HIV VACCINE;IRINOTECAN;KLEBSIELLA PNEUMONIAE;LENTIVIRUS;MELANOCYTIC NEVUS;MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;MISSENSE MUTATION;MOLECULAR EPIDEMIOLOGY;MONOCLONAL;MULTILOCUS SEQUENCE TYPING;NKG2D;OXALIPLATIN;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PENETRANCE;PHOTOLYASE;PROMOTER;SAPS II;SENTINEL LYMPH NODE;SENTINEL NODE;SEXUAL TRANSMISSION;STEREOTACTIC RADIATION THERAPY;TAXANE;TRANSACTIVATION;TRASTUZUMAB;TUMOR-INFILTRATING LYMPHOCYTES;USTEKINUMAB;WILD TYPE","4;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;MALE;ADULT;AGED;SKIN NEOPLASMS;;LUNG NEOPLASMS;TREATMENT OUTCOME;BREAST NEOPLASMS;MELANOMA;THYMUS NEOPLASMS;HIV INFECTIONS;NEOPLASM RECURRENCE, LOCAL;PAPILLOMAVIRUS INFECTIONS;YOUNG ADULT;DERMATOLOGIC AGENTS;ITALY;RETROSPECTIVE STUDIES","64;42;39;37;27;24;22;21;14;14;12;12;12;11;11;11;11;10;10;10","HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;MELANOMA;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCES IN PHOTOACOUSTIC IMAGING AND TOMOGRAPHY;ANKYLOGLOSSIA AND ITS IMPACT ON BREASTFEEDING AND SPEECH;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;AUTOFOCUSING IN MICROSCOPY AND PHOTOGRAPHY;AUTOIMMUNE ENCEPHALITIS: CLINICAL CHARACTERISTICS AND MANAGEMENT","4;4;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","HIV;NONMELANOMA SKIN CANCER;THYMIC TUMORS;ELECTROCHEMOTHERAPY;PHOTODYNAMIC THERAPY;UNIVARIATE ANALYSIS;ADJUVANT THERAPY;ANAL SEX;CADAVERIC SPASM;CANCER THERAPY;CORONA (PLANETARY GEOLOGY);CUTIS;DERMOSCOPY;ERYTHEMA;GROUND-GLASS OPACITY;HPV VACCINATION;IMMEDIATE BREAST RECONSTRUCTION;LYMPHOPROLIFERATIVE DISORDERS;MEDICAL IMAGE ANALYSIS;MICROSURGICAL RECONSTRUCTION","4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MULTIPLE SCLEROSIS;CANCER PATIENTS;CELL CARCINOMA;CONFOCAL MICROSCOPY;MULTICENTER STUDY;REFLECTANCE CONFOCAL;ANAL CANAL;BREAST CANCER;BREAST RECONSTRUCTION;FDG PET-CT;GAMMA HUMAN;GROUND-GLASS OPACITY;HUMAN PAPILLOMAVIRUS;HUMAN PAPILLOMAVIRUSES;HUMAN SKIN;HYPERPLASIA SIMULTANEOUSLY;INTERFERON-Β THERAPY;LUNG CANCER;NEWLY DIAGNOSED;PANCREATIC CANCER;PLAQUE PSORIASIS;RADIOLOGICAL SEED;RARE SKIN;RISK FACTORS;SCLEROSIS PATIENTS;SENTINEL NODE;SIMULTANEOUSLY DETECTED;SYNCHRONOUS TRIPLE;THYMIC HYPERPLASIA;TRIPLE THYMOMA","5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","DERMATOLOGY UNIVERSITY;THORACIC SURGERY;INTERFERON-Β THERAPY;SURGERY UNIT;VIKTORIA ELEFTHERIADOU;CONFIDENCE INTERVAL;RAM DOC;RARE SKIN;SKIN DISEASES;BORDEAUX NATIONAL;BREAST CANCER;DISEASES HÔPITAL;HIGH-DOSE INTERFERON-Β;HÔPITAL ST-ANDRÉ;KHALED EZZEDINE;LEUZZI MD;MS PATIENTS;NATIONAL REFERENCE;REFERENCE CENTRE;ST-ANDRÉ BORDEAUX;MALDI-TOF MS;NERVE FIBERS;RATIO CONFIDENCE;STR PATIENTS;AL ISSA;BASED DERMATOLOGY;BELLARIA HOSPITALS;BOARON MD;BOLOGNA ITALYSEARCH;BORDEAUX FRANCESEARCH","14;9;8;8;8;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4",11,0.13,5.6,9,14.75,2,0,24,8.5,1,0,10.5,0,0,5,0,1,1.5,1.5,3.5,2,0,0,95.5,95.5,2,1,0,0,0,0,1,0,1,0,0,0,2,1,0,0,3.66666666666667,5.24,1.33333333333333,0,1,2,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BIFFONI MAURO;DE MARIA MARCHIANO RUGGERO;HAAS TOBIAS LONGIN;RICCI VITIANI LUCIA;DI MODUGNO FRANCESCA;NISTICO' PAOLA;PINO MARIA SIMONA","2;2;2;2;1;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;IST FISIOTERAP OSPITALROMA","3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","4;2","PREVENTION","2","5.1 PHARMACEUTICALS","2","C07K16/28;C12N15/113;A61P35/00;C12Q1/68","2;2;1;1","A61K2039/505;A61P35/00;C07K16/2842;C07K2317/24;C07K2317/54;C07K2317/55;C07K2317/622;C07K2317/76;C12N15/1138;C12N2310/14","2;2;2;2;2;2;2;2;2;2",19,5.59,1092.76,18.81,8,0.42,83.16,0,0,6,0,7,0,1,5,0,15,2,0,0,0,0,0,0,12,6,1,17,2,0,0,0,0,0,0,0,0,"Australia;Belgium;Germany;Japan;United States","1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4205 NURSING","19;16;7;3;2;2;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BREAST CANCER;RARE DISEASES;LUNG;LUNG CANCER;NEUROSCIENCES;PATIENT SAFETY;AGING;BRAIN CANCER;BRAIN DISORDERS;BIOMEDICAL IMAGING;CHRONIC PAIN;COLO-RECTAL CANCER;DIGESTIVE DISEASES;ESTROGEN;HEMATOLOGY;OVARIAN CANCER;PAIN RESEARCH","15;15;13;5;5;3;3;3;3;2;2;2;1;1;1;1;1;1;1;1","CANCER;BLOOD;NEUROLOGICAL","15;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES","13;4;2;1;1","BREAST CANCER;BRAIN TUMOR;LUNG CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;OVARIAN CANCER;PANCREATIC CANCER;PROSTATE CANCER","6;3;3;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","14;3;2",1,6026455,376653.44,4,16,7,1,51,125738.359375,0.691912956654164,"AMIRES (CZECHIA);AUSTRIAN INSTITUTE OF TECHNOLOGY;FUTURE DIAGNOSTICS (NETHERLANDS);HORIBA (FRANCE);INSTITUTE OF PHOTONICS AND ELECTRONICS;ISTITUTI FISIOTERAPICI OSPITALIERI;ISTITUTO NAZIONALE BIOSTRUTTURE E BIOSISTEMI;SCRIBA NANOTECNOLOGIE (ITALY);SEIBERSDORF LABORATORIES (AUSTRIA);UNIVERSITY OF CATANIA;UNIVERSITY OF FERRARA;UNIVERSITY OF FLORENCE;UNIVERSITY OF PARMA;UNIVERSITY OF SIEGEN;UNIVERSITY OF TWENTE;VTT TECHNICAL RESEARCH CENTRE OF FINLAND","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-PHC-2014-TWO-STAGE (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;40 ENGINEERING","1;1;1","BIOENGINEERING;BIOTECHNOLOGY;CANCER;COLO-RECTAL CANCER;DIGESTIVE DISEASES;GENETICS","1;1;1;1;1;1","CANCER","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1","COLON AND RECTAL CANCER","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD","1;1","B12 ENGINEERING","1",NA,NA,25,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;AMERICAN CHEMICAL SOCIETY;TAYLOR & FRANCIS GROUP","20;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3202 CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3203 DENTISTRY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4205 NURSING;49 MATHEMATICAL SCIENCES","30;17;11;7;5;4;4;4;2;1;1;1;1;1","CANCER;GENETICS;BIOTECHNOLOGY;RARE DISEASES;ESTROGEN;STEM CELL RESEARCH;AGING;BRAIN DISORDERS;BREAST CANCER;GENETIC TESTING;HEMATOLOGY;KIDNEY DISEASE;OVARIAN CANCER;PREVENTION;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","7;5;4;3;2;2;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE","9;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","6;4;4;3;1","BIOMEDICAL;CLINICAL","6;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","10;7","BREAST CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA","5;3;3;1;1",NA,NA
"IRCCS_IFO",2016,110,11.4363636363636,2.32727272727273,0.336363636363636,0.336363636363636,0.381818181818182,2.03174603174603,1.27586206896552,1.37037037037037,1.27272727272727,0.5,1,51,26,14,12,0.46,0.24,0.13,0.11,32.17,0.990447841768486,4.0173501577287,0.327272727272727,0.9,0.429,0.338,0.337,0.373,"MAURO PICARDO;CARLO COTA;ALESSANDRA LATINI;GIOVANNI PAOLINO;MARCO ARDIGÒ;ANTONIO CRISTAUDO;MANUELA COLAFIGLI;MASSIMO GIULIANI;LIDIA STRIGARI;E. CAGNI;PIETRO MANCOSU;DAVID A. FEDELE;LUCA MUSCARDIN;VIVIANA LORA;F.R. GIGLIOLI;CARLO RICCARDO ROSSI;B. NARDIELLO;ANDREA ANTINORI;CHIARA PANETTA;VIRGINIA FERRARESI","11;9;8;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4","CARLO COTA;MARCO ARDIGÒ;LIDIA STRIGARI;MAURO PICARDO;GIOVANNI PAOLINO;VIVIANA LORA;LUCA MUSCARDIN;SALVADOR GONZÁLEZ;ALESSANDRA LATINI;CHIARA PANETTA;PIETRO DONATI;PASQUALE FRASCIONE;ANTONIO CRISTAUDO;ENZO BERARDESCA;CARMINE ZOCCALI;ANNA CARBONE;DANIELA KOVACS;DANIELA POZZI;GIULIO CARACCIOLO;SARA PALCHETTI","1.72;1.43;1.23;1.23;1.06;1.06;0.98;0.78;0.77;0.72;0.72;0.65;0.64;0.61;0.6;0.57;0.55;0.54;0.54;0.54","MAURO PICARDO;CARLO COTA;ALESSANDRA LATINI;MARCO ARDIGÒ;ANTONIO CRISTAUDO;MANUELA COLAFIGLI;MASSIMO GIULIANI;LIDIA STRIGARI;LUCA MUSCARDIN;VIVIANA LORA;CHIARA PANETTA;VIRGINIA FERRARESI;ENZO BERARDESCA;A BONADIES;PASQUALE FRASCIONE;PIETRO DONATI;MARIA GABRIELLA DONÀ;DANIELA KOVACS;ANNA CARBONE;S. BUCHER","11;9;8;7;6;6;6;6;5;5;4;4;4;4;4;4;4;4;4;4","CARLO COTA;MARCO ARDIGÒ;LIDIA STRIGARI;MAURO PICARDO;VIVIANA LORA;LUCA MUSCARDIN;ALESSANDRA LATINI;CHIARA PANETTA;PIETRO DONATI;PASQUALE FRASCIONE;ANTONIO CRISTAUDO;ENZO BERARDESCA;CARMINE ZOCCALI;ANNA CARBONE;DANIELA KOVACS;DANIELA POZZI;GIULIO CARACCIOLO;SARA PALCHETTI;ALBINA PATERNIANI;FRANCESCA GAMBALUNGA","1.72;1.43;1.23;1.23;1.06;0.98;0.77;0.72;0.72;0.65;0.64;0.61;0.6;0.57;0.55;0.54;0.54;0.54;0.53;0.53","ALESSANDRO TESTORI;PAOLO A. ASCIERTO;VIRGINIA FERRARESI;CAROLINE ROBERT;CÉLÈSTE LEBBÉ;JEAN‐JACQUES GROB;L. THOMAS;ALEXANDER M.M. EGGERMONT;CORINA TAITT;GAETAN DE SCHAETZEN;HENRIK SCHMIDT;JEDD D. WOLCHOK;JEFFREY S. WEBER;JON RICHARDS;MICHAEL SMYLIE;OMID HAMID;REINHARD DUMMER;STEFAN SUCIU;VANNA CHIARION‐SILENI;VEERLE DE PRIL","1306;1306;1236;1215;1215;1215;1207;1201;1201;1201;1201;1201;1201;1201;1201;1201;1201;1201;1201;1201","VIRGINIA FERRARESI;MAURO PICARDO;ENZO BERARDESCA;DANIELA POZZI;SARA PALCHETTI;MARCO ARDIGÒ;A BONADIES;S. BUCHER;GIOVANNI BLANDINO;SILVIA DI AGOSTINO;GIULIO CARACCIOLO;ALESSANDRA LATINI;R. BIAGINI;MANUELA COLAFIGLI;EMANUELA CAMERA;DANIELA KOVACS;VITALIANO SILIPO;JO LINDA SINAGRA;LUCA MUSCARDIN;GIAN LUCA GRAZI","1236;365;204;201;201;167;138;138;126;126;116;114;108;107;102;92;76;72;70;69","MAURO PICARDO;CARLO COTA;MARCO ARDIGÒ;ALESSANDRA LATINI;LIDIA STRIGARI;VIVIANA LORA;ANTONIO CRISTAUDO;LUCA MUSCARDIN;A BONADIES;ANNA CARBONE;DANIELA KOVACS;ENZO BERARDESCA;MANUELA COLAFIGLI;MASSIMO GIULIANI;PASQUALE FRASCIONE;S. BUCHER;VIRGINIA FERRARESI;PIETRO DONATI;CARMINE ZOCCALI;CATERINA CATRICALÀ","11;9;7;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATHEMATICS;COMPUTER SCIENCE;MATERIALS SCIENCE;ECONOMICS;PHILOSOPHY;PSYCHOLOGY;SOCIOLOGY;ENGINEERING;ART;HISTORY","99;31;17;11;10;9;7;3;3;3;3;2;1;1","INTERNAL MEDICINE;DERMATOLOGY;SURGERY;PATHOLOGY;ONCOLOGY;IMMUNOLOGY;CANCER RESEARCH;RADIOLOGY;GENETICS;CELL BIOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;OPTICS;PHARMACOLOGY;VIROLOGY;ENVIRONMENTAL HEALTH;GEOMETRY;PALEONTOLOGY;QUANTUM MECHANICS;ANATOMY;NUCLEAR MEDICINE;PHYSICAL THERAPY;PSYCHIATRY","65;34;30;29;19;16;15;15;14;13;12;12;11;7;7;6;6;6;6;5;5;5;5","CANCER;CHEMOTHERAPY;CONFIDENCE INTERVAL;GENE;DISEASE;CLINICAL TRIAL;HUMAN IMMUNODEFICIENCY VIRUS (HIV);MELANOMA;RADIATION THERAPY;ADVERSE EFFECT;CONFOCAL MICROSCOPY;POPULATION;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);MALIGNANCY;MULTIVARIATE ANALYSIS;REGIMEN;RESECTION;VITILIGO","30;11;10;10;9;8;8;8;8;6;6;6;6;6;5;5;5;5;5;5;5","BREAST CANCER;HAZARD RATIO;PROSTATE CANCER;TOLERABILITY;VIRAL LOAD;BLEOMYCIN;RADIOSURGERY;CERVICAL CANCER;CLINICAL ENDPOINT;IMMUNOTHERAPY;INTRACLASS CORRELATION;RELIABILITY (SEMICONDUCTOR);T CELL;UNIVARIATE ANALYSIS;ABLATIVE CASE;ADALIMUMAB;ADJUVANT RADIOTHERAPY;AMPHOTERICIN B;COLORECTAL CANCER;CORONA (PLANETARY GEOLOGY);CUMULATIVE INCIDENCE;DOCETAXEL;IMMUNIZATION;LINEAR PARTICLE ACCELERATOR;LIVER TRANSPLANTATION;METASTASIS;OVERWEIGHT;PANCREATIC CANCER;PAPILLARY DERMIS;PATIENT-REPORTED OUTCOME;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PI3K/AKT/MTOR PATHWAY;PLACEBO;POLYMERIZATION;PROGRESSIVE DISEASE;RADIATION TREATMENT PLANNING;RECEPTOR TYROSINE KINASE;SOFT TISSUE SARCOMA;STOCHASTIC VOLATILITY;SYPHILIS;TENOFOVIR;UNIVARIATE","10;7;5;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;ELECTROCHEMOTHERAPY;HPV INFECTION;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;BENZOYL PEROXIDE;BONE METASTASIS;CANNABINOID RECEPTOR;CYBERKNIFE;IPILIMUMAB;LAMIVUDINE;MEN WHO HAVE SEX WITH MEN;SABR VOLATILITY MODEL;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTHRACYCLINE;ANTIBODY TITER;AXILLA;BETA-CATENIN;BREAST RECONSTRUCTION;CANCER IMMUNOTHERAPY;CATENIN;CEFIXIME;CERTOLIZUMAB PEGOL;DNA VACCINATION;DOCOSAHEXAENOIC ACID;ELISPOT;FEBRILE NEUTROPENIA;GENETICALLY MODIFIED MOUSE;GENITAL WARTS;GENOTYPING;GLUTATHIONE S-TRANSFERASE;GLUTATHIONE TRANSFERASE;GOLIMUMAB;HIV VACCINE;HORMONAL THERAPY;IFOSFAMIDE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KLUYVEROMYCES LACTIS;KRAS;LYMPHOCYTE SUBSETS;MASTECTOMY;MEK INHIBITOR;METASTATIC BREAST CANCER;METHYLENETETRAHYDROFOLATE REDUCTASE;MILAN CRITERIA;NFKB1;PERIPHERAL T-CELL LYMPHOMA;POSACONAZOLE;PRIMARY TUMOR;REVERSE TRANSCRIPTASE;SENTINEL LYMPH NODE;SIDA;STEREOTACTIC RADIOTHERAPY;SYSTEMIC THERAPY;TAMOXIFEN;TARGET LESION;TOBRAMYCIN;TRAMETINIB;TRANSSPHENOIDAL SURGERY;TRASTUZUMAB;TRUEBEAM;USTEKINUMAB","4;4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;ADULT;MIDDLE AGED;SKIN NEOPLASMS;AGED;HIV INFECTIONS;RETROSPECTIVE STUDIES;MELANOMA;YOUNG ADULT;ITALY;SKIN;TREATMENT OUTCOME;HIV-1;MICROSCOPY, CONFOCAL;ADOLESCENT;AGED, 80 AND OVER;LUNG NEOPLASMS","68;47;45;41;37;35;30;24;22;18;16;16;13;13;12;11;11;10;10;10","MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;MELANIN PIGMENTATION IN MAMMALIAN SKIN;RADIOTHERAPY PHYSICS AND TECHNOLOGY;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MELANOMA;VASCULAR TUMORS AND ANGIOSARCOMA;ATOPIC DERMATITIS AND SKIN MICROBIOME;GENOMIC REARRANGEMENT DISORDERS IN SKIN DISEASES;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;CANCER OF UNKNOWN PRIMARY SITE;MANAGEMENT OF SPINAL METASTATIC TUMORS;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;AUTOIMMUNE ENCEPHALITIS: CLINICAL CHARACTERISTICS AND MANAGEMENT;BACTERIAL BIOFILMS AND QUORUM SENSING MECHANISMS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM","5;5;5;4;4;4;4;3;3;3;2;2;1;1;1;1;1;1;1;1","MELANOMA;ANTIRETROVIRAL THERAPY;SKIN MICROBIOME;REGIMEN;TOLERABILITY;TREATMENT;VITILIGO;ANGIOSARCOMA;ELECTROCHEMOTHERAPY;METASTATIC ANGIOSARCOMAS;RADIATION-ASSOCIATED ANGIOSARCOMA;CLINICAL ENDPOINT;CLINICAL PRACTICE;HISTOPATHOLOGY;HPV VACCINATION;RADIOTHERAPY;RITONAVIR;SKIN CANCERS;UNIVARIATE ANALYSIS;ABLATIVE CASE","7;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;2","CONFOCAL MICROSCOPY;REFLECTANCE CONFOCAL;MULTICENTER STUDY;RETROSPECTIVE STUDY;ANGIOSARCOMAS EFFICACY;BREAST CANCER;EXTENT SCORE;LOCAL TREATMENT;PLANNING COMPARISON;PROSTATE CANCER;SAFETY RESULTS;SUPERFICIAL ANGIOSARCOMAS;SURGICAL TREATMENT;VITILIGO EXTENT;ABC PATIENTS;ADVANCED BREAST;BODY MASS;CANCER ABC;CANCER MCRPC;CASTRATION RESISTANT;CLINICAL TRIAL;CUTANEOUS METASTASES;HAILEY-HAILEY DISEASE;HUMAN PAPILLOMAVIRUS;III MELANOMA;INDEX BMI;INFLAMMATORY SKIN;MASS INDEX;METASTATIC CASTRATION;MICROSCOPY FEATURES","6;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;MODERATE ACNE;CROSSREF PUBMED;ACNE SEBUM;LIPID SPECIES;LIPID RES;PROSTATE CANCER;ATAZANAVIRRITONAVIR LAMIVUDINE;DERMATOL -ABSTRACT;DERMATOL -CROSSREF;HAZARD RATIO;RES -ABSTRACT;ROME ITALY;ADVERSE EVENTS;CANCER PATIENTS;INVEST DERMATOL;MONTHS NA;PANCREATIC CANCER;RELATIVE ABUNDANCE;SEBACEOUS LIPIDS;SKIN SURFACE;ACNE PATHOGENESIS;ACNE SEVERITY;AGILENT TECHNOLOGIES;ANTI-TAT ANTIBODIES;CANCER CELL;CELL LINES;COPIESML MEDIAN;FATTY ACIDS;FATTY ACYLS","27;15;14;10;10;8;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5",16,0.15,9.86,7.75,5.5,1.75,0,23,6,0,2.5,7.75,0,0,4,0,1,4.5,28.5,3,14,0,0,76,76.25,4,0,3,1,0,1,1,0,0,0,0,0,4,2,0,3,4.33333333333333,10.16,1.16666666666667,0,1,3,0,0,2,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"DI MODUGNO FRANCESCA;BENASSI MARCELLO;CARPINO SANDRO;D ANDREA MARCO;IACCARINO GIUSEPPE;NISTICO' PAOLA;SORIANI ANTONELLA;STRIGARI LIDIA;ABBRUZZESE SACCARDI ALBERTO;CARAGLIA MICHELE","3;2;2;2;2;2;2;2;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;IST FISIOTERAP OSPITALROMA;ISTITUTI FISIOTERAPICI OSPITALIERI (IFO) ISTITUTO REGINA ELENA PER LO STUDIO E LA CURA DEI TUMORI","5;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;51 PHYSICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;5105 MEDICAL AND BIOLOGICAL PHYSICS;3107 MICROBIOLOGY;3206 MEDICAL BIOTECHNOLOGY","9;4;3;2;2;2;2;1;1","CANCER;BIOENGINEERING;NANOTECHNOLOGY;RARE DISEASES;UROLOGIC DISEASES","3;1;1;1;1","5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","2;2","C12Q1/68;A61N5/10;G01N33/50;G01N33/574;A61K38/17;A61K47/48;A61K9/127;C07K14/435","3;2;2;2;1;1;1;1","C07K14/435;C12Q1/6886;C12Q2600/118;C12Q2600/136;C12Q2600/158;G01N33/5011;G01N33/57407;G01N33/57415;G01N33/57419;G01N33/57423","3;3;3;3;3;3;3;3;3;3",18,5.11,293.67,15.38,11,0.61,58.83,0,1,3,1,7,0,0,6,0,13,5,0,0,0,0,0,0,17,1,0,17,0,0,1,0,0,0,0,0,0,"United States;Italy","4;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;50 PHILOSOPHY AND RELIGIOUS STUDIES;5002 HISTORY AND PHILOSOPHY OF SPECIFIC FIELDS","18;11;11;3;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;DIGESTIVE DISEASES;LUNG;LUNG CANCER;PATIENT SAFETY;BREAST CANCER;LIVER CANCER;LIVER DISEASE;PREVENTION;BIOENGINEERING;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES - (GALLBLADDER);HEMATOLOGY;INFECTIOUS DISEASES;KIDNEY DISEASE;LYMPHOMA;ORPHAN DRUG","17;15;13;6;4;4;4;3;2;2;2;2;1;1;1;1;1;1;1;1","CANCER","8","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","13;2;2;1;1;1;1","LUNG CANCER;BREAST CANCER;LIVER CANCER;SARCOMA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;ENDOMETRIAL CANCER;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;MELANOMA;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER","4;2;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","10;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,"PUBLIC LIBRARY OF SCIENCE","16","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;49 MATHEMATICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4905 STATISTICS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3202 CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;3406 PHYSICAL CHEMISTRY;42 HEALTH SCIENCES;44 HUMAN SOCIETY","11;6;4;4;3;2;2;2;1;1;1;1;1;1;1;1","CANCER;GENETICS;BIOTECHNOLOGY;DIGESTIVE DISEASES;BIOENGINEERING;CERVICAL CANCER;CLINICAL RESEARCH;COLO-RECTAL CANCER;HUMAN GENOME","3;3;2;2;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","4;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS","2;2","BIOMEDICAL;CLINICAL","2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","3;1","CERVICAL CANCER;COLON AND RECTAL CANCER;NOT SITE-SPECIFIC CANCER","2;2;1",NA,NA
"IRCCS_IFO",2017,90,14.3,2.87777777777778,0.344444444444444,0.344444444444444,0.455555555555556,2.08870967741935,1.34782608695652,1.72222222222222,1.24242424242424,0.577777777777778,1,50,19,11,3,0.56,0.21,0.12,0.03,25.79,0.87494029444474,4.33785822021116,0.311111111111111,0.888888888888889,0.463,0.312,0.406,0.398,"MAURO PICARDO;CARLO COTA;ISABELLA SPERDUTI;MONICA OTTAVIANI;MARCO CHIAPPETTA;ALESSANDRA LATINI;FRANCESCO FACCIOLO;DANIELA KOVACS;ANTONIO CRISTAUDO;GIOVANNI PAOLINO;MAURO ZACCARELLI;EMANUELA CAMERA;ANDREA ANTINORI;BARBARA BELLEI;LORENZO SPAGGIARI;CHRISTOS C. ZOUBOULIS;DANIELE FORCELLA;DANIELA POZZI;STEFANIA BRIGANTI;MANUELA COLAFIGLI","14;8;8;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4","MAURO PICARDO;CARLO COTA;VERONICA VILLANI;MARCO CHIAPPETTA;FRANCESCO FACCIOLO;GIOVANNI PAOLINO;MONICA OTTAVIANI;DANIELA KOVACS;SANDRA REA;EMANUELA CAMERA;ISABELLA SPERDUTI;BARBARA BELLEI;CHIARA PANETTA;MICHELE DONATI;PIETRO DONATI;EMILIA MIGLIANO;STEFANIA BRIGANTI;ARIANNA MASTROFRANCESCO;F. M. SOLIVETTI;MARIA MARIANO","1.6;1.1;1;0.98;0.98;0.89;0.82;0.72;0.67;0.66;0.66;0.64;0.6;0.6;0.6;0.56;0.54;0.54;0.53;0.53","MAURO PICARDO;CARLO COTA;ISABELLA SPERDUTI;MONICA OTTAVIANI;MARCO CHIAPPETTA;ALESSANDRA LATINI;FRANCESCO FACCIOLO;DANIELA KOVACS;ANTONIO CRISTAUDO;EMANUELA CAMERA;BARBARA BELLEI;DANIELE FORCELLA;DANIELA POZZI;STEFANIA BRIGANTI;MANUELA COLAFIGLI;GIORGIA CARDINALI;FABRIZIO ENSOLI;EMILIA MIGLIANO;MASSIMO GIULIANI;SARA PALCHETTI","14;8;8;7;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4","MAURO PICARDO;CARLO COTA;VERONICA VILLANI;MARCO CHIAPPETTA;FRANCESCO FACCIOLO;MONICA OTTAVIANI;DANIELA KOVACS;SANDRA REA;EMANUELA CAMERA;ISABELLA SPERDUTI;BARBARA BELLEI;CHIARA PANETTA;MICHELE DONATI;PIETRO DONATI;EMILIA MIGLIANO;STEFANIA BRIGANTI;ARIANNA MASTROFRANCESCO;F. M. SOLIVETTI;MARIA MARIANO;NORMA CAMELI","1.6;1.1;1;0.98;0.98;0.82;0.72;0.67;0.66;0.66;0.64;0.6;0.6;0.6;0.56;0.54;0.54;0.53;0.53;0.53","CAROLINE ROBERT;CÉLÈSTE LEBBÉ;JEAN-JACQUES GROB;MICHAEL SMYLIE;MICHELE MAIO;OMID HAMID;PAOLO A. ASCIERTO;VANNA CHIARION‐SILENI;VIRGINIA FERRARESI;ANA ARANCE;ANDRZEJ MAĆKIEWICZ;ANILA QURESHI;BRIGITTE DRÉNO;CARMEN LOQUAI;CATRIONA M. MCNEIL;CHRISTOPH HÖELLER;CLAUS GARBE;DELPHINE HENNICKEN;DIRK SCHADENDORF;FLORENT GRANGE","532;532;532;532;532;532;532;532;532;438;438;438;438;438;438;438;438;438;438;438","VIRGINIA FERRARESI;MAURO PICARDO;DANIELA POZZI;SARA PALCHETTI;CARLO COTA;EMILIA MIGLIANO;MONICA OTTAVIANI;DANIELA KOVACS;BARBARA BELLEI;FRANCESCO MARCHESI;GIORGIA CARDINALI;EMANUELA BASTONINI;MARIA LUCIA DELL’ANNA;GIOVANNI LEONE;ALESSANDRA LATINI;ENRICA FLORI;MARIA MARIANO;NORMA CAMELI;ELVA ABRIL;ARIANNA MASTROFRANCESCO","532;283;238;238;199;149;143;138;132;131;116;99;99;98;80;73;73;73;70;69","MAURO PICARDO;CARLO COTA;ISABELLA SPERDUTI;MONICA OTTAVIANI;DANIELA KOVACS;ALESSANDRA LATINI;BARBARA BELLEI;EMANUELA CAMERA;ANTONIO CRISTAUDO;ARIANNA MASTROFRANCESCO;DANIELA POZZI;EMILIA MIGLIANO;ENRICA FLORI;SARA PALCHETTI;STEFANIA BRIGANTI;GIORGIA CARDINALI;R. BIAGINI;CARMINE ZOCCALI;EMANUELA BASTONINI;ENZO BERARDESCA","14;8;7;7;6;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;ECONOMICS;ENGINEERING;GEOLOGY","86;36;11;6;5;4;4;3;2;2;1;1;1","INTERNAL MEDICINE;DERMATOLOGY;SURGERY;PATHOLOGY;ONCOLOGY;CANCER RESEARCH;IMMUNOLOGY;BIOCHEMISTRY;GENETICS;CELL BIOLOGY;GASTROENTEROLOGY;VIROLOGY;MICROBIOLOGY;ENVIRONMENTAL HEALTH;NURSING;PHARMACOLOGY;ENDOCRINOLOGY;FAMILY MEDICINE;RADIOLOGY;ASTROBIOLOGY;NANOTECHNOLOGY;NEUROSCIENCE;OPTICS;PALEONTOLOGY;PROGRAMMING LANGUAGE","59;27;26;25;18;17;15;14;14;12;10;9;7;6;5;5;4;4;4;3;3;3;3;3;3","CANCER;GENE;MELANOMA;ADVERSE EFFECT;HUMAN IMMUNODEFICIENCY VIRUS (HIV);CONFIDENCE INTERVAL;DISEASE;POPULATION;VITILIGO;RANDOMIZED CONTROLLED TRIAL;CELL GROWTH;CHEMOTHERAPY;ENZYME;ANTIBIOTICS;CELL CULTURE;COHORT;EVEROLIMUS;IMMUNOHISTOCHEMISTRY;KINASE;LUNG CANCER;ODDS RATIO;PSORIASIS;QUALITY OF LIFE (HEALTHCARE);RETROSPECTIVE COHORT STUDY","22;11;11;10;9;8;7;7;7;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4","BREAST CANCER;HAZARD RATIO;IMMUNOTHERAPY;MELANOCYTE;VIRAL LOAD;CARCINOGENESIS;CLINICAL ENDPOINT;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;CORONA (PLANETARY GEOLOGY);PANCREATIC CANCER;PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR;PHASES OF CLINICAL RESEARCH;PROGRESSIVE DISEASE;TRANSEPIDERMAL WATER LOSS;ACTINIC KERATOSIS;BIOFILM;CUMULATIVE INCIDENCE;DERMATOSCOPY;DNA DAMAGE;DNA REPAIR;ETANERCEPT;GENOTYPE;INVOLUTION (ESOTERISM);LIFE EXPECTANCY;MAPK/ERK PATHWAY;MELANOCYTE-STIMULATING HORMONE;METASTATIC MELANOMA;MYELOFIBROSIS;NEUTROPENIA;NEVUS;PHENOTYPE;PI3K/AKT/MTOR PATHWAY;PROTEIN KINASE A;PSORIATIC ARTHRITIS;SKIN CANCER;SYPHILIS;T CELL;TOLERABILITY;TRANSCRIPTION FACTOR","6;6;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;AROMATASE;IPILIMUMAB;MELANOCORTIN 1 RECEPTOR;MEN WHO HAVE SEX WITH MEN;NIVOLUMAB;THYMIC INVOLUTION;VEMURAFENIB;BIOMARKER DISCOVERY;CAMP-DEPENDENT PATHWAY;CARDIOLIPIN;CEFIXIME;CHEMOKINE RECEPTOR;CHLORAMBUCIL;CONVERGENT VALIDITY;CUTANEOUS LYMPHOMA;CYTOREDUCTIVE SURGERY;DNA METHYLATION;DNA MISMATCH REPAIR;ELECTROCHEMOTHERAPY;ERYTHROPOIETIC PROTOPORPHYRIA;ESTROGEN RECEPTOR;FERROCHELATASE;GENOTYPING;GOLIMUMAB;HORMONAL THERAPY;HPV INFECTION;INEFFECTIVE ERYTHROPOIESIS;INSULIN RECEPTOR;LAMIVUDINE;MEK INHIBITOR;MELANOCYTIC NEVUS;METASTATIC BREAST CANCER;MILAN CRITERIA;MITOPHAGY;NUCLEAR RECEPTOR;PANCREATIC DUCTAL ADENOCARCINOMA;PHYLOGENETIC RELATIONSHIP;POLY ADP RIBOSE POLYMERASE;PTEN;PULSED-FIELD GEL ELECTROPHORESIS;SCORAD;SEXUALLY TRANSMITTED DISEASE;SOX2;TAMOXIFEN;TAXANE;TRAMETES VERSICOLOR;TRAMETINIB;TRIPLE-NEGATIVE BREAST CANCER;ZINC PROTOPORPHYRIN","4;4;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;MALE;ADULT;AGED;;HIV INFECTIONS;MELANOMA;HIV-1;SKIN NEOPLASMS;VITILIGO;ITALY;TREATMENT OUTCOME;ANTI-HIV AGENTS;PPAR GAMMA;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;BREAST NEOPLASMS;PSORIASIS","61;42;40;38;32;29;28;25;23;16;16;16;15;13;12;12;12;11;11;11","MELANIN PIGMENTATION IN MAMMALIAN SKIN;MELANOMA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;CANCER IMMUNOTHERAPY;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;PANCREATIC CANCER RESEARCH AND TREATMENT;VAGINAL MICROBIOME AND SEXUALLY TRANSMITTED INFECTIONS;;ADVANCEMENTS IN LUNG CANCER RESEARCH;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING","8;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1","MELANOMA;VITILIGO;HIV;ANTIRETROVIRAL THERAPY;EVEROLIMUS;MELANOCYTE;CLINICAL ENDPOINT;DERMOSCOPY;DISCONTINUATION;ERYTHEMA;EXEMESTANE;REGIMEN;SENESCENCE;SKIN AGING;TRANSEPIDERMAL WATER LOSS;ACTINIC KERATOSES;ACTINIC KERATOSIS;CANCER THERAPY;CLINICAL PRACTICE;CONCORDANCE","7;7;6;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2","BREAST CANCER;CANCER PATIENTS;CASE-CONTROL STUDY;LUNG CANCER;PANCREATIC CANCER;ADVANCED BREAST;ADVERSE EVENTS;CANCER CELLS;CELL CARCINOMA;CLINICAL PRACTICE;CONSENSUS CONFERENCE;DRUG RESISTANCE;EPITHELIAL TUMOUR;EXPANDED ACCESS;F-FDG PETCT;FATTY THYMIC;GRUPPO LAZIALE;HUMAN PAPILLOMAVIRUS;INVOLUTION UPTAKE;IPILIMUMAB MGKG;JOINT HYPERMOBILITY;MECHANICAL STRESS;MULTICENTRE ANALYSIS;NON-SMALL-CELL LUNG;OBSERVATIONAL STUDY;PETCT STUDY;PHASE TRIAL;PRIMARY MYELOFIBROSIS;PROTEIN CORONA;PSORIATIC ARTHRITIS","5;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADVERSE EVENTS;BORDEAUX FRANCE;MELANOMA CELL;DERMATOLOGIC INSTITUTE;GALLICANO DERMATOLOGIC;SAN GALLICANO;BORDEAUX BORDEAUX;BORDEAUX UNIVERSITY;CELL LINES;DERMATOLOGY BORDEAUX;FRANCE DEPARTMENT;HIV- DNA;HOSPITALS BORDEAUX;INSTITUTE ROME;ROME ITALYSEARCH;UNIVERSITY HOSPITALS;CLINICALLY RELEVANT;EXTENT SCORE;POSTMENOPAUSAL WOMEN;PTS AGED;ROME ITALY;TRANSMISSION CLUSTERS;VITILIGO EXTENT;ACADEMIC MEDICAL;BORDEAUX FRANCESEARCH;CENTRE AMSTERDAM;CONFIDENCE INTERVAL;DERMATOLOGY ACADEMIC;DISORDERS NIPD;MEDICAL CENTRE","10;10;10;9;9;9;8;8;8;8;8;8;8;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6;6",13,0.14,11.15,9,1,1,0,5.5,6,0,0,9,0,0,5,0,0,2,5.75,7.5,2,0,0,101,101,2,1,0,1,0,4,1,0,0,0,0,0,1,5,1,2,4.57142857142857,12.36,2.71428571428571,0,6,4,0,0,2,0,0,2,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"GERTLER FRANK;GOSWAMI SUMANTA;NISTICO PAOLA;CONDEELIS JOHN S;BENASSI MARCELLO;CARPINO SANDRO;D'ANDREA MARCO;IACCARINO GIUSEPPE;SORIANI ANTONELLA;STRIGARI LIDIA","5;5;5;4;2;2;2;2;2;2","ALBERT EINSTEIN COLLEGE OF MEDICINE;IFO-REGINA ELENA CANCER INSTITUTE;MASSACHUSETTS INSTITUTE OF TECHNOLOGY;IFO-REGINA ELENA CANCER INST;ISTITUTI FISIOTERAPICI OSPITALIERI IFO;ALBERT EINSTEIN COLLEGE MEDICINE INC;MASSACHUSETTS INST TECHNOLOGY;ST FISIOTERAPICI OSPITALIERI","4;4;4;2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;51 PHYSICAL SCIENCES;3202 CLINICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS","12;6;2;1;1","CANCER;GENETICS;BRAIN DISORDERS;RARE DISEASES","3;3;2;1",NA,NA,"A61K31/713;C12Q1/68;G01N33/50;G01N33/574;A61N5/10;C07H21/04","5;5;5;5;2;1","A61K31/713;A61P35/00;C12Q1/6886;C12Q2600/106;C12Q2600/112;C12Q2600/136;G01N33/5011;G01N33/57415;G01N33/57419;G01N33/57434","5;5;5;5;5;5;5;5;5;5",20,5.55,645.45,18.18,15,0.75,115.95,1,2,1,0,10,0,1,5,0,17,3,0,0,0,0,0,0,17,2,1,20,0,0,0,0,0,0,0,0,0,"United States;Italy","8;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;50 PHILOSOPHY AND RELIGIOUS STUDIES","20;15;13;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;LUNG;LUNG CANCER;PATIENT SAFETY;BREAST CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;HEMATOLOGY;AUTOIMMUNE DISEASE;BIOENGINEERING;BIOMEDICAL IMAGING;BIOTECHNOLOGY;BRAIN DISORDERS;CHILDHOOD LEUKEMIA;DIGESTIVE DISEASES;GENETICS;KIDNEY DISEASE;LIVER CANCER","18;17;11;7;5;5;5;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","10;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;5.1 PHARMACEUTICALS;5.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","15;3;2;2;1;1;1","LUNG CANCER;BREAST CANCER;MELANOMA;CERVICAL CANCER;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;NOT SITE-SPECIFIC CANCER;PROSTATE CANCER;SARCOMA;THYROID CANCER","6;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","13;2;2;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;AMERICAN CHEMICAL SOCIETY","28;8;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;34 CHEMICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;49 MATHEMATICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3207 MEDICAL MICROBIOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3108 PLANT BIOLOGY;4904 PURE MATHEMATICS;51 PHYSICAL SCIENCES;3004 CROP AND PASTURE PRODUCTION;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;33 BUILT ENVIRONMENT AND DESIGN;3303 DESIGN","35;13;9;6;6;5;5;4;3;2;2;2;2;1;1;1;1;1;1;1","CANCER;GENETICS;RARE DISEASES;BIOTECHNOLOGY;DENTAL/ORAL AND CRANIOFACIAL DISEASE;ADOLESCENT SEXUAL ACTIVITY;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN CANCER;BRAIN DISORDERS;BREAST CANCER;CLINICAL RESEARCH;HIV/AIDS;HUMAN GENOME;INFECTIOUS DISEASES;NEUROSCIENCES;NUTRITION;PEDIATRIC;SEXUALLY TRANSMITTED INFECTIONS;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","9;4;4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION","7;3","5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","3;2","BIOMEDICAL;CLINICAL;POPULATION & SOCIETY","3;1;1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","10;10;2","NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;CERVICAL CANCER;HEAD AND NECK CANCER;PHARYNGEAL CANCER;BRAIN TUMOR;BREAST CANCER;LARYNGEAL CANCER;MELANOMA;SALIVARY GLAND CANCER","6;4;2;2;2;1;1;1;1;1",NA,NA
"IRCCS_IFO",2018,88,15,2.39772727272727,0.261363636363636,0.215909090909091,0.25,1.81896551724138,1.0952380952381,1.1875,1.04761904761905,0.568181818181818,2,40,19,18,3,0.45,0.22,0.2,0.03,46.76,1.53274465370924,4.02864938608458,0.375,0.977272727272727,0.472,0.326,0.342,0.305,"ANTONIO CRISTAUDO;ALESSANDRA LATINI;MARCO ARDIGÒ;MAURO PICARDO;CARLO COTA;ANDREA DE LUCA;SIMONA DI GIAMBENEDETTO;MANUELA COLAFIGLI;STEFANO RUSCONI;GIOVANNI PELLACANI;ANDREA ANTINORI;VIRGINIA FERRARESI;FRANCESCA LOMBARDI;PASQUALE FRASCIONE;LIDIA STRIGARI;AMEDEO CAPETTI;CATERINA LONGO;ALDO MORRONE;ARTURO CICCULLO;CLAUDIO BONIFATI","10;10;8;8;7;7;7;6;6;5;5;5;5;5;5;4;4;4;4;4","M TEDESCO;ALDO MORRONE;MARCO ARDIGÒ;CARLO COTA;ANTONIO CRISTAUDO;MAURO PICARDO;ALESSANDRA LATINI;ENZO BERARDESCA;MARIA MARIANO;LIDIA STRIGARI;MARCO CHIAPPETTA;FRANCESCO FACCIOLO;PASQUALE FRASCIONE;PIETRO DONATI;VIVIANA LORA;PAOLO IACOVELLI;GIOVANNI LEONE;NORMA CAMELI;GIOVANNI DAMIANI;GIOVANNI PAOLINO","1.34;1.31;1.26;1.04;1.01;0.95;0.71;0.65;0.62;0.61;0.6;0.6;0.52;0.48;0.47;0.46;0.46;0.45;0.43;0.42","ANTONIO CRISTAUDO;ALESSANDRA LATINI;MARCO ARDIGÒ;MAURO PICARDO;CARLO COTA;SIMONA DI GIAMBENEDETTO;MANUELA COLAFIGLI;VIRGINIA FERRARESI;PASQUALE FRASCIONE;LIDIA STRIGARI;ALDO MORRONE;CLAUDIO BONIFATI;GIOVANNI DAMIANI;R. BIAGINI;ANDREA PACE;ISABELLA SPERDUTI;PIETRO DONATI;PAOLO IACOVELLI;FRANCESCA ROLLO;EMILIA MIGLIANO","10;10;8;8;7;7;6;5;5;5;4;4;4;4;4;4;4;3;3;3","M TEDESCO;ALDO MORRONE;MARCO ARDIGÒ;CARLO COTA;ANTONIO CRISTAUDO;MAURO PICARDO;ALESSANDRA LATINI;ENZO BERARDESCA;MARIA MARIANO;LIDIA STRIGARI;MARCO CHIAPPETTA;FRANCESCO FACCIOLO;PASQUALE FRASCIONE;PIETRO DONATI;VIVIANA LORA;PAOLO IACOVELLI;GIOVANNI LEONE;NORMA CAMELI;GIOVANNI DAMIANI;ISABELLA SPERDUTI","1.34;1.31;1.26;1.04;1.01;0.95;0.71;0.65;0.62;0.61;0.6;0.6;0.52;0.48;0.47;0.46;0.46;0.45;0.43;0.39","VIRGINIA FERRARESI;A. BASSIM HASSAN;AKMAL SAFWAT;ALESSANDRO GRONCHI;ANDREA FERRARI;ANGELA BUONADONNA;ANGELO PAOLO DEI TOS;ANNA MARIA FREZZA;ANTONIO LÓPEZ–POUSA;AXEL LE CESNE;BERND KASPER;DAGMAR ADÁMKOVÁ KRÁKOROVÁ;ENRIQUE DE ÁLAVA;EVA WARDELMANN;FRITS VAN COEVORDEN;GIOVANNI GRIGNANI;HANS GELDERBLOM;HEIKKI JOENSUU;I. BOUKOVINAS;IAN JUDSON","2526;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525","R. BIAGINI;VIRGINIA FERRARESI;MAURO PICARDO;ANTONIO CRISTAUDO;EMANUELA CAMERA;ALESSANDRA LATINI;BARBARA BELLEI;EMILIA MIGLIANO;ENZO BERARDESCA;MARCO ARDIGÒ;DANIELA KOVACS;CARLO COTA;MANUELA COLAFIGLI;ALESSIA PACIFICO;M TEDESCO;FEDERICA PAPACCIO;GIANLUCA LOPEZ;SILVIA CAPUTO;MATTEO LUDOVICI;NINA KOZUL","2525;467;295;197;166;161;138;138;138;131;123;115;97;92;89;61;61;61;56;56","ALESSANDRA LATINI;MARCO ARDIGÒ;MAURO PICARDO;CARLO COTA;ANTONIO CRISTAUDO;MANUELA COLAFIGLI;ALDO MORRONE;ANDREA PACE;CLAUDIO BONIFATI;LIDIA STRIGARI;PASQUALE FRASCIONE;PIETRO DONATI;MARIA MARIANO;R. BIAGINI;ALESSIA PACIFICO;BARBARA BELLEI;DANIELA KOVACS;EMILIA MIGLIANO;ENZO BERARDESCA;ISABELLA SPERDUTI","9;8;8;7;7;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;MATERIALS SCIENCE;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;HISTORY;POLITICAL SCIENCE","79;29;14;11;5;4;3;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;DERMATOLOGY;ONCOLOGY;SURGERY;BIOCHEMISTRY;IMMUNOLOGY;GASTROENTEROLOGY;GENETICS;CANCER RESEARCH;VIROLOGY;OPTICS;RADIOLOGY;NURSING;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;CELL BIOLOGY;ENDOCRINOLOGY;ANATOMY;ARTIFICIAL INTELLIGENCE;BOTANY;CHROMATOGRAPHY;CLINICAL PSYCHOLOGY;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;ORGANIC CHEMISTRY;PHYSICAL THERAPY;PSYCHIATRY","46;31;29;18;16;15;15;14;14;12;10;9;8;7;6;6;5;5;3;3;3;3;3;3;3;3;3;3","CANCER;GENE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);PSORIASIS;REGIMEN;ADVERSE EFFECT;MELANOMA;QUALITY OF LIFE (HEALTHCARE);VIRUS;POPULATION;RANDOMIZED CONTROLLED TRIAL;BIOMARKER;DISEASE;LESION;STRATUM CORNEUM;APOPTOSIS;ATOPIC DERMATITIS;BIOPSY;CHEMOTHERAPY;CONFOCAL;SARCOMA;VITILIGO","15;11;11;9;8;7;7;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4","VIRAL LOAD;BREAST CANCER;HEPATITIS B VIRUS;TOLERABILITY;DERMATOLOGY LIFE QUALITY INDEX;PSORIATIC ARTHRITIS;BONE SARCOMA;CLINICAL ENDPOINT;COLORECTAL CANCER;METASTASIS;PHENOTYPE;TEMOZOLOMIDE;TRANSEPIDERMAL WATER LOSS;BREAST IMPLANT;CERVICAL CANCER;CYCLOPHOSPHAMIDE;DERMATOSCOPY;ECZEMA AREA AND SEVERITY INDEX;GENOTYPE;GLANS PENIS;HAIR DYES;LINEAR PARTICLE ACCELERATOR;MUTATION;PATCH TEST;PHASES OF CLINICAL RESEARCH;PSORIASIS AREA AND SEVERITY INDEX;SOFT TISSUE SARCOMA;SYPHILIS","8;5;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;LAMIVUDINE;MEN WHO HAVE SEX WITH MEN;REGORAFENIB;VINCRISTINE;ANTIVIRAL THERAPY;AROMATASE;ASCUS (BRYOZOA);AUTOPHAGOSOME;BONE METASTASIS;BREAST RECONSTRUCTION;CAPECITABINE;CERVICAL INTRAEPITHELIAL NEOPLASIA;CIRCULATING TUMOR CELL;CLINICAL PHENOTYPE;CONDITIONAL GENE KNOCKOUT;CTL*;CYBERKNIFE;DISEASE MANAGEMENT;ENTHESITIS;GALACTORRHEA;GENOTYPING;HEMOPHAGOCYTOSIS;HPV INFECTION;IMATINIB MESYLATE;IONIZATION CHAMBER;JUNB;KAEMPFEROL;LIQUID-BASED CYTOLOGY;LYMPHOMATOID PAPULOSIS;MASTECTOMY;MELANOCYTIC NEVUS;METASTATIC BREAST CANCER;MISSENSE MUTATION;MUTAGENESIS;OMALIZUMAB;OPEN READING FRAME;PANCREATIC DUCTAL ADENOCARCINOMA;PAPILLOMAVIRIDAE;PAZOPANIB;PDGFRA;PENETRANCE;PROGENITOR;PROMOTER;RIBAVIRIN;SCORAD;SECUKINUMAB;SENTINEL LYMPH NODE;SPECTINOMYCIN;TRABECTEDIN;TRUEBEAM;TUBERCULOID LEPROSY;USTEKINUMAB","8;5;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;HIV INFECTIONS;;AGED;SKIN NEOPLASMS;YOUNG ADULT;HIV-1;PSORIASIS;SKIN;ADOLESCENT;DERMATOLOGIC AGENTS;ITALY;TREATMENT OUTCOME;DERMATITIS, ATOPIC;ANTI-HIV AGENTS;PAPILLOMAVIRUS INFECTIONS","61;47;44;43;40;28;24;18;17;16;15;15;15;13;13;13;13;11;10;10","EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;MELANIN PIGMENTATION IN MAMMALIAN SKIN;ATOPIC DERMATITIS AND SKIN MICROBIOME;GLIOMAS;MELANOMA;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;INNOVATIONS IN TRANSDERMAL DRUG DELIVERY SYSTEMS;SARCOMA RESEARCH AND TREATMENT;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL SKIN INFECTIONS;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENETIC AND MOLECULAR STUDIES OF CONNECTIVE TISSUE DISORDERS;MALE CIRCUMCISION FOR HIV PREVENTION AND PENILE HEALTH;REGULATION AND FUNCTION OF HAIR FOLLICLE STEM CELLS;SKIN SENSITIZATION AND CONTACT ALLERGY RESEARCH;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM","5;5;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;1","REGIMEN;ANTIRETROVIRAL THERAPY;PSORIASIS;SKIN SENSITIZATION;TOLERABILITY;DERMOSCOPY;DOLUTEGRAVIR;MELANOMA;SKIN MICROBIOME;VITILIGO;BONE SARCOMA;CLINICAL ENDPOINT;DISCONTINUATION;GLIOBLASTOMA;PATHOGENESIS;SEBACEOUS GLAND;SKIN PERMEATION ENHANCEMENT;SOFT TISSUE SARCOMA;TEMOZOLOMIDE;TRANSEPIDERMAL WATER LOSS","8;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","CLINICAL PRACTICE;CONFOCAL MICROSCOPY;REFLECTANCE CONFOCAL;ATOPIC DERMATITIS;CLINICAL TRIAL;DIAGNOSIS TREATMENT;HIV--INFECTED PATIENTS;ITALIAN SOCIETY;PRACTICE GUIDELINES;VIROLOGICALLY SUPPRESSED;ACTINIC KERATOSIS;CELL CARCINOMA;COHERENCE TOMOGRAPHY;CONTROLLED OPEN-LABEL;ESMOEURACAN CLINICAL;EVALUATING REGORAFENIB;GLIOBLASTOMA GBM;HAIR DYE;II CLINICAL;MULTICENTER CONTROLLED;MULTICENTRE COHORT;OPEN-LABEL PHASE;OPTICAL COHERENCE;PATIENTS PTS;PHASE II;PITYRIASIS LICHENOIDES;PSORIATIC ARTHRITIS;RANDOMIZED MULTICENTER;RELAPSED GLIOBLASTOMA;SQUAMOUS CELL","5;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;GASTROINTESTINAL STROMAL;ONCOL -CROSSREF;CLIN ONCOL;SOFT TISSUE;ONCOL -ABSTRACT;OBSERVER -OBSERVER;BONE SARCOMAS;STANDARD TREATMENT;STROMAL TUMORS;PROGNOSTIC FACTORS;LOCAL RECURRENCE;LYMPH NODES;BONE SARCOMA;CANCER -ABSTRACT;CLINICAL PRACTICE;PUBMED GOOGLE;REFERENCE CENTRES;BIELACK SS;BONE TUMORS;BRIERLEY JD;GOSPODAROWICZ MK;GRIMER RJ;GT COPIESML;JD GOSPODAROWICZ;MALIGNANT BONE;MALIGNANT TUMOURSIN;MEDIAN AGE;MK WITTEKIND","115;80;33;31;26;23;21;16;13;13;13;12;11;11;10;10;10;10;10;9;9;9;9;9;9;9;9;9;9;9",7,0.08,30.7,42.5,1.75,0,1,1,0,0,1,47,0,1,43,0,0,2.5,14.75,27,3.75,1,0,329.5,330.5,3,0,0,1,0,5,0,0,0,0,0,0,0,5,1,0,3.83333333333333,10.9,1.66666666666667,0,2,4,0,0,1,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"LEONETTI CARLO;MARRA MONICA;SALZANO GIUSEPPINA;BENASSI MARCELLO;CARPINO SANDRO;D'ANDREA MARCO;IACCARINO GIUSEPPE;SORIANI ANTONELLA;STRIGARI LIDIA;DI MODUGNO FRANCESCA","3;3;3;2;2;2;2;2;2;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;CARAGLIA MICHELE;DE ROSA GIUSEPPE;ISTITUTI FISIOTERAPICI OSPITALIERI;LA ROTONDA MARIA IMMACOLATA;ST FISIOTERAPICI OSPITALIERI","5;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;51 PHYSICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;5105 MEDICAL AND BIOLOGICAL PHYSICS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3206 MEDICAL BIOTECHNOLOGY","6;4;2;2;1;1;1","BIOENGINEERING;CANCER;NANOTECHNOLOGY","1;1;1","5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","1;1","A61K47/50;A61P35/00;A61N5/10;C07K14/435;C12Q1/00;C12Q1/68;G01N33/50;G01N33/574","3;3;2;1;1;1;1;1","A61K38/1709;A61K47/62;A61K47/6911;A61K47/6923;A61K9/1271;A61P35/00;A61N2005/1034;A61N2005/1089;A61N5/1031;A61N5/1039","3;3;3;3;3;3;2;2;2;2",20,5.05,587.79,19.23,8,0.4,68.6,0,0,7,0,5,0,1,7,0,13,6,0,0,0,0,0,0,16,4,0,19,1,0,0,0,0,0,0,0,0,"United States;Italy","6;5","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;4205 NURSING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","19;13;12;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BIOTECHNOLOGY;GENETICS;PATIENT SAFETY;PEDIATRIC;BREAST CANCER;RARE DISEASES;AGING;IMMUNIZATION;PREVENTION;BIOENGINEERING;BIOMEDICAL IMAGING;CERVICAL CANCER;CHILDHOOD LEUKEMIA;COMPARATIVE EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;HEMATOLOGY;HUMAN GENOME","15;13;11;5;4;4;4;3;3;2;2;2;1;1;1;1;1;1;1;1","CANCER;SKIN","12;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS","13;3;2;1;1;1","BREAST CANCER;NOT SITE-SPECIFIC CANCER;SARCOMA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;CERVICAL CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA","4;2;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","8;4;2;1;1",1,3687312,204850.67,5,18,7,1,37,135133.492708333,0.651207914753862,"B. BRAUN (GERMANY);BEIJING INSTITUTE OF GENOMICS;CAPITAL MEDICAL UNIVERSITY;ENGAGE (GERMANY);HUNAN UNIVERSITY;IMPERIAL COLLEGE LONDON;ISTITUTI FISIOTERAPICI OSPITALIERI;KAROLINSKA INSTITUTET;KU LEUVEN;PRINCESS MÁXIMA CENTER;RADBOUD UNIVERSITY NIJMEGEN;SCRIBA NANOTECNOLOGIE (ITALY);STOCKHOLM UNIVERSITY;TEESSIDE UNIVERSITY;THE HYVE (NETHERLANDS);UNIVERSITY COLLEGE LONDON;UNIVERSITY OF CATANIA;UNIVERSITY OF PLYMOUTH","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.1.3. - EXCELLENT SCIENCE - MARIE SKŁODOWSKA-CURIE ACTIONS (PROGRAMME);H2020-MSCA-ITN-2017 (CALL FOR PROPOSAL);MSCA-ITN - MARIE SKŁODOWSKA-CURIE INNOVATIVE TRAINING NETWORKS (ITN) (FUNDING SCHEME)","1;1;1","46 INFORMATION AND COMPUTING SCIENCES;4605 DATA MANAGEMENT AND DATA SCIENCE","1;1","BRAIN CANCER;BRAIN DISORDERS;CANCER;CLINICAL RESEARCH;NEUROSCIENCES;RARE DISEASES","1;1;1;1;1;1",NA,NA,"4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1","BRAIN TUMOR","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS","1;1","B11 COMPUTER SCIENCE AND INFORMATICS","1",NA,NA,7,"AMERICAN ASSOCIATION FOR CANCER RESEARCH;FRONTIERS;PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE","3;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES","13;6;3;2;1;1","CLINICAL RESEARCH;BRAIN DISORDERS;CANCER;NEURODEGENERATIVE;NEUROSCIENCES;PARKINSON'S DISEASE;PREVENTION;UROLOGIC DISEASES","2;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","6;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;6.1 PHARMACEUTICALS","2;1;1","BIOMEDICAL;CLINICAL","5;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","4;3","BREAST CANCER;BLADDER CANCER;KIDNEY CANCER","4;1;1",NA,NA
"IRCCS_IFO",2019,91,13.6043956043956,2.49450549450549,0.274725274725275,0.296703296703297,0.351648351648352,1.99122807017544,1,1.22727272727273,1.18518518518519,0.648351648351648,1,40,18,13,5,0.44,0.2,0.14,0.05,14.68,0.603749917758646,4.52380952380953,0.241758241758242,0.967032967032967,0.443,0.433,0.412,0.427,"MANUELA COLAFIGLI;ANTONIO CRISTAUDO;ALESSANDRA LATINI;PAOLO D. PIGATTO;ALESSIA PACIFICO;GIOVANNI DAMIANI;NICOLA LUIGI BRAGAZZI;MAURO PICARDO;ALDO MORRONE;GAETANA STERRANTINO;PIERGIORGIO MALAGOLI;MARCO ARDIGÒ;VIVIANA LORA;SIMONA DI GIAMBENEDETTO;AMEDEO CAPETTI;ARTURO CICCULLO;LUCA STINGENI;ENZO BERARDESCA;MOHAMMAD ADAWI;STEFANO RUSCONI","12;11;10;8;8;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5","ENZO BERARDESCA;ANTONINO GUERRISI;ANTONIO CRISTAUDO;ALESSIA PACIFICO;MAURO PICARDO;VIVIANA LORA;MARCO ARDIGÒ;MANUELA COLAFIGLI;ALDO MORRONE;PAOLO D. PIGATTO;GIOVANNI DAMIANI;NICOLA LUIGI BRAGAZZI;ALESSANDRA LATINI;EMANUELA CAMERA;PIERGIORGIO MALAGOLI;ANDREA SAGGINI;EMILIA MIGLIANO;ANGELA FILONI;CATERINA FOTI;GIANNI PAULIS","1.09;1;0.98;0.93;0.88;0.88;0.84;0.79;0.76;0.75;0.73;0.73;0.68;0.62;0.62;0.54;0.52;0.52;0.51;0.5","MANUELA COLAFIGLI;ANTONIO CRISTAUDO;ALESSANDRA LATINI;ALESSIA PACIFICO;MAURO PICARDO;ALDO MORRONE;MARCO ARDIGÒ;VIVIANA LORA;ENZO BERARDESCA;EMILIA MIGLIANO;EMANUELA CAMERA;MASSIMO GIULIANI;MARIA GABRIELLA DONÀ;DANIELA BEOMONTE ZOBEL;ENEA GINO DI DOMENICO;FRANCESCA ROLLO;VALENTINA GARELLI;CLAUDIO BONIFATI;ANGELA FILONI;BARBARA PICHI","12;11;10;8;7;6;6;6;5;4;4;4;4;3;3;3;3;3;3;3","ENZO BERARDESCA;ANTONINO GUERRISI;ANTONIO CRISTAUDO;ALESSIA PACIFICO;MAURO PICARDO;VIVIANA LORA;MARCO ARDIGÒ;MANUELA COLAFIGLI;ALDO MORRONE;ALESSANDRA LATINI;EMANUELA CAMERA;EMILIA MIGLIANO;ANGELA FILONI;MARIA GABRIELLA DONÀ;NORMA CAMELI;MASSIMO GIULIANI;CLAUDIO BONIFATI;FRANCESCA ROLLO;BARBARA PICHI;RAUL PELLINI","1.09;1;0.98;0.93;0.88;0.88;0.84;0.79;0.76;0.68;0.62;0.52;0.52;0.45;0.43;0.38;0.35;0.35;0.35;0.35","PAOLO D. PIGATTO;ALESSIA PACIFICO;GIOVANNI DAMIANI;NICOLA LUIGI BRAGAZZI;PIERGIORGIO MALAGOLI;MOHAMMAD ADAWI;‬‬‬‬ABDULLA WATAD;LUCA STINGENI;MANUELA COLAFIGLI;ROSALYNN R.Z. CONIC;ANNALISA PATRIZI;ANNAMARIA OFFIDANI;ANTONIO CRISTAUDO;GIUSEPPE MICALI;CHARLIE BRIDGEWOOD;ALDO MORRONE;ALESSANDRA LATINI;SIMONA DI GIAMBENEDETTO;KETTY PERIS;HOWARD AMITAL","342;279;278;278;250;227;227;193;193;183;175;175;163;146;137;133;130;115;114;113","ALESSIA PACIFICO;MANUELA COLAFIGLI;ANTONIO CRISTAUDO;ALDO MORRONE;ALESSANDRA LATINI;ENZO BERARDESCA;FABRIZIO ENSOLI;ENEA GINO DI DOMENICO;ELISABETTA TRENTO;GIOVANNA D’AGOSTO;MARIA TERESA GALLO;MARCO ARDIGÒ;NORMA CAMELI;DANIELA KOVACS;GIORGIA CARDINALI;ILARIA CAVALLO;LUIGI TOMA;MAURO PICARDO;EMILIA MIGLIANO;DANIELA POZZI","279;193;163;133;130;110;107;86;83;83;82;78;69;65;64;64;64;58;55;48","MANUELA COLAFIGLI;ANTONIO CRISTAUDO;ALESSANDRA LATINI;ALESSIA PACIFICO;MAURO PICARDO;ALDO MORRONE;MARCO ARDIGÒ;VIVIANA LORA;ENZO BERARDESCA;EMANUELA CAMERA;EMILIA MIGLIANO;MARIA GABRIELLA DONÀ;MASSIMO GIULIANI;GIORGIO CARLINO;ANGELA FILONI;CLAUDIO BONIFATI;DANIELA BEOMONTE ZOBEL;FABRIZIO ENSOLI;MIRKO FRASCA;ENEA GINO DI DOMENICO","12;11;10;8;7;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATERIALS SCIENCE;MATHEMATICS;ENGINEERING;BUSINESS;PSYCHOLOGY;ART;ECONOMICS;GEOGRAPHY;PHILOSOPHY;POLITICAL SCIENCE","85;34;12;7;6;5;5;4;3;2;1;1;1;1;1","INTERNAL MEDICINE;DERMATOLOGY;PATHOLOGY;IMMUNOLOGY;BIOCHEMISTRY;SURGERY;ONCOLOGY;GENETICS;CANCER RESEARCH;RADIOLOGY;GASTROENTEROLOGY;PHARMACOLOGY;VIROLOGY;CELL BIOLOGY;OPTICS;PALEONTOLOGY;ENDOCRINOLOGY;PHYSICAL THERAPY;PSYCHIATRY;BIOMEDICAL ENGINEERING;ENVIRONMENTAL HEALTH;FOOD SCIENCE;INTENSIVE CARE MEDICINE;MEDICAL PHYSICS;MICROBIOLOGY;NANOTECHNOLOGY;ORGANIC CHEMISTRY","61;30;20;17;16;16;15;11;10;9;8;8;8;7;7;5;4;4;4;3;3;3;3;3;3;3;3","CANCER;DISEASE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);ADVERSE EFFECT;GENE;REGIMEN;PSORIASIS;CHEMOTHERAPY;COHORT;CLINICAL TRIAL;DISCONTINUATION;OBSERVATIONAL STUDY;RECEPTOR;RETROSPECTIVE COHORT STUDY;ARTHRITIS;CONTEXT (ARCHAEOLOGY);MELANOMA;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;VISUAL ANALOGUE SCALE;VITILIGO","13;12;12;11;11;10;9;7;7;6;5;5;5;5;4;4;4;4;4;4;4","VIRAL LOAD;PSORIATIC ARTHRITIS;TOLERABILITY;BREAST CANCER;PSORIASIS AREA AND SEVERITY INDEX;GENOTYPE;HEPATITIS B VIRUS;HIDRADENITIS SUPPURATIVA;ADALIMUMAB;BIOFILM;CD8;CERVICAL CANCER;DOWNREGULATION AND UPREGULATION;ENDOVASCULAR TREATMENT;HEAD AND NECK CANCER;HISTOGENESIS;PHASES OF CLINICAL RESEARCH;PI3K/AKT/MTOR PATHWAY;T CELL;TEMOZOLOMIDE","10;9;7;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;LAMIVUDINE;BASDAI;CETUXIMAB;ENTHESITIS;PAPILLOMAVIRIDAE;REVERSE TRANSCRIPTASE;SECUKINUMAB;TRASTUZUMAB;AGGRESSIVE LYMPHOMA;ALCOHOL USE DISORDERS IDENTIFICATION TEST;APREMILAST;ARYL HYDROCARBON RECEPTOR;AUTOPHAGOSOME;AXITINIB;CARBOPLATIN;CD38;CERTOLIZUMAB PEGOL;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY;CONTACT ALLERGY;CUTANEOUS MASTOCYTOSIS;CXCR4;DISTANT METASTASIS;ELECTROCHEMOTHERAPY;ENTEROCOCCUS FAECALIS;ERBB3;FUSIDIC ACID;GENOTYPING;GOLIMUMAB;GP41;HIV VACCINE;JUNCTIONAL EPIDERMOLYSIS BULLOSA (VETERINARY MEDICINE);LYMPHOCYTE SUBSETS;MAMMOGRAPHY;MEN WHO HAVE SEX WITH MEN;MERKEL CELL;MERKEL CELL POLYOMAVIRUS;METASTATIC BREAST CANCER;MTORC1;NEOPLASTIC TRANSFORMATION;NICKEL ALLERGY;NONALCOHOLIC FATTY LIVER DISEASE;OBINUTUZUMAB;PALONOSETRON;SENTINEL LYMPH NODE;STEATOHEPATITIS;TAMOXIFEN;TOBRAMYCIN;USTEKINUMAB;VANCOMYCIN","10;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;;MIDDLE AGED;MALE;ADULT;HIV INFECTIONS;SKIN NEOPLASMS;AGED;ITALY;HETEROCYCLIC COMPOUNDS, 3-RING;ANTI-HIV AGENTS;HIV-1;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;BREAST NEOPLASMS;ADOLESCENT;ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL;ARTHRITIS, PSORIATIC;DERMATITIS, ALLERGIC CONTACT","53;44;37;37;36;33;27;19;17;17;16;15;14;14;12;11;9;9;9;9","EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;MELANIN PIGMENTATION IN MAMMALIAN SKIN;ATOPIC DERMATITIS AND SKIN MICROBIOME;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;IMMUNOGENICITY OF BIOSIMILAR THERAPEUTICS IN DRUG DEVELOPMENT;SKIN SENSITIZATION AND CONTACT ALLERGY RESEARCH;TREATMENT AND PATHOGENESIS OF HIDRADENITIS SUPPURATIVA;BIOLOGY AND PATHOLOGY OF KERATINS AND RELATED DISORDERS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;GLIOMAS;MALE CIRCUMCISION FOR HIV PREVENTION AND PENILE HEALTH;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;MANAGEMENT OF MESENTERIC ISCHEMIA AND ANEURYSMS;NEUROFIBROMATOSIS TYPE 1 AND TYPE 2;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;REGULATION AND FUNCTION OF HAIR FOLLICLE STEM CELLS;SKIN SCARRING AND REMODELING MECHANISMS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH","7;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1","REGIMEN;ANTIRETROVIRAL THERAPY;HIV;TOLERABILITY;DISCONTINUATION;DOLUTEGRAVIR;VITILIGO;CONCOMITANT;HIDRADENITIS SUPPURATIVA;HPV INFECTION;TREATMENT;ALLERGEN EXPOSURE;ALOPECIA AREATA;BIOSIMILAR;BREAST CANCER;CART;CONTACT ALLERGY;DERMAL REMODELING;DERMOSCOPY;DISEASE-MODIFYING ANTIRHEUMATIC DRUGS","10;7;7;7;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2","PSORIATIC ARTHRITIS;CANCER PATIENTS;BREAST CANCER;COHORT STUDY;CONFOCAL MICROSCOPY;HIDRADENITIS SUPPURATIVA;HUMAN PAPILLOMAVIRUS;PATIENTS RESULTS;PHASE II;PSORIATIC PATIENTS;RAMADAN FASTING;ADVANCED BREAST;APULIAN REGISTRY;BIOLOGIC DRUGS;CELL CARCINOMA;CLINICAL TRIALS;DISEASE ACTIVITY;DOLUTEGRAVIR-BASED REGIMENS;ENDOVASCULAR TREATMENT;EPIDERMOLYSIS BULLOSA;FASTING RAMADAN;II STUDY;INTEGRASE STRAND;LYMPHOMA PATIENTS;MERKEL CELL;MULTICENTER COHORT;MULTICENTER SIDAPA;MULTICENTER STUDY;MULTICENTRE STUDY;MYCOSIS FUNGOIDES","6;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","SPEAKER HONORARIA;CONSULTANCY FEES;RECEIVED CONSULTANCY;ANDOR SPEAKER;DERMATOLOGY DEPARTMENT;FEES ANDOR;MEDICINE UNIVERSITY;MSD BMS;SPEAKERS BUREAU;EPIDERMOLYSIS BULLOSA;ABBVIE MSD;DYSTROPHIC EPIDERMOLYSIS;ORCIDORG--- SECTION;PANNICULITIC MCC;PERUGIA PERUGIA;RECESSIVE DYSTROPHIC;SENSITIVE SKIN;STEM CELL;DISEASE ACTIVITY;CLINICAL PRACTICE;HPV DNA;PASI SCORE;RAMADAN FASTING;SEVERITY INDEX;ADVERSE EVENTS;BARI ITALYSEARCH;DELAYED PHASE;HIGHRISK HPV;LUCA STINGENI;MSD NOVARTIS","24;22;22;20;20;20;16;14;14;12;10;10;10;10;10;10;10;9;8;7;7;7;7;7;6;6;6;6;6;6",8,0.09,1.76,3,1,0,0,0,0,0,0,3,0,0,2.5,0,1,2,1,1,1,0,0,50.75,50.75,6,0,1,0,1,0,0,2,2,0,0,0,4,2,0,0,4.5,11.89,2.33333333333333,0,4,2,0,3,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ASCIERTO PAOLO ANTONIO;BARBABELLA URBANO;BENASSI MARCELLO;BERTRAM JOACHIM;BOTTI GERARDO;CENTOLA FABIO;CILIBERTO GENNARO;CONDEELIS JOHN S;DI MODUGNO FRANCESCA;FATTORE LUIGI","1;1;1;1;1;1;1;1;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;AGENZIA NAZIONALE PER LE NUOVE TECNOLOGIE LENERGIA E LO SVILUPPO ECONOMICO SOSTENIBILE ENEA;ALBERT EINSTEIN COLLEGE OF MEDICINE;IFO-REGINA ELENA CANCER INSTITUTE;ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI SPA;ISTITUTO NAZIONALE TUMORI IRCCS ""FONDAZIONE G PASCALE"";JOACHIM BERTRAM IBA GMBH;MASSACHUSETTS INSTITUTE OF TECHNOLOGY;UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA;UNIVERSITAETSKLINIKUM JENA","5;1;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;51 PHYSICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;5105 MEDICAL AND BIOLOGICAL PHYSICS","8;3;3;2;1;1;1;1;1","CANCER;BIOTECHNOLOGY;BIOMEDICAL IMAGING;BREAST CANCER;GENETICS;IMMUNIZATION;PREVENTION;VACCINE RELATED","5;3;1;1;1;1;1;1","5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","2;1","A61P35/00;G01N33/574;A61K31/7088;A61K39/12;A61K39/395;A61K45/00;A61K47/66;A61N5/10;C07K14/025;C07K14/47","2;2;1;1;1;1;1;1;1;1","C12Q1/6886;G01N33/57415;A61P35/00;C12Q2600/106;C12Q2600/136;C12Q2600/158;G01N33/5011;G01N33/57419;G01N33/57434;G01N33/57438","3;3;2;2;2;2;2;2;2;2",35,5.47,629.26,33.02,15,0.43,61.2,1,2,12,1,9,0,0,10,0,23,9,0,0,0,0,0,0,29,5,1,32,3,0,0,0,0,0,0,0,0,"United States;Italy;Germany;Switzerland;United Kingdom","5;3;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3105 GENETICS;3107 MICROBIOLOGY;3203 DENTISTRY;3204 IMMUNOLOGY;4205 NURSING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","34;24;15;3;3;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;BREAST CANCER;LUNG;LUNG CANCER;PATIENT SAFETY;AGING;BRAIN DISORDERS;GENETICS;BRAIN CANCER;HEMATOLOGY;NEUROSCIENCES;PREVENTION;UROLOGIC DISEASES;BIOMEDICAL IMAGING;BIOTECHNOLOGY;DIGESTIVE DISEASES;ESTROGEN","30;28;17;10;7;6;6;5;4;4;4;3;3;3;3;3;2;2;2;2","CANCER;INFECTION;NEUROLOGICAL","23;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS","22;6;2;2;1;1;1;1","BREAST CANCER;LUNG CANCER;BRAIN TUMOR;LIVER CANCER;OVARIAN CANCER;PROSTATE CANCER;BLADDER CANCER;EAR CANCER;HEAD AND NECK CANCER;KIDNEY CANCER;LARYNGEAL CANCER;LEUKEMIA / LEUKAEMIA;MYELOMA;NASAL CAVITY AND PARANASAL SINUS CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","8;6;4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.2 CANCER INITIATION: ALTERATIONS IN CHROMOSOMES;3.1 INTERVENTIONS TO PREVENT CANCER: PERSONAL BEHAVIORS THAT AFFECT CANCER RISK;3.3 CHEMOPREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.2 SURVEILLANCE","14;4;2;2;1;1;1;1;1;1;1;1;1",1,0,0,5,10,1,1,121,40970.1333333333,2.22113018914591,"FIRC INSTITUTE OF MOLECULAR ONCOLOGY;INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY;ISTITUTI FISIOTERAPICI OSPITALIERI;MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH;OSPEDALE PAPA GIOVANNI XXIII;UNIVERSITY OF MILAN;UNIVERSITY OF MODENA AND REGGIO EMILIA;UNIVERSITY OF PADUA;UNIVERSITY OF PALERMO;VENETIAN INSTITUTE OF MOLECULAR MEDICINE","1;1;1;1;1;1;1;1;1;1","ITALIAN ASSOCIATION FOR CANCER RESEARCH","1","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","1",NA,NA,"31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1;1;1","BIOENGINEERING;BREAST CANCER;CANCER;CLINICAL RESEARCH;PREVENTION","1;1;1;1;1","CANCER","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1;1","BREAST CANCER","1","1.4 CANCER PROGRESSION AND METASTASIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1;1","A01 CLINICAL MEDICINE","1",NA,NA,30,"SPRINGER NATURE;FRONTIERS;PUBLIC LIBRARY OF SCIENCE;MENDELEY DATA","11;9;9;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;3105 GENETICS;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","52;9;9;8;3;3;2;1;1;1","HEMATOLOGY;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;CANCER;CLINICAL RESEARCH;PREVENTION;RARE DISEASES;BIOMEDICAL IMAGING;DENTAL/ORAL AND CRANIOFACIAL DISEASE;SEXUALLY TRANSMITTED INFECTIONS;VACCINE RELATED","11;9;9;2;2;2;2;1;1;1;1","CANCER","3","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","9","BIOMEDICAL;CLINICAL","9;3","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","13;8","LEUKEMIA / LEUKAEMIA;MYELOMA;ORAL CAVITY AND LIP CANCER;BRAIN TUMOR;HEAD AND NECK CANCER;NASAL CAVITY AND PARANASAL SINUS CANCER;PHARYNGEAL CANCER","12;3;2;1;1;1;1","3 GOOD HEALTH AND WELL BEING","2"
"IRCCS_IFO",2020,118,12.0508474576271,2.69491525423729,0.313559322033898,0.271186440677966,0.313559322033898,2.74137931034483,1.27586206896552,1.45454545454545,1.42307692307692,0.652542372881356,1,49,25,19,9,0.42,0.21,0.16,0.08,15.97,0.633947817813311,5.07628128724672,0.347457627118644,0.983050847457627,0.52,0.399,0.38,0.407,"ALDO MORRONE;ANTONIO CRISTAUDO;ALESSANDRA LATINI;MARIA GABRIELLA DONÀ;ALESSIA PACIFICO;MASSIMO GIULIANI;ENEA GINO DI DOMENICO;GIOVANNI DAMIANI;MARCO ARDIGÒ;DIANA GIANNARELLI;PAOLO D. PIGATTO;GENNARO CILIBERTO;PASQUALE FRASCIONE;NICOLA LUIGI BRAGAZZI;MAURO PICARDO;RAUL PELLINI;NORMA CAMELI;FULVIA PIMPINELLI;FRANCESCA ROLLO;CARLO COTA","19;16;12;12;10;10;9;8;8;8;7;7;7;6;6;6;6;5;5;5","ALDO MORRONE;ANTONIO CRISTAUDO;ALESSIA PACIFICO;MARIA GABRIELLA DONÀ;MARCO ARDIGÒ;ALESSANDRA LATINI;MASSIMO GIULIANI;GIOVANNI DAMIANI;NORMA CAMELI;ENEA GINO DI DOMENICO;MAURO PICARDO;NICOLA LUIGI BRAGAZZI;PASQUALE FRASCIONE;DIANA GIANNARELLI;EMILIA MIGLIANO;CARLO COTA;ENRICA FLORI;ARIANNA MASTROFRANCESCO;MAURO ZACCARELLI;VIVIANA LORA","3.69;1.67;1.48;1.47;1.43;1.27;1.15;1.14;1.07;0.85;0.83;0.82;0.79;0.73;0.71;0.69;0.68;0.67;0.62;0.62","ALDO MORRONE;ANTONIO CRISTAUDO;ALESSANDRA LATINI;MARIA GABRIELLA DONÀ;ALESSIA PACIFICO;MASSIMO GIULIANI;ENEA GINO DI DOMENICO;MARCO ARDIGÒ;DIANA GIANNARELLI;GENNARO CILIBERTO;PASQUALE FRASCIONE;MAURO PICARDO;NORMA CAMELI;FULVIA PIMPINELLI;CARLO COTA;EMILIA MIGLIANO;ISABELLA SPERDUTI;FRANCESCA SPERATI;LAURA EIBENSCHUTZ;ANGELA FERRARI","19;16;12;12;10;10;9;8;8;7;7;6;6;5;5;5;5;5;4;4","ALDO MORRONE;ANTONIO CRISTAUDO;ALESSIA PACIFICO;MARIA GABRIELLA DONÀ;MARCO ARDIGÒ;ALESSANDRA LATINI;MASSIMO GIULIANI;NORMA CAMELI;ENEA GINO DI DOMENICO;MAURO PICARDO;PASQUALE FRASCIONE;DIANA GIANNARELLI;EMILIA MIGLIANO;CARLO COTA;ENRICA FLORI;ARIANNA MASTROFRANCESCO;VIVIANA LORA;MARIA MARIANO;CHIARA FRANCESCHINI;CLAUDIO BONIFATI","3.69;1.67;1.48;1.47;1.43;1.27;1.15;1.07;0.85;0.83;0.79;0.73;0.71;0.69;0.68;0.67;0.62;0.62;0.56;0.54","GENNARO CILIBERTO;ALESSIA PACIFICO;GIOVANNI DAMIANI;ANTONIO CRISTAUDO;ALDO MORRONE;NICOLA LUIGI BRAGAZZI;RUGGERO DE MARIA;FRANCESCA SPERATI;EDOARDO PESCARMONA;ENZO GALLO;PAOLO D. PIGATTO;PIERGIORGIO MALAGOLI;IRENE TERRENATO;PATRIZIA VICI;DANIELE MARINELLI;ERISELD KRASNIQI;FRANCESCA DE NICOLA;FRAUKE GOEMAN;LAURA PIZZUTI;LUDOVICA CIUFFREDA","321;305;295;280;258;239;227;208;205;200;196;195;192;190;185;185;185;185;185;185","ALESSIA PACIFICO;ANTONIO CRISTAUDO;ALDO MORRONE;FRANCESCA SPERATI;ALESSANDRA LATINI;MARIA GABRIELLA DONÀ;MASSIMO GIULIANI;ENEA GINO DI DOMENICO;DIANA GIANNARELLI;ENRICA FLORI;MARCO ARDIGÒ;ARIANNA MASTROFRANCESCO;STEFANIA BRIGANTI;CLAUDIO BONIFATI;GENNARO CILIBERTO;MARTA MASCHIO;ANDREA MAIALETTI;PASQUALE FRASCIONE;DARIO GRACEFFA;FRANCESCO MORI","305;280;258;208;161;153;125;120;97;90;82;78;70;66;66;65;64;58;57;55","ALDO MORRONE;ANTONIO CRISTAUDO;MARIA GABRIELLA DONÀ;ALESSANDRA LATINI;MASSIMO GIULIANI;ALESSIA PACIFICO;ENEA GINO DI DOMENICO;MARCO ARDIGÒ;PASQUALE FRASCIONE;MAURO PICARDO;DIANA GIANNARELLI;NORMA CAMELI;FRANCESCA SPERATI;EMILIA MIGLIANO;ANGELA FERRARI;ANNA CARBONE;ARIANNA MASTROFRANCESCO;LAURA EIBENSCHUTZ;MARTA MASCHIO;VIVIANA LORA","19;16;12;12;10;10;8;8;7;6;6;6;5;5;4;4;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;POLITICAL SCIENCE;ECONOMICS;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;SOCIOLOGY;GEOGRAPHY;BUSINESS;MATHEMATICS;PHILOSOPHY;ART","110;46;12;9;8;7;5;5;5;5;4;3;2;2;1","INTERNAL MEDICINE;DERMATOLOGY;PATHOLOGY;GENETICS;IMMUNOLOGY;CANCER RESEARCH;VIROLOGY;ONCOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;SURGERY;CELL BIOLOGY;NURSING;PALEONTOLOGY;OPTICS;PEDIATRICS;GASTROENTEROLOGY;MICROBIOLOGY;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;LAW","79;39;35;25;22;19;17;15;14;13;13;11;11;10;9;9;8;8;7;7;7","CANCER;DISEASE;GENE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);POPULATION;OUTBREAK;PSORIASIS;MELANOMA;QUALITY OF LIFE (HEALTHCARE);COHORT;OBSERVATIONAL STUDY;RECEPTOR;ADVERSE EFFECT;CLINICAL TRIAL;HUMAN PAPILLOMAVIRUS;INCIDENCE (GEOMETRY);LUNG CANCER;PROSPECTIVE COHORT STUDY;BACTERIA;CELL CULTURE;EPIDEMIOLOGY;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY","25;23;17;13;11;10;10;9;8;7;7;7;6;6;6;6;6;6;5;5;5;5;5","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;PSORIATIC ARTHRITIS;VIRAL LOAD;SYPHILIS;BREAST CANCER;IMMUNOTHERAPY;PSEUDOMONAS AERUGINOSA;CERVICAL CANCER;CLINICAL ENDPOINT;BIOFILM;CARCINOGENESIS;CELL CYCLE;DERMATOLOGY LIFE QUALITY INDEX;KERATINOCYTE;POLYMERASE CHAIN REACTION;VIRULENCE;ADALIMUMAB;ADENOCARCINOMA;ANTIEMETIC;CANCER CELL;CDKN2A;COLORECTAL CANCER;DERMATOSCOPY;ESCHERICHIA COLI;GENE EXPRESSION;GROWTH FACTOR;HAZARD RATIO;METASTASIS;MULTICENTER STUDY;MUTATION;PANCREATIC CANCER;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PI3K/AKT/MTOR PATHWAY;PLATELET-RICH PLASMA;POISSON REGRESSION;SKIN CANCER;SOCIOECONOMIC STATUS;TOLERABILITY;VENTILATOR-ASSOCIATED PNEUMONIA","16;7;7;7;6;5;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);MEN WHO HAVE SEX WITH MEN;ANTIRETROVIRAL THERAPY;HPV INFECTION;AMPLICON;APREPITANT;GENE SIGNATURE;METASTATIC BREAST CANCER;PAPILLOMAVIRIDAE;SECUKINUMAB;SEROSTATUS;ACANTHOSIS NIGRICANS;AMPA RECEPTOR;ANTIBODY-DRUG CONJUGATE;APREMILAST;ASCUS (BRYOZOA);BREAST RECONSTRUCTION;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;COMPLEMENTARITY DETERMINING REGION;COMPLEMENTATION;CONFORMATIONAL EPITOPE;CTGF;CYCLIN-DEPENDENT KINASE;CYTOREDUCTIVE SURGERY;DIFFUSE REFLECTANCE INFRARED FOURIER TRANSFORM;DISCOID LUPUS ERYTHEMATOSUS;ENTEROBACTERIACEAE;ERYTHROPOIETIC PROTOPORPHYRIA;EXHALED NITRIC OXIDE;FEBRILE NEUTROPENIA;FRAMESHIFT MUTATION;GALLERIA MELLONELLA;GENOME INSTABILITY;GERMLINE MUTATION;INTERLEUKIN 23;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INVOLUCRIN;IΚB KINASE;JUNCTIONAL EPIDERMOLYSIS BULLOSA (VETERINARY MEDICINE);KLEBSIELLA PNEUMONIA;KLEBSIELLA PNEUMONIAE;LDL RECEPTOR;LYMPHOCYTE SUBSETS;MASTECTOMY;MEDIASTINAL LYMPH NODE;MICROARRAY ANALYSIS TECHNIQUES;MTORC1;MULTIPLEX POLYMERASE CHAIN REACTION;MUSCULOSKELETAL DISORDER;NEOPLASTIC TRANSFORMATION;NFKB1;PALONOSETRON;PAPANICOLAOU STAIN;PARTNER NOTIFICATION;PEMBROLIZUMAB;PERITONEAL CARCINOMATOSIS;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;PROHORMONE CONVERTASE;PYOVERDINE;QUORUM SENSING;SENTINEL LYMPH NODE;SEROPREVALENCE;SEXUAL TRANSMISSION;SIDA;SOLITARY FIBROUS TUMOR;TRIPLE-NEGATIVE BREAST CANCER;UNDIFFERENTIATED PLEOMORPHIC SARCOMA","16;5;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;SKIN NEOPLASMS;ITALY;LUNG NEOPLASMS;PAPILLOMAVIRUS INFECTIONS;HIV INFECTIONS;PAPILLOMAVIRIDAE;PSORIASIS;AGED;RETROSPECTIVE STUDIES;SKIN DISEASES;BREAST NEOPLASMS;DERMATOLOGY;QUALITY OF LIFE;BIOMARKERS, TUMOR","73;44;18;16;15;14;14;13;11;11;10;10;10;9;9;9;7;7;7;6","RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;MELANOMA;ATOPIC DERMATITIS AND SKIN MICROBIOME;EPILEPSY AND SEIZURES;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;CANCER IMMUNOTHERAPY;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CUTANEOUS MANIFESTATIONS OF COVID-19: A COMPREHENSIVE REVIEW;DIAGNOSIS AND MANAGEMENT OF URTICARIA;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MALE CIRCUMCISION FOR HIV PREVENTION AND PENILE HEALTH;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;MELANIN PIGMENTATION IN MAMMALIAN SKIN;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GLOBAL BURDEN OF CHRONIC PAIN;GLOBAL EPIDEMIOLOGY OF HIV AND DRUG USE;IMPACT OF HOMELESSNESS ON HEALTH AND WELL-BEING;MECHANISMS OF SKIN AGING AND PHOTODAMAGE","7;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","PANDEMIC;PSORIASIS;2019-20 CORONAVIRUS OUTBREAK;HIV;DERMOSCOPY;SKIN CANCERS;CLINICAL ENDPOINT;EPILEPSY;MELANOMA;ANTIRETROVIRAL THERAPY;BIOMARKERS FOR IMMUNOTHERAPY;CANCER IMMUNOEDITING;CORONAVIRUS;DISCONTINUATION;HPV INFECTION;NONMELANOMA SKIN CANCER;REGIMEN;SKIN MICROBIOME;TREATMENT;ALLERGIC CONTACT DERMATITIS","10;7;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2","CONFOCAL MICROSCOPY;REFLECTANCE CONFOCAL;OBSERVATIONAL STUDY;PSEUDOMONAS AERUGINOSA;BREAST CANCER;CANCER PATIENTS;CELL CARCINOMA;CLINICAL PRACTICE;HUMAN PAPILLOMAVIRUS;LICHEN SCLEROSUS;LUNG CANCER;ADIPOSE TISSUE;AERUGINOSA STRAINS;ATOPIC DERMATITIS;BRAIN TUMOR-RELATED;CAUSING VENTILATOR-ASSOCIATED;CELL LUNG;CHRONIC SPONTANEOUS;COHERENCE TOMOGRAPHY;COHORT STUDY;CORONAVIRUS PANDEMIC;DIAGNOSTIC CHALLENGE;GENITAL LICHEN;HEALTH DISPARITIES;HIV PREVENTION;HUMAN PAPILLOMAVIRUSES;INTEGRASE INHIBITORS;ITALIAN MULTICENTER;ITALIAN SOCIETY;MEASURING HEALTH","6;6;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","INSTITUTE IRCCS;SAN GALLICANO;IRCCS ROME;ROME ITALYSEARCH;MDS PATIENTS;UNIT SAN;DERMATOLOGIC INSTITUTE;GALLICANO DERMATOLOGIC;DERMATOLOGICAL INSTITUTE;GALLICANO DERMATOLOGICAL;STIHIV UNIT;ROME ITALY;SCLEROTIC FIBROMA-LIKE;AHR CI;INVEST DERMATOL;MD ORCIDORG---;ORIGINAL MAGNIFICATION;MEDIAN AGE;CLINICAL PRACTICE;HPV INFECTION;INCREASED RISK;LUNG CANCER;MORRONE MD;ORCIDORG--- STIHIV;SCIENCEGOOGLE SCHOLAR;ADVERSE EVENTS;BIOFILM PRODUCTION;IRE COHORT;STATISTICALLY SIGNIFICANT;WNT TUMORS","26;25;24;24;16;16;14;14;13;13;13;11;11;10;10;10;10;9;8;8;8;8;8;8;8;7;7;7;7;7",13,0.11,10,9,0,0,0,1.5,0,0,0,18,1,0,11.25,0,0,1.75,6,7.25,5,0,0,50,50,4,2,1,0,2,0,0,0,0,0,0,0,5,0,0,2,4.4,6.92,2.4,0,2,3,1,0,1,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"DI MODUGNO FRANCESCA;NISTICO' PAOLA;ASCIERTO PAOLO ANTONIO;BANASSI MARCELLO;BARBABELLA URBANO;BERTRAM JOACHIM;BOTTI GERARDO;CENTOLA FABIO;CILIBERTO GENNARO;FATTORE LUIGI","2;2;1;1;1;1;1;1;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;IBA GMBH;ISTITUTI FISIOTERAPICI OSPITALIERI IFO ISTITUTO REGINA PER LO STUDIO E LA CURA DEI TUMORI IRE;ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI SPA;ISTITUTO NAZ TUMORI I R C C S FONDAZIONE G PASCALE;JOACHIM BERTRAM IBA GMBH;ST FISIOTERAPICI OSPITALIERI;UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA;UNIVERSITAETSKLINIKUM JENA","4;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;51 PHYSICAL SCIENCES;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;5105 MEDICAL AND BIOLOGICAL PHYSICS","9;4;2;2;1;1;1","CANCER;CLINICAL RESEARCH;VACCINE RELATED;BIOMEDICAL IMAGING;BIOTECHNOLOGY;BREAST CANCER","5;2;2;1;1;1","5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","2;1","C12Q1/6886;G01N33/574;A61B6/00;A61B6/04;A61K31/537;A61K47/64;A61K47/68;A61N5/10;C07K14/435;C07K14/47","3;2;1;1;1;1;1;1;1;1","C12Q1/6886;C12Q2600/158;C07K14/435;C07K14/47;C07K14/705;C07K14/70517;C07K14/70596;C07K14/78;C07K16/00;C07K16/2815","3;3;2;2;2;2;2;2;2;2",35,4.31,392.31,33.02,20,0.57,51.14,0,1,8,0,10,0,0,16,0,20,15,0,0,0,0,0,0,29,5,1,33,0,0,2,0,0,0,0,0,0,"Italy;United States;United Kingdom;France;Netherlands","7;7;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3207 MEDICAL MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE","35;21;18;3;3;2;2;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;PREVENTION;BREAST CANCER;HEMATOLOGY;LUNG;GENETICS;LUNG CANCER;BIOMEDICAL IMAGING;BRAIN CANCER;BRAIN DISORDERS;INFECTIOUS DISEASES;PEDIATRIC;UROLOGIC DISEASES;BIOTECHNOLOGY;CERVICAL CANCER;DIGESTIVE DISEASES","33;30;21;14;8;7;5;5;5;4;4;3;3;3;3;3;3;2;2;2","CANCER;INFECTION","20;2","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;3.4 VACCINES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);7.1 INDIVIDUAL CARE NEEDS","20;4;3;3;2;1;1;1;1;1","BREAST CANCER;LUNG CANCER;BRAIN TUMOR;LEUKEMIA / LEUKAEMIA;BLADDER CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;CERVICAL CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;SARCOMA;THYROID CANCER;BLOOD CANCER;COLON AND RECTAL CANCER;KIDNEY CANCER;LIVER CANCER;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;PROSTATE CANCER","6;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;1.2 CANCER INITIATION: ALTERATIONS IN CHROMOSOMES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.2 SURVEILLANCE","17;3;2;2;2;1;1;1;1",18,10999659,687478.69,4.11111111111111,2.11111111111111,1.22222222222222,0.111111111111111,14.5833333333333,139181.374404762,0.847814590886543,"ISTITUTI FISIOTERAPICI OSPITALIERI;AGOSTINO GEMELLI UNIVERSITY POLYCLINIC;AGÈNCIA DE QUALITAT I AVALUACIÓ SANITÀRIES DE CATALUNYA;ALLEANZA CONTRO IL CANCRO;BELGIAN SOCIETY OF MEDICAL ONCOLOGY;CANDIOLO CANCER INSTITUTE;CHARITÉ - UNIVERSITY MEDICINE BERLIN;EUROPEAN INSTITUTE OF ONCOLOGY;FONDAZIONE HUMANITAS PER LA RICERCA;FRENCH NATIONAL CANCER INSTITUTE;HOSPICES CIVILS DE LYON;INSTITUT CATALÀ D'ONCOLOGIA;INSTITUT JULES BORDET;INSTITUTE CURIE;INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEÓN;IRCCS OSPEDALE SAN RAFFAELE;LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN;SCIENSANO (BELGIUM);UNIVERSITY OF TURIN;UNIVERSITY OF VERONA","18;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ITALIAN ASSOCIATION FOR CANCER RESEARCH;EUROPEAN COMMISSION","17;1","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;COALITION S;EC & ERC - EUROPEAN UNION","17;1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);PCP - PRE-COMMERCIAL PROCUREMENT (FUNDING SCHEME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3202 CLINICAL SCIENCES;3105 GENETICS","18;16;11;7;4;3;1","CANCER;GENETICS;CLINICAL RESEARCH;RARE DISEASES;BIOTECHNOLOGY;HUMAN GENOME;ORPHAN DRUG;DIGESTIVE DISEASES;BREAST CANCER;DENTAL/ORAL AND CRANIOFACIAL DISEASE;HEMATOLOGY;PREVENTION;BIOMEDICAL IMAGING;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COLO-RECTAL CANCER;GENETIC TESTING;LUNG;LUNG CANCER;OVARIAN CANCER","18;10;9;9;8;5;4;3;2;2;2;2;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","18;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","13;11;4;2;1;1","BREAST CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;COLON AND RECTAL CANCER;HEAD AND NECK CANCER;MELANOMA;MYELOMA;PHARYNGEAL CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER;SALIVARY GLAND CANCER;STOMACH CANCER","3;3;3;2;2;2;2;2;1;1;1;1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;1.4 CANCER PROGRESSION AND METASTASIS;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;1.2 CANCER INITIATION: ALTERATIONS IN CHROMOSOMES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","7;6;5;4;3;2;2;1;1;1","A01 CLINICAL MEDICINE;C21 SOCIOLOGY","17;1","3 GOOD HEALTH AND WELL BEING","2",22,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;MENDELEY DATA;SPRINGER NATURE","8;8;2;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;40 ENGINEERING;42 HEALTH SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3206 MEDICAL BIOTECHNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","29;8;7;7;3;2;2;1;1;1;1;1;1;1","CANCER;BIOTECHNOLOGY;CLINICAL RESEARCH;VACCINE RELATED;IMMUNIZATION;PATIENT SAFETY;BIODEFENSE;BIOMEDICAL IMAGING;BRAIN DISORDERS;DENTAL/ORAL AND CRANIOFACIAL DISEASE;EMERGING INFECTIOUS DISEASES;EPILEPSY;GENETICS;INFECTIOUS DISEASES;NEURODEGENERATIVE;NEUROSCIENCES;PREVENTION;RARE DISEASES;REGENERATIVE MEDICINE;STEM CELL RESEARCH","7;4;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;MUSCULOSKELETAL;NEUROLOGICAL","6;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","3;2;1;1;1","BIOMEDICAL;CLINICAL","2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","7;4","NOT SITE-SPECIFIC CANCER;SARCOMA;HEAD AND NECK CANCER;MELANOMA;ORAL CAVITY AND LIP CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;LARYNGEAL CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","3;3;2;2;2;1;1;1;1;1",NA,NA
"IRCCS_IFO",2021,109,14.1192660550459,3.72477064220183,0.339449541284404,0.321100917431193,0.293577981651376,2.76190476190476,1.23333333333333,1.59090909090909,1.28,0.660550458715596,1,38,23,17,7,0.35,0.21,0.16,0.06,15.53,1.00722396171954,5.32087912087913,0.302752293577982,1,0.476,0.474,0.462,0.458,"ALDO MORRONE;ANTONIO CRISTAUDO;FULVIA PIMPINELLI;ALESSANDRA LATINI;DIANA GIANNARELLI;MARTINA PONTONE;ENEA GINO DI DOMENICO;PAOLO D. PIGATTO;GENNARO CILIBERTO;CARLO COTA;FABRIZIO ENSOLI;ALESSIA PACIFICO;MAURO PICARDO;RAUL PELLINI;LUCA STINGENI;MARCO ARDIGÒ;MAURO TRUGLIO;GIOVANNI PELLACANI;BRANKA VUJOVIC;BARBARA PICHI","25;17;11;10;10;9;9;9;9;8;8;8;8;8;7;7;7;6;6;6","ALDO MORRONE;ANTONIO CRISTAUDO;ALESSANDRA LATINI;MAURO PICARDO;NORMA CAMELI;CARLO COTA;MAURO TRUGLIO;MARIA MARIANO;ALESSIA PACIFICO;ANGELA SANTONI;EMANUELA CAMERA;SEBASTIANO MERCADANTE;EDOARDO ARCURI;FULVIA PIMPINELLI;MARIA GABRIELLA DONÀ;MARCO ARDIGÒ;DIANA GIANNARELLI;MASSIMO GIULIANI;MARTINA PONTONE;RAUL PELLINI","2.68;2.49;1.07;0.95;0.95;0.88;0.85;0.79;0.76;0.75;0.73;0.67;0.67;0.6;0.59;0.58;0.57;0.55;0.53;0.52","ALDO MORRONE;ANTONIO CRISTAUDO;FULVIA PIMPINELLI;ALESSANDRA LATINI;DIANA GIANNARELLI;MARTINA PONTONE;ENEA GINO DI DOMENICO;GENNARO CILIBERTO;CARLO COTA;FABRIZIO ENSOLI;ALESSIA PACIFICO;MAURO PICARDO;RAUL PELLINI;LUCA STINGENI;MARCO ARDIGÒ;MAURO TRUGLIO;BRANKA VUJOVIC;BARBARA PICHI;EMANUELA CAMERA;SIMONA DI MARTINO","25;17;11;10;10;9;9;9;8;8;8;8;8;7;7;7;6;6;6;6","ALDO MORRONE;ANTONIO CRISTAUDO;ALESSANDRA LATINI;MAURO PICARDO;NORMA CAMELI;CARLO COTA;MAURO TRUGLIO;MARIA MARIANO;ALESSIA PACIFICO;EMANUELA CAMERA;EDOARDO ARCURI;FULVIA PIMPINELLI;MARIA GABRIELLA DONÀ;MARCO ARDIGÒ;DIANA GIANNARELLI;MASSIMO GIULIANI;MARTINA PONTONE;RAUL PELLINI;FELICE MUSICCO;ENEA GINO DI DOMENICO","2.68;2.49;1.07;0.95;0.95;0.88;0.85;0.79;0.76;0.73;0.67;0.6;0.59;0.58;0.57;0.55;0.53;0.52;0.52;0.5","ALDO MORRONE;FULVIA PIMPINELLI;DIANA GIANNARELLI;GENNARO CILIBERTO;MARTINA PONTONE;FABRIZIO ENSOLI;ENEA GINO DI DOMENICO;BRANKA VUJOVIC;SIMONA DI MARTINO;ORNELLA DI BELLA;GIULIA PIAGGIO;VIRGINIA FERRARESI;R. BIAGINI;ANGELO PAOLO DEI TOS;ALESSANDRO GRONCHI;A.B. HASSAN;AISHA MIAH;AKIRA KAWAI;AKMAL SAFWAT;ANDREA FERRARI","677;547;535;532;521;512;507;474;474;468;451;390;347;342;330;329;329;329;329;329","ALDO MORRONE;FULVIA PIMPINELLI;MARTINA PONTONE;ENEA GINO DI DOMENICO;FABRIZIO ENSOLI;BRANKA VUJOVIC;ORNELLA DI BELLA;R. BIAGINI;DIANA GIANNARELLI;GENNARO CILIBERTO;GIOVANNI BLANDINO;FLAMINIA CAMPO;FRANCESCO MAZZOLA;ALDO VENUTI;ANTONELLO VIDIRI;BARBARA PICHI;CHIARA MANDOJ;ELVA ABRIL;FABRIZIO PETRONE;FEDERICO DE MARCO","630;544;521;500;500;432;432;347;278;277;277;258;258;253;253;253;253;253;253;253","ALDO MORRONE;ANTONIO CRISTAUDO;FULVIA PIMPINELLI;ALESSANDRA LATINI;MARTINA PONTONE;MAURO PICARDO;ALESSIA PACIFICO;ENEA GINO DI DOMENICO;FABRIZIO ENSOLI;MARCO ARDIGÒ;MAURO TRUGLIO;CARLO COTA;EMANUELA CAMERA;NORMA CAMELI;DIANA GIANNARELLI;ANNA CARBONE;FRANCESCA SPERATI;GENNARO CILIBERTO;MARIA GABRIELLA DONÀ;MARIA MARIANO","23;16;10;10;9;8;8;7;7;7;7;7;6;6;6;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;PSYCHOLOGY;POLITICAL SCIENCE;ECONOMICS;ENGINEERING;HISTORY;MATERIALS SCIENCE;SOCIOLOGY;ART;GEOGRAPHY;PHILOSOPHY","100;40;15;7;7;6;6;5;2;2;2;2;2;1;1;1","INTERNAL MEDICINE;DERMATOLOGY;IMMUNOLOGY;PATHOLOGY;GENETICS;ONCOLOGY;SURGERY;CANCER RESEARCH;VIROLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;CELL BIOLOGY;FAMILY MEDICINE;GASTROENTEROLOGY;NURSING;STATISTICS;ANATOMY;GERONTOLOGY;LAW;PALEONTOLOGY;PEDIATRICS;PHARMACOLOGY;RADIOLOGY","65;32;27;26;19;17;17;16;13;12;11;10;7;6;6;6;5;5;5;5;5;5;5","DISEASE;CANCER;GENE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);ANTIBODY;PSORIASIS;COHORT;IMMUNE SYSTEM;MELANOMA;ADVERSE EFFECT;ATOPIC DERMATITIS;POPULATION;DISCONTINUATION;OBSERVATIONAL STUDY;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;IN VITRO;LOGISTIC REGRESSION;ASYMPTOMATIC;CLINICAL TRIAL;PROSPECTIVE COHORT STUDY;QUALITY OF LIFE (HEALTHCARE);REGIMEN;STRATUM CORNEUM;VITILIGO","21;19;12;11;10;9;8;8;8;7;7;7;6;6;6;6;5;5;4;4;4;4;4;4;4","INFECTIOUS DISEASE (MEDICAL SPECIALTY);IMMUNOGENICITY;SYPHILIS;TITER;VIRAL LOAD;CERVICAL CANCER;GENOTYPE;ADALIMUMAB;CANCER CELL;COLORECTAL CANCER;CONTACT DERMATITIS;IMMUNOTHERAPY;METASTASIS;MULTICENTER STUDY;PSORIASIS AREA AND SEVERITY INDEX;SEROLOGY;TOLERABILITY;ALLERGIC CONTACT DERMATITIS;ANAL CANCER;ANTIBODY RESPONSE;BASAL (MEDICINE);BASAL CELL CARCINOMA;DERMATOLOGY LIFE QUALITY INDEX;DNA DAMAGE;DOWNREGULATION AND UPREGULATION;DUPILUMAB;ECZEMA AREA AND SEVERITY INDEX;ETANERCEPT;HEDGEHOG SIGNALING PATHWAY;HIDRADENITIS SUPPURATIVA;IMMUNITY;INFLIXIMAB;MYCOSIS FUNGOIDES;NEVUS;OPIOID;PROGRAMMED CELL DEATH;PSORIATIC ARTHRITIS;RELIABILITY (SEMICONDUCTOR);RNA;SKIN BIOPSY;TRANSCRIPTION FACTOR;TRANSEPIDERMAL WATER LOSS;TUMOR MICROENVIRONMENT;TUMOR PROGRESSION;WNT SIGNALING PATHWAY","12;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);ANTIRETROVIRAL THERAPY;HPV INFECTION;MEN WHO HAVE SEX WITH MEN;ANTIBODY TITER;MITOTIC CATASTROPHE;NIVOLUMAB;VISMODEGIB;(+)-NALOXONE;ARYL HYDROCARBON RECEPTOR;AXILLARY LYMPH NODES;BOOSTER DOSE;BUPRENORPHINE;CANCER-ASSOCIATED FIBROBLASTS;CASPASE;CELL CYCLE CHECKPOINT;CEREBRAL AMYLOID ANGIOPATHY;CHANCRE;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;CONTACT ALLERGY;CYANOACRYLATE;DASATINIB;DOMESTIC VIOLENCE;EARLY SYPHILIS;ENTHESITIS;EPITHELIAL–MESENCHYMAL TRANSITION;ERLOTINIB;ERYTHROPOIETIC PROTOPORPHYRIA;GEFITINIB;GENOTYPING;GLI1;HAND ECZEMA;HISTONE DEACETYLASE;HONEYCOMBING;HYPERALGESIA;IMMUNE CHECKPOINT;INTRAVOXEL INCOHERENT MOTION;IRRITANT CONTACT DERMATITIS;KRAS;LAMIVUDINE;LONG NON-CODING RNA;MASTECTOMY;MENINGOCOCCAL DISEASE;MONOCLONAL;MULTILOCUS SEQUENCE TYPING;MYELOPROLIFERATIVE NEOPLASM;NEVOID BASAL-CELL CARCINOMA SYNDROME;NILOTINIB;NOCICEPTOR;PALONOSETRON;PATCH TESTING;PEMBROLIZUMAB;POLY ADP RIBOSE POLYMERASE;PTCH1;RAD51;RETINOID;REVERSE TRANSCRIPTASE;RUXOLITINIB;SCORAD;SECUKINUMAB;SENTINEL LYMPH NODE;SEROPREVALENCE;SPITZ NEVUS;SYPHILIS SERODIAGNOSIS;TISSUE TROPISM;TNF INHIBITOR;TREPONEMA;TRK RECEPTOR;UNDERWEIGHT;USTEKINUMAB;VASCULOGENESIS","12;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;ADULT;SKIN NEOPLASMS;MIDDLE AGED;COVID-19;HIV INFECTIONS;ITALY;ANTINEOPLASTIC AGENTS;LUNG NEOPLASMS;TREATMENT OUTCOME;AGED;MELANOMA;PROSPECTIVE STUDIES;SYPHILIS;AGED, 80 AND OVER;COVID-19 VACCINES;SARS-COV-2","56;52;19;18;17;17;15;12;11;11;10;10;10;9;9;9;8;7;7;7","ATOPIC DERMATITIS AND SKIN MICROBIOME;CORONAVIRUS DISEASE 2019 RESEARCH;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;MELANIN PIGMENTATION IN MAMMALIAN SKIN;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;SKIN SENSITIZATION AND CONTACT ALLERGY RESEARCH;MELANOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER STEM CELLS AND TUMOR METASTASIS;CARDIOTOXICITY OF CANCER TREATMENTS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;HEDGEHOG SIGNALING IN DEVELOPMENT AND CANCER;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;MOLECULAR MECHANISMS OF HEME BIOSYNTHESIS AND RELATED DISORDERS","6;6;4;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2","HIV;DISCONTINUATION;REGIMEN;SKIN SENSITIZATION;VITILIGO;DOLUTEGRAVIR;IMMUNITY;PANDEMIC;PSORIASIS;SKIN MICROBIOME;TOLERABILITY;VACCINES;ANTIBODY;ANTIBODY RESPONSE;ANTIBODY TITER;BASAL (MEDICINE);BASAL CELL CARCINOMA;BIOMARKERS FOR IMMUNOTHERAPY;CANCER STEM CELLS;DELPHI METHOD","7;6;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","ATOPIC DERMATITIS;BASAL CELL;BNTB VACCINE;ITALIAN SOCIETY;CELL CARCINOMA;CONFOCAL MICROSCOPY;PATIENTS UNDERGOING;PROSPECTIVE STUDY;AGE GENDER;BARRIER FUNCTION;BICTAFFTC SINGLE-TABLET;CANCER STEM;CANCER-ASSOCIATED FIBROBLASTS;COHORT STUDY;COLORECTAL CANCER;COVID PANDEMIC;ENLARGING MELANOCYTIC;ERYTHROPOIETIC PROTOPORPHYRIA;GLOBULAR PATTERN;HIDRADENITIS SUPPURATIVA;LUNG CANCER;MEDICATION ERRORS;MELANOCYTIC LESIONS;MICROSCOPY STUDY;MULTICENTER COHORT;MULTICENTER STUDY;MYCOSIS FUNGOIDES;OBSERVATIONAL STUDY;PATIENT REPORTED;PERIPHERAL GLOBULAR","5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ATOPIC DERMATITIS;ROME ITALYSEARCH;BED BUGS;IMMUNE RESPONSE;AD PATIENTS;CONTACT DERMATITIS;COVID- PANDEMIC;HUMAN SKIN;FATTY ACIDS;OBSERVATIONAL STUDY;STATISTICALLY SIGNIFICANT;AGE GENDER;ANTIBODY TITRE;CD T-CELL;DERMATOLOGY DEPARTMENT;HPV INFECTION;HPV STATUS;IMMUNE RESPONSES;MARIA TERESA;PATIENTS CONTINUING;SIGNIFICANT DIFFERENCES;BNTB VACCINE;CROSSREF MEDLINE;DENTAL PERSONNEL;DISEASE ACTIVITY;DISEASE SEVERITY;FACIAL DERMATOSES;HIV-INFECTED MSM;LOGISTIC REGRESSION;MEDLINE GOOGLE","11;10;9;9;8;8;8;8;7;7;7;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5",17,0.16,3.6,5,1,1,0,1,0,0,0,6,1,0,5,0,0,1,7,4,1,0,0,37,37,1,0,2,0,0,0,0,0,0,0,0,0,2,0,0,0,5,2.46,3,0,2,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ASCIERTO PAOLO ANTONIO;BOTTI GERARDO;CILIBERTO GENNARO;FATTORE LUIGI;MANCINI RITA","2;2;2;2;2","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;ISTITUTO NAZIONALE TUMORI IRCCS ""FONDAZIONE G PASCALE"";UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA","2;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","4;2","BIOTECHNOLOGY;CANCER;ANTIMICROBIAL RESISTANCE","2;2;1","5.1 PHARMACEUTICALS","2","C12Q1/6886;A61K45/06;C12N15/113","2;1;1","A61K45/06;C12N15/113;C12N2310/141;C12N2310/3231;C12N2320/31;C12Q1/6886;C12Q2600/106;C12Q2600/158;C12Q2600/178","2;2;2;2;2;2;2;2;2",37,3.65,1060.27,25.87,20,0.54,67.41,0,1,14,0,9,0,0,13,0,25,9,0,0,0,0,0,0,31,3,3,34,3,0,0,0,0,0,0,0,0,"United States;Italy;Germany","8;5;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3203 DENTISTRY;3207 MEDICAL MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4203 HEALTH SERVICES AND SYSTEMS","36;25;19;3;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;LUNG;LUNG CANCER;PATIENT SAFETY;BREAST CANCER;ORPHAN DRUG;GENETICS;IMMUNIZATION;INFECTIOUS DISEASES;PEDIATRIC;PREVENTION;VACCINE RELATED;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;OVARIAN CANCER;AGING;BIODEFENSE","32;29;27;13;6;6;6;4;4;3;3;3;3;3;3;2;2;2;1;1","CANCER;INFECTION","24;3","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.4 VACCINES;5.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING","24;5;2;1;1;1;1;1;1","LUNG CANCER;BREAST CANCER;SARCOMA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;MELANOMA;OVARIAN CANCER;PROSTATE CANCER;BLADDER CANCER;CERVICAL CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;THYROID CANCER","7;4;4;2;2;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.4 CANCER PROGRESSION AND METASTASIS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","18;3;2;2;1;1;1;1",2,0,0,4,1,1,0,13,139181.374404762,0.783150766157909,"ISTITUTI FISIOTERAPICI OSPITALIERI","2","ITALIAN ASSOCIATION FOR CANCER RESEARCH","2","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","2",NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3204 IMMUNOLOGY","2;2;1;1;1","CANCER;BREAST CANCER;CLINICAL RESEARCH;GENETICS;IMMUNIZATION;RARE DISEASES;VACCINE RELATED","2;1;1;1;1;1;1","CANCER","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","2;1","BREAST CANCER;MELANOMA","1;1","1.2 CANCER INITIATION: ALTERATIONS IN CHROMOSOMES;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;1.4 CANCER PROGRESSION AND METASTASIS;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1;1;1;1;1","A01 CLINICAL MEDICINE","2",NA,NA,31,"SPRINGER NATURE;FRONTIERS;ZENODO;AMERICAN CHEMICAL SOCIETY;LEIBNIZ-INSTITUT FÜR ARBEITSFORSCHUNG AN DER TU DORTMUND (IFADO)","16;11;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;49 MATHEMATICAL SCIENCES;3105 GENETICS;3106 INDUSTRIAL BIOTECHNOLOGY;42 HEALTH SCIENCES","41;17;12;7;7;6;2;2;2;1;1;1","CANCER;CLINICAL RESEARCH;RARE DISEASES;BRAIN DISORDERS;BRAIN CANCER;NEUROSCIENCES;BIOMEDICAL IMAGING;ATAXIA TELANGIECTASIA;BIOENGINEERING;DIGESTIVE DISEASES;GENETICS;HEMATOLOGY;NEURODEGENERATIVE;PANCREATIC CANCER;PATIENT SAFETY;PREVENTION","14;9;7;5;4;4;2;1;1;1;1;1;1;1;1;1","CANCER","15","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY","8;2;2;1;1;1;1","BIOMEDICAL;CLINICAL;HEALTH SERVICES & SYSTEMS","9;3;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","12;10","BRAIN TUMOR;OVARIAN CANCER;LUNG CANCER;ENDOMETRIAL CANCER;LIVER CANCER;MYELOMA;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER","10;8;2;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","2"
"IRCCS_IFO",2022,91,14.7032967032967,2.91208791208791,0.263736263736264,0.230769230769231,0.362637362637363,2.13709677419355,1.09090909090909,1.5,1.32,0.714285714285714,0,25,25,14,4,0.27,0.27,0.15,0.04,8.08,0.904794037908029,5.09385113268608,0.32967032967033,0.989010989010989,0.441,0.493,0.38,0.496,"ALDO MORRONE;FULVIA PIMPINELLI;GENNARO CILIBERTO;ANTONIO CRISTAUDO;ALESSANDRA LATINI;FRANCESCA SPERATI;PAOLO D. PIGATTO;MASSIMO COSTANTINI;MARIA GABRIELLA DONÀ;NICOLA SILVESTRIS;MARTINA PONTONE;CLAUDIO BONIFATI;DARIO GRACEFFA;LUCA STINGENI;FAUSTO BALDANTI;ALBERTO MANTOVANI;ALESSIA PACIFICO;GIOVANNI APOLONE;EUGENIA GIULIANI;MAURO PICARDO","22;12;11;10;8;8;7;6;6;6;5;5;5;5;5;5;5;5;5;5","ALDO MORRONE;ANTONIO CRISTAUDO;FULVIA PIMPINELLI;ALESSANDRA LATINI;FRANCESCA SPERATI;EMILIA MIGLIANO;VALENTINA GARELLI;M TEDESCO;MARIA GABRIELLA DONÀ;NORMA CAMELI;GENNARO CILIBERTO;PAOLO D. PIGATTO;ERNESTO MARIA BUCCHERI;AMEDEO VILLANUCCI;ROY DE VITA;EUGENIA GIULIANI;GIOVANNI PELLACANI;MASSIMO GIULIANI;ALESSIA PACIFICO;EMANUELE DI SIMONE","2.07;1.19;0.95;0.73;0.67;0.62;0.54;0.54;0.49;0.49;0.48;0.48;0.45;0.45;0.45;0.44;0.42;0.4;0.39;0.39","ALDO MORRONE;FULVIA PIMPINELLI;GENNARO CILIBERTO;ANTONIO CRISTAUDO;ALESSANDRA LATINI;FRANCESCA SPERATI;MARIA GABRIELLA DONÀ;MARTINA PONTONE;CLAUDIO BONIFATI;DARIO GRACEFFA;ALESSIA PACIFICO;EUGENIA GIULIANI;MAURO PICARDO;RAUL PELLINI;ILARIA CAVALLO;FRANCESCA SIVORI;LUCA BIANCHI;ENEA GINO DI DOMENICO;EMILIA MIGLIANO;MAURO TRUGLIO","22;12;11;10;8;8;6;5;5;5;5;5;5;5;5;4;4;4;4;4","ALDO MORRONE;ANTONIO CRISTAUDO;FULVIA PIMPINELLI;ALESSANDRA LATINI;FRANCESCA SPERATI;EMILIA MIGLIANO;VALENTINA GARELLI;M TEDESCO;MARIA GABRIELLA DONÀ;NORMA CAMELI;GENNARO CILIBERTO;AMEDEO VILLANUCCI;ROY DE VITA;EUGENIA GIULIANI;MASSIMO GIULIANI;ALESSIA PACIFICO;EMANUELE DI SIMONE;CLAUDIO BONIFATI;DARIO GRACEFFA;MAURO PICARDO","2.07;1.19;0.95;0.73;0.67;0.62;0.54;0.54;0.49;0.49;0.48;0.45;0.45;0.44;0.4;0.39;0.39;0.38;0.38;0.37","ALDO MORRONE;FULVIA PIMPINELLI;GENNARO CILIBERTO;MAURO PICARDO;FRANCESCA SPERATI;MASSIMO COSTANTINI;NICOLA SILVESTRIS;ALBERTO MANTOVANI;CARLO SALVARANI;FAUSTO BALDANTI;GIOVANNI APOLONE;ENEA GINO DI DOMENICO;ILARIA CAVALLO;ANTONIO UCCELLI;CHIARA AGRATI;MAURO TRUGLIO;FRANCESCA SIVORI;LAURA PIZZUTI;PAOLO CORRADINI;MARTINA PONTONE","225;158;134;122;113;99;99;97;97;97;97;95;95;90;90;90;85;84;84;78","ALDO MORRONE;FULVIA PIMPINELLI;MAURO PICARDO;FRANCESCA SPERATI;GENNARO CILIBERTO;ILARIA CAVALLO;MAURO TRUGLIO;FRANCESCA SIVORI;MARTINA PONTONE;ANTONIO CRISTAUDO;ALESSANDRA LATINI;STEFANIA BRIGANTI;MARIA GABRIELLA DONÀ;CLAUDIO BONIFATI;DARIO GRACEFFA;GIORGIA CARDINALI;ALESSIA PACIFICO;DANIELA KOVACS;MONICA OTTAVIANI;ARIANNA MASTROFRANCESCO","151;130;122;113;97;95;90;85;78;65;62;61;58;55;55;55;52;51;49;46","ALDO MORRONE;FULVIA PIMPINELLI;ANTONIO CRISTAUDO;FRANCESCA SPERATI;ALESSANDRA LATINI;GENNARO CILIBERTO;MARTINA PONTONE;CLAUDIO BONIFATI;DARIO GRACEFFA;ILARIA CAVALLO;MARIA GABRIELLA DONÀ;MAURO PICARDO;ALESSIA PACIFICO;EMILIA MIGLIANO;EUGENIA GIULIANI;FRANCESCA SIVORI;MASSIMO GIULIANI;MAURO TRUGLIO;NORMA CAMELI;ANNA RITA BUONOMINI","17;11;10;8;7;5;5;5;5;5;5;5;5;4;4;4;4;4;4;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ECONOMICS;SOCIOLOGY;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE;PHILOSOPHY;GEOGRAPHY;PSYCHOLOGY","85;26;11;5;4;4;3;3;3;3;3;2;1;1","INTERNAL MEDICINE;DERMATOLOGY;PATHOLOGY;SURGERY;IMMUNOLOGY;GENETICS;CANCER RESEARCH;ONCOLOGY;VIROLOGY;BIOCHEMISTRY;NURSING;RADIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;ENDOCRINOLOGY;OPTICS;PEDIATRICS;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;PSYCHIATRY","58;30;27;25;21;13;9;9;9;8;8;8;7;7;7;6;6;6;5;5;5","DISEASE;CANCER;PSORIASIS;ADVERSE EFFECT;GENE;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;COHORT;POPULATION;ALTERNATIVE MEDICINE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);OUTBREAK;QUALITY OF LIFE (HEALTHCARE);VACCINATION;ANTIBODY;CONFIDENCE INTERVAL;OBSERVATIONAL STUDY;ATOPIC DERMATITIS;CONCOMITANT;HEALTH CARE;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);LICHEN SCLEROSUS","20;17;12;10;9;9;9;8;8;7;6;6;6;6;6;5;5;5;4;4;4;4;4;4","INFECTIOUS DISEASE (MEDICAL SPECIALTY);BREAST CANCER;DERMATOLOGY LIFE QUALITY INDEX;2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;PSORIATIC ARTHRITIS;ANAL CANCER;HAZARD RATIO;IMMUNOGENICITY;MULTICENTER STUDY;PROSTATE CANCER;SYPHILIS;TITER;TOLERABILITY;BIOFILM;CANCER CELL;DUPILUMAB;ECZEMA AREA AND SEVERITY INDEX;IMMUNOTHERAPY;LYMPHADENECTOMY;MERKEL CELL CARCINOMA;MICRORNA;PLACEBO;PROTOCOL (SCIENCE);PSORIASIS AREA AND SEVERITY INDEX;REPROGRAMMING;VIRAL LOAD","14;6;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);BOOSTER DOSE;MEN WHO HAVE SEX WITH MEN;ANTIRETROVIRAL THERAPY;BREAST RECONSTRUCTION;ENTHESITIS;(+)-NALOXONE;ACINIC CELL CARCINOMA;ANTIBODY TITER;BUPRENORPHINE;CXCR4;ESTROGEN RECEPTOR;EXTERNAL BEAM RADIOTHERAPY;HORMONE RECEPTOR;HPV INFECTION;ILLUMINA DYE SEQUENCING;INJURY SEVERITY SCORE;IRRITANT CONTACT DERMATITIS;KAPOSI'S SARCOMA;LNCAP;MALE BREAST CANCER;MAMMOGRAPHY;MASTECTOMY;MEDICATION ERROR;MERKEL CELL POLYOMAVIRUS;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;NUCLEAR RECEPTOR;OBINUTUZUMAB;OLIGOARTHRITIS;ONCOMIR;PEMBROLIZUMAB;PEMPHIGOID;PENCIL-BEAM SCANNING;PHYLOTYPE;PIOGLITAZONE;PROSTATECTOMY;RUXOLITINIB;SECUKINUMAB;SEXUAL CONTACT;SKIN INFECTION;STAPHYLOCOCCAL INFECTIONS;TAMOXIFEN;TARGET LESION;TELEDERMATOLOGY;VANCOMYCIN;VASCULOGENIC MIMICRY","14;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;COVID-19;SKIN NEOPLASMS;HIV INFECTIONS;PSORIASIS;MALE;FEMALE;BREAST NEOPLASMS;PAPILLOMAVIRUS INFECTIONS;RETROSPECTIVE STUDIES;ADULT;MELANOMA;MIDDLE AGED;ITALY;TREATMENT OUTCOME;ANTI-HIV AGENTS;DERMATITIS, ATOPIC;MICROSCOPY, CONFOCAL;PROSTATIC NEOPLASMS","54;37;15;15;14;14;12;11;10;10;10;9;9;9;8;8;7;7;7;7","CORONAVIRUS DISEASE 2019 RESEARCH;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;ATOPIC DERMATITIS AND SKIN MICROBIOME;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;MALE CIRCUMCISION FOR HIV PREVENTION AND PENILE HEALTH;MELANIN PIGMENTATION IN MAMMALIAN SKIN;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;DIAGNOSIS AND MANAGEMENT OF URTICARIA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL SKIN INFECTIONS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;PATHOGENESIS AND TREATMENT OF PEMPHIGOID DISEASES;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;BIOACTIVE PEPTIDES IN FOOD AND HEALTH;BIOLOGICAL BASIS AND CLINICAL MANAGEMENT OF SYPHILIS","6;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1","PANDEMIC;PSORIASIS;CLINICAL ENDPOINT;CONCOMITANT;2019-20 CORONAVIRUS OUTBREAK;BOOSTER DOSE;CONCORDANCE;HISTOPATHOLOGY;TOLERABILITY;TREATMENT;VACCINES;VENEREOLOGY;VITILIGO;VULVAR DISEASE;ANTIBODY RESPONSE;ANTIBODY TITER;ANTIRETROVIRAL THERAPY;BOOSTER (ROCKETRY);CANCER;CHRONIC SPONTANEOUS URTICARIA","9;7;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","COVID- PANDEMIC;CLINICAL PRACTICE;CONFOCAL MICROSCOPY;LICHEN SCLEROSUS;PROSPECTIVE STUDY;PROSTATE CANCER;REFLECTANCE CONFOCAL;ATOPIC DERMATITIS;BREAST CANCER;CELL CARCINOMA;PSORIATIC ARTHRITIS;RETROSPECTIVE STUDY;SOFT TISSUE;VULVAR LICHEN;BNTB VACCINE;CASE-CONTROL STUDY;CHRONIC SPONTANEOUS;CLINICAL TRIAL;COOPERATIVE COMPLEXES;COVID- VACCINATION;CUTANEOUS ACUTE;FRAIL PATIENTS;HUMAN PAPILLOMAVIRUS;HUMORAL RESPONSE;HYALURONIC ACID;HYBRID COOPERATIVE;IMMUNE RESPONSE;INJECTING HYBRID;ITALIAN COHORT;ITALIAN VAXFRAIL","5;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADVERSE EVENTS;AHR CI;RCM READERS;PHOENIX RISING;BOOSTER DOSE;INTEROBSERVER REPRODUCIBILITY;REPRESENTATIVE IMAGES;BREAST CANCER;FRAIL PATIENTS;HEALTHCARE WORKERS;IMMUNE RESPONSE;LICHEN SCLEROSUS;SAFETY PROFILE;AGVHD FEATURES;BIOFILM PRODUCERS;CHRONIC DISEASES;COVID- PANDEMIC;HUMORAL RESPONSE;PRELIMINARY STUDY;SIGNIFICANTLY LOWER;SOFT TISSUE;ACNE VULGARIS;ANTIBODY RESPONSE;BC PATIENTS;BIOFILM PRODUCTION;BURNING SENSATION;CALBD FOAM;CELL CARCINOMA;CLINICAL PRACTICE;CONFIDENCE INTERVAL","11;9;9;8;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4",17,0.19,3,4,0,2,0,11,0,1,0,5,0,0,4,0,0,1,1.5,3.5,2.25,0,0,19,19,2,0,0,0,1,2,0,0,0,0,0,0,1,2,0,0,4.66666666666667,5.28,3,0,3,2,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ASCIERTO PAOLO ANTONIO;BOTTI GERARDO;CILIBERTO GENNARO;FATTORE LUIGI;MANCINI RITA;CONDEELIS JOHN S;GERTLER FRANK;GOSWAMI SUMANTA;NISTICO PAOLA","2;2;2;2;2;1;1;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA;ALBERT EINSTEIN COLLEGE OF MEDICINE;IFO-REGINA ELENA CANCER INSTITUTE;ISTITUTO NAZIONALE TUMORI IRCCS ""FONDAZIONE G PASCALE"";ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G PASCALE;MASSACHUSETTS INSTITUTE OF TECHNOLOGY","2;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","4;2","CANCER;ANTIMICROBIAL RESISTANCE;BIOTECHNOLOGY;BRAIN DISORDERS;GENETICS","2;1;1;1;1","5.1 PHARMACEUTICALS","1","C12Q1/6886;A61K31/713;A61K45/06;C12N15/113;G01N33/50;G01N33/574","3;1;1;1;1;1","C12Q1/6886;C12Q2600/106;A61K45/06;C12N15/113;C12N2310/141;C12N2310/3231;C12N2320/31;C12Q2600/158;C12Q2600/178;A61K31/713","3;3;2;2;2;2;2;2;2;1",35,4,1025.76,29.41,20,0.57,81.17,1,0,8,0,13,0,1,12,0,24,11,0,0,0,0,0,0,31,3,1,35,0,0,0,0,0,0,0,0,0,"United States;Italy;Japan;Belgium;Israel;United Kingdom","14;6;4;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4206 PUBLIC HEALTH;31 BIOLOGICAL SCIENCES;3105 GENETICS;3215 REPRODUCTIVE MEDICINE;34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","33;24;17;7;4;2;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;LUNG CANCER;RARE DISEASES;GENETICS;BRAIN DISORDERS;BREAST CANCER;PATIENT SAFETY;BIOMEDICAL IMAGING;BRAIN CANCER;ESTROGEN;GENETIC TESTING;HUMAN GENOME;NEUROSCIENCES;OVARIAN CANCER;BIOENGINEERING;COMPARATIVE EFFECTIVENESS RESEARCH;COMPLEMENTARY AND INTEGRATIVE HEALTH","31;29;20;11;11;9;5;3;3;3;2;2;2;2;2;2;2;1;1;1","CANCER;MUSCULOSKELETAL;INFECTION;RESPIRATORY","27;2;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","21;3;3;2;2;1;1;1;1","LUNG CANCER;BREAST CANCER;MELANOMA;OVARIAN CANCER;BLADDER CANCER;BRAIN TUMOR;ENDOMETRIAL CANCER;HEAD AND NECK CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;RESPIRATORY SYSTEM;SALIVARY GLAND CANCER;SARCOMA","11;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;1.5 RESOURCES AND INFRASTRUCTURE;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.2 SURVEILLANCE","16;2;1;1;1;1;1;1;1;1;1;1",5,3495440.5,416046.92,2.8,4.2,3.8,0.4,1.66666666666667,350007.207738095,0.259994645790534,"ISTITUTI FISIOTERAPICI OSPITALIERI;AUSTRIAN INSTITUTE OF TECHNOLOGY;GESUNDHEIT ÖSTERREICH;HEALTH SERVICE EXECUTIVE;INSTITUT CATALÀ D'ONCOLOGIA;INSTITUTE OF ONCOLOGY LJUBLJANA;INSTITUTE OF PHYSICS;MINISTRY FOR HEALTH;NATIONAL HEALTH INFORMATION CENTER;NATIONAL INSTITUTE OF ONCOLOGY;NORWEGIAN DIRECTORATE OF HEALTH;PROCOMCURE BIOTECH (AUSTRIA);REGION OF SOUTHERN DENMARK;SCIENSANO (BELGIUM);UNIVERSITY OF CATANIA;VILNIUS UNIVERSITY;VTT TECHNICAL RESEARCH CENTRE OF FINLAND","5;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ITALIAN ASSOCIATION FOR CANCER RESEARCH;EUROPEAN COMMISSION","3;2","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;COALITION S;EC & ERC - EUROPEAN UNION","3;2;2","EU4HEALTH PROGRAMME (EU4H) (PROGRAMME);HORIZON-EIC - HORIZON EIC GRANTS (FUNDING SCHEME);HORIZON-EIC-2021-PATHFINDEROPEN-01 (CALL FOR PROPOSAL);HORIZON.3.1.1 - THE PATHFINDER FOR ADVANCED RESEARCH (PROGRAMME)","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","4;3;2;2;2;1;1;1;1","CANCER;CLINICAL RESEARCH;BIOENGINEERING;BIOTECHNOLOGY;GENETICS;HEALTH SERVICES;LUNG;LUNG CANCER;NANOTECHNOLOGY;PREVENTION;RURAL HEALTH","5;2;1;1;1;1;1;1;1;1;1","CANCER","4","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","2;1;1;1;1","MELANOMA;BREAST CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER","2;1;1;1","1.4 CANCER PROGRESSION AND METASTASIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;1.5 RESOURCES AND INFRASTRUCTURE;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;6.4 COST ANALYSES AND HEALTH CARE DELIVERY;6.5 EDUCATION AND COMMUNICATION","3;2;1;1;1;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B12 ENGINEERING","3;1;1","3 GOOD HEALTH AND WELL BEING","2",48,"FRONTIERS;ZENODO;SPRINGER NATURE;KARGER PUBLISHERS","39;4;3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;3008 HORTICULTURAL PRODUCTION;42 HEALTH SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3207 MEDICAL MICROBIOLOGY;4205 NURSING","80;32;14;11;8;6;4;3;3;2;2;2;2;1;1","CANCER;CLINICAL RESEARCH;EMERGING INFECTIOUS DISEASES;GENETICS;RARE DISEASES;VACCINE RELATED;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;PREVENTION;BIOTECHNOLOGY;IMMUNIZATION;NEUROSCIENCES;BRAIN DISORDERS;INFECTIOUS DISEASES;PATIENT SAFETY;AUTOIMMUNE DISEASE;DENTAL/ORAL AND CRANIOFACIAL DISEASE;BIODEFENSE;PSORIASIS;BRAIN CANCER","29;24;16;16;16;15;9;9;9;8;8;7;6;5;5;4;4;3;3;2","CANCER;GENERIC HEALTH RELEVANCE;INFECTION;MUSCULOSKELETAL;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","22;2;2;2;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;3.4 VACCINES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;7.1 INDIVIDUAL CARE NEEDS","18;9;4;3;2;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","19;7;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","28;5","NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;LUNG CANCER;ORAL CAVITY AND LIP CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BRAIN TUMOR;BREAST CANCER;HODGKIN'S DISEASE;MELANOMA;OVARIAN CANCER;SARCOMA;BLADDER CANCER;ENDOMETRIAL CANCER","7;5;4;4;2;2;2;2;2;2;2;1;1","3 GOOD HEALTH AND WELL BEING","6"
"IRCCS_IFO",2023,93,16.3010752688172,2.8494623655914,0.365591397849462,0.21505376344086,0.473118279569892,1.76666666666667,1.25925925925926,1.11111111111111,1.18918918918919,0.78494623655914,0,30,16,9,8,0.32,0.17,0.1,0.09,3.17,0.723700271410051,4.93333333333333,0.354838709677419,0.956989247311828,0.456,0.346,0.382,0.383,"ALDO MORRONE;CARLO COTA;ANTONIO CRISTAUDO;DIEGO ORSINI;ALESSIA PACIFICO;EMILIA MIGLIANO;MAURO PICARDO;GIOVANNI PELLACANI;EMANUELE DI SIMONE;CLAUDIO BONIFATI;ANTONIO COSTANZO;MARIA CONCETTA FARGNOLI;ENRICA FLORI;KETTY PERIS;LUCA BIANCHI;LUIGI GARGIULO;PIERGIORGIO MALAGOLI;AURORA DE LEO;FLAVIO ANDREA GOVONI;SANTO RAFFAELE MERCURI","9;9;7;7;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4","CARLO COTA;ALDO MORRONE;ANTONIO CRISTAUDO;DIEGO ORSINI;FLAVIA PIGLIACELLI;MARIA MARIANO;ALESSIA PACIFICO;EMILIA MIGLIANO;ENRICA FLORI;EMANUELE DI SIMONE;FABRIZIO PETRONE;PASQUALE FRASCIONE;FLAVIO ANDREA GOVONI;SARAH MOSCA;DANIELA KOVACS;ARIANNA MASTROFRANCESCO;AURORA DE LEO;MAURO PICARDO;ANTONIO COSTANZO;DARIO GRACEFFA","0.99;0.89;0.81;0.8;0.73;0.73;0.72;0.64;0.6;0.53;0.47;0.45;0.44;0.44;0.44;0.44;0.43;0.4;0.38;0.38","ALDO MORRONE;CARLO COTA;ANTONIO CRISTAUDO;DIEGO ORSINI;ALESSIA PACIFICO;EMILIA MIGLIANO;MAURO PICARDO;EMANUELE DI SIMONE;CLAUDIO BONIFATI;ENRICA FLORI;AURORA DE LEO;MARCO ARDIGÒ;GENNARO CILIBERTO;FABRIZIO PETRONE;MAURO TRUGLIO;PASQUALE FRASCIONE;SARAH MOSCA;FRANCESCA SPERATI;DANIELA KOVACS;ARIANNA MASTROFRANCESCO","9;9;7;7;7;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4","CARLO COTA;ALDO MORRONE;ANTONIO CRISTAUDO;DIEGO ORSINI;FLAVIA PIGLIACELLI;MARIA MARIANO;ALESSIA PACIFICO;EMILIA MIGLIANO;ENRICA FLORI;EMANUELE DI SIMONE;FABRIZIO PETRONE;PASQUALE FRASCIONE;SARAH MOSCA;DANIELA KOVACS;ARIANNA MASTROFRANCESCO;AURORA DE LEO;MAURO PICARDO;DARIO GRACEFFA;MARCO ARDIGÒ;CLAUDIO BONIFATI","0.99;0.89;0.81;0.8;0.73;0.73;0.72;0.64;0.6;0.53;0.47;0.45;0.44;0.44;0.44;0.43;0.4;0.38;0.37;0.37","MAURO PICARDO;AI‐YOUNG LEE;ALAIN TAÏEB;ALBERT WOLKERSTORFER;AMIT G. PANDYA;ATSUSHI TANEMURA;AUGUST́IN ALOMAR;BOON KEE GOH;CAROLINE LE POOLE;DAVID ROSMARIN;DAVINDER PARSAD;DEEPTI GHIA;ERIC LAN;FLORA XIANG;GEORG PLISZEWSKI;GIOVANNI LEONE;HARVEY LUI;HENRY W. LIM;ICHIRO KATAYAMA;ILTEFAT HAMZAVI","74;70;70;70;70;70;70;70;70;70;70;70;70;70;70;70;70;70;70;70","GIOVANNI LEONE;DIEGO ORSINI;ANTONIO CRISTAUDO;ALESSIA PACIFICO;PASQUALE FRASCIONE;CARLO COTA;FABIANA LETIZIA CECERE;GENNARO CILIBERTO;EMANUELA CAMERA;MIRIAM MAIELLARO;ALDO MORRONE;FRANCESCA SIVORI;LAURA IACOROSSI;AURORA DE LEO;CECILIA COCCIA;FEDERICO PIERCONTI;MAURO TRUGLIO;PAOLO IACOVELLI;EMANUELE DI SIMONE;ENRICA FLORI","70;58;41;37;19;17;13;13;11;11;10;10;8;7;7;7;7;7;6;6","CARLO COTA;ALDO MORRONE;ANTONIO CRISTAUDO;ALESSIA PACIFICO;DIEGO ORSINI;CLAUDIO BONIFATI;EMILIA MIGLIANO;ENRICA FLORI;ARIANNA MASTROFRANCESCO;AURORA DE LEO;DANIELA KOVACS;MARCO ARDIGÒ;PASQUALE FRASCIONE;SARAH MOSCA;EMANUELA CAMERA;MIRIAM MAIELLARO;ALESSANDRA LATINI;DARIO GRACEFFA;FABRIZIO PETRONE;FRANCESCA SIVORI","12;7;7;7;7;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;MATHEMATICS;POLITICAL SCIENCE;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE;SOCIOLOGY;ECONOMICS;BUSINESS;GEOGRAPHY;HISTORY;PHILOSOPHY","83;28;11;8;8;5;4;3;3;3;3;2;1;1;1;1","INTERNAL MEDICINE;DERMATOLOGY;PATHOLOGY;GENETICS;ONCOLOGY;SURGERY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;FAMILY MEDICINE;VIROLOGY;CANCER RESEARCH;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;NURSING;CLINICAL PSYCHOLOGY;RADIOLOGY;OPTICS;CELL BIOLOGY;ENDOCRINOLOGY;LAW;MICROBIOLOGY;PHYSICAL THERAPY","53;34;28;16;16;16;14;11;10;10;10;8;8;8;8;6;6;5;4;4;4;4;4","CANCER;DISEASE;PSORIASIS;GENE;POPULATION;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;CLINICAL TRIAL;ALTERNATIVE MEDICINE;OUTBREAK;COHORT;OBSERVATIONAL STUDY;INCIDENCE (GEOMETRY);QUALITY OF LIFE (HEALTHCARE);TRANSPLANTATION;BASAL CELL;CHEMOTHERAPY;EPIDEMIOLOGY;LYMPHOMA;RANDOMIZED CONTROLLED TRIAL;SIGNAL TRANSDUCTION;VITILIGO","19;19;13;11;9;9;8;8;7;7;6;6;5;5;5;4;4;4;4;4;4;4","INFECTIOUS DISEASE (MEDICAL SPECIALTY);PLAQUE PSORIASIS;2019-20 CORONAVIRUS OUTBREAK;COLORECTAL CANCER;GENE EXPRESSION;PSORIASIS AREA AND SEVERITY INDEX;PSORIATIC ARTHRITIS;METASTASIS;CLINICAL ENDPOINT;CRONBACH'S ALPHA;PLACEBO;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BLEOMYCIN;BORTEZOMIB;BREAST CANCER;CARCINOGENESIS;CELL CYCLE;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;CONTACT DERMATITIS;DERMATOLOGY LIFE QUALITY INDEX;DOWNREGULATION AND UPREGULATION;GENOTYPE;HIDRADENITIS SUPPURATIVA;KERATINOCYTE;LIPID SIGNALING;LIPOGENESIS;MYCOSIS FUNGOIDES;POLYUNSATURATED FATTY ACID;PROINFLAMMATORY CYTOKINE;PUSTULAR PSORIASIS;STAPHYLOCOCCUS AUREUS;TOLERABILITY","10;8;7;5;5;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);KRAS;SECUKINUMAB;TRANSCRIPTOME;DARATUMUMAB;ELECTROCHEMOTHERAPY;EPITHELIAL–MESENCHYMAL TRANSITION;GENE SIGNATURE;ACINIC CELL CARCINOMA;ACTIN CYTOSKELETON;ADHERENS JUNCTION;AGROBACTERIUM TUMEFACIENS;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTIRETROVIRAL THERAPY;BENDAMUSTINE;BREAST RECONSTRUCTION;CANNABINOID RECEPTOR;CARBOPLATIN;CD33;CEFIXIME;CYBERKNIFE;CYCLIN D1;DISEASE MANAGEMENT;DOCOSAHEXAENOIC ACID;GENE EXPRESSION PROFILING;GENOTYPING;GERMLINE MUTATION;HPV INFECTION;IBRUTINIB;IRRITANT CONTACT DERMATITIS;JAK-STAT SIGNALING PATHWAY;KAPOSI'S SARCOMA;LY294002;LYMPHOVASCULAR INVASION;MOLECULAR EPIDEMIOLOGY;MULTILEAF COLLIMATOR;MULTILOCUS SEQUENCE TYPING;OBINUTUZUMAB;ONCOGENE;PEMBROLIZUMAB;PEMETREXED;PIMECROLIMUS;PRIMARY TUMOR;SENTINEL LYMPH NODE;SENTINEL NODE;SKIN INFECTION;STAT PROTEIN;STEREOTACTIC RADIOTHERAPY;STEROID SULFATASE;STIMULATOR OF INTERFERON GENES;USTEKINUMAB;VISMODEGIB","10;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;SKIN NEOPLASMS;RETROSPECTIVE STUDIES;COVID-19;FEMALE;ADULT;MALE;PSORIASIS;ITALY;MELANOMA;CARCINOMA, SQUAMOUS CELL;MYCOSIS FUNGOIDES;TREATMENT OUTCOME;VITILIGO;HIV INFECTIONS;MIDDLE AGED;NEOPLASMS;SARS-COV-2;SURVEYS AND QUESTIONNAIRES","50;41;17;13;10;9;8;8;8;7;7;6;6;6;6;5;5;5;5;5","RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;MELANIN PIGMENTATION IN MAMMALIAN SKIN;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;ATOPIC DERMATITIS AND SKIN MICROBIOME;IMPROVING PATIENT SAFETY IN HEALTHCARE SETTINGS;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL SKIN INFECTIONS;MELANOMA;TREATMENT AND PATHOGENESIS OF HIDRADENITIS SUPPURATIVA;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANIMAL RESEARCH STUDIES;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;BIOMEDICAL APPLICATIONS OF GRAPHENE NANOMATERIALS;BODY ART AND MODIFICATION PRACTICES IN SOCIETY;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES;CANCER IMMUNOTHERAPY","10;5;4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","2019-20 CORONAVIRUS OUTBREAK;PANDEMIC;PSORIASIS;SKIN MICROBIOME;VITILIGO;CLINICAL ENDPOINT;DISCONTINUATION;ETIOLOGY;MEDICATION ERRORS;MELANOMA;TREATMENT;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CROSS-SECTIONAL STUDY;DARATUMUMAB;ELECTROCHEMOTHERAPY;ERYTHEMA;GENE SIGNATURE;HEMATOLOGY;HIDRADENITIS SUPPURATIVA;INAPPROPRIATE MEDICATION USE","7;7;7;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","PLAQUE PSORIASIS;MULTIPLE MYELOMA;CELL CARCINOMA;COVID- PANDEMIC;MULTICENTER STUDY;OBSERVATIONAL STUDY;ACTIVE NONSEGMENTAL;CELL YIELDS;COLORECTAL CANCER;CONTACT DERMATITIS;DIAGNOSED MULTIPLE;EXPERT RECOMMENDATIONS;FITZPATRICK SKIN;INTERNATIONAL VITILIGO;MYCOSIS FUNGOIDES;MYELOMA LAZIO;MYELOMA REPORT;NEWLY DIAGNOSED;NONSEGMENTAL VITILIGO;POSITION STATEMENT;PSORIATIC ARTHRITIS;STEM CELL;SUPREME STUDY;VITILIGO POSITION;VITILIGO TASK;WORLDWIDE EXPERT;A-HT QUESTIONNAIRE;AB CUTANEOUS;ABSTRACT MOLECULAR;ACID AMIDE","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","INDUCTION THERAPY;MOBILIZATION THERAPY;STEM CELL;PLAQUE PSORIASIS;MULTIPLE SCLEROSIS;COLLECTION GOAL;MOBILIZATION ATTEMPT;DRUG SURVIVAL;ADVERSE EVENTS;CELL YIELDS;HR PAMPLT;ADULT PATIENTS;CLINICAL PRACTICE;DARKER FST;PATIENTS AFFECTED;RETROSPECTIVE STUDY;DISEASE RELAPSE;SAFETY PROFILE;SIGNIFICANTLY LOWER;TH-TYPE CYTOKINES;TIDAL VOLUME;CELL CARCINOMA;CLINICAL TRIALS;COHORT STUDY;ELN RISK;FST I-III;FST IV-VI;INDEX PASI;MEDIAN AGE;MEDIAN OS","17;14;14;13;12;10;10;9;8;8;8;7;7;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5",10,0.11,2.15,3,0,2,0,0,0,1,0,5.25,1,0,3,0,0,4,1.5,3,5,0,0,10,10,4,0,0,0,3,1,0,0,0,0,0,0,3,1,0,0,4,6.04,1.5,0,2,1,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BLANDINO GIOVANNI;GANCI FEDERICA;FIORENTINO FRANCESCO;FRANCONI ROSELLA;MANCIOCCO VALENTINA;MASSA SILVIA;MORRONE ALDO;PELLINI RAUL;PULITO CLAUDIO;SACCONI ANDREA","3;2;1;1;1;1;1;1;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO;AGENZIA NAZIONALE PER LE NUOVE TECNOLOGIE LENERGIA E LO SVILUPPO ECONOMICO SOSTENIBILE ENEA;EUROFINS GENOMA GROUP SRL","4;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","6;3;2;1;1;1;1","CANCER;DENTAL/ORAL AND CRANIOFACIAL DISEASE;RARE DISEASES;BIOTECHNOLOGY;CLINICAL RESEARCH;PREVENTION","3;2;2;1;1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1","C12Q1/6886;A61K39/12;A61P35/00;C07K14/025;C12N15/62;C12N15/82","3;1;1;1;1;1","C12Q1/6886;C12Q2600/178;A61K2039/53;A61K2039/6031;A61K39/12;C07K14/005;C07K14/415;C07K2319/02;C12N2710/20034;C12N2770/40034","3;2;1;1;1;1;1;1;1;1",15,2.73,326.47,11.03,4,0.27,44,0,0,6,0,3,0,0,6,0,12,3,0,0,0,0,0,0,14,1,0,15,0,0,0,0,0,0,0,0,0,"Italy;United States;Belgium","4;4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","14;11;6;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;LUNG;LUNG CANCER;NEUROSCIENCES;RARE DISEASES;BREAST CANCER;GENETICS;BIOTECHNOLOGY;HEMATOLOGY;PREVENTION;AGING;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN CANCER;BRAIN DISORDERS;COMPLEMENTARY AND INTEGRATIVE HEALTH;HEALTH SERVICES;KIDNEY DISEASE;LYMPHOMA","15;12;11;4;4;4;4;3;3;2;2;2;1;1;1;1;1;1;1;1","CANCER","11","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS","9;2;2;1;1;1;1;1","LUNG CANCER;BREAST CANCER;BLADDER CANCER;BRAIN TUMOR;ENDOMETRIAL CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","4;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;3.3 CHEMOPREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","5;2;1;1;1;1;1",6,9749579.33,459831.34,2.83333333333333,12.8333333333333,7.33333333333333,0.5,0,653910.581272894,0.142221280192419,"ISTITUTI FISIOTERAPICI OSPITALIERI;ALLEANZA CONTRO IL CANCRO;ANTONI VAN LEEUWENHOEK HOSPITAL;EUROPEAN CANCER ORGANISATION;EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER;FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;GERMAN CANCER RESEARCH CENTER;INSTITUT GUSTAVE ROUSSY;INSTITUTE CURIE;MASARYK MEMORIAL CANCER INSTITUTE;ORGANISATION OF EUROPEAN CANCER INSTITUTES;OSLO UNIVERSITY HOSPITAL;TARTU UNIVERSITY HOSPITAL;TRINITY COLLEGE DUBLIN;TU DRESDEN;UNICANCER GROUP;AGOSTINO GEMELLI UNIVERSITY POLYCLINIC;CAPITAL REGION OF DENMARK;CHARITÉ - UNIVERSITY MEDICINE BERLIN;EUROPEAN INSTITUTE OF ONCOLOGY","6;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","EUROPEAN COMMISSION;ITALIAN ASSOCIATION FOR CANCER RESEARCH","3;3","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","3;3;3","HORIZON.2.1 - HEALTH (PROGRAMME);HORIZON-CSA - HORIZON COORDINATION AND SUPPORT ACTIONS (FUNDING SCHEME);HORIZON-MISS-2021-CANCER-02 (CALL FOR PROPOSAL);HORIZON-MISS-2022-CANCER-01 (CALL FOR PROPOSAL);INTERREGIONAL INNOVATION INVESTMENTS INSTRUMENT (I3) (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;4205 NURSING;46 INFORMATION AND COMPUTING SCIENCES","3;3;3;3;1;1;1;1","CANCER;CLINICAL RESEARCH;DIGESTIVE DISEASES;GENETICS;HEALTH SERVICES;RARE DISEASES;BIOTECHNOLOGY;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COLO-RECTAL CANCER;LIVER DISEASE;LUNG;PANCREATIC CANCER","5;3;2;2;2;2;1;1;1;1;1;1;1","CANCER","5","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","2;1;1;1","NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;LUNG CANCER;PANCREATIC CANCER","3;1;1;1","1.4 CANCER PROGRESSION AND METASTASIS;6.9 RESOURCES AND INFRASTRUCTURE RELATED TO CANCER CONTROL, SURVIVORSHIP, AND OUTCOMES RESEARCH;1.1 NORMAL FUNCTIONING;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","2;2;1;1;1;1;1;1;1","A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","3;2;1","3 GOOD HEALTH AND WELL BEING;9 INDUSTRY, INNOVATION AND INFRASTRUCTURE","1;1",17,"FRONTIERS;SPRINGER NATURE;ZENODO;AMERICAN CHEMICAL SOCIETY;PUBLIC LIBRARY OF SCIENCE","8;5;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3106 INDUSTRIAL BIOTECHNOLOGY;34 CHEMICAL SCIENCES;49 MATHEMATICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3207 MEDICAL MICROBIOLOGY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;42 HEALTH SCIENCES;4905 STATISTICS","25;12;7;5;3;2;2;2;2;1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;BREAST CANCER;BIOTECHNOLOGY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;GENETICS;PREVENTION;RARE DISEASES;BIOMEDICAL IMAGING;DENTAL/ORAL AND CRANIOFACIAL DISEASE;IMMUNIZATION;LUNG;VACCINE RELATED;AGING;BIODEFENSE;BIOENGINEERING;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;INFECTIOUS DISEASES;LUNG CANCER","10;5;4;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;INFECTION","10;1","5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;3.4 VACCINES","3;2;2;2;1","BIOMEDICAL;CLINICAL","5;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","7;3","BREAST CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LUNG CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;MELANOMA;NOT SITE-SPECIFIC CANCER","4;2;2;2;2;2;2;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","3"
"IRCCS_IFO",2024,106,17.2735849056604,2.97169811320755,0.292452830188679,0.264150943396226,0.39622641509434,1.96875,1.14814814814815,1.27272727272727,1.16666666666667,0.726415094339623,0,40,18,9,8,0.38,0.17,0.08,0.08,0.89,0.927893951725627,3.93949394939494,0.254716981132075,1,0.469,0.415,0.357,0.401,"DIEGO ORSINI;MARCO ARDIGÒ;ANTONIO COSTANZO;ALESSANDRA NARCISI;GIOVANNI PELLACANI;FRANCESCO LOCONSOLE;FULVIA PIMPINELLI;LUCA BIANCHI;MATTEO MEGNA;EMANUELA CAMERA;PAOLO DAPAVO;CHIARA ASSORGI;ANNA BALATO;MARTINA BURLANDO;GIACOMO CALDAROLA;ANNUNZIATA DATTOLA;LUIGI GARGIULO;PIERGIORGIO MALAGOLI;SANTO RAFFAELE MERCURI;VALENTINA DINI","13;10;10;10;9;9;8;8;8;8;8;8;8;8;8;7;7;7;7;7","MARCO ARDIGÒ;EMANUELA CAMERA;NORMA CAMELI;VIVIANA LORA;ALESSIA PACIFICO;MAURO TRUGLIO;GIOVANNI DAMIANI;GRAZIA BOTTILLO;DIEGO ORSINI;FULVIA PIMPINELLI;MAURO PICARDO;EMANUELE DI SIMONE;NICOLÒ PANATTONI;ELVA ABRIL;FRANCESCA SPERATI;BARBARA BELLEI;FABRIZIO PETRONE;IRENE TERRENATO;PASQUALE FRASCIONE;ENZO BERARDESCA","0.96;0.9;0.88;0.76;0.72;0.66;0.66;0.64;0.64;0.58;0.58;0.57;0.57;0.55;0.54;0.54;0.53;0.52;0.5;0.5","DIEGO ORSINI;MARCO ARDIGÒ;FULVIA PIMPINELLI;EMANUELA CAMERA;CHIARA ASSORGI;MAURO TRUGLIO;FRANCESCA SIVORI;EMANUELE DI SIMONE;GRAZIA BOTTILLO;ALESSANDRA LATINI;FABRIZIO PETRONE;ILARIA CAVALLO;BARBARA BELLEI;IRENE TERRENATO;ELVA ABRIL;PASQUALE FRASCIONE;RAUL PELLINI;NORMA CAMELI;FRANCESCA SPERATI;MARIA BENEVOLO","13;10;8;8;8;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5","MARCO ARDIGÒ;EMANUELA CAMERA;NORMA CAMELI;VIVIANA LORA;ALESSIA PACIFICO;MAURO TRUGLIO;GRAZIA BOTTILLO;DIEGO ORSINI;FULVIA PIMPINELLI;MAURO PICARDO;EMANUELE DI SIMONE;ELVA ABRIL;FRANCESCA SPERATI;BARBARA BELLEI;FABRIZIO PETRONE;IRENE TERRENATO;PASQUALE FRASCIONE;FRANCESCA SIVORI;ILARIA CAVALLO;CHIARA ASSORGI","0.96;0.9;0.88;0.76;0.72;0.66;0.64;0.64;0.58;0.58;0.57;0.55;0.54;0.54;0.53;0.52;0.5;0.49;0.49;0.43","DIEGO ORSINI;ALESSANDRA NARCISI;ANTONIO COSTANZO;LUCIANO IBBA;LUIGI GARGIULO;LUCA BIANCHI;MATTEO MEGNA;ANGELO VALERIO MARZANO;ANNA BALATO;CARLO GIOVANNI CARRERA;CLAUDIA LASAGNI;ELENA CAMPIONE;FRANCESCA MARIA GAIANI;FRANCESCO LOCONSOLE;FULVIA PIMPINELLI;MARTINA BURLANDO;PAOLO DAPAVO;PIERGIORGIO MALAGOLI;VALENTINA DINI;ELVA ABRIL","26;20;20;20;20;18;18;17;17;17;17;17;17;17;17;17;17;17;17;16","DIEGO ORSINI;FULVIA PIMPINELLI;ELVA ABRIL;FRANCESCA SIVORI;ILARIA CAVALLO;ARIANNA MASTROFRANCESCO;MARTINA PONTONE;ANTONIO CRISTAUDO;CHIARA ASSORGI;PASQUALE FRASCIONE;GRAZIA BOTTILLO;ALESSIA CAVALLO;CHRISTOF STINGONE;EMANUELA CAMERA;MAURO TRUGLIO;MIRIAM MAIELLARO;MONIA DI PRETE;CLAUDIO BONIFATI;DARIO GRACEFFA;FABIO CALABRÒ","26;17;16;16;16;12;12;11;10;9;8;7;7;7;7;7;7;6;6;4","DIEGO ORSINI;FULVIA PIMPINELLI;EMANUELA CAMERA;MARCO ARDIGÒ;MAURO TRUGLIO;FABRIZIO PETRONE;FRANCESCA SIVORI;ILARIA CAVALLO;ELVA ABRIL;GRAZIA BOTTILLO;NORMA CAMELI;RAUL PELLINI;VIVIANA LORA;ALESSANDRA LATINI;ANTONIO CRISTAUDO;BARBARA BELLEI;CLAUDIO BONIFATI;PASQUALE FRASCIONE;ALESSIA CAVALLO;DARIO GRACEFFA","13;8;7;7;7;6;6;6;5;5;5;5;5;4;4;4;4;4;3;3","MEDICINE;BIOLOGY;CHEMISTRY;SOCIOLOGY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;MATHEMATICS;PHILOSOPHY;MATERIALS SCIENCE;ART;HISTORY;POLITICAL SCIENCE;BUSINESS;ENVIRONMENTAL SCIENCE;GEOLOGY","96;31;9;8;7;6;5;5;4;4;4;3;2;2;2;1;1;1","INTERNAL MEDICINE;DERMATOLOGY;PATHOLOGY;ONCOLOGY;IMMUNOLOGY;GENETICS;SURGERY;NURSING;BIOCHEMISTRY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;VIROLOGY;CELL BIOLOGY;MICROBIOLOGY;RADIOLOGY;MEDICAL PHYSICS;ENDOCRINOLOGY;FAMILY MEDICINE;GASTROENTEROLOGY;NUCLEAR MEDICINE;PHARMACOLOGY;SOCIAL SCIENCE","57;40;25;20;17;15;15;11;9;9;8;8;8;7;7;7;6;5;5;5;5;5;5","CANCER;PSORIASIS;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;GENE;CLINICAL TRIAL;DISEASE;ADVERSE EFFECT;POPULATION;QUALITY OF LIFE (HEALTHCARE);ANTIBODY;BACTERIA;LYMPHOMA;MELANOMA;OBSERVATIONAL STUDY;ALTERNATIVE MEDICINE;BASAL CELL;BIOPSY;CHEMOTHERAPY;COHORT;DRUG;HEALTH CARE;IMMUNE SYSTEM;PATHOLOGICAL;RADIATION THERAPY","20;18;12;11;10;9;8;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","BREAST CANCER;MULTICENTER STUDY;IMMUNOTHERAPY;PSORIASIS AREA AND SEVERITY INDEX;PLAQUE PSORIASIS;PSORIATIC ARTHRITIS;BASAL CELL CARCINOMA;BIOFILM;CLINICAL ENDPOINT;INFECTIOUS DISEASE (MEDICAL SPECIALTY);MYCOSIS FUNGOIDES;SKIN CANCER;STAPHYLOCOCCUS AUREUS;ANTIBIOTIC RESISTANCE;BLADDER CANCER;CERVICAL CANCER;DERMATOLOGY LIFE QUALITY INDEX;DERMATOSCOPY;GENOTYPE;IMMUNOGENICITY;INTERLEUKIN 17;INTERPRETATIVE PHENOMENOLOGICAL ANALYSIS;MICRORNA;PHASES OF CLINICAL RESEARCH;PLACEBO;PROTON THERAPY;RADIOSURGERY;TELEMEDICINE;TOLERABILITY;TUMOR MICROENVIRONMENT;VIRAL LOAD","8;7;6;6;5;5;4;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);GENOTYPING;NIVOLUMAB;SECUKINUMAB;TUMOR-INFILTRATING LYMPHOCYTES;ANDROSTENEDIONE;ANTIRETROVIRAL THERAPY;AXITINIB;BASDAI;BREAST RECONSTRUCTION;CERVICAL INTRAEPITHELIAL NEOPLASIA;CIRCULATING TUMOR CELL;CONTACT ALLERGY;CUTANEOUS LYMPHOMA;CYBERKNIFE;DEOXYCYTIDINE;DOUBLE BLINDED;DYSPLASTIC NEVUS;ENTHESITIS;ERBB3;ESTROGEN RECEPTOR;INTERLEUKIN 23;IPILIMUMAB;IRINOTECAN;IRRITANT CONTACT DERMATITIS;JAK-STAT SIGNALING PATHWAY;LACTOBACILLUS CRISPATUS;LACTOBACILLUS PARACASEI;LYME BORRELIOSIS;MELANOCYTIC NEVUS;MERKEL CELL;METASTATIC BREAST CANCER;MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;MONOCLONAL;NEOADJUVANT THERAPY;PAPILLOMAVIRIDAE;PEMBROLIZUMAB;PEMPHIGOID;REACTOGENICITY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SENTINEL LYMPH NODE;SKIN INFECTION;STAT PROTEIN;STEREOTACTIC RADIOTHERAPY;TELEDERMATOLOGY;TELEHEALTH;TRASTUZUMAB;UROTHELIAL CANCER;UROTHELIAL CARCINOMA;VACCINIA;VANCOMYCIN","4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;RETROSPECTIVE STUDIES;ITALY;TREATMENT OUTCOME;PSORIASIS;SEVERITY OF ILLNESS INDEX;ANTIBODIES, MONOCLONAL, HUMANIZED;DERMATOLOGIC AGENTS;AGED, 80 AND OVER;SKIN NEOPLASMS;CARCINOMA, SQUAMOUS CELL;EARLY DETECTION OF CANCER;LUNG NEOPLASMS;MELANOMA","62;44;29;28;26;23;18;13;12;10;8;7;6;6;4;4;3;3;3;3","RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL SKIN INFECTIONS;ATOPIC DERMATITIS AND SKIN MICROBIOME;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CORONAVIRUS DISEASE 2019 RESEARCH;MELANIN PIGMENTATION IN MAMMALIAN SKIN;RADIOMICS IN MEDICAL IMAGING ANALYSIS;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;HEDGEHOG SIGNALING IN DEVELOPMENT AND CANCER;HEPATOCELLULAR CARCINOMA;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MELANOMA;REGULATION AND FUNCTION OF HAIR FOLLICLE STEM CELLS;RENAL CELL CARCINOMA;WOUND HEALING AND REGENERATION;;BACTERIAL BIOFILMS AND QUORUM SENSING MECHANISMS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES","14;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1","PSORIASIS;CLINICAL ENDPOINT;MEDICATION ADHERENCE;TOLERABILITY;TREATMENT;CANCER IMAGING;MELANOMA;SKIN MICROBIOME;TUMOR HETEROGENEITY;VITILIGO;ANTIFUNGAL THERAPY;BASAL CELL CARCINOMA;CLINICAL PRACTICE;COMBINATION THERAPIES;CONCORDANCE;CYTOLOGY SCREENING;DERMATOPATHOLOGY;DERMATOSCOPY;DERMOSCOPY;DISCONTINUATION","12;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","CONFOCAL MICROSCOPY;ITALIAN LANDSCAPE;LANDSCAPE PSORIASIS;PSO ITALIAN;PLAQUE PSORIASIS;REFLECTANCE CONFOCAL;CELL CARCINOMA;MULTICENTER RETROSPECTIVE;RETROSPECTIVE STUDY;WEEK MULTICENTER;ATOPIC DERMATITIS;BASAL CELL;CHLORMETHINE GEL;CLINICAL PRACTICE;ELDERLY PATIENTS;IL PSO;LUNG CANCER;MULTICENTER STUDY;MYCOSIS FUNGOIDES;NAIL PSORIASIS;REAL-WORLD DATA;TILDRAKIZUMAB MG;ADVANCED BASAL;CANCER PATIENTS;CENTRAL VENOUS;CLINICAL EXPERIENCES;CLINICAL RESPONSE;COHORT STUDY;CONTROLLED TRIAL;ITALIAN STUDY","7;6;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","SIGNALING TECHNOLOGY;PUBMED SCOPUS;ERBBDEL MICE;CL GEL;CROSSREF PUBMED;NAIL PSORIASIS;ERBBDEL CELLS;PLAQUE PSORIASIS;SUPPLEMENTARY FIGURE;CONFOCAL MICROSCOPY;SEXUAL FUNCTION;ADVERSE EVENTS;CLINICAL PRACTICE;CONFLUENT CELLS;FATTY ACID;MODERATE-TO-SEVERE PLAQUE;SIGNIFICANTLY INCREASED;CLINICAL TRIALS;ELDERLY PATIENTS;HIV INFECTION;MAINTENANCE THERAPY;NURSING STUDENTS;PROTEIN KINASE;SEVERITY INDEX;WESTERN BLOT;WOUND HEALING;ADRENAL INSUFFICIENCY;ALOPECIA AREATA;AREATA INCOGNITA;BIOFILM FORMATION","17;14;13;12;12;12;11;11;11;9;9;8;8;8;8;8;8;7;6;6;6;6;6;6;6;6;5;5;5;5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,2,1,0,0,0,0,0,0,2,1,0,0,3.66666666666667,3.49,1,0,0,2,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"SACCONI ANDREA;BLANDINO GIOVANNI;DI MODUGNO FRANCESCA;DÍAZ MÉNDEZ ANA BELÉN;MORRONE ALDO;NISTICO' PAOLA;PULITO CLAUDIO;REGAZZO GIULIA;RIZZO MARIA;STRANO SABRINA","2;1;1;1;1;1;1;1;1;1","ISTITUTI FISIOTERAPICI OSPITALIERI IFO","3","32 BIOMEDICAL AND CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;42 HEALTH SCIENCES;4205 NURSING","2;2;1;1;1;1","BIOTECHNOLOGY;CANCER;BRAIN CANCER;BRAIN DISORDERS;DENTAL/ORAL AND CRANIOFACIAL DISEASE;GENETICS;NEUROSCIENCES;RARE DISEASES","2;2;1;1;1;1;1;1",NA,NA,"C12Q1/6886;C07K14/435;G01N33/574","3;1;1","C12Q1/6886;C12Q2600/158;C12Q2600/178;C07K14/435;C07K14/47;C07K14/705;C07K14/70517;C07K14/70596;C07K14/78;C07K16/00","3;2;2;1;1;1;1;1;1;1",3,4,1735.33,2.01,0,0,112,0,0,0,0,2,0,0,1,0,2,1,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"Belgium;Denmark;France;Germany;Netherlands;Switzerland;United Kingdom;United States","1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","2;2;2;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LUNG;LUNG CANCER;LYMPHOMA;RARE DISEASES","3;3;2;1;1;1;1;1","CANCER","3","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;7.2 END OF LIFE CARE","2;1;1;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;1;1",1,2988461,597692.2,4,5,3,1,0,803333.631272894,0.131950158531321,"CAMPUS BIO MEDICO UNIVERSITY HOSPITAL;CROWDHELIX (UNITED KINGDOM);ISTITUTI FISIOTERAPICI OSPITALIERI;SAPIENZA UNIVERSITY OF ROME;UNIVERSITÄTSKLINIKUM ERLANGEN","1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","HORIZON-EIC - HORIZON EIC GRANTS (FUNDING SCHEME);HORIZON-EIC-2023-PATHFINDEROPEN-01 (CALL FOR PROPOSAL);HORIZON.3.1 - THE EUROPEAN INNOVATION COUNCIL (EIC) (PROGRAMME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY","1;1","BIOENGINEERING;BIOTECHNOLOGY;CANCER;DIGESTIVE DISEASES;NANOTECHNOLOGY;PANCREATIC CANCER;RARE DISEASES","1;1;1;1;1;1;1","CANCER","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1","PANCREATIC CANCER","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD","1;1","A01 CLINICAL MEDICINE","1",NA,NA,1,"FRONTIERS","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY","2;1","BIOTECHNOLOGY;CLINICAL RESEARCH;EMERGING INFECTIOUS DISEASES;IMMUNIZATION;INFECTIOUS DISEASES;LUNG;PNEUMONIA & INFLUENZA;PREVENTION;VACCINE RELATED","1;1;1;1;1;1;1;1;1",NA,NA,NA,NA,"BIOMEDICAL","1","CLINICAL MEDICINE AND SCIENCE","1",NA,NA,"3 GOOD HEALTH AND WELL BEING","1"
